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ABSTRACT	  
Myocardial	   protective	   strategies	   during	   cardiac	   surgery	   continue	   to	   improve	   yet	   they	  remain	  imperfect.	  Patients	  with	  left	  ventricular	  hypertrophy	  (LVH)	  are	  considered	  to	  be	  at	  greater	  risk	  of	  myocardial	  injury	  post	  cardiac	  surgery.	  Perhexiline	  is	  an	  anti-­‐anginal	  agent	   known	   to	   modulate	   myocardial	   metabolism	   towards	   a	   more	   efficient	   glucose	  metabolic	  pathway.	  This	  metabolic	  modulation	  may	  improve	  myocardial	  protection.	  	  
In	  this	  thesis	  I	  present	  a	  multi-­‐centre	  double-­‐blind	  randomised	  placebo	  controlled	  trial	  evaluating	   the	   role	   of	   perhexiline	   as	   an	   adjunct	   to	   standard	  myocardial	   protection	   in	  patients	  with	  LVH	  secondary	  to	  aortic	  stenosis	  undergoing	  an	  aortic	  valve	  replacement.	  Perhexiline	  does	  not	  augment	  myocardial	  protection.	  Magnetic	  Resonance	  Spectroscopy	  based	   energetic	   studies,	   echocardiographic	   and	   functional	   assessments	   in	   a	  homogenous	   patient	   cohort	   show	   no	   added	   benefit	   with	   perhexiline	   therapy	   in	   LVH.	  Therefore	   perhexiline	   should	   be	   limited	   to	   those	   patients	   refractory	   to	   maximum	  medical	  therapy.	  	  
Metabolomic	   assessment	   of	   LVH	   has	   shown	   no	   change	   in	   the	   metabolomic	   profile	  within	  the	  myocardium.	  However	  any	  changes	  that	  do	  exist	  may	  be	  subtle.	  In	  LVH	  there	  is	   an	   increased	   activity	   of	   some	   innate	   cardioprotective	   mechanistic	   pathways	   in	  patients	  that	  do	  not	  sustain	  a	  low	  cardiac	  output	  episode	  post	  cardiac	  surgery.	  Further	  examination	  of	  these	  cardioprotective	  regulators	  is	  warranted.	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  role	  of	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  in	  myocardial	  protection	   in	   patients	  with	   left	   ventricular	   hypertrophy	   (HYPER	   trial).	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   of	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  outlined	  in	  the	  reminder	  of	  this	  thesis	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  from	  this	  trial.	  	  	  
Chapter	  1	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  and	  background	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  to	  the	  research	  presented	  in	  this	  thesis	  is	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  my	  own	  work.	  The	  hypotheses	  outlined	   at	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   end	  of	   this	   chapter	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  been	  generated	  through	  discussions	  with	  my	  supervisors	  during	  the	  conceptual	  stages	  of	  the	  various	  components	  of	  this	  research.	  	  
Chapter	  2	  	  
This	   trial	   was	   designed	   by	   Prof	   Domencio	   Pagano	   and	   Mr	   Neil	   Howell	   and	   was	  developed	  on	  the	  same	  principles	  as	  the	  preceding	  trial	  (CASPER),	  evaluating	  the	  role	  of	  perhexiline	   during	   coronary	   artery	   surgery	   and	   followed	   the	   same	   principles	   to	   the	  preceding	   trials	   that	   were	   conducted	   in	   the	   department,	   evaluating	   myocardial	  protection.	   	  The	  original	   trial	  protocol	  and	  grant	  application	  were	  written	  by	  Mr.	  Neil	  Howell	  and	  Mr.	  Aaron	  Ranasinghe.	  The	  ethical	  approval	  and	  approval	   from	  the	  MHRA	  were	   obtained	   by	   my	   predecessor	   Mr	   Nigel	   Drury.	   	   Funding	   and	   approvals	   were	  obtained	  prior	  to	  my	  appointment.	  The	  power	  calculations	  and	  randomisation	  schedule	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for	  the	  trial	  were	  undertaken	  my	  Prof	  Nick	  Freemantle	  and	  Dr	  Melanine	  Clavert	  prior	  to	  my	  appointment.	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  to	  the	  ethics	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  and	  MHRA,	  to	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  the	  trial	  to	  other	  centres,	  which	  also	  included	  obtaining	  local	  trust	  approvals.	  	  Following	  my	  appointment	   I	  was	   responsible	   for	   all	   aspects	   of	   trial	  management.	   This	   included	   the	  management	   of	   local	   and	  multi-­‐centre	   trial	   logistics	   and	   the	   financial	  management	   of	  the	  BHF	  and	  charities	  grants.	  I	  undertook	  training	  in	  Good	  Clinical	  Practice	  related	  to	  all	  aspects	  of	  clinical	  research	  including	  ethics,	  consent,	  trial	  methodology	  and	  investigator	  responsibilities.	  I	  also	  completed	  courses	  in	  database	  management	  in	  Microsoft	  Access	  and	  statistical	  analysis	  in	  SPSS,	  at	  the	  University	  of	  Birmingham.	  	  
In	   the	   first	   2	   months	   Mr.	   Nigel	   Drury	   assisted	   with	   trial	   management.	   I	   recruited	  patients	  into	  the	  trial,	  which	  included	  screening	  patients,	  consenting,	  randomising	  and	  prescribing	   the	   trial	   therapy.	   I	   was	   responsible	   for	   the	   management	   of	   trial	   therapy	  thereafter.	  I	  coordinated	  with	  the	  administrative	  staff	  regarding	  scheduling	  of	  cases	  and	  provided	  a	  first	  port	  of	  call	  for	  all	  trial	  patients	  for	  reporting	  of	  potential	  side	  effects	  and	  therapy	  management.	  I	  managed	  the	  trial	  and	  patients	  recruited	  into	  the	  trial,	  as	  per	  the	  trial	  protocol	  and	  adhered	  to	  the	  trial	  protocol	  in	  the	  pre-­‐operative,	  peri-­‐operative	  and	  postoperative	  stages;	  in	  addition	  I	  was	  responsible	  for	  the	  reporting	  of	  serious	  adverse	  events.	  	  
I	   collected	   trial	   patient’s	   tissue	   samples,	   processed	   them	   and	   stored	   them	   for	   later	  analysis	   in	   accordance	   with	   the	   Human	   Tissue	   Act	   2007.	   In	   theatre,	   I	   managed	   the	  patients’	  haemodynamic	  status	  and	  this	  continued	  onto	  the	  Intensive	  Care	  Unit	  were	  I	  managed	  the	  patient	  for	  a	  further	  4	  –	  6	  hours	  post	  operatively.	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I	   collected	   all	   the	   data	   and	   entered	   it	   into	   an	   MS	   Access	   database	   that	   I	   wrote,	   in	  accordance	   with	   the	   Data	   Protection	   Act	   1998.	   This	   data	   was	   cleaned	   and	   used	   for	  presentation	  at	  the	  blinded	  end-­‐points	  committee	  meeting	  that	  I	  chaired,	  the	  data	  safety	  monitoring	  board	  meetings	   and	   for	   the	   final	   trial	   statistical	   analysis.	   I	   also	   submitted	  data	  monthly	  to	  the	  UK	  Clinical	  Research	  Network	  database.	  	  
The	   expansion	   of	   the	   trial	   to	   other	   centres	   involved	   establishing	   relations	   and	  collaborations	   with	   the	   departments	   involved	   with	   the	   trial	   at	   each	   new	   site,	   and	  education	  of	  the	  local	  administrative	  and	  nursing	  staff,	  which	  I	  provided.	  I	  visited	  these	  sites	  regularly	   to	  establish	   these	  networks	  at	   the	   initial	  stages,	  and	  then	  subsequently	  for	  every	  case	   that	  was	  performed	  at	  each	  site,	   to	  manage	   the	  patient	  as	  per	   the	   trial	  protocols	  as	  outlined	  above.	  	  
Chapter	  3	  	  
The	   presentation	   of	   the	  main	   clinical	   trial	   results	   in	   this	   chapter	   is	   entirely	  my	   own	  work.	   The	   statistical	   analysis	   plan	  was	   drawn	   up	   following	   discussions	   between	   Prof	  Nick	   Freemantle	   and	  myself.	   Prof	   Nick	   Freemantle	  was	   responsible	   for	   the	   statistical	  analysis	  of	  the	  main	  trial	  outcomes	  and	  the	  futility	  analysis.	  I	  performed	  the	  remainder	  of	  the	  analyses	  related	  to	  the	  secondary	  end-­‐points	  presented	  in	  this	  chapter.	  	  
Chapter	  4	  
I	  conceived	  and	  designed	  the	  study	  outlined	  in	  this	  chapter	  with	  advice	  from	  Mr.	  Aaron	  Ranansinghe.	   I	  wrote	   the	   study	   protocol	   and	   collaborated	  with	  Dr	  Roger	  Beadle	  who	  had	  previous	  experience	  in	  performing	  Magnetic	  Resonance	  Spectroscopy.	  Through	  this	  collaboration	   I	   learnt	   the	   techniques	   of	  MRS,	  which	   included	   acquiring	   and	   analysing	  
	   x	  
the	  spectra.	   I	  prepared	   the	  documentation	  required	   for	  ethical	  approval	  and	  obtained	  approval	   from	   the	  University	   of	   Birmingham.	   I	   recruited	   all	   the	   participants	   enrolled	  into	   this	  study.	   	   I	  performed	  the	  MRS	  scan	  with	   the	  help	  of	  Dr	  Roger	  Beadle	  and	  then	  performed	   the	   spectral	   analysis.	   Subsequently	   I	   performed	   all	   of	   the	   data	   analysis	  outlined	  in	  this	  chapter.	  
Chapter	  5	  
This	  study	  was	  conceived	  as	  a	  sub-­‐study	  to	  the	  main	  HYPER	  trial.	   I	  was	  involved	  with	  the	   groundwork	   for	   obtaining	   approval	   from	   the	   ethics	   committee	   and	   regulatory	  bodies	   as	   part	   of	   a	   substantial	   amendment	   to	   the	  main	   trial.	   The	   techniques	   I	   learnt	  from	  the	  preceding	  validation	  study	  on	  MRS	  were	  applied	  in	  this	  study.	  I	  recruited	  all	  of	  the	  patients	   enrolled	  onto	   this	   study	   similar	   to	   the	  principles	  of	   recruitment	  outlined	  above,	   managed	   their	   trial	   therapy,	   and	   coordinated	   with	   the	   administrative	   staff	  regarding	  scheduling	  of	   cases.	   I	   took	  blood	   for	  serum	  perhexiline	  monitoring,	  and	   the	  doses	  were	  adjusted	  by	  a	  blinded	  contact.	  	  
The	   baseline	   and	   follow-­‐up	   echocardiography	   scans	   as	   per	   the	   protocol,	   were	  performed	  by	  Drs	  Roger	  Beadle	  and	  Michal	  Kuel.	   I	  performed	  all	  of	   the	  other	  baseline	  and	   follow-­‐up	   investigations.	   I	   performed	   the	  MRS	   scans	  with	   the	   help	   of	   Drs	   Roger	  Beadle	   and	   Michal	   Kuel.	   I	   collected	   all	   the	   data	   and	   performed	   all	   of	   the	   analysis	  presented	  in	  this	  chapter.	  	  
Chapter	  6	  	  
This	   study	   was	   conceived	   following	   discussions	   I	   had	   with	   Mr	   Neil	   Howell	   and	   this	  study	  led	  to	  consolidating	  collaborations	  made	  with	  Prof	  Mark	  Viant’s	  group.	  The	  tissue	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samples	  used	  in	  this	  study	  were	  obtained	  from	  patients	  recruited	  into	  the	  HYPER	  trial.	  I	  processed	  the	  tissue	  samples	  at	  the	  time	  they	  were	  obtained	  for	   later	  analysis.	  During	  the	  conceptual	  stages	  of	  this	  study,	  I	  spent	  time	  in	  the	  lab	  understanding	  the	  principles	  of	   metabolomics	   and	   learning	   some	   of	   the	   laboratory	   techniques.	   This	   was	   initially	  under	   the	   supervision	   of	   Dr	   Jennifer	   Hill.	   During	   this	   time,	   the	   measurement	   and	  analysis	   of	   small	   myocardial	   tissue	   samples	   using	   mass	   spectrometry	   metabolomic	  techniques	  were	  optimised.	  I	  was	  involved	  in	  these	  discussions	  and	  contributed	  from	  a	  clinical	  perspective.	  	  
The	  tissue	  samples	  used	  in	  this	  study	  were	  prepared	  for	  analysis,	  and	  the	  data	  gathered	  from	   these	   experiments	   were	   analysed	   by	   Dr	   Ralf	   Weber.	   The	   highly	   specialized	  laboratory	   techniques	   and	   statistical	   analysis	   used	   in	   this	   study	   extend	   beyond	   my	  capabilities.	   However	   I	   was	   involved	   with	   the	   interpretation	   of	   these	   results	   from	   a	  clinical	  context.	  
Chapter	  7	  	  
This	   study	  was	   conceptualised	   following	   discussion	  with	  Mr	  Neil	   Howell	   and	  Dr	   Dan	  Tennant	   and	   consolidated	   existing	   collaborations	   with	   Dr	   Dan	   Tennant’s	   group.	   The	  tissue	   samples	   for	   this	   study	   were	   obtained	   from	   patients	   recruited	   into	   the	   HYPER	  trial.	  I	  prepared	  the	  tissue	  samples	  once	  obtained,	  for	  later	  analysis.	  	  
During	   this	   study,	   I	   attended	   Dr	   Dan	   Tennant’s	   laboratory	   and	   initially	   learnt	   the	  techniques	  of	  extracting	  proteins	  through	  Western	  blotting.	  I	  used	  these	  techniques	  to	  prepare	   the	   tissue	   and	   perform	   the	   Westerns	   presented	   in	   this	   chapter	   under	   the	  supervision	  of	  Dr	  Dan	  Tennant.	  The	  data	  obtained	  from	  these	  Westerns,	  were	  analysed	  with	  the	  help	  of	  Dr	  Dan	  Tennant.	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  8	  	  
The	   discussion	   related	   to	   the	   preceding	   chapters	   and	   conclusions	   drawn	   from	   my	  research	   presented	   in	   this	   thesis,	   is	   entirely	   my	   own	   work.	   The	   avenues	   for	   future	  research	   in	   this	   field	  are	  drawn	  from	  discussions	   I	  have	  had	  with	  my	  supervisors	  and	  collaborators.	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  Ireland	  SUSAR	   suspected	  unexpected	  serious	  adverse	  reaction	  TOE	   Transoesophageal	  echocardiogram	  TTE	   transthoracic	  echocardiogram	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1 INTRODUCTION	  
1.1 Aortic	  stenosis	  
1.1.1 Pathology	  	  
Aortic	  stenosis	  (AS)	  results	  from	  calcification	  of	  the	  aortic	  valve	  leaflets,	  producing	  rigid	  cusps.	  This	  is	  a	  degenerative	  condition	  and	  is	  more	  common	  in	  the	  elderly	  population.	  Less	  commonly	  a	  bicuspid	  aortic	  valve,	  a	  congenital	  abnormality	  predisposes	  the	  aortic	  valve	   to	   early	   calcific	   degeneration	   and	   hence	   affects	   young	   adults.	   Rheumatic	   fever	  causes	  progressive	  fusion	  of	  the	  commissures,	  and	  eventual	  thickening	  and	  calcification	  of	  the	  aortic	  cusps,	  leading	  to	  AS.	  	  
The	   commonest	   cause	   of	   aortic	   stenosis	   in	   adults	   is	   degenerative	   calcification	   (Selzer	  1987;	  Dare,	  Veinot	   et	   al.	   1993;	  Roberts	   and	  Ko	  2005).	  This	   is	   an	   active	   inflammatory	  process	   with	   thickening	   of	   the	   subendothelium	   and	   fibrosis	   (Olsson,	   Dalsgaard	   et	   al.	  1994;	  Otto,	  Kuusisto	  et	  al.	  1994;	  Mohler,	  Chawla	  et	  al.	  1999;	  Olsson,	  Thyberg	  et	  al.	  1999;	  Mohler,	  Gannon	  et	  al.	  2001;	  O'Brien,	  Shavelle	  et	  al.	  2002;	  Rajamannan,	  Subramaniam	  et	  al.	   2003).	   The	   lesions	   contain	   lipoproteins,	   which	   accumulate	   and	   calcify.	   The	  calcification	   starts	   at	   the	   base	   of	   the	   cusps	   and	   progresses	   to	   the	   valve	   leaflets.	   This	  calcification	  causes	  the	  leaflets	  to	  be	  stiff	  and	  less	  mobile	  leading	  to	  a	  smaller	  effective	  valve	  orifice	  area,	  without	  commissural	  fusion.	  	  
1.1.2 Natural	  history	  	  
The	  natural	  progression	  of	  aortic	  stenosis	  is	  individual	  dependent	  and	  there	  is	  marked	  individual	   variability	   in	   haemodynamic	   progression.	   It	   is	   known	   that	   there	   is	   a	   long	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latent	  period,	  where	  there	  are	  no	  clinical	  manifestations	  of	  signs	  or	  symptoms.	  During	  this	  latent	  period	  morbidity	  and	  mortality	  associated	  with	  AS	  is	  low.	  	  
Faggiano	   et	   al	   estimates	   the	   progression	   of	   AS	   using	   results	   from	   invasive	   and	   non-­‐invasive	   studies	   (Faggiano,	   Aurigemma	   et	   al.	   1996).	   Once	   moderate	   stenosis	   is	  established,	   jet	  velocity	   increases	  by	  0.3m/s	  and	  mean	  pressure	  gradient	   increases	  by	  7mmHg	  per	  year	  with	  a	   resultant	  decrease	   in	  valve	  area	  of	  0.1cm2	  per	  year	   (Cheitlin,	  Gertz	  et	  al.	  1979;	  Wagner	  and	  Selzer	  1982;	  Jonasson,	  Jonsson	  et	  al.	  1983;	  Otto,	  Pearlman	  et	  al.	  1989;	  Roger,	  Tajik	  et	  al.	  1990;	  Davies,	  Gershlick	  et	  al.	  1991;	  Peter,	  Hoffmann	  et	  al.	  1993;	  Rosenhek,	  Binder	  et	  al.	  2000).	  	  
Degenerative	   calcific	   aortic	   stenosis	   is	   considered	   to	   progress	   more	   rapidly	   than	  stenosis	  affecting	  a	  congenitally	  bicuspid	  aortic	  valve	  or	  aortic	  stenosis	  associated	  with	  rheumatic	   fever	   (Vaturi,	   Porter	   et	   al.	   1999;	   Rosenhek,	   Binder	   et	   al.	   2000).	   As	  progression	   is	   individual	  and	  pathology	  dependent,	   regular	  echocardiographic	   follow-­‐up	   is	   essential	   in	   those	   who	   are	   asymptomatic	   but	   have	   mild	   or	   moderate	   AS,	   to	  establish	  the	  rate	  of	  progression	  of	  the	  disease	  (Bonow,	  Carabello	  et	  al.	  2008).	  	  
Otto	  et	  al	  in	  a	  prospective	  echocardiographic	  study	  describes	  the	  rate	  of	  progression	  of	  AS	  in	  asymptomatic	  patients	  with	  a	   jet	  velocity	  of	  >	  2.6m/s	  and	  shows	  that	  event	  free	  survival	  was	  93%,	  62%	  and	  26%	  at	  1,	  3	  and	  5	  years	  respectively	  (Otto,	  Burwash	  et	  al.	  1997).	  However	  they	  highlight	  that	  a	  baseline	  jet	  velocity	  of	  >	  4m/s	  allows	  an	  event	  free	  survival	  of	  only	  21%	  at	  2	  years	  compared	  to	  84%	  for	  those	  with	  a	  jet	  velocity	  of	  ≤	  4m/s.	  This	  relationship	  between	  disease	  progression	  relative	  to	  jet	  velocity	  is	  evident	  in	  other	  studies.	  Rosenhek	  et	  al	  describe	  the	  progression	  of	  128	  consecutive	  patients	  classified	  as	  having	  severe	  aortic	  stenosis	  (Rosenhek,	  Binder	  et	  al.	  2000).	  	  In	  this	  study	  event	  free	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survival	  was	  67%	  at	  1	  year	  and	  dropped	  to	  33%	  at	  4	  years.	  Furthermore	  they	  showed	  through	   multivariable	   analysis	   that	   the	   extent	   of	   aortic	   valve	   calcification	   was	   an	  independent	   predictor	   of	   outcome.	   Furthermore	   they	   state	   that	   79%	  of	   patients	  who	  had	  moderate	  to	  severe	  aortic	  valve	  calcification	  and	  a	  jet	  velocity	  that	  increased	  by	  ≥	  0.3m/s	   within	   a	   year,	   underwent	   surgery	   or	   died	   within	   2	   years	   of	   the	   observed	  increase.	  	  
Following	  the	  latent	  period,	  symptoms	  of	  AS;	  angina,	  syncope,	  dyspnoea	  and	  symptoms	  of	   congestive	   heart	   failure	   develop.	   Following	   the	   onset	   of	   symptoms	   survival	   is	  dramatically	  reduced	  with	  an	  average	  survival	  of	  2-­‐3	  years	   if	   left	  untreated	  (Ross	  and	  Braunwald	  1968;	   Schwarz,	  Baumann	  et	   al.	   1982;	  Turina,	  Hess	   et	   al.	   1987;	  Horstkotte	  and	  Loogen	  1988;	  Kelly,	  Rothbart	  et	  al.	  1988;	  Iivanainen,	  Lindroos	  et	  al.	  1996)	  with	  an	  associated	   high	   risk	   of	   sudden	   death.	   The	   risk	   of	   sudden	   death	   is	   rare	   in	  echocardiographic	   studies	   with	   prospective	   follow-­‐up,	   and	   thought	   to	   occur	   without	  preceding	  symptoms	  at	  a	  rate	  of	  <	  1%	  per	  year	  (Ross	  and	  Braunwald	  1968;	  Horstkotte	  and	  Loogen	  1988;	  Pellikka,	  Sarano	  et	  al.	  2005).	  	  
1.1.3 Pathophysiology	  
Stenosis	   of	   the	   aortic	   valve	   occurs	   gradually	   and	   increases	   over	   time.	   This	   advancing	  stenosis	   leads	   to	   an	   increasing	   obstruction	   of	   the	   left	   ventricular	   outflow	   tract.	   Thus,	  over	   time	   there	   is	  a	  gradual	   increase	   in	   the	  systolic	  pressure	  within	   the	   left	  ventricle.	  Increasing	  left	  ventricular	  pressure	  overload	  over	  time,	  leads	  to	  a	  pathological	  response	  of	   left	   ventricular	   hypertrophy	   (LVH);	   increased	   left	   ventricular	   wall	   thickness,	  maintaining	   a	   normal	   chamber	   volume	   (Sasayama,	   Ross	   et	   al.	   1976;	   Gaasch	   1979;	  Spann,	  Bove	  et	  al.	  1980).	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Laplace’s	  law	  outlined	  below,	  illustrates	  the	  effect	  on	  circumferential	  wall	  stress	  by	  the	  relationship	  between	  pressure,	  chamber	  radius	  and	  wall	  thickness	  
𝑊𝑎𝑙𝑙  𝑠𝑡𝑟𝑒𝑠𝑠 =   𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒  ×  𝑐ℎ𝑎𝑚𝑏𝑒𝑟  𝑟𝑎𝑑𝑖𝑢𝑠𝑤𝑎𝑙𝑙  𝑡ℎ𝑖𝑐𝑘𝑒𝑛𝑠𝑠 	  
Left	   ventricular	   hypertrophy	   allows	   the	   left	   ventricular	   wall	   stress	   to	   remain	   low,	  despite	   the	   increase	   in	   intra-­‐cavity	   systolic	   pressure.	   Therefore	   the	   afterload	   (LV	  systolic	  wall	  stress)	  remains	  within	  the	  normal	  range	  (Krayenbuehl,	  Hess	  et	  al.	  1988).	  This	   allows	   the	   ejection	   fraction	   to	   be	  maintained,	   as	   an	   increase	   in	   afterload	  would	  have	   an	   inverse	   effect	   on	   ejection	   fraction.	   Therefore	   if	   the	   hypertrophic	   process	   is	  inadequate	  and	  wall	  thickness	  does	  not	  increase	  proportional	  to	  intra-­‐cavity	  pressure,	  wall	  stress	  increases	  resulting	  in	  a	  low	  ejection	  fraction	  (Gunther	  and	  Grossman	  1979;	  Krayenbuehl,	  Hess	  et	  al.	  1988).	  
Ejection	   fraction	   is	   also	   affected	   by	   the	   contractility	   of	   the	   myocardium.	   Depressed	  contractility	  will	  produce	  a	  lower	  ejection	  fraction.	  In	  these	  patients	  surgical	  treatment	  of	   AS	   may	   not	   have	   the	   same	   beneficial	   effects	   as	   compared	   to	   patients	   with	   a	   low	  ejection	  fraction	  secondary	  to	  increased	  wall	  stress	  (Carabello,	  Green	  et	  al.	  1980).	  	  
Left	   ventricular	   hypertrophy	   renders	   the	   myocardium	   to	   be	   less	   compliant	   (Gaasch,	  Levine	   et	   al.	   1976).	   Furthermore	   LVH	   causes	   an	   increased	   wall	   thickness	   and	   low	  volume/mass	  ratio.	  These	  features	  result	  in	  an	  increased	  end-­‐diastolic	  pressure	  without	  chamber	   dilatation	   (Gaasch,	   Levine	   et	   al.	   1976;	   Murakami,	   Hess	   et	   al.	   1986).	   An	  increased	   end-­‐diastolic	   pressure	   is	   consistent	   with	   features	   of	   diastolic	   dysfunction	  (Gaasch	  1994).	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Left	  ventricular	  hypertrophy	  is	  an	  adaptive	  feature	  to	  AS,	  and	  may	  seem	  to	  counteract	  the	  increased	  pressure	  overload,	  however	  the	  pathophysiological	  responses	  are	  more	  a	  result	   of	   LVH	   rather	   than	   the	   aortic	   stenosis	   per	   se.	   These	   responses	   are	   further	  explored	  later	  in	  this	  chapter.	  	  
The	  stenosis	  would	   lead	   to	   inadequate	   flow	  out	  of	   the	   left	  ventricle	  and	  hence	  reduce	  the	  overall	  cardiac	  output	  or	  may	  maintain	  a	   fixed	  cardiac	  output.	  This	   in	   turn	  causes	  reduced	   coronary	   perfusion.	   Furthermore	   there	   is	   also	   reduced	   perfusion	   to	   the	  cerebrum.	   A	   conjunction	   of	   these	   features	   leads	   to	   the	   symptoms	   and	   signs	   outlined	  below.	  	  
1.1.4 Clinical	  manifestations	  
The	  narrowing	  of	  the	  aortic	  valve	  secondary	  to	  degenerative	  calcific	  aortic	  stenosis	  has	  clinical	   features	   consistent	   with	   reduced	   ejection	   of	   blood	   from	   the	   heart.	   There	   are	  usually	   no	   symptoms	   until	   the	   aortic	   stenosis	   is	   moderate	   to	   severe.	   When	  symptomatic,	   angina,	   dyspnoea	   and	   syncope	   or	   pre-­‐syncope	   features	   of	   dizziness	   or	  light-­‐headedness	  are	  the	  predominate	  features.	  	  	  
On	  examination	  the	  pulse	  is	  of	  small	  volume	  and	  slow	  rising.	  A	  systolic	  thrill	  may	  be	  felt	  in	   the	   aortic	   area.	   On	   auscultation	   an	   ejection	   systolic	   murmur	   would	   classically	   be	  evident.	  The	  murmur	  is	  usually	  longer	  as	  the	  disease	  is	  more	  severe	  due	  to	  the	  extended	  ejection	  time.	  A	  single	  or	  paradoxically	  split	  second	  heart	  sound	  may	  also	  be	  present.	  	  
Over	  time,	   if	  heart	   failure	  ensues,	  symptoms	  and	  signs	  of	  congestive	  heart	   failure	  may	  be	  present.	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1.1.5 Diagnosis	  and	  quantification	  
Transthoracic	  or	  trans-­‐oesophageal	  echocardiography	  confirms	  the	  diagnosis	  of	  aortic	  valve	  stenosis	  (Bonow,	  Carabello	  et	  al.	  2008).	  However,	  quantification	  requires	  a	  series	  of	  measurements	  calculated	  through	  echocardiography	  that	   include	  aortic	   jet	  velocity,	  mean	   pressure	   gradient	   and	   valve	   area	   (Bonow,	   Carabello	   et	   al.	   2008).	   Using	   these	  measurements,	  aortic	  stenosis	  is	  categorised	  into	  mild,	  moderate	  or	  severe	  as	  outlined	  in	  Table	  1-­‐1.	  	  
	   Mild	   Moderate	   Severe	  
Jet	  velocity	  (m/sec)	   <	  3.0	   3.0	  –	  4.0	   >	  4.0	  
Valve	  area	  (cm2)	   >	  1.5	   1.0	  –	  1.5	   <	  1.0	  
Mean	  gradient	  (mmHg)	   <	  25	   25	  –	  40	   >	  40	  
Table	  1-­‐1	  Grading	  of	  aortic	  valve	  stenosis	  
The	   two	  dimensional	   (2D)	  echocardiogram	   is	  useful	   for	   the	  evaluation	  of	   the	  valvular	  anatomy,	   pathology	   and	   function.	   Doppler	   echocardiography	   is	   used	   to	   calculate	   the	  maximum	  jet	  velocity,	  pressure	  gradients	  and	  valve	  area	  using	  the	  continuity	  equation	  (Cheitlin,	  Armstrong	  et	  al.	  2003).	  Echocardiography	  is	  also	  recommended	  for	  the	  initial	  assessment	  of	  LV	  wall	  thickness,	  size	  and	  function.	  Thereafter	  serial	  assessment	  of	  this	  is	  recommended	  using	  echocardiography	  (Bonow,	  Carabello	  et	  al.	  2008).	  	  
These	  measurements	   remain	  a	  guide	   to	  quantify	   the	  disease.	  Hence	  an	  absolute	  valve	  area	  or	  mean	  gradient	  is	  not	  used	  as	  the	  primary	  determinant,	  in	  deciding	  surgery.	  If	  a	  patient	  has	  a	  low	  cardiac	  output	  it	  is	  possible	  that	  the	  mean	  gradient	  and	  jet	  velocity	  is	  lower	  than	  someone	  with	  a	  normal	  cardiac	  output	  and	  yet	  they	  may	  have	  severe	  aortic	  stenosis.	  These	  patients	  fall	  under	  the	  category	  of	  low	  flow	  low	  gradient	  aortic	  stenosis	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and	   need	   further	   thorough	   assessment	   and	  work	   up	   before	   a	   therapeutic	   decision	   is	  made.	  	  	  
1.1.6 Management	  and	  treatment	  
1.1.6.1 Management	  of	  the	  symptomatic	  patient	  	  
Aortic	   valve	   replacement	   (AVR)	   remains	   the	  most	   appropriate	   form	   of	   treatment	   for	  patients	  with	   severe	   symptomatic	   calcific	   aortic	   valve	   stenosis	   and	  more	   so	   for	   those	  patients	  who	  are	  not	  too	  high	  risk	  for	  conventional	  open	  valve	  surgery.	  	  
In	  symptomatic	  patients	  AVR	  improves	  symptoms	  and	  survival	  (Murphy,	  Lawson	  et	  al.	  1981;	   Schwarz,	   Baumann	   et	   al.	   1982;	   Lund	   1990;	   Connolly,	   Oh	   et	   al.	   1997;	   Kvidal,	  Bergstrom	  et	  al.	  2000).	  Survival	  is	  comparative	  in	  patients	  with	  moderate	  LV	  function,	  secondary	  to	  excessive	  afterload	  secondary	  to	  pressure	  overload,	  to	  those	  with	  normal	  LV	  function.	  However	  in	  those	  with	  severe	  LV	  impairment	  secondary	  to	  afterload,	  there	  would	  be	  survival	  benefit,	  but	  symptomatic	  benefit	  may	  be	   limited	  by	   the	  residual	  LV	  dysfunction	  (Smith,	  McAnulty	  et	  al.	  1978;	  Connolly,	  Oh	  et	  al.	  1997).	  	  
Therefore	  AVR	   is	   indicated	   in	   all	   symptomatic	  patients	  with	   severe	  AS	  and	   should	  be	  performed	  as	  soon	  as	  possible	  after	  symptom	  onset	  (Appendix	  9.1).	  	  
1.1.6.2 Management	  of	  the	  asymptomatic	  patient	  
Patients	   who	   are	   asymptomatic	  may	   have	   a	   spectrum	   of	   aortic	   disease	   from	  mild	   to	  severe	  and	  may	  also	  have	  varying	  degree	  of	  calcification.	  It	  has	  been	  recommended	  that	  these	  patients	  need	  to	  be	  monitored	  for	  the	  development	  of	  symptoms	  and	  assessment	  of	  disease	  progression	  (Bonow,	  Carabello	  et	  al.	  2008).	   	  Trans-­‐thoracic	  echo	  is	  used	  for	  the	  serial	  assessment	  of	  asymptomatic	  patients	  in	  addition	  to	  routine	  clinical	  follow-­‐up.	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There	  still	  remains	  controversy	  and	  contention	  regarding	  the	  optimal	  timing	  for	  aortic	  valve	  replacement	  in	  the	  asymptomatic	  patient	  in	  relation	  to	  the	  risk/benefit	  balance.;	  likely	  long-­‐term	  complications	  of	  structural	  deterioration	  associated	  with	  implanting	  a	  biological	  valve	  in	  a	  relatively	  young	  patient	  (Emery,	  Erickson	  et	  al.	  2003)	  or	  the	  long-­‐term	  complications	  associated	  with	  a	  mechanical	  valve	  implantation	  (Kvidal,	  Bergstrom	  et	  al.	  2000).	  
The	  current	  AHA	  guidelines	  (Appendix	  9.1)	  recommend	  AVR	  for	  those	  with	  severe	  AS	  with	  LV	  systolic	  dysfunction.	  Furthermore	  it	  is	  indicated	  in	  asymptomatic	  patients	  with	  severe	   AS	   undergoing	   any	   other	   form	   of	   cardiac	   surgery.	   Furthermore	   AVR	   is	  reasonable	  under	   these	   circumstances,	  when	   the	  AS	   is	  moderate.	  AHA	  guidelines	  also	  suggest	   that	   AVR	   may	   be	   considered	   in	   asymptomatic	   patients	   with	   an	   abnormal	  response	  to	  exercise	  testing	  or	  if	  there	  is	  likelihood	  of	  rapid	  progression	  and	  in	  patients	  with	  extremely	  severe	  AS.	  	  	  
1.1.6.3 Cardiac	  catheterisation	  	  
Cardiac	   catheterisation	   to	   perform	   pressure	   studies,	   is	   indicated	   in	   those	   patients	  where	   echocardiographic	   evidence	   is	   not	   confirmatory	   regarding	   the	   diagnosis	   or	  severity	  of	  AS	  or	  when	   there	   is	   a	  discrepancy	  between	  non-­‐invasive	   tests	  and	  clinical	  finding	   regarding	   the	   severity	   of	   AS	   (Bonow,	   Carabello	   et	   al.	   2008).	   Coronary	  angiography	   is	   most	   useful	   in	   assessing	   the	   coronary	   circulation	   and	   hence	  recommended	  in	  patients	  undergoing	  an	  AVR	  for	  AS,	  who	  have	  a	  risk	  of	  coronary	  artery	  disease.	  Furthermore	  it	  aids	  in	  surgical	  planning	  for	  an	  AVR.	  
	  1-­‐9	  
1.2 Myocardial	  metabolism	  	  
1.2.1 Fuels	  for	  the	  heart	  
Myocardial	  metabolism	  consists	  of	  a	  number	  of	  processes	  and	  includes	  glycolysis,	   free	  fatty	   acid	   metabolism,	   the	   citric	   acid	   cycle	   and	   oxidative	   phosphorylation	   which	   all	  contribute	  in	  forming	  high	  energy	  phosphates	  that	  are	  utilised	  in	  order	  for	  myocardial	  contraction	   to	  occur.	  The	  key	   fuels	   the	  myocardium	  utilises	  are	  glucose	  and	   free	   fatty	  acids	   and	   their	   usage	   is	   dictated	   by	   their	   overall	   availability	   and	   the	   state	   the	  myocardium	  is	  in	  i.e.	  aerobic	  or	  anaerobic	  metabolism.	  	  
1.2.2 Glycolysis	  	  
Glycolysis	   is	   the	   first	   step	   in	   a	   cascade	   of	   processes	   necessary	   to	  metabolise	   glucose,	  both	   in	   aerobic	   and	   anaerobic	   conditions.	   The	   end	   product	   of	   glycolysis	   is	   further	  oxidized	   to	   provide	   energy.	   The	   process	   that	   takes	   place	   in	   glycolysis	   is	   outlined	   in	  Figure	  1-­‐1,	  whereby	  a	  single	  glucose	  molecule	  is	  split	  to	  form	  2	  molecules	  of	  pyruvate.	  
Initially	  glucose	   taken	  up	   into	   the	  cardiac	  myocytes’	   cytosol	   is	   trapped	  and	  converted	  into	   glucose	  6-­‐phosphate	  by	   the	   enzyme	  hexokinase.	  Glycolysis	  begins	   at	   the	  point	   at	  which	   glucose	   6-­‐phosphate	   is	   split	   into	   fructose-­‐1,6-­‐bisphosphate,	   influenced	   by	   the	  enzyme	   phosphofructokinase	   (PFK).	   Each	   bisphosphate	   is	   then	   split	   further	   into	   2	  molecules	   of	   glyceraldehyde-­‐3-­‐phosphate.	   Each	   glyceraldehyde-­‐3-­‐phospate	   is	   finally	  converted	   into	   pyruvate.	   Through	   glycolysis,	   there	   is	   a	   net	   release	   of	   2	   pyruvate	  molecules,	  2	  ATP	  molecules	  and	  4H+	  ions.	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Figure	  1-­‐1	  Glycolysis	  pathway	  
1.2.3 Role	  of	  pyruvate	  	  
Pyruvate	   is	   formed	   by	   glycolysis	   under	   aerobic	   conditions.	   In	   the	   aerobic	   heart,	  pyruvate	   is	   further	   oxidized	   through	   oxidative	   decarboxylation	   to	   Acetyl-­‐CoA	   by	  combining	  with	  Coenzyme	  A	  under	  the	  action	  of	  the	  enzyme	  pyruvate	  dehydrogenase,	  found	   in	   the	   inner	   mitochondrial	   membrane.	   This	   stage	   forms	   2	   carbon	   dioxide	  molecules	   and	   4	   hydrogen	   atoms,	   which	   later	   enters	   the	   oxidative	   phosphorylation	  cascade	  to	  form	  ATP.	  Acetyl-­‐CoA	  enters	  the	  citric	  acid	  cycle.	  Pyruvate	  dehydrogenase	  is	  activated	   by	   increased	   heart	   work	   and	   catecholamines.	   It	   is	   inhibited	   by	   NADH2	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formation	   during	   hypoxia	   or	   ischaemia.	   Furthermore	   pyruvate	   dehydrogenase	   is	   also	  inhibited	  by	  fatty	  acid	  oxidation,	  in	  turn	  slowing	  down	  glycolysis	  (Lopaschuk,	  Rebeyka	  et	  al.	  2002).	  	  
Under	   anaerobic	   conditions	   pyruvate	   forms	   lactate.	   When	   aerobic	   conditions	   exist,	  lactate	  is	  reversibly	  converted	  back	  into	  pyruvate	  by	  the	  enzyme	  lactate	  dehydrogenase	  (Figure	  1-­‐2).	  
	  
Figure	  1-­‐2	  Lactate	  formation	  
1.2.4 Fatty	  acid	  metabolism	  and	  β-­‐oxidation	  
The	   extent	   of	   fatty	   acid	  metabolism	   is	   proportional	   to	   the	   concentration	   of	   free	   fatty	  acids	   (FFA)	   in	   the	   circulation.	   FFAs	   are	   transported	   in	   the	   blood	   stream	   to	  cardiomyocytes,	   bound	   to	   albumin	   (van	   der	   Vusse,	   van	   Bilsen	   et	   al.	   2000).	   FFA	  metabolism	  occurs	  only	  in	  the	  mitochondrion;	  therefore	  the	  1st	  step	  in	  the	  metabolism	  of	  FFA	  is	  their	  entry	  into	  the	  mitochondrion.	  	  
The	   carrier	   substance	   carnitine	   is	   involved	   in	   the	   passage	   of	   FFA	   into	   the	  mitochondrion.	  The	  first	  step	  is	  activation	  of	  intracellular	  fatty	  acid	  by	  CoA	  to	  from	  fatty	  acyl-­‐CoA	  derivatives.	  As	   the	  mitochondrial	  membrane	   is	  not	  permeable	   to	   these	   acyl-­‐CoA	  molecules	  a	  staged	  transfer	  occurs	  using	  carnitine	   to	   form	  acylcarnitine,	  which	   is	  transferred	  into	  the	  mitochondrial	  space	  (Kantor	  PF	  2001;	  Opie	  and	  Lopaschuk	  2004).	  The	  sequence	  of	  events	   that	  occur	   is	  outlined	  below	   in	  Figure	  1-­‐3,	  where	  palmitate	   is	  considered	  to	  be	  the	  FFA.	  
	  1-­‐12	  
	  
Figure	  1-­‐3	  Free	  Fatty	  Acid	  metabolism	  
The	  enzyme	  carnitine	  palmitoyltransferase	  1	  (CPT-­‐1)	  catalyses	  one	  of	  the	  key	  steps	  in	  the	   conversion	   of	   FFA	   to	   a	   form	   amenable	   for	   translocation	   into	   the	  mitochondrion.	  Then	  the	  enzyme	  carnitine	  acylcarnitine	  translocase	  is	  involved	  in	  the	  translocation	  of	  palmityl	   carnitine	   to	   within	   the	   space	   between	   the	   inner	   and	   outer	   mitochondrial	  membranes.	  Carnitine	  palmitoyltransferase	  2	   (CPT-­‐2)	   is	   then	   involved	   in	   the	   reaction	  between	  intra-­‐mitochondrial	  palmityl	  carnitine	  with	  CoA,	  liberating	  intra-­‐mitochondrial	  palmitoly-­‐CoA	  and	  carnitine	  (Figure	  1-­‐3).	  Carnitine	  is	  then	  exported	  back	  into	  the	  intra-­‐mitochondrial	  space.	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Therefore	   once	   inside	   the	   mitochondrion,	   FFA	   splits	   away	   from	   carnitine	   and	   is	  degraded	   and	   oxidized.	   FFA	   is	   degraded	   into	   Acetyl-­‐CoA	   through	   the	   process	   of	   β-­‐oxidation.	  	  
If	   excess	   FFA	   reaches	   the	   mitochondrion,	   there	   is	   a	   risk	   of	   uncoupling	   between	  oxidation	   and	   phosphorylation	   causing	   oxygen	   wastage.	   To	   prevent	   this	   occurring,	  malonyl-­‐CoA	   is	   involved	   in	   limiting	   excess	   FFA	   entering	   the	  mitochondrion.	  Malonyl-­‐CoA	  inhibits	  the	  action	  of	  CPT-­‐1,	  reducing	  FFA	  metabolism	  (Dyck	  and	  Lopaschuk	  2002).	  Malonyl-­‐CoA	   is	   synthesised	   by	   the	   enzyme	   acetyl-­‐CoA	   carboxylase.	   Acetyl-­‐CoA	  carboxylase	  is	  inhibited	  by	  another	  enzyme,	  AMP	  protein	  kinase.	  	  
β-­‐oxidation	   converts	   the	   intra-­‐mitochondrial	   long	   acyl-­‐CoA	   into	   acetyl-­‐CoA.	   There	   is	  progressive	  oxidation	  of	  carbon	  atoms	  in	  the	  long	  fatty	  acyl-­‐CoA	  molecule	  by	  oxidizing	  the	  beta	  carbon	  (second	  carbon	  from	  the	  right)	  of	   the	   fatty	  acyl-­‐CoA,	  releasing	  acetyl-­‐CoA.	   At	   this	   point,	   another	   CoA	   attaches	   to	   the	   remaining	   portion	   of	   the	   fatty	   acid	  molecule	  to	  form	  a	  new	  fatty	  acyl-­‐CoA.	  This	  shorter	  fatty	  acyl-­‐CoA	  gets	  further	  oxidized	  as	  before,	  to	  release	  another	  acetyl-­‐CoA.	  This	  process	  continues	  until	  the	  original	  fatty	  acyl-­‐CoA	  is	  fully	  oxidized.	  	  	  
During	  this	  process	  of	  β-­‐oxidation	  each	  FFA	  molecule	  releases	  approximately	  9	  acetyl-­‐CoA	  molecules	   and	   approximately	   32	   extra	   hydrogen	   atoms	   are	   removed.	   Acetyl-­‐CoA	  released	  through	  β-­‐oxidation	  then	  enters	  the	  citric	  acid	  cycle.	  	  
During	   anaerobic	   conditions,	   there	   is	   impaired	   β-­‐oxidation.	   Intermediates	   of	   FFA	  metabolism	   such	   as	   acyl	   carnitine	   and	   acyl-­‐CoA	   accumulate	   and	   damage	   cardiac	   cell	  membranes.	   Furthermore	   during	   ischaemic	   conditions	   the	   action	   of	   malonyl-­‐CoA	   is	  inhibited,	  as	  AMP	  protein	  kinase	  is	  activated	  and	  in	  turn	  inhibits	  acetyl	  CoA	  carboxylase.	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Therefore	   in	   ischaemia,	  more	   long	   chain	   fatty	   acids	   enter	   the	  mitochondrion	   as	   acyl-­‐CoA.	  This	  in	  turn	  utilizes	  any	  remaining	  residual	  oxygen	  for	  FFA	  metabolism.	  	  	  
1.2.5 Citric	  Acid	  Cycle	  	  
The	  citric	  acid	  cycle	   (CAC)	   is	   the	  next	   series	  of	   reactions,	  where	  Acetyl	  CoA	   is	  broken	  down	  resulting	   in	  CO2	  and	  H+	  atoms	  being	  released.	  Figure	  1-­‐4	  describes	   this	  process.	  Initially	   oxaloacetate	   combines	   with	   acetyl-­‐CoA	   to	   form	   citrate.	   The	   CoA	   portion	   is	  released	  and	  is	  available	  to	  form	  more	  Acetyl	  CoA.	  	  
	  
	  
Figure	  1-­‐4	  Citric	  Acid	  Cycle	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For	  each	  molecule	  of	  glucose,	  2	  molecules	  of	  acetyl-­‐CoA	  enter	  the	  CAC;	  net	  release	  of	  4	  CO2,	   16H+,	   2	   CoA	   molecules	   and	   2	   ATPs.	   	   For	   each	   molecule	   of	   FFA,	   9	   molecules	   of	  acetyl-­‐CoA	  enter	  the	  CAC;	  net	  release	  of	  18	  CO2,	  72	  H+,	  18	  CoA	  molecules	  and	  9	  ATPs.	  The	   H+	   atoms	   released	   during	   the	   CAC	   are	   subsequently	   oxidised	   through	   oxidative	  phosphorylation	  to	  produce	  ATP.	  
1.2.6 Oxidative	  phosphorylation	  	  
The	  hydrogen	  atoms	  released	  during	  glycolysis,	  formation	  of	  Acetyl-­‐CoA	  and	  during	  the	  CAC	  undergo	  a	  reaction	  catalysed	  by	  the	  enzyme	  dehydrogenase	  to	   form	  NADH+	  +	  H+.	  Each	  H+	  is	  released	  in	  packets	  of	  2	  and	  undergoes	  the	  reaction	  as	  show	  in	  Figure	  1-­‐5.	  	  
	  
	  
Figure	  1-­‐5	  NADH2	  formation	  
Hydrogen	   ions	   formed	   during	   the	   earlier	   outlined	   processes	   combine	  with	   NAD+	  and	  enter	   the	   cascade	   of	   oxidative	   phosphorylation.	   A	   small	   number	   directly	   enters	   the	  oxidative	  process	  without	  combing	  with	  NAD+.	  	  
Formation	  of	  ATP	  occurs	   in	   the	  mitochondrion	  as	  a	  result	  of	   this	  cascade	  of	   reactions	  named	   the	   chemiosmotic	   mechanism	   and	   this	   manner	   of	   ATP	   formation	   is	   termed	  oxidative	  phosphorylation.	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NADH++H+	  (NADH2)	   is	  oxidized	  and	  split	   in	   the	  mitochondrion	   to	   form	  hydrogen	   ions	  and	  electrons.	  The	  electrons	  enter	  a	   series	  of	   enzymatically	   catalysed	  reactions	  called	  the	   electron	   transport	   chain	   within	   the	   inner	   membrane	   of	   the	   mitochondrion.	   The	  electrons	   are	   shuttled	   between	   a	   series	   of	   electron	   acceptors	   until	   it	   reaches	  cytochrome	   oxidase.	   Cytochrome	   oxidase	   gives	   up	   2	   electrons,	   which	   combine	   with	  dissolved	  oxygen	   to	   form	  hydroxyl	   ions.	  These	  hydroxyl	   ions	  and	   the	  earlier	   released	  hydrogen	  ions	  eventually	  combine	  to	  form	  water.	  	  During	  the	  transport	  of	  the	  electrons	  through	  the	  electron	  transport	  chain	  energy	  is	  released,	  which	  is	  used	  to	  pump	  out	  the	  hydrogen	   ions	   from	   the	   inner	   mitochondrial	   membrane	   into	   the	   space	   between	   the	  inner	   and	   outer	   mitochondrial	   membrane	   (intra-­‐mitochondrial	   membrane)	   (Guyton	  and	  Hall	  2000).	  	  
This	   creates	   a	   high	   concentration	   of	   positively	   charged	   hydrogen	   ions	   within	   this	  chamber	   and	   also	   creates	   an	   increased	   negative	   electrical	   potential	   in	   the	   inner	  mitochondrial	  matrix.	  This	  causes	  the	  hydrogen	  ions	  to	  flow	  from	  the	  inter-­‐membrane	  space	  into	  the	  inner	  mitochondrial	  matrix	  through	  a	  large	  protein	  molecule	  called	  ATP	  synthetase,	  positioned	  through	  the	  inner	  mitochondrial	  membrane	  and	  protruding	  into	  the	  inner	  mitochondrial	  matrix	  (Opie	  and	  Lopaschuk	  2004).	   	  The	  energy	  derived	  from	  this	  hydrogen	  ion	  flow	  is	  used	  by	  ATP	  synthetase	  to	  convert	  ADP	  into	  ATP,	  by	  combing	  ADP	  with	  an	  ionic	  phosphate	  radical	  (Pi).	  	  
The	  newly	  formed	  ATP	  undergoes	  facilitated	  diffusion	  through	  the	  inner	  mitochondrial	  membrane	   via	   the	   ADP-­‐ATP	   carrier	   called	   translocase.	   	   Thereafter	   ATP	   undergoes	  simple	   diffusion	   through	   the	   outer	   mitochondrial	   membrane	   into	   the	   cytoplasm.	  Similarly	  ADP	  is	  transferred	  in	  the	  opposite	  direction	  for	  conversion	  into	  ATP.	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For	   each	   2	   electrons	   that	   are	   transported	   through	   the	   chemiosmotic	   mechanisms	  explained	  above,	  up	   to	  3	  ATP	  are	   synthesised	  utilising	  up	   to	  1	  molecule	  of	  oxygen.	   In	  this	  way	  the	  oxidation	  of	  NADH2	  is	  coupled	  to	  phosphorylation	  of	  ADP.	  	  
1.2.7 ATP	  utilisation	  
ATP	   energizes	   the	   synthesis	   of	   important	   cellular	   components,	   such	   as	   protein	  synthesis.	   Furthermore	   it	   energizes	   muscle	   contraction	   and	   active	   transport	   across	  membranes.	  The	  majority	  of	  ATP	  synthesized	  is	  used	  for	  heat	  production,	  and	  only	  20-­‐25%	   of	   ATP	   hydrolysed	   is	   actually	   used	   in	   mechanical	   work	   (Opie	   and	   Lopaschuk	  2004).	   The	   rest	   is	   used	   for	   contraction	   and	   other	   essential	   mechanisms	   i.e.	   calcium	  uptake	   by	   sarcoplasmic	   reticulum.	   Up	   to	   15%	   of	   ATP	   may	   be	   used	   by	   the	   sodium-­‐potassium	   pump.	   A	   small	   percentage	   is	   used	   for	   the	   generation	   of	   action	   potentials,	  phosphorylation	   of	   proteins,	   glycogen	   and	   triglyceride	   turn	   over,	   and	   calcium	  uptake	  and	  release.	  	  
ATP	   wastage	   occurs	   in	   pathological	   processes	   where	   futile	   cycles	   speed	   up	   or	   are	  abnormal.	  Furthermore	  excess	  FFA	  oxidation	  increases	  non-­‐phosphorylating	  pathways	  of	  oxygen	  uptake,	  causing	  oxygen	  wastage.	  	  
1.2.8 Phosphocreatine	  and	  ATP	  	  
The	  ATP	  generated	  through	  the	  processes	  of	  oxidative	  phosphorylation	  is	  converted	  to	  phosphocreatine	  (PCr),	  the	  form	  in	  which	  ATP	  is	  stored.	  	  Thereby	  PCr	  acts	  as	  a	  reserve	  of	   energy	   (Ye,	   Gong	   et	   al.	   2001).	   ATP	   is	   transported	   to	   the	   cytoplasm	   forming	  phosphocreatine	   by	   the	   mitochondrial	   CK	   isoenzyme,	   situated	   on	   the	   outside	   of	   the	  inner	  mitochondrial	  membrane,	  close	  to	  the	  ADP-­‐ATP	  carrier	  translocase.	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When	  required	  phosphocreatine	  is	  rapidly	  converted	  to	  ATP	  for	  utilisation	  (Figure	  1-­‐6).	  This	   reaction	   is	   catalysed	   by	   the	   enzyme	   creatine	   phosphokinase	   (CK).	   Under	   the	  influence	   of	   CK,	   ATP	   is	   provided	   at	   the	   site	   where	   ATP	   is	   used.	   This	   reaction	   highly	  favours	  the	  formation	  of	  ATP,	  when	  the	  slightest	  amount	  of	  ATP	  is	  expended.	  	  At	  times	  when	  ATP	  is	  required	  the	  above	  process	  allows	  ATP	  to	  be	  maintained	  at	  the	  expense	  of	  phosphocreatine.	  	  
	  
Figure	  1-­‐6	  Formation	  of	  ATP	  from	  phosphocreatine	  
1.2.9 Controls	  in	  metabolism	  	  
The	  above	  mechanisms	  of	  metabolism	  have	  a	  number	  of	  controlling	  feedback	  pathways	  adapted	  to	  provide	  energy	  when	  most	  needed.	  The	  cell	  concentrations	  of	  ADP	  and	  ATP	  have	  a	  major	  impact	  in	  controlling	  these	  pathways.	  High	  ATP	  concentrations	  inhibit	  PFK	  thereby	   inhibiting	   glycolysis.	   Conversely,	   high	   ADP	   concentrations	   have	   the	   opposite	  effect,	   promoting	   glycolysis	   and	   thereby	   promoting	   the	   production	   of	   ATP.	   Another	  mechanism	  is	  via	  citrate	  produced	  in	  the	  CAC.	  High	  citrate	  concentrations	  inhibit	  PFK.	  Furthermore	   ATP	   and	   ADP	   are	   in	   constant	   equilibrium.	   If	   all	   the	   ADP	   is	   used	   in	   the	  formation	  of	  ATP,	  then	  no	  further	  ATP	  can	  be	  formed.	  Therefore	  equipoise	  between	  ATP	  and	  ADP	  is	  needed	  to	  allow	  more	  ATP	  generation.	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1.3 Left	  ventricular	  hypertrophy	  	  
1.3.1 Pathophysiology	  	  
Left	  ventricular	  hypertrophy	  initially	  develops	  as	  a	  physiologically	  response	  to	  pressure	  overload.	   Aortic	   stenosis,	   which	   causes	   gradual	   reduction	   in	   the	   aortic	   orifice	   area,	  eventually	  leads	  to	  pressure	  overload.	  Over	  time	  if	  left	  untreated,	  it	  leads	  to	  ventricular	  contractile	  dysfunction	  and	  dilatation.	  
Left	  ventricular	  hypertrophy	  is	  associated	  with	  reduced	  coronary	  blood	  flow	  per	  gram	  of	  muscle	  (Bache,	  Vrobel	  et	  al.	  1981).	  Furthermore	  LVH	  renders	  the	  coronary	  vessels	  to	  have	  less	  vasodilatory	  reserve	  (Bache	  1998)	  (an	  index	  of	  coronary	  artery	  vasodilatory	  response;	   ratio	   of	   peak	   coronary	  blood	   flow	   to	  baseline	   flow),	   even	   in	   the	   absence	  of	  coronary	  artery	  disease	  (Marcus,	  Doty	  et	  al.	  1982;	  Carabello	  2002).	  This	  lack	  of	  normal	  coronary	   blood	   flow	   and	   reserve	  makes	   the	   hypertrophied	   heart	  more	   susceptible	   to	  the	  stressors	  of	  exercise	  and	  tachycardia	  by	  producing	  a	  maldistribution	  of	  blood	  flow	  and	  subendocardial	  ischaemia.	  This	  leads	  to	  systolic	  and	  diastolic	  dysfunction	  of	  the	  left	  ventricle.	  	  	  
Hypertrophic	   hearts	   are	   also	   more	   susceptible	   to	   ischaemia,	   with	   larger	   infarct	   and	  higher	  mortality	  rates	  compared	  to	  that	  seen	  with	  no	  hypertrophy	  (Koyanagi,	  Eastham	  et	   al.	   1982;	   Gaasch,	   Zile	   et	   al.	   1990).	   There	   is	   also	   evidence	   of	   an	   inappropriate	  hypertrophic	   response,	  particular	   common	   in	   females	   (Aurigemma,	   Silver	   et	   al.	   1994;	  Carabello	   2002).	   Inappropriate	   LVH	   has	   been	   associated	   with	   high	   perioperative	  morbidity	  and	  mortality	  (Orsinelli,	  Aurigemma	  et	  al.	  1993).	  	  
A	  key	  feature	  of	  LVH	  is	  myocardial	  fibrosis.	  This	  process	  of	  fibrosis	  has	  been	  linked	  to	  the	  renin-­‐angiotensin-­‐aldosterone	  system	  (Weber	  and	  Brilla	  1991).	  This	  is	  particularly	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evident	   in	   LVH	   associated	   with	   hypertension	   where	   there	   is	   a	   heterogeneous	  accumulation	   of	   fibrillar	   collagen.	   Furthermore	   there	   is	   evidence	   to	   suggest	   that	  circulating	   aldosterone	   and	   associated	   hypertension	   contribute	   towards	   cardiac	  fibroblast	   involvement	   necessary	   for	   collagen	   deposition	   (Weber	   and	   Brilla	   1991).	  	  Moreover	   fibrosis	   is	   also	   stimulated	   by	   chronic	   pressure	   overload	   by	   activation	   of	  procollagen	  gene	  expression	  and	  collagen	  protein	  synthesis	  (Cuspidi,	  Ciulla	  et	  al.	  2006).	  	  Angiotensin	  II	  increases	  fibroblast	  proliferation	  and	  in	  turn	  alters	  the	  fibrillar	  collagen	  turnover	  with	  deposition	  of	  collagen	  type	  I	  and	  III	  fibres,	  ultimately	  leading	  to	  fibrosis	  (Campbell,	   Janicki	   et	   al.	   1995).	  This	  deposition	  of	   collagen	  and	   fibrosis	   contributes	   to	  the	  ventricular	  dysfunction	  and	  myocardial	  stiffness.	  
1.3.2 Clinical	  manifestations	  
Angina	  may	  result	  from	  increased	  myocardial	  oxygen	  demand.	  Angina	  may	  occur	  with	  or	  without	   coronary	   artery	   disease	   due	   to	   the	   pathophysiological	   process	   of	   reduced	  coronary	  perfusion	  outlined	  earlier.	  	  
Investigation	   with	   an	   electrocardiogram	   (ECG)	   may	   reveal	   LVH,	   however	   there	   are	  several	  confounding	  factors	  such	  as	  age,	  gender,	  race,	  body	  habitus	  etc	  (Hancock,	  Deal	  et	  al.	  2009).	  A	  tall	  R	  wave	  (>	  25mm)	  in	  leads	  V5	  and	  V6	  and	  a	  deep	  S	  wave	  in	  leads	  V1	  or	  V2	  suggests	  LVH.	  	  
1.3.3 Echocardiographic	  quantification	  
The	  widespread	  use	  of	  echocardiography	  and	  more	  recently	   its	  reproducibility	  due	   to	  the	  technological	  advances	  of	   this	  technique	  has	  allowed	  this	  mode	  of	   investigation	  to	  be	   a	   reasonable	   choice	   to	   quantify	   LVH	   accurately.	   Measuring	   LV	   dimensions;	   inter-­‐
	  1-­‐21	  
ventricular	  septal	  diameter	  (IVSd)	  and	  left	  ventricular	  posterior	  wall	  diameter	  (LVPWd)	  at	  end	  diastole	  can	  assess	  LVH	  crudely	  (Table	  1-­‐2).	  	  	  	  
A	  more	  accurate	  quantification	  of	  LVH	  can	  be	  made	  by	  estimating	  left	  ventricular	  mass	  (LVM),	   assuming	   that	   LVM	   increases	   with	   LVH	   (Table	   1-­‐2).	   This	   requires	   the	  measurement	  of	  left	  ventricular	  end	  diastolic	  diameter	  (LVIDd)	  in	  addition	  to	  lVSd	  and	  LVPWd.	  The	  algorithms	  used	  to	  calculate	  LVM	  initially	  estimates	  LV	  cavity	  volume	  and	  subtracts	  this	  from	  the	  volume	  enclosed	  by	  the	  LV	  epicardium	  (Swamy	  and	  Lang	  2010).	  This	   gives	   the	   LV	   volume,	  which	   is	  multiplied	   by	   the	  muscle	   density	   to	   calculate	   the	  LVM.	  More	  recently	  3D	  echocardiography	  has	  made	  this	  assessment	  less	  subjective	  and	  has	   eliminated	   the	   2D	   limitations	   of	   LV	   foreshortening,	   technical	   error	   and	   other	  geometric	   assumptions.	  However	  2D	  echo	   remains	   the	  more	  widely	  used	  modality	   to	  assess	  LV	  dimensions.	  Cardiac	  Magnetic	  Resonance	  (CMR)	  has	  become	  more	  frequently	  used	   due	   to	   its	   advantages	   in	   accurately	   quantifying	   LVM	   with	   good	   reproducibility	  (Bluemke,	  Kronmal	  et	  al.	  2008).	  However	  CMR	  is	  associated	  with	  greater	  cost	  and	  is	  less	  practical	  compared	  to	  2D	  echo	  due	  to	  the	  space	  and	  equipment	  required.	  	  
Table	  1-­‐2	  2D	  Echocardiographic	  quantification	  of	  LVH	  
Left	  ventricular	  mass	  index	  can	  be	  calculated	  by	  the	  following	  equation:	  -­‐	  
LVMI	  (g/m2)	  =	  (1.04[(IVSd	  +	  LVIDd	  +	  LVPWd)3	  –	  LVID3]	  –	  14g)	  /	  Body	  surface	  area	  
	   Mild	   Moderate	   Severe	  
	   Men	   Women	   Men	   Women	   Men	   Women	  
IVSd	  (cm)	   1.1-­‐1.3	   1.0-­‐1.2	   1.4-­‐1.6	   1.3-­‐1.5	   ≥	  1.7	   ≥	  1.6	  
LVPWd	  (cm)	   1.1-­‐1.3	   1.0-­‐1.2	   1.4-­‐1.6	   1.3-­‐1.5	   ≥	  1.7	   ≥	  1.6	  
LV	  mass/BSA,	  (g/m2)	   103-­‐116	   89-­‐100	   117-­‐130	   101-­‐112	   ≥	  131	   ≥	  112	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This	   formulae	   was	   initially	   described	   and	   validated	   by	   Devereux	   and	   colleagues	  (Devereux	  and	  Reichek	  1977;	  Devereux,	  Alonso	  et	  al.	  1986),	  who	  described	  that	  LVMI	  was	  considered	  increased	  if	  it	  was	  >	  134g/m2	  in	  men	  and	  >	  110g/m2	  in	  women.	  	  	  
1.3.4 Metabolism	  in	  LVH	  
Metabolism	  and	  substrate	  utilisation	   in	   the	  hypertrophied	  heart	   is	  different	   to	   that	  of	  the	   non-­‐LVH	   heart.	   It	   has	   been	   implicated	   that	   such	   alterations,	   including	   the	  metabolism	   of	   glucose	   is	   a	   contributing	   factor	   to	   the	   pathophysiology	   of	   the	   cardiac	  hypertrophy	   (Cunningham,	   Apstein	   et	   al.	   1990;	   Gaasch,	   Zile	   et	   al.	   1990).	   Allard	   and	  colleagues	   have	   demonstrated	   that	   glycolysis	   is	   accelerated	   in	   hypertrophied	   hearts	  (Allard,	   Schonekess	   et	   al.	   1994)	   and	   lactate	   production	   is	   greater	   in	   hypertrophied	  hearts	   during	   hypoxia	   and	   ischaemia	   (Anderson,	   Allard	   et	   al.	   1990),	   supporting	   the	  theory	   that	   glycolytic	   capacity	   is	   enhanced	   in	   hypertrophy.	   To	   validate	   this	   further	  Allard	   and	   colleagues	   performed	   a	   series	   of	   animal	   studies	   to	   assess	   the	   extent	   of	  glycogen	   turnover	   in	   hypertrophy	   and	   found	   that	   glycogen	   metabolism	   contributes	  significantly	  to	  myocardial	  ATP	  production	  in	  hypertrophy	  and	  is	  similar	  to	  the	  normal	  heart,	   but	   overall	   glucose	   oxidation	   may	   be	   impaired	   (Allard,	   Henning	   et	   al.	   1997)	  including	   an	   alteration	   in	   the	   exogenous	   glucose	  metabolism;	   increased	   glycolysis	   of	  exogenous	   glucose	   and	   decreased	   exogenous	   glucose	   oxidation.	   The	   increased	  glycolysis	  but	  decreased	  or	  no	  change	  in	  glucose	  oxidation	  causes	  an	  uncoupling	  effect	  of	   glucose	  metabolism	  and	  has	  been	   supported	  by	   a	  number	  of	   other	   studies	   (Allard,	  Schonekess	  et	  al.	  1994;	  Wambolt,	  Henning	  et	  al.	  1999)	  
In	   hypertrophy,	   the	   fuel	   preference	   tends	   to	   switch	   back	   towards	   a	   foetal	   metabolic	  pattern	  with	  reliance	  on	  glucose	  metabolism	  (Razeghi,	  Young	  et	  al.	  2001;	  Kolwicz	  and	  
	  1-­‐23	  
Tian	   2011).	   With	   an	   accelerated	   glycolytic	   rate	   there	   is	   a	   greater	   quantity	   of	   NADH	  produced	  from	  glycolysis	  and	  is	  shuttled	  through	  the	  malate-­‐aspartate	  shuttle	  (Kolwicz	  and	  Tian	  2011).	  	  Despite	  these	  findings	  the	  overall	  rate	  of	  lactate	  oxidation	  is	  the	  same	  as	   in	   non-­‐hypertrophied	   hearts	   and	   conversely,	   the	   rate	   of	   fatty	   acid	   oxidation	   is	  decreased	  (Allard,	  Schonekess	  et	  al.	  1994).	  However,	   there	   is	  now	  growing	  consensus	  that	  there	  is	  an	  overall	  downregulation	  of	  all	  metabolic	  processes	  associated	  with	  LVH.	  	  
Additionally,	  there	  is	  evidence	  to	  suggest	  that	  anaplerosis,	  a	  process	  whereby	  pyruvate	  enters	  accessory	  pathways	  to	  supply	  carbon	  based	  substrates	  to	  the	  CAC	  is	  enhanced	  in	  hypertrophy	   (Sorokina,	   O'Donnell	   et	   al.	   2007;	   Pound,	   Sorokina	   et	   al.	   2009).	   This	  however	  reduces	  the	  efficiency	  of	  ATP	  production	  from	  pyruvate.	  	  
The	  increased	  reliance	  in	  glucose	  following	  hypertrophy	  is	  likely	  to	  be	  a	  compensatory	  mechanism	   to	   the	   down-­‐regulation	   of	   fatty	   acid	   oxidation	   and	   oxidative	   metabolism	  present	   in	   the	   hypertrophied	   heart.	   Animal	   studies	   evaluating	   the	   role	   of	   key	  master	  transcriptional	   regulators	   such	   as	   peroxisome	   proliferator-­‐activator	   receptor	   alpha	  (PPARα)	  and	  peroxisome	  proliferator-­‐activator	  receptor	  gamma	  co-­‐activator-­‐1	  (PGC-­‐1)	  have	   shown	   these	   to	   be	   down	   regulated	   in	   hypertrophy	   (Barger,	   Brandt	   et	   al.	   2000;	  Lehman	   and	   Kelly	   2002;	   Arany,	   Novikov	   et	   al.	   2006).	   Furthermore	   there	   is	   down-­‐regulation	  of	  CPT-­‐1	   (Depre,	   Shipley	  et	   al.	  1998;	  Sorokina,	  O'Donnell	   et	   al.	   2007).	  This	  overall	  down-­‐regulation	  of	  key	  pathways	  required	  for	  FFA	  oxidation	  results	  in	  reduced	  FFA	  metabolism.	   Furthermore	   the	   intracellular	   energy	   sensor,	   AMPK	   is	   activated	   and	  shown	  to	  be	  a	  stimulus	  for	  glucose	  uptake	  and	  enhances	  glycolysis	  by	  activation	  of	  PFK	  (Marsin,	  Bertrand	  et	  al.	  2000).	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The	  adaptive	  responses	  that	  result	   in	  an	   increased	  glycolytic	   flux	  does	  not	  necessarily	  lead	  to	  heart	  failure,	  providing	  there	  is	  sufficient	  fuel	  for	  oxidative	  metabolism	  (Kolwicz	  and	  Tian	   2011).	  However	   further	   animal	   and	   clinical	   studies	   are	   required	   to	   test	   the	  capabilities	  of	  the	  pathologically	  hypertrophied	  heart	  under	  stressors	  of	  ischaemia	  and	  reperfusion.	  
1.4 Ischaemia	  and	  reperfusion	  	  
1.4.1 Ischaemia	  	  
Ischaemia	  to	   the	  myocardium	  can	  be	  partial	  or	  complete.	   In	  partial	   ischaemia	  there	   is	  limited	   blood	   flow	   to	   the	   ischaemic	   region;	   reduced	   flow	   of	   blood	   through	   narrowed	  coronary	   circulation	   or	   alternative	   source	   of	   coronary	   perfusion	   albeit	   reduced,	   from	  collateral	   circulations.	  Thus	   in	   ischaemic	  heart	  disease	   there	   is	  partial	   ischaemia	  until	  total	   occlusion	   occurs,	   to	   a	   particular	   territory	   of	   myocardium	   that	   does	   not	   have	  collateral	  perfusion.	  	  
During	  partial	  ischaemia	  there	  is	  reduced	  tissue	  oxygen	  tension	  resulting	  in	  hypoxia.	  In	  complete	  ischaemia	  there	  is	  no	  tissue	  oxygenation	  and	  hence	  anoxia	  ensues	  (Opie	  and	  Lopaschuk	  2004).	  The	  extent	  of	  myocardial	  metabolism	  during	  ischaemia	  is	  dependent	  on	  the	  degree	  of	  ischaemia	  present.	  During	  cardiac	  surgery,	  once	  the	  aortic	  cross	  clamp	  is	   placed,	   there	   is	   no	   coronary	   blood	   flow	   hence	   the	   myocardium	   is	   completely	  ischaemic.	  	  
1.4.1.1 Partial	  ischaemia	  	  Partial	   ischaemia	   is	   associated	  with	   a	   reduction	   in	  mechanical	  work	   and	  depletion	   of	  high-­‐energy	  phosphates	  such	  creatine	  phosphate,	  with	  the	  production	  of	  lactate	  during	  metabolism.	  However	  over	  time	  (30-­‐90mins),	  lactate	  output	  decreases	  (Fedele,	  Gewirtz	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et	   al.	   1988),	   and	   there	   is	   regeneration	   of	   	   phosphocreatine	   concentrations	   (Pantely,	  Malone	  et	  al.	  1990),	  yet	  contractile	  work	  does	  not	  return	  back	   to	  normal.	  Expectantly	  normal	   contractile	   work	   is	   regained	   once	   normal	   coronary	   perfusion	   is	   restored.	  Therefore	   in	   periods	   of	   partial	   ischaemia	   there	   is	   a	   downregulation	   of	   the	  metabolic	  needs	  of	  the	  myocardium	  to	  maintain	  myocardial	  viability,	  thereby	  resetting	  the	  oxygen	  supply/demand	  ratio.	  	  This	  period	  of	  transient	  contractile	  dysfunction	  is	  referred	  to	  as	  myocardial	  hibernation	  (Rahimtoola	  1985).	  	  
During	   this	   period	   of	   partial	   ischaemia,	   the	  main	   fuel	   of	   the	   heart	   is	   free	   fatty	   acids.	  Liedtke	  et	  al	  showed	  in	  an	  animal	  model	  with	  50%	  reduction	  in	  coronary	  flow,	  that	  FFA	  oxidation	  supplies	  most	  of	  the	  energy	  of	  ATP	  synthesis	  during	  ischaemia	  (Liedtke,	  Nellis	  et	  al.	  1978;	  Liedtke,	  Nellis	  et	  al.	  1984).	  	  	  
1.4.1.2 Complete	  ischaemia	  	  If	   ischaemia	   is	   induced	   for	   a	   long	   period	   of	   time,	   there	   is	   an	   increase	   in	   lactate	  accumulation,	  contractile	  dysfunction	  and	  this	  eventually	   leads	  to	  myocardial	  necrosis	  and	  infarction	  (Stanley,	  Lopaschuk	  et	  al.	  1997).	  	  
Complete	  lack	  of	  coronary	  perfusion	  and	  failure	  to	  eliminate	  by-­‐products	  of	  metabolism	  results	   in	   cumulative	   accumulation	   of	   lactate	   causing	   a	   rise	   in	   intracellular	   acidosis.	  Furthermore	  there	  is	  complete	  dependence	  on	  anaerobic	  metabolism	  using	  endogenous	  substrates,	  hence	  a	  shift	  towards	  glycogen	  utilisation	  (Stanley,	  Lopaschuk	  et	  al.	  1997).	  Anaerobic	   glycolysis	   is	   controlled	   by	   2	   main	   enzymes,	   PFK	   and	   glyceraldehyde	   3-­‐phosphate	  dehydrogenase.	  PFK	  is	  sensitive	  to	  low	  molecular	  weight	  metabolites	  such	  as	  ATP,	  ADP,	  and	  AMP.	  During	  ischaemia,	  the	  level	  of	  ATP	  falls	  and	  those	  of	  ADP	  and	  AMP	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increase,	  which	   stimulates	   PFK	   resulting	   in	   an	   increase	   of	   anaerobic	   glycolysis	   (Opie	  and	  Lopaschuk	  2004).	  	  
However,	  the	  increasing	  acidotic	  environment	  secondary	  to	  a	  rise	  in	  H+	  inhibits	  PFK	  and	  in	  turn,	  anaerobic	  glycolysis.	  Furthermore	  the	  depleting	  levels	  of	  glycogen	  and	  glucose	  delivery	  add	  further	  insult	  to	  this	  limited	  process	  and	  therefore	  anaerobic	  glycolysis	  is	  halted.	  The	  acidotic	  environment	  and	   increasing	   lactate	   levels	   secondary	   to	  anaerobic	  glycolysis	   also	   affects	   glyceraldehyde	   3-­‐phosphate	   dehydrogenase.	   Therefore	  metabolism	  in	  complete	  ischemia	  is	  short-­‐lived	  due	  to	  this	  vicious	  cycle	  of	  events.	  
These	  effects	  of	  ischaemia	  lead	  to	  failure	  of	  internal	  ion	  regulators;	  ATP	  dependent	  Ca2+	  pumps	  within	  the	  sarcoplasmic	  reticulum	  and	  plasma	  membrane	  fail.	  Increased	  acidosis	  activates	   the	   Na+-­‐H+	   exchange	   within	   the	   plasma	   membrane.	   A	   resultant	   increase	   in	  intracellular	   Na+	   activates	   the	   Na+-­‐Ca2+	   pumps	  within	   the	   plasma	  membrane	   causing	  intracellular	  calcium	  overload.	  	  
1.4.2 Reperfusion	  	  
Reperfusion	   refers	   to	   the	   return	   of	   blood	   to	   a	   previously	   ischaemic	   tissue.	   During	  cardiac	  surgery	  ischaemia	  is	  electively	  enforced	  (for	  a	  variable	  period)	  and	  reperfusion	  occurs	  on	  restoration	  of	  coronary	  blood	  flow.	  On	  reperfusion,	  the	  unwanted	  metabolites	  built	   up	   during	   the	   period	   of	   ischaemia	   and	   cardioplegia	   washout	   via	   the	   coronary	  sinus.	  Reperfusion	  is	  vital	  to	  prevent	  irreversible	  ischaemic	  injury.	  However	  it	  is	  evident	  that	  reperfusion	  too	  can	  exacerbate	  the	  pre-­‐existing	  ischaemic	  injury,	  and	  cause	  further	  damage,	  known	  as	  reperfusion	  injury.	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1.4.2.1 Reperfusion	  injury	  Reperfusion	   injury	   cannot	   be	   taken	   in	   isolation,	   but	   is	   coupled	   and	   associated	   to	   the	  pre-­‐existing	   damage	   caused	   during	   ischaemia	   dependent	   on	   the	   length	   of	   ischaemia.	  Reperfusion	  injury	  is	  primarily	  associated	  with	  the	  re-­‐introduction	  of	  oxygen	  hence	  the	  oxygen	  paradox	  (Hearse,	  Humphrey	  et	  al.	  1973).	  This	  theory	  was	  further	  consolidated	  when	  Hearse	  et	  al	  demonstrated	  a	   change	   in	   the	  ultrastructure	  of	   the	  myocardial	   cell	  and	   decline	   of	   its	   function	   with	   the	   introduction	   of	   oxygen	   to	   anoxic	   myocardium	  (Hearse,	   Humphrey	   et	   al.	   1975).	   A	   number	   of	   other	   experimental	   studies	   have	  supported	   the	   concept	   that	   Reactive	   Oxygen	   Species	   (ROS)	   and	   free	   radicals	   are	   the	  primary	   component	   of	   reperfusion	   injury	   (Lucchesi	   2001).	  Re-­‐oxygenation,	   inevitable	  with	  reperfusion	  causes	  the	  release	  of	  reactive	  oxygen	  species	  and	  oxygen	  free	  radicals	  such	   as	   O2-­‐	   which	   reacts	   with	   hydrogen	   peroxide	   (H2O2)	   to	   form	   a	  more	   potent	   free	  radical,	  OH.	  Free	  radicals	  can	  transfer	  easily	  between	  cell	  membranes,	  are	  cytotoxic,	  and	  all	   components	   of	   the	   cell	   are	   susceptible	   to	   attack	   including	   lipids	   within	   the	   cell	  membrane	   and	  membrane	   proteins.	   This	   oxidative	   stress	   results	   in	   cell	   damage	   and	  causes	  reduced	  cell	  viability.	  It	  is	  thought	  that	  the	  non-­‐uniform	  introduction	  of	  oxygen	  during	   reperfusion	   makes	   it	   more	   likely	   for	   ROS	   and	   oxygen	   derived	   free	   radical	  formation	  (Lucchesi	  2001).	  Endogenous	  antioxidants	  and	  free	  radical	  scavengers	  such	  as	   superoxide	   dismutase,	   catalase	   and	   glutathione	   peroxidase	   are	   able	   to	   reduce	   the	  extent	   of	   cell	   injury	   due	   to	   ROS,	   but	   are	   eventually	   overwhelmed	   by	   the	   extent	   of	  oxidative	  stress	  and	  are	  hence	  unable	  to	  provide	  adequate	  protection.	  	  
In	  addition	  to	  oxidative	  stress	  through	  ROS	  and	  oxygen	  free	  radicals,	  reperfusion	  injury	  is	   also	   due	   to	   the	   neutrophil	   mediated	   tissue	   damage.	   Neutrophils	   are	   activated	   by	  chemotactic	   factors	   i.e.	   C5a,	   IL-­‐8	   and	   platelet	   activating	   factors.	   Once	   activated	   the	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neutrophils	   can	   cause	   further	   injury	   by	   forming	   oxygen	   derived	   free	   radicals	   and	  release	   of	   cytotoxic	   lysosomal	   enzymes.	   A	   vicious	   cycle	   ensues	   where	   free	   radical	  formation	  aggregates	  more	  neutrophils	  that	  cause	  small	  capillaries	  to	  plug	  off	  (Engler,	  Dahlgren	   et	   al.	   1986;	   Engler,	   Dahlgren	   et	   al.	   1986)	   resulting	   in	   the	   no-­‐reflow	  phenomenon,	   which	   in	   turn	   contributes	   to	   the	   release	   of	   more	   ROS	   and	   greater	  oxidative	  stress.	  Further	  insult	  to	  injury	  is	  caused	  by	  the	  activation	  of	  platelets	  from	  the	  release	  of	  platelet	  activating	  factors	  causing	  further	  decrease	  in	  perfusion.	  	  	  
Moreover,	  the	  activation	  of	  the	  complement	  system	  plays	  a	  further	  role	  in	  reperfusion	  injury.	   Ischaemia	   induces	  the	  activation	  of	   the	  complement	  pathway	  and	  the	  extent	  of	  activation	   may	   depend	   on	   the	   length	   of	   ischaemia.	   This	   complement	   activation	   is	  present	   into	  and	  during	  reperfusion.	  Activation	  of	  the	  complement	  pathway	  generates	  anaphylatoxins	   C3a,	   C4a	   and	  C5a,	  which	   cause	   an	   inflammatory	   reaction	   due	   to	   their	  chemo-­‐attractant	   properties,	   causing	   further	   damage	   to	   the	   injured	   tissue	   through	  alteration	   in	   vascular	   permeability,	   smooth	  muscle	   contraction	   and	  histamine	   release	  (Lucchesi	  2001).	   	  C5a	   is	  a	  potent	  neutrophil	  activating	  peptide.	   In	  animal	  models	  C5a	  concentration	  is	  higher	  during	  reperfusion	  and	  is	  associated	  with	  increased	  neutrophil	  accumulation	   within	   the	   ischaemic	   zone	   (Shandelya,	   Kuppusamy	   et	   al.	   1993;	   Ivey,	  Williams	  et	  al.	  1995).	  It	  is	  evident	  that	  complement	  activation	  also	  results	  in	  activation	  of	   neutrophils	   enhancing	   the	   neutrophil	   dependent	   tissue	   injury	   (Lucchesi	   2001).	  Furthermore	   free	   radical	   generation	   during	   reperfusion	   activates	   the	   complement	  system	  and	  its	  derived	  mediators	  of	  injury.	  	  
A	  probable	  common	  pathway	  to	  cell	  damage	  and	  injury	   is	  associated	  to	  the	  activity	  of	  the	  mitochondrial	  permeability	  transition	  pore	  (mPTP);	  formed	  by	  a	  complex	  of	  voltage	  dependent	   anion	   channels	   (VDAC),	   adenine	   nucleotide	   translocase	   (ANT)	   and	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cyclophillin-­‐D	   (CyP-­‐d).	   This	   pore	   is	   thought	   to	   exist	   between	   the	   inner	   and	   outer	  mitochondrial	  membranes.	   	  Calcium	  overload	  causes	  opening	  of	   the	  mPTP	  (Crompton	  1999).	   Intracellular	   acidosis,	   increased	   concentration	   of	   inorganic	   phosphates,	   loss	   of	  ATP,	   loss	   of	   adenine	   nucleotides	   all	   influence	   mPTP	   opening.	   Opening	   of	   the	   mPTP	  results	  in	  loss	  of	  the	  inner	  membrane	  potential	  causing	  free	  diffusion	  of	  solutes	  leading	  to	  loss	  of	  the	  ionic	  haemostasis.	  Furthermore	  mPTP	  opening	  causes	  the	  mitochondrion	  to	  become	  uncoupled	  (Zorov,	  Filburn	  et	  al.	  2000;	  Halestrap,	  Clarke	  et	  al.	  2004)	  resulting	  in	   mitochondrial	   ATP	   hydrolysis	   (Crompton	   1999).	   This	   initiates	   a	   vicious	   cycle	   of	  impaired	   energy	  metabolism,	   deregulation	   of	   calcium	   haemostasis	   leading	   to	   further	  mPTP	  opening,	  ultimately	   leading	  to	  necrotic	  cell	  death.	   In	  addition	  to	  necrosis,	  mPTP	  opening	  leads	  to	  release	  of	  cytochrome-­‐c	  and	  other	  pro-­‐apoptotic	  molecules.	  Therefore	  even	  after	  mPTP	  closure,	  cell	  death	  continues	  down	  an	  apoptotic	  pathway	  rather	  than	  a	  necrotic	  pathway	  (Halestrap,	  Clarke	  et	  al.	  2004).	  
1.4.2.2 Effects	  of	  ischaemia-­‐reperfusion	  injury	  	  Reperfusion	  injury	  causes	  cell	  swelling	  and	  contraction	  band	  necrosis	  and	  is	  associated	  with	  high	  intracellular	  calcium	  concentrations	  (Black,	  Gralinski	  et	  al.	  1994).	  The	  extent	  of	   irreversible	   tissue	   injury	   due	   to	   reperfusion	   is	   dependent	   on	   the	   duration	   of	   the	  initial	   ischaemic	   insult.	   If	   the	   ischaemic	   insult	   is	   short	   and	   has	   not	   resulted	   in	  irreversible	   injury,	  myocardial	   tissue	  necrosis	   is	  not	  evident	  on	   reperfusion.	  However	  there	   may	   be	   a	   period	   of	   reduced	   myocardial	   contractility	   known	   as	   myocardial	  stunning.	  This	  is	  reversible	  and	  improves	  with	  time.	  	  
As	   a	   result	   of	   the	   ischaemia-­‐reperfusion	   injury	   intracellular	   calcium	   overload	   ensues	  (Shandelya,	   Kuppusamy	   et	   al.	   1993;	   Ivey,	  Williams	   et	   al.	   1995).	   During	   the	   period	   of	  ischaemia	   there	   is	   depletion	   of	   ATP	   and	   high-­‐energy	   phosphates.	   This	   stimulates	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anaerobic	   glycolysis	   causing	   a	   gradual	   increase	   in	   intracellular	   acidosis	   and	   lactate	  production.	   Intracellular	   acidosis	   is	   counteracted	   by	   activation	   of	   the	   Na+-­‐H+	   pump,	  which	  would	  increase	  the	  intracellular	  Na+	  concentration	  (Lazdunski,	  Frelin	  et	  al.	  1985).	  Lack	   of	   ATP	   would	   inhibit	   the	   Na+-­‐K+	   ATPase	   activity,	   which	   would	   increase	   the	  intracellular	  Na+	  concentration	  further	  (van	  Echteld,	  Kirkels	  et	  al.	  1991).	  This	  causes	  the	  Na+-­‐Ca+	  exchange	  to	  work	  in	  reverse,	  to	  expel	  the	  high	  intracellular	  Na+,	  increasing	  the	  intracellular	  concentration	  of	  calcium	  (Stone,	  Darley-­‐Usmar	  et	  al.	  1989).	  Furthermore,	  during	  ischaemia	  long	  chain	  fatty	  acids	  accumulate	  and	  incorporate	  into	  the	  membrane;	  reducing	  membrane	  stability	  and	  increasing	  permeability,	  resulting	  in	  calcium	  overload	  (Wu	   and	   Corr	   1992).	  Moreover	   the	   storage	   and	   release	   of	   Ca+	   from	   the	   sarcolemmal	  membrane	  and	  sarcoplasmic	  reticulum	  is	  affected	  during	  ischaemia	  due	  to	  deficiencies	  in	   ATP.	   This	   depressed	   mitochondrial	   state	   leads	   to	   calcium	   overload	   (Osada,	  Netticadan	  et	  al.	  1998).	  	  
The	   processes	   that	   lead	   to	   calcium	   overload	   occur	   during	   ischaemia	   and	   are	   made	  worse	   during	   reperfusion	   (Brooks,	   Conrad	   et	   al.	   1995;	   Meissner	   and	   Morgan	   1995;	  Dhalla,	   Temsah	   et	   al.	   2001).	   Calcium	   overload	   causes	   cardiac	   dysfunction,	   cellular	  damage	  and	  cardiac	  contracture	  (Steenbergen,	  Murphy	  et	  al.	  1990;	  Billman,	  McIlroy	  et	  al.	  1991)	  and	  is	  therefore	  detrimental	  during	  reperfusion.	  	  
There	   is	   evidence	   to	   suggest	   that	  oxidative	   stress	  due	   to	  oxygen	  derived	   free	   radicals	  and	   ROS	   attack	   calcium	   cycling	   proteins	   and	   other	   structures	   involved	   in	   the	  homeostasis	   of	   intracellular	   calcium	   i.e.	   sarcoplasmic	   reticulum,	   sarcolemmal	  membrane,	   Ca2+	   pump	   ATPase,	   L-­‐type	   Ca2+	   channels	   and	   other	   calcium	   regulating	  pumps	  (Dhalla,	  Temsah	  et	  al.	  2001)	  leading	  to	  calcium	  overload.	  Increased	  intracellular	  calcium	  activates	  proteases	  and	  phospholipases	   that	  are	   involved	  with	  changes	   in	   the	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structure	   of	   the	   cardiomyocyte.	  With	   time,	   this	   leads	   to	   increased	   calcium	  within	   the	  mitochondrion	   resulting	   in	   diminished	   energy	   production.	   These	   changes	   translate	  clinically	   to	   myocardial	   dysfunction	   due	   to	   myocardial	   cell	   damage	   and	   metabolic	  derangement.	  	  	  
1.4.2.3 Clinical	  manifestation	  of	  ischaemia-­‐reperfusion	  injury	  	  Clinically,	   reperfusion	   injury	   causing	   four	   types	   of	   cardiac	   dysfunction:	   myocardial	  stunning,	   no-­‐reflow	   phenomenon,	   cardiac	   arrhythmias	   and	   lethal	   reperfusion	   injury	  (Yellon	  and	  Hausenloy	  2007).	  Stunning	  refers	  to	  the	  a	  recoverable	  state	  of	  mechanical	  dysfunction,	   despite	   the	   absence	   of	   irreversible	   injury	   and	   despite	   restoration	   of	  coronary	   blood	   flow	   (Braunwald	   and	   Kloner	   1982).	   No-­‐reflow	   phenomenon	   is	   the	  inability	   to	   restore	   blood	   flow	   to	   the	   ischaemic	   territory	   secondary	   to	   impedance	   of	  microvascular	  blood	  flow	  (Ito	  2006).	  Arrhythmias	  can	  be	   life	  threatening	  but	  effective	  treatments	   exist	   (Manning	   and	   Hearse	   1984).	   All	   the	   above	   processes	   that	   include;	  mitochondrial	  calcium	  overload,	  oxidative	  stress,	  restoration	  of	  pH,	  and	  ATP	  depletion	  contribute	   to	   lethal	   reperfusion	   injury	   (Yellon	   and	   Hausenloy	   2007).	   Targeting	   the	  common	  final	  pathway	  to	  cell	  injury	  (mPTP),	  activating	  the	  RISK	  pathway	  and	  exploring	  ischaemic	  pre	  and	  postconditioning	  remain	  potential	  avenues	  to	  limit	  lethal	  reperfusion	  injury,	  however	  the	  latter	  mechanisms	  are	  beyond	  the	  scope	  of	  this	  thesis.	  	  
1.4.3 Cell	  signalling	  during	  ischaemia-­‐reperfusion	  	  
During	   ischaemia	   there	   is	   recruitment	   of	   glucose	   transporters	   GLUT-­‐1	   and	   GLUT-­‐4,	  which	   increases	   the	   uptake	   of	   glucose	   across	   the	   cell	   membrane.	   There	   is	   also	   an	  acceleration	   of	   glycolytic	   flux	   due	   to	   activation	   of	   PFK-­‐1	   secondary	   to	   an	   increase	   in	  AMP	  and	  decrease	  in	  ATP	  during	  ischaemia.	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During	  reperfusion,	  FFA	  oxidation	  is	  preferred	  over	  glucose.	  There	  is	  a	  decreased	  level	  of	  malonyl-­‐CoA	  hence	  limited	  inhibition	  of	  CPT-­‐1	  activity.	  Malonyl-­‐CoA	  is	  reduced	  due	  to	   the	   inhibition	   of	   ACC.	   Inhibition	   of	   ACC	   is	   by	   a	   specific	   AMP-­‐dependent	   kinase	  (AMPK)	   activated	  by	   the	  AMP	  accumulated	  during	   ischaemia	   (Kudo,	  Barr	   et	   al.	   1995;	  Kudo,	  Gillespie	  et	  al.	  1996).	  	  
1.4.4 Ischaemia	  and	  hypertrophy	  	  
The	  presence	   of	   LVH	   is	   associated	  with	   greater	   susceptibility	   to	   ischaemia	   (Otterstad	  1993;	   Otterstad,	   Davies	   et	   al.	   1993;	   Maron,	   Olivotto	   et	   al.	   2009).	   This	   renders	   this	  population	   of	   patients	   undergoing	   cardiac	   surgery,	   at	   a	   higher	   risk	   of	   ischaemia-­‐reperfusion	  injury.	  However	  there	  is	  considerable	  variation	  to	  the	  susceptibility	  of	  the	  hypertrophic	   heart	   to	   ischaemia.	   A	   multitude	   of	   factors	   influence	   this	   and	   include,	  associated	  abnormalities	  in	  coronary	  vasculature,	  previous	  ischaemic	  injury	  before	  the	  cardiac	   surgical	   ischaemic	   insult,	   the	   consequences	   of	   ventricular	   fibrillation	   at	   the	  onset	   or	   during	   ischaemia	   or	   inherent	   biochemical	   and	   metabolic	   derangements	  present	  with	  hypertrophy	  (Sink,	  Pellom	  et	  al.	  1981;	  Peyton,	  Jones	  et	  al.	  1982).	  Gaasch	  et	  al	  showed	  that	  hypertrophied	  hearts	  in	  dogs,	  were	  particularly	  vulnerable	  to	  ischaemia	  if	   they	   were	   in	   a	   failing	   state	   and	   have	   a	   reduced	   capacity	   for	   anaerobic	   glycolysis	  contributing	  to	  diastolic	  dysfunction	  (Gaasch,	  Zile	  et	  al.	  1990).	  
Friehs	   and	   colleagues	   in	   an	   animal	   model	   of	   pressure	   overload	   hypertrophy	  demonstrated	   that	   glucose	   uptake	   was	   impaired	   pre-­‐ischaemia	   and	   remained	   lower	  during	   re-­‐perfusion	   (Friehs,	   Cao-­‐Danh	   et	   al.	   2005);	   related	   to	   restricted	   GLUT-­‐4	  (molecule	   that	   augments	   glucose	   uptake)	   translocation	   due	   to	   impaired	   insulin	  signalling	   causing	   reduced	   recovery	   of	   contractile	   function.	   Therefore	   the	   altered	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reliance	   on	   glucose	   metabolism	   is	   linked	   to	   the	   susceptibility	   of	   the	   hypertrophied	  myocardium	  to	  ischaemia.	  	  
The	  effects	  of	   ischaemia-­‐reperfusion	   seen	   in	  normal	  hearts	   (outlined	   in	   sections	  1.4.1	  and	  1.4.2)	  are	  exaggerated	  in	  hypertrophied	  hearts	  and	  include	  accelerated	  loss	  of	  high-­‐energy	   phosphates,	   greater	   accumulation	   of	   tissue	   lactate	   and	   acidosis,	   accelerated	  calcium	   overload	   and	   ischaemic	   contracture	   (Allard,	   Flint	   et	   al.	   1994;	   Friehs	   and	   del	  Nido	  2003).	  This	  susceptibility	  to	  ischaemia-­‐reperfusion	  could	  also	  be	  secondary	  to	  the	  pathological	  alteration	  in	  the	  structure	  and	  composition	  of	  the	  left	  ventricle;	  changes	  to	  the	   collagen	   matrix	   (thickening	   of	   the	   collagen	   layer),	   increase	   in	   diffusion	   distance	  between	   myocytes	   and	   vessels,	   alteration	   in	   the	   coronary	   circulation	   and	   decreased	  myocardial	   capillary	   density.	   Friehs	   and	   colleagues	   have	   shown	   an	   increased	  vulnerability	   to	   ischaemia/reperfusion	   associated	   with	   diminished	   microvascular	  supply	  (Allard,	  Flint	  et	  al.	  1994;	  Friehs	  and	  del	  Nido	  2003).	  Diminished	  microvascular	  density	   can	   affect	   overall	   substrate	   utilisation;	   experimental	   work	   has	   shown	   that	  vascular	  endothelial	  growth	  factor	  can	  stimulate	  capillary	  growth	  and	  through	  this	  post	  ischaemic	  contractile	  function	  is	  preserved	  (Friehs	  and	  del	  Nido	  2003)	  
1.5 Cardiac	  surgery	  
Conventional	  cardiac	  surgery	  is	  performed	  on	  a	  still	  heart	  allowing	  a	  bloodless	  field	  and	  better	  surgical	  manipulation.	  This	  requires	  the	  heart	  to	  be	  arrested,	  commonly	  by	  using	  cardioplegia	  solution.	  During	  this	  period	  of	  elective	  cardiac	  arrest,	  the	  cardiopulmonary	  bypass	  machine	   takes	  over	   the	  work	  of	   the	  heart	   and	   supplies	  blood	   to	   the	  head	  and	  body.	  Once	  the	  surgical	  procedure	   is	  complete,	   the	  heart	   is	  reperfused	  and	  allowed	  to	  regain	  its	  function	  and	  cardiopulmonary	  bypass	  is	  discontinued.	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1.5.1 Patient	  demographics	  undergoing	  aortic	  valve	  replacement	  
Aortic	  valve	  replacement	  is	  a	  common	  cardiac	  procedure	  and	  over	  the	  last	  10	  years	  the	  demographic	  population	  of	  patients	  undergoing	  AVR	  in	  the	  UK	  continue	  to	  change.	  The	  SCTS	  6th	  National	  cardiac	  surgical	  database	  report	  has	  shown	  that	  there	  has	  been	  a	  50%	  increase	   in	   both	   isolated	   AVR	   and	   AVR+CABG	   procedures	   between	   2001	   to	   2008	  (Bridgewater	   and	   Keogh	   2009).	   Furthermore	   the	   average	   age	   of	   patients	   undergoing	  both	  procedures	  has	   increased	  over	   time;	   in	  2008	  mean	  age	  undergoing	   isolated	  AVR	  and	  combined	  AVR+ACBG	  was	  68	  and	  72	  years	  respectively.	  In	  addition	  the	  proportion	  of	  elderly	  patients	  has	  increased	  further.	  	  
The	  proportion	  of	  females	  undergoing	  AVR	  and	  AVR+CABG	  in	  the	  UK	  is	  40%	  and	  30%	  respectively	  (Bridgewater	  B,	  Keogh	  B	  et	  al.	  2008).	  This	  proportion	  has	  not	  changed	  over	  time.	  The	  majority	  of	  isolated	  AVR	  cases	  are	  performed	  on	  an	  elective	  basis	  (75%),	  with	  just	  2%	  being	  done	  as	  an	  emergency	  with	  the	  remaining	  being	  on	  an	  urgent	  basis.	  This	  proportion	   is	   similar	   for	   AVR+CABG	   surgery.	   The	   proportion	   of	   patients	   undergoing	  AVR	  for	  stenosis	  has	  not	  changed	  over	   time	  and	  stands	  at	  62%	  for	   isolated	  AVR,	  with	  16%	  being	  performed	  for	  regurgitation	  and	  the	  remainder	  consists	  of	  mixed	  disease.	  	  
The	   aortic	   valve	   can	   be	   replaced	  with	   either	   a	  mechanical	   or	   biological	   prosthesis	   or	  homograft.	   The	   latter	   is	   rare	   and	   only	   used	   in	   special	   circumstances.	   The	  majority	   of	  implanted	   valves	   tend	   to	   be	   biological	   with	   70%	   for	   an	   isolated	   AVR	   and	   82%	   for	   a	  combined	  AVR+CABG	  procedure.	  Between	  2004	  and	  2008	  there	  has	  been	  an	  increase	  in	  the	   use	   of	   biological	   prostheses.	   Typically	   a	   biological	   implant	   was	   reserved	   for	   the	  elderly	  patient	  but	  more	  recently	  there	  has	  been	  an	  increase	  in	  the	  number	  of	  biological	  implants	  being	  placed	   in	   the	  younger	  population	  overall,	  with	   the	  greatest	   increase	   in	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patients	   aged	   61-­‐65	   years	   (Bridgewater	   and	   Keogh	   2009).	   This	   could	   be	   due	   to	   the	  improved	  longevity	  of	  the	  modern	  biological	  valve.	  	  
1.5.2 Aortic	  valve	  replacement	  	  
Aortic	  valve	  replacement	  is	  an	  established	  procedure	  (Emery,	  Emery	  et	  al.	  2012)	  and	  is	  routinely	  performed	  in	  adult	  cardiac	  surgery.	  The	  principles	  and	  technique	  of	  an	  aortic	  valve	  replacement	  are	  outline	  in	  Appendix	  9.2.	  
1.5.3 Mortality	  associated	  with	  an	  aortic	  valve	  replacement	  	  
Mortality	  associated	  with	  an	  AVR	  is	  now	  considered	  to	  be	  low.	  In	  the	  United	  States	  the	  average	  peri-­‐operative	  mortality	  in	  the	  Society	  of	  Thoracic	  Surgeons	  (STS)	  database	  is	  2	  –	  3%	  for	  an	  isolated	  AVR	  and	  4	  –	  5%	  for	  a	  combined	  AVR	  plus	  CABG	  (Surgeons	  2012).	  This	  is	  variable	  in	  relation	  to	  the	  volume	  of	  work	  at	  each	  centre	  and	  in	  centres	  with	  low	  volume	  the	  mortality	  rates	  are	  33%	  higher	  (Birkmeyer,	  Siewers	  et	  al.	  2002).	  Goodney	  et	  al	   evaluated	   the	  Medicare	  data	   involving	  684	  US	  hospitals	   involving	  142,000	  patients	  and	  shows	  that	  in-­‐hospital	  mortality	  for	  AVR	  in	  patients	  >	  65	  years	  is	  8.8%	  (13%	  in	  low	  volume	  centres	  and	  6%	  in	  high	  volume	  centres)	  (Goodney,	  O'Connor	  et	  al.	  2003).	  	  
In	   the	   UK,	   a	   review	   of	   the	   data	   submitted	   to	   the	   Society	   for	   Cardiothoracic	   Surgery	  (SCTS)	   in	   Great	   Britain	   and	   Ireland	   over	   a	   5	   year	   period	   from	   2003	   showed	   that	   in-­‐hospital	  mortality	   for	   isolated	  AVR	  and	  combined	  AVR	  +	  CABG	   for	  England	  was	  2-­‐3%	  and	  4-­‐5%	  respectively	  in	  2008	  (Bridgewater	  and	  Keogh	  2009).	  	  	  
Increasing	  age	  has	  always	  been	  associated	  with	  a	  greater	  mortality	  and	  this	  is	  more	  so	  in	   a	   combined	   procedure.	   In	   patients	   >	   85	   years	   undergoing	   an	   isolated	   AVR	   and	  combined	   AVR	   +	   CABG	  mortality	   was	   5.5%	   and	   10.7%	   respectively	   between	   2004	   –	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2008	  (Bridgewater	  and	  Keogh	  2009).	  Gender	  in	  particular	  is	  associated	  as	  a	  risk	  factor	  for	  poor	  prognosis,	  with	   females	  having	  a	  higher	  mortality	   for	  both	   isolated	  AVR	  and	  AVR+CABG	  compared	  to	  males	  (3.2	  %	  and	  6.8%	  vs.	  2.6%	  and	  4.6%).	  	  	  
In	  the	  UK	  as	  seen	  from	  the	  SCTS	  database,	  mortality	   is	  associated	  with	  the	  urgency	  of	  the	   procedure	   with	   a	   proportional	   increase	   in	   mortality	   associated	   with	   urgent,	  emergent	   and	   salvage	   procedures	   for	   both	   isolated	   and	   combined	   procedures.	   An	  urgent	   AVR	   is	   associated	  with	   a	  mortality	   of	   4.9%	   as	   apposed	   to	   1.9%	   in	   an	   elective	  setting	   (Bridgewater	  and	  Keogh	  2009)	  and	  mortality	   in	  an	  emergent	   setting	   is	  10.4%	  for	  an	  isolated	  AVR.	  	  
Mortality	   for	  patients	  undergoing	   an	   isolated	  AVR	   for	   stenotic	  disease	   is	   less	   at	   2.6%	  compared	   to	   3.7%	   for	   regurgitant	   pathology.	   However	   for	   a	   combined	   procedure	  mortality	  is	  independent	  of	  the	  underlying	  haemodynamic	  pathology.	  	  
In	  addition	  to	  the	  above	  mentioned	  mortality	  figures,	  review	  of	  the	  SCTS	  database	  has	  shown	  that	  a	  lower	  body	  mass	  index,	  ejection	  fraction	  of	  <	  50%,	  left	  main	  stem	  disease,	  previous	   cardiac	   surgery,	   diabetes,	   hypertension,	   extra-­‐cardiac	   arteriopathy,	   renal	  disease,	  angina	  (CCS	  class	  4),	  dyspnoea	  (NYHA	  class	  4)	  are	  all	  associated	  with	  a	  greater	  mortality.	  	  
1.5.4 Consequences	  and	  morbidity	  post	  aortic	  valve	  replacement	  	  	  
The	   SCTS	   in	   their	   6th	   national	   adult	   cardiac	   surgical	   database	   reported	   on	   data	  pertaining	   to	  post-­‐operative	  outcomes	  and	  survival	  post	   isolated	  AVR	  and	  AVR+CABG	  (sub-­‐divided	  on	  risk	  factors)	  (Bridgewater	  and	  Keogh	  2009).	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Patients	  who	  are	  elderly	  have	  a	  lower	  survival	  rate	  at	  5	  years	  for	  both	  an	  isolated	  AVR	  and	  AVR+CABG	  (>	  80	  years	  having	  survival	  rate	  of	  65%	  post	  isolated	  AVR).	  Conversely	  those	  that	  are	  <	  61	  years	  have	  a	  survival	  rate	  of	  >	  90%	  at	  5	  years.	  Rate	  of	  survival	  is	  less	  for	   females	   compared	   to	   males,	   a	   difference	   that	   is	   more	   marked	   following	   an	  AVR+CABG	   with	   a	   survival	   rate	   of	   75-­‐80%	   as	   apposed	   to	   85%	   in	   males.	   Similarly	  urgency	   is	   strongly	   associated	  with	  poor	  mid-­‐term	   survival	  with	  only	   a	  50%	  survival	  rate	   at	   5	   years	   post	   emergency	   AVR+CABG	   and	   ~65%	   post	   isolated	   AVR.	   Although	  mortality	  rates	  are	  more	  favourable	  post	  AVR	  for	  stenosis,	  there	  is	  no	  mid-­‐term	  survival	  difference	  based	  on	  haemodynamic	  pathology.	  Survival	  rates	  follow	  a	  similar	  pattern	  to	  that	  of	  mortality	  for	  all	  other	  major	  risk	  facts	  i.e.	  BMI,	  ejection	  fraction,	  left	  main	  stem	  disease	  etc.	  	  
Average	  post-­‐operative	  stay	  for	  men	  following	  an	  isolated	  AVR	  and	  AVR+CABG	  is	  10.6	  and	   12.8	   days	   respectively	   and	   is	   greater	   for	   women	   by	   up	   to	   2	   days	   following	   a	  combined	   AVR+CABG	   (Bridgewater	   B,	   Keogh	   B	   et	   al.	   2008).	   Similarly	   a	   non-­‐elective	  procedure	  was	  associated	  with	  longer	  in-­‐patient	  stays	  with	  a	  mean	  stay	  of	  19.5	  and	  18.3	  days	  for	  an	  emergency	  AVR	  and	  AVR+CABG	  respectively.	  	  As	  with	  overall	  survival	  there	  is	  no	  difference	  in	  post-­‐operative	  length	  of	  stay	  based	  on	  haemodynamic	  pathology.	  As	  with	   other	  makers	   of	   outcome	  mentioned	   above	   for	  mortality,	   post-­‐op	   stay	   follows	   a	  similar	  trend	  based	  on	  individual	  risk	  factors.	  	  
The	  overall	  rate	  of	  re-­‐operation	  for	  bleeding	  following	  an	  AVR	  is	  5.5%	  and	  is	  higher	  at	  7%	   for	   AVR+CABG	   between	   2004	   and	   2008.	   There	   is	   a	   similar	   association	  with	   post	  operative	  stroke	  with	  a	  higher	  post-­‐op	  stroke	  rate	  for	  AVR+CABG	  at	  2.9%	  compared	  to	  1.9%	  post	  isolated	  AVR.	  New	  post-­‐operative	  haemofiltration/dialysis	  is	  3%	  and	  5%	  for	  isolated	   and	   combined	  AVR+CABG	   respectively.	   These	   rates	   are	   all	   higher	   than	   those	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reported	  for	  CABG	  alone	  and	  are	  reflective	  of	  the	  risk	  of	  the	  procedure	  and	  the	  patients’	  haemodynamic	  pathophysiology.	  
1.6 Myocardial	  protection	  	  
The	   placement	   of	   an	   aortic	   cross	   clamp	   during	   elective	   cardiac	   arrest	   requires	   the	  myocardium	  to	  be	  adequately	  protected.	  Complete	  cardiac	  standstill	  requires	  cessation	  of	   coronary	   perfusion	   and	   therefore	   the	   heart	   is	   made	   globally	   ischaemic.	   This	  ischaemic	   state	   has	   a	   multitude	   of	   negative	   consequences	   as	   outlined	   earlier,	   and	  ischaemic	   time	   can	   vary	   according	   to	   the	   complexity	   of	   the	   procedure.	   Therefore	   the	  primary	   aim	   of	  myocardial	   protection	   is	   to	  minimize	   the	   effects	   of	   ischaemia	   and	   re-­‐introduce	  flow	  at	  the	  earliest	  opportunity,	  with	  an	  aim	  to	  achieve	  minimal	  myocardial	  injury	   during	   reperfusion.	   A	   number	   of	   techniques	   have	   been	   developed	   to	   achieve	  maximal	   myocardial	   protection.	   The	   most	   reproducible	   and	   at	   present	   widely	   used	  method	  uses	  an	  infusion	  of	  cardioprotective	  solution	  (cardioplegia)	  down	  the	  coronary	  arteries	  to	  achieve	  diastolic	  cardiac	  arrest.	  	  	  
1.6.1 Cardioplegia	  	  
1.6.1.1 A	  brief	  history	  	  
The	  advent	  of	  the	  cardiopulmonary	  bypass	  machine	  in	  1954	  by	  Gibbon	  (Gibbon	  1954)	  allowed	  surgeons	   to	  operate	   in	  a	  bloodless	   field	  with	   the	  consequence	  of	  global	  heart	  ischemia.	   This	   resulted	   in	   intermittent	   cardiac	   contraction	   in	   the	   face	   of	   ischaemia,	  causing	   further	  myocardial	   injury.	  This	   led	   to	   the	  development	  of	   a	  potassium	  citrate	  rich	  blood	  based	  solution	  (Melrose,	  Dreyer	  et	  al.	  1955)	  which	  when	   infused	  down	  the	  coronary	   arteries	   caused	   diastolic	   arrest	   of	   the	   heart	   and	   was	   used	   clinically	   during	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cardiac	  surgery	  in	  the	  late	  1950s	  (Gerbode	  and	  Melrose	  1958;	  Sones	  1958).	  This	  soon	  fell	   out	   of	   favour	   as	   it	   was	   realised	   that	   potassium	   citrate	   was	   more	   damaging	   and	  caused	  myocardial	   necrosis	   (Helmsworth,	  Kaplan	   et	   al.	   1959).	   It	  was	  only	  much	   later	  that	  it	  was	  realised,	  that	  the	  high	  concentration	  of	  citrate	  was	  the	  culprit	  in	  myocardial	  injury	  (Holscher	  1967).	  Therefore	  until	  the	  mid	  1970s	  other	  means	  of	  operating	  on	  the	  heart	   were	   adopted	   such	   as	   continuous	   coronary	   perfusion,	   at	   times	   with	   the	   aid	   of	  ventricular	  fibrillation	  and	  intermittent	  coronary	  perfusion.	  	  
Non-­‐potassium	   based	   cardioprotective	   solutions	   were	   being	   used	   particularly	   in	  Germany	  in	  the	  1960s.	  This	  was	  mainly	  a	  sodium	  poor,	  calcium	  free	  solution	  containing	  procaine	   and	   known	   as	   the	   ‘Bretschneider	   solution’	   (Sondergaard,	   Berg	   et	   al.	   1975).	  Similarly	  Kirsch	  and	  colleagues	  developed	  a	  cardioprotective	  solution,	  which	  was	  used	  in	   clinical	   practice	   and	   was	   based	   on	   a	   magnesium,	   aspartate	   and	   procaine	   mixture	  (Kirsch,	  Rodewald	  et	  al.	  1972).	  	  
Gradually,	  potassium	  based	  citrate	  free	  cardioplegia	  re-­‐emerged	  in	  the	  mid	  1970s.	  This	  was	   after	   successful	   cardioprotection	   with	   25mmol/litre	   of	   potassium	   chloride	   after	  1hr	  of	   ischaemia	   in	  dog	  hearts	  (Gay	  and	  Ebert	  1973).	  Roe	  and	  colleagues	  reported	  on	  204	   patients	   using	   potassium	   based	   cardioplegia	   with	   a	   mortality	   of	   5.4%	   (Roe,	  Hutchinson	  et	  al.	  1977).	  Similarly	  another	  clinical	  series	  of	  over	  100	  patients	  using	  the	  same	  concentration	  of	  potassium	  showed	  good	  myocardial	  protection	  (Tyers,	  Manley	  et	  al.	  1977).	  Hence	  potassium	  based	  cardioplegia	  regained	  popularity	  and	  the	  St	  Thomas’	  hospital	  cardioplegia	  solution	  was	  conceived	  in	  the	  UK.	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1.6.1.2 St	  Thomas’	  hospital	  cardioplegia	  solution	  	  
The	  St	  Thomas	  group	  reported	  on	  a	  series	  of	  experiments	  using	  isolated	  rat	  hearts,	  on	  the	   effects	   of	   adding	   a	   series	   of	   anti-­‐ischaemic	   agents	   i.e.	   Magnesium,	   ATP,	  phosphocreatine,	   to	   a	  potassium	  rich	   solution	  and	   their	   role	   in	   enhancing	  myocardial	  protection	  (Hearse,	  Stewart	  et	  al.	  1976).	  This	  led	  to	  the	  development	  of	  the	  St	  Thomas’	  hospital	  cardioplegia	  solution	  No.	  1	  (Braimbridge,	  Chayen	  et	  al.	  1977)	  (Table	  1-­‐3)	  and	  was	   introduced	   into	   clinical	   practice	   in	   1975.	   This	   was	   later	  modified	   to	   St	   Thomas’	  hospital	   cardioplegia	   No.	   2	   (commercially	   produced	   as	   Plegisol)	   (Jynge,	   Hearse	   et	   al.	  1981)	  and	  was	  widely	  used	  throughout	  the	  United	  States	  and	  UK	  (Robinson,	  Schwarz	  et	  al.	  1995).	  	  
Components	  (mmol/litre)	   St	  Thomas’	  solution	  No	  1	   St	  Thomas’	  solution	  No	  2	  
Sodium	  chloride	   144	   110	  
Potassium	  chloride	   20	   16	  
Magnesium	  chloride	   16	   16	  
Calcium	  chloride	   2.2	   1.2	  
Procaine	   1	   -­‐	  
Sodium	  bicarbonate	   -­‐	   10	  
pH	   5.5-­‐7.0	   7.8	  
Osmolarity	  (mOsm/kg	  H2O)	   300-­‐320	   324	  
Table	  1-­‐3	  Composition	  of	  St	  Thomas's	  solution	  
The	  St	  Thomas’	  solution	  was	  infused	  at	  4°C	  for	  2	  minuets	  at	  the	  start	  of	  ischaemia	  at	  a	  perfusion	  pressure	  of	  80mmHg	  until	  cardiac	  arrest	  ensues	  and	  was	  reduced	  to	  50mmHg	  after	  arrest	  (total	  volume	  1000ml).	  Subsequent	  infusions	  of	  300-­‐500ml	  were	  infused	  at	  50mmHg.	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1.6.1.3 Characteristics	  of	  cardioplegia	  solution	  	  Cardioplegia	  can	  either	  be	  an	  intracellular	  or	  extracellular	  composition.	  An	  intracellular	  composition	  consists	  of	  one	  or	  more	  of	  the	  following:	  low	  sodium	  (10-­‐15mmol/L),	  high	  potassium	   (100-­‐140mmol/L)	   and	   low/no	   calcium.	   An	   extracellular	   composition	   can	  consist	  of	   one	  of	   the	   following:	  high	   sodium	   (100-­‐140mmol/L),	   lower	  potassium	   (15-­‐25mmol/L)	   and	   normal	   calcium	   concentrations	   (0.5-­‐2.5mml/L).	   The	   St	   Thomas’	  solution	  is	  an	  extracellular	  composition	  whereas	  the	  commercially	  available	  Custodiol,	  which	  is	  the	  Bretschneider–HTK	  solution	  is	  an	  intracellular	  composition.	  	  
There	   are	   still	   on-­‐going	   studies	   to	   elucidate	   which	   composition	   will	   provide	   better	  myocardial	   protection	   however	   at	   present,	   the	   extracellular	   composition	   seems	   to	  provide	   an	   overall	   benefit	   (Kempsford	   and	   Hearse	   1989;	   Galinanes,	   Murashita	   et	   al.	  1992)	   with	   the	   added	   advantage	   that	   the	   extracellular	   solution	   can	   either	   be	   purely	  crystalloid	  or	  diluted	  in	  blood	  (with	  its	  added	  advantages).	  	  
1.6.1.4 Mechanism	  of	  elective	  cardiac	  arrest	  
Cardioplegia	   aims	   to	   arrest	   the	   heart	   in	   diastole	   rapidly	   and	   safely	   at	   the	   onset	   of	  ischaemia.	   This	   would	   provide	   a	   flaccid	   heart,	   which	   is	   the	  most	   optimum	   condition	  required	   to	  operate	  effectively.	  Achieving	  cardiac	  arrest	  would	   reduce	   the	  myocardial	  oxygen	  consumption/demand	  and	  reduce	  the	  depletion	  of	  useful	  cellular	  energy	  stores.	  	  
Cardioplegia	   causes	   a	   depolarised	   arrest	   of	   the	   heart	   due	   to	   the	   high	   potassium	  concentration	   in	   the	   solution.	   Infusion	   of	   cardioplegia	   increases	   the	   extracellular	  concentration	   of	   potassium,	   in	   turn	   causing	   depolarisation	   of	   the	   myocytes’	  transmembrane	   potential.	   A	   gradual	   increase	   of	   the	   extracellular	   potassium	  concentration	   makes	   the	   resting	   membrane	   potential	   more	   depolarised.	   At	   a	   resting	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membrane	   potential	   of	   approximately	   -­‐65mV	   (threshold	   potential)	   the	   voltage	  dependent	   sodium	   channels	   are	   inactivated	   preventing	   the	   sodium	   induced	   action	  potential	   that	   leads	   to	   contraction.	  Hence	   the	   heart	   is	   arrested	   in	   a	   diastolic	   state	   by	  depolarisation	  (Chambers	  and	  Hearse	  2001).	  
Despite	  the	  rapid	  elective	  diastolic	  arrest	  achieved	  with	  potassium	  rich	  cardioplegia,	  its	  optimum	  range	  of	  concentration	  for	  maximum	  effect	  is	  relatively	  narrow.	  An	  increase	  in	  extracellular	   concentration	   may	   depolarise	   the	   membrane	   potential	   further	   at	   the	  expense	   of	   activating	   the	   slow	   calcium	   channels	   (around	   -­‐40mV)	   causing	   calcium	   to	  enter	   the	  myocyte.	   	  Hence	   the	  narrow	  window	  of	   optimal	  potassium	  concentration	   is	  10-­‐30mmol/L	  (Chambers	  and	  Hearse	  2001).	  Even	  at	  optimum	  potassium	  concentration	  and	   membrane	   potentials	   other	   sodium	   channels	   may	   operate	   which	   may	   gradually	  increase	  intracellular	  sodium	  levels,	  in	  turn	  causing	  calcium	  channels	  to	  open	  resulting	  in	  contracture	  and	  further	  calcium	  overload	  (Chambers	  and	  Hearse	  2001).	  	  
An	  alternative	  to	  depolarized	  arrest	  (achieved	  with	  cardioplegia)	  is	  polarised	  arrest,	  by	  maintaining	   the	   transmembrane	   potential	   closer	   to	   the	   normal	   resting	   membrane	  potential.	  Polarized	  arrest	  can	  be	  achieved	  in	  the	  following	  manner/agents:	  -­‐	  
-­‐ Sodium	  channel	  blockade	  -­‐ ATP-­‐sensitive	  potassium	  channel	  activation	  	  -­‐ Adenosine	  -­‐ Acetylcholine	  
In	  addition	   to	   the	  above-­‐mentioned	  methods	  of	  polarised	  arrest,	   inhibition	  of	   calcium	  influx	   by	   promoting	   hypocalcaemia	   using	   calcium	   antagonists	   and	   promoting	  hypermagnesemia	   can	   induce	   polarised	   diastolic	   cardiac	   arrest.	   These	   methods	   of	  polarised	   arrest	   have	   therefore	   been	   suggested	   as	   superior	   to	   depolarised	   arrest	   but	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remain	  contentious.	  As	  cardioplegia	   is	   the	  main	  agent	  of	  myocardial	  protection	   in	   the	  studies	   outlined	   in	   this	   thesis,	   further	   expansion	   into	   polarised	   diastolic	   arrest	   is	  beyond	  the	  scope	  of	  this	  thesis.	  	  
1.6.2 Hypothermia	  
Hypothermia	  is	  used	  as	  an	  adjunct	  to	  cardioplegia	  and	  aids	  to	  lower	  the	  metabolic	  rate.	  Shumway	  and	  colleagues	  used	  profound	  topical	  hypothermia	  (<4°C)	  only,	  as	  means	  of	  myocardial	   protection	   with	   good	   clinical	   effect	   (Hurley,	   Lower	   et	   al.	   1964).	  Hypothermia	   can	   reduce	   the	   ischaemic	   injury	   by	   slowing	   the	   metabolic	   demands	  (temperature	   dependent	   enzyme	   activity)	   and	   depletion	   of	   high-­‐energy	   phosphates	  during	   ischaemia.	   A	   10°C	   drop	   in	   temperature	   can	   reduce	   enzyme	   activity	   by	   50%	  (Belzer	  and	  Southard	  1988).	  Therefore	  deep	  hypothermia	  alone	  can	  achieve	  myocardial	  arrest	  and	  thus	  myocardial	  protection	  (Greenberg	  and	  Edmunds	  1961;	  Griepp,	  Stinson	  et	  al.	  1973).	  	  
Studies	   on	   the	   effect	   of	   hypothermia	   on	   myocardial	   metabolism	   by	   Buckberg	   and	  colleagues	  showed	  that	  at	  22°C	  an	  arrested	  heart	  had	  a	  myocardial	  oxygen	  consumption	  of	  0.3	  ±	  0.1	  compared	  to	  1.1	  ±	  0.4	  at	  37°C	  (Buckberg,	  Brazier	  et	  al.	  1977).	  	  Furthermore	  in	   a	   rat	   heart	   model	   Hearse	   and	   colleagues	   demonstrated	   the	   additive	   myocardial	  protective	  benefits	  of	  hypothermia	   in	  addition	  to	  cardioplegia	  during	   ischaemia	  arrest	  (Hearse,	   Stewart	   et	   al.	   1980).	   This	   was	   again	   confirmed	   in	   an	   in	   vivo	   dog	   model	  (Rosenfeldt,	  Hearse	  et	  al.	  1980).	  	  
Despite	   the	   advantages	   of	   hypothermia,	   this	   too	   can	   have	   negative	   consequences	  causing	  contracture	  and	  diastolic	  abnormalities.	  At	  temperatures	  below	  5°C	  calcium	  is	  released	   from	  intracellular	  stores	  causing	  contracture	  (Kurihara	  and	  Sakai	  1985;	  Bers	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1987).	  Furthermore	  high	  intracellular	  calcium	  causes	  reduced	  function	  (Ting,	  Spotnitz	  et	   al.	   1994).	   In	   addition	   to	   ischaemia,	   hypothermia	   too	   causes	   rapid	   sodium	   pump	  inactivation.	  Over	  time	  an	  inability	  to	  pump	  sodium	  into	  the	  extracellular	  space	  results	  in	   an	   increasing	   osmotic	   pressure	   gradient,	   which	   causes	   cell	   swelling	   (Belzer	   and	  Southard	  1988;	  Knerr	  and	  Lieberman	  1993).	   	  Therefore	  it	   is	   important	  to	  maintain	  an	  optimum	   temperature	   to	   allow	  maximum	   protection	   and	  minimum	   hypothermic	   cell	  injury.	  	  
Hearse	  et	  al	  showed	  that	  the	  greatest	  benefit	  gained	  by	  hypothermia	  was	  from	  37°C	  to	  24°C	   (Hearse,	   Stewart	   et	   al.	   1976).	   Further	   clinical	   studies	   concluded	   that	   the	   most	  optimal	  temperature	  was	  11-­‐15°C	  to	  achieve	  maximal	  myocardial	  protection.	   In	  order	  to	   achieve	   this	   degree	   of	   myocardial	   hypothermia,	   cardioplegia	   would	   need	   to	   be	  administered	  at	  around	  4°C	  (Rabinov,	  Chen	  et	  al.	  1989)	  
1.6.3 Other	  adjuncts	  and	  additives	  to	  cardioplegia	  	  
Although	   polarised	   diastolic	   cardiac	   arrest	   can	   be	   achieved	   with	   additives	   and	  techniques	  briefly	  mentioned	  earlier,	  these	  could	  also	  be	  used	  as	  an	  additive	  to	  standard	  potassium	   rich	   cardioplegia	   solution	   with	   enhanced	   benefits.	   Potassium	   channel	  openers	   that	   promote	   ATP-­‐sensitive	   potassium	   channel	   activation	   causing	   a	  hyperpolarised	   membrane	   potential	   has	   been	   shown	   to	   enhance	   post	   ischaemic	  recovery	  (Jansson,	  Bomfim	  et	  al.	  1987;	  Hosoda,	  Sunamori	  et	  al.	  1994;	  Qiu,	  Galinanes	  et	  al.	   1995)	   and	   may	   reduce	   the	   impact	   of	   potassium	   induced	   calcium	   influx	   (Lopez,	  Jahangir	   et	   al.	   1996).	   Similarly	   adenosine	   has	   been	   used	   as	   an	   additive	   to	   standard	  extracellular	  cardioplegia	  (Chambers	  and	  Hearse	  2001).	  Inhibition	  of	  calcium	  influx,	  by	  using	   calcium	   antagonists	   (i.e.	   diltiazem,	   verapamil)	   and	   magnesium	   as	   additives	   to	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potassium	   cardioplegia	   has	   shown	   to	   improve	   myocardial	   protection	   (Takemoto,	  Kuroda	  et	  al.	  1994;	  Kronon,	  Bolling	  et	  al.	  1997).	   	  The	  calcium	  channel	  antagonist	  may	  play	  a	  role	   in	  reducing	   the	  calcium	   influx	   that	   is	  associated	  with	  reperfusion	   injury	   in	  normothermic	  ischaemia	  (Chambers	  and	  Hearse	  2001),	  yet	  due	  to	  their	  instability	  and	  irreproducibility,	  calcium	  channel	  antagonist	  are	  not	  used	  in	  routine	  surgical	  practice.	  	  
Cardioplegia	  can	  be	  administered	  as	  a	  pure	  crystalloid	  solution	  or	  diluted	  in	  blood	  with	  blood	  acting	  as	  a	  delivery	  agent.	  Animal	  models	  showing	  the	  advantage	  of	  blood	  based	  potassium	   rich	   cardioplegia	   (Follette,	   Mulder	   et	   al.	   1978)	   and	   subsequent	   clinically	  successful	  studies	  (Buckberg	  1979)	  established	  the	  role	  of	  blood	  cardioplegia.	  However	  the	   debate	   of	   blood	   cardioplegia	   being	   superior	   to	   pure	   crystalloid	   cardioplegia	  continues	  (Chambers	  and	  Hearse	  2001),	  as	  previous	  studies	  have	  been	  suboptimal	  and	  conducting	   an	   ideal	   study	   between	   blood	   and	   crystalloid	   cardioplegia	   would	   involve	  multiple	   assessments	   of	   all	   the	   possible	   variables	   between	   the	   two	   and	   would	   be	   a	  labour	  intensive	  process.	  Disadvantages	  of	  blood	  cardioplegia	  include	  the	  requirement	  to	  make	  up	  the	  solution	  and	  less	  scope	  for	  the	  inclusion	  of	  other	  additives.	  	  
One	   of	   the	   main	   advantages	   of	   blood	   cardioplegia	   was	   the	   simultaneous	   delivery	   of	  oxygen	  to	  the	  myocardium	  during	  ischaemia.	  However	  at	  lower	  temperatures	  (10-­‐15°C)	  the	   oxygen	   dissociation	   from	   blood	   becomes	   more	   difficult,	   allowing	   <	   50%	   of	   the	  available	   oxygen	   for	   release.	   In	   comparison,	   crystalloid	   solution	   has	   a	   lower	   biding	  capacity	  of	  oxygen,	  hence	  all	  of	  the	  oxygen	  is	  available	  for	  release	  (Digerness,	  Vanini	  et	  al.	   1981).	   Studies	   have	   shown	   a	   beneficial	   effect	   of	   oxygenating	   cold	   crystalloid	  cardioplegia	   (Ledingham,	   Braimbridge	   et	   al.	   1988;	   Chambers,	   Kosker	   et	   al.	   1990;	  Coetzee,	   Roussouw	   et	   al.	   1990)	   but	   this	   is	   technically	   difficult	   and	   needs	   correct	  manipulation	  to	  maintain	  the	  carbon	  dioxide	  content	  and	  pH.	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Cardioplegia	   can	   be	   delivered	   cold,	   a	   more	   conservative	   approach	   achieving	   a	  hypothermic	  myocardium.	  However	   studies	  have	   shown	   that	   there	   is	   equal	  benefit	   in	  delivering	  warm	  blood	  cardioplegia	  or	  even	  a	  combination	  of	  continuous	  warm	  blood	  cardioplegia	   to	   induce	   arrest	   and	   then	  use	   cold	  blood	   cardioplegia	   to	  maintain	   arrest	  (advocated	   for	   more	   susceptible	   hearts)	   (Rosenkranz,	   Vinten-­‐Johansen	   et	   al.	   1982;	  Rosenkranz,	  Buckberg	  et	  al.	  1983).	  There	  has	  been	  and	  continues	  to	  be	  further	  debate	  regarding	   continuous	   or	   intermittent	   cardioplegia	   perfusion	   with	   neither	   having	   a	  greater	   overall	   benefit	   (Chambers	   and	   Hearse	   2001).	   Theoretically	   continuous	  cardioplegia	  perfusion	  can	  provide	  an	  aerobic,	   ischaemic	  free	  environment	  however	  it	  is	   technically	   challenging	   and	   can	   hamper	   key	   stages	   of	   a	   cardiac	   procedure	   (distal	  coronary	   graft	   anastomosis).	   If	   intermittent	   cardioplegia	   is	   used,	   then	   the	   periods	   of	  ischaemia	   should	   be	   kept	   to	   a	   minimum,	   ideally	   10-­‐15	   mins	   in	   duration	   (Rousou,	  Engelman	  et	  al.	  1995;	  de	  Oliveira,	  Boeve	  et	  al.	  1997;	  Kawasuji,	  Yasuda	  et	  al.	  1997),	   to	  reduce	  the	  risk	  of	  ischaemic	  injury.	  	  
Intracellular	  acidosis	  is	  proportional	  to	  the	  length	  of	  ischaemia.	  An	  additional	  advantage	  of	  blood	   cardioplegia	   is	   the	   inherent	  buffering	   capacity	   that	   can	   combat	   this	   acidosis;	  hence	   may	   be	   more	   beneficial	   in	   myocardial	   protection.	   Therefore	   the	   inclusion	   of	  bicarbonate	  in	  St	  Thomas’s	  No.2	  to	  make	  this	  more	  alkaline,	  allows	  for	  the	  gradual	  drop	  in	  pH	  (to	  a	  physiologically	  normal	  range)	  in	  a	  hypothermic	  state	  (Chambers	  and	  Hearse	  2001).	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1.6.4 Adjuncts	  to	  combat	  oxidative	  stress	  	  
Oxidative	   stress	   due	   to	   the	   production	   of	   free	   oxygen	   radicals	   during	   ischaemia	   and	  reperfusion	  has	  been	  implicated	  in	  myocardial	   injury.	  During	  ischaemia	  the	  protective	  effects	   of	   endogenous	   anti-­‐oxidants	   systems	   (superoxide	   dismutase	   and	   catalase)	   are	  suppressed	   (Galinanes,	   Ferrari	   et	   al.	   1992).	   Despite	   positive	   experimental	   studies	  showing	  the	  myocardial	  protective	  benefit	  in	  using	  anti-­‐oxidant	  agents,	  these	  have	  not	  translated	   into	   clinical	   practice	   (Chambers	   and	  Hearse	   2001).	   	   Superoxide	   dismutase	  and	   catalase	   are	   expensive	   to	   produce	   and	   unsuitable	   (large	   protein	   molecules)	   for	  administration	  to	  patients.	  Similarly,	  organic	  anti-­‐oxidants	  such	  vitamin	  E	  &	  C,	  although	  experimentally	  have	  shown	  to	  improve	  post	  ischemic	  recovery	  (Chambers,	  Astras	  et	  al.	  1989)	  have	  not	  been	  taken	  up	  into	  clinical	  practice.	  It	  is	  thought	  that	  free	  oxygen	  radical	  production	   and	  oxidative	   stress	   is	  maximal	   during	   reperfusion	  hence	  oxidative	   stress	  combating	   agents	  would	   be	  most	   beneficial	   in	   a	   reperfusion	   solution	   rather	   than	   the	  cardioplegia	  solution.	  	  
Therefore	   there	   are	   a	   myriad	   of	   variables	   to	   enhance	   standard	   potassium	   rich	  cardioplegia.	   These	   variables	   include:	   the	   vehicle	   of	   delivery	   (blood	   vs.	   crystalloid),	  temperature	  (cold	  vs.	  warm),	  and	  frequency	  (continuous	  vs.	  intermittent).	  Furthermore	  there	   are	   a	   number	   of	   established	   additives	   that	   may	   reduce	   ischaemic	   injury	   and	  improve	   myocardial	   protection.	   These	   methods	   may	   enhance	   the	   capabilities	   of	   the	  cardiomyocyte	  to	  deal	  with	  ischaemia.	  Yet	  there	  are	  mechanisms	  that	  could	  improve	  the	  metabolism	  or	  optimise	  the	  metabolism	  of	  the	  cardiomyocyte,	  which	  could	  improve	  its	  ability	  to	  deal	  with	  ischaemia	  and	  the	  stressors	  of	  reperfusion.	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1.7 Metabolic	  modulation	  	  
Metabolic	  modulation	   refers	   to	   the	  manipulation	  of	   the	   cellular	  metabolism.	   It	   can	  be	  achieved	  by	   enriching	   cardioplegic	   solution	  with	  metabolites	   and	   substrates	   i.e.	   high-­‐energy	  phosphates,	  amino	  acids	  etc.,	  beneficial	  to	  myocardial	  metabolism.	  By	  infusion	  of	  cardioplegia	   through	   the	   coronary	   arteries,	   it	   is	   assured	   that	   these	   substrates	   are	  reaching	   the	   myocardium	   during	   induction	   and	   maintenance	   of	   cardiac	   arrest.	   The	  principle	  of	  metabolic	  modulation	  is	  to	  reduce	  high-­‐energy	  phosphate	  (ATP)	  depletion	  during	  ischaemia	  or	  enhance	  anaerobic	  ATP	  production	  and/or	  availability	  (Chambers	  and	  Hearse	  2001).	  	  	  
ATP	   and	   phosphocreatine	   as	   additives	   to	   cardioplegia	   have	   been	   demonstrated	  experimentally	   and	   clinically	   to	   improve	   myocardial	   protection,	   although	   the	  mechanism	   of	   protection	   is	   as	   yet	   unclear	   (Semenovsky,	   Shumakov	   et	   al.	   1987;	  Chambers,	   Braimbridge	   et	   al.	   1991;	   Chambers,	   Haire	   et	   al.	   1996).	   Exogenous	   ATP	  should	  not	  be	  able	   to	  gain	  access	   into	   the	  cell	  hence	   their	  action	  may	  be	  extracellular	  and	  act	  similar	  to	  chelating	  calcium,	  reducing	  the	  calcium	  concentration	  (Robinson	  and	  Harwood	  1991).	   In	  addition	  exogenous	  high-­‐energy	  phosphates	  may	  reduce	  oxidative	  stress	  (Zucchi,	  Poddighe	  et	  al.	  1989).	  	  
Other	   substrates	   such	  as	   glutamate	   and	  aspartate,	   amino	  acids	   involved	   in	   the	  Kreb’s	  cycle	   and	   malate-­‐aspartate	   shuttle	   are	   involved	   in	   the	   production	   of	   ATP.	   Early	  experimental	   and	   clinical	   studies	   have	   shown	   that	   glutamate	   and	   aspartate	   may	  improve	  myocardial	   oxygen	   consumption	   and	   anaerobic	  metabolism	  particular	   in	   the	  energy	  depleted	  heart	   (Rosenkranz,	  Okamoto	   et	   al.	   1984;	  Rosenkranz,	  Okamoto	   et	   al.	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1986;	  Pisarenko,	  Portnoy	  et	  al.	  1987).	  Yet	  further	  evaluation	  for	  routine	  clinical	  use	  is	  necessary.	  	  
The	   addition	   of	   glucose	   and	   thereby	   promoting	   the	   anaerobic	   glycolytic	   pathway	  producing	  ATP,	   can	  hypothetically	   improve	  myocardial	   protection.	  Hence	   glucose	   has	  been	   added	   to	   cardioplegia	   solution	  with	  mixed	   benefits.	   In	   the	   absence	   of	   coronary	  flow,	  anaerobic	  glycolysis	  can	  lead	  to	  lactate	  accumulation	  and	  acidosis	  (Chambers	  and	  Hearse	   2001).	   Other	   intermediates	   of	   glycolysis	   such	   as	   pyruvate	   and	   fructose	  diphosphate	  have	  shown	  to	  be	  beneficial	  as	  additives	  to	  cardioplegia	  (Wikman-­‐Coffelt,	  Wagner	   et	   al.	   1991;	   Cargnoni,	   Condorelli	   et	   al.	   1992;	   Schaefer,	   Prussel	   et	   al.	   1995).	  However	   additives	   to	   cardioplegic	   solution	   with	   an	   aim	   to	   achieve	   metabolic	  modulation	   in	   clinical	   cardiac	   surgery	  have	  yet	   to	  be	   fully	  established	   (Chambers	  and	  Hearse	   2001).	   Therefore,	   metabolic	   modulation	   irrespective	   of	   the	   constituents	   of	  cardioplegia	  solution	  per	  se	  could	  be	  a	  feasible	  alternative.	  	  
Metabolic	   modulation	   independent	   of	   cardioplegia	   aims	   to	   promote	   a	   more	   efficient	  cardiomyocyte	  metabolism	  prior	   to	   the	   insult	  of	   ischaemia,	  during	   ischaemia	  and	   into	  reperfusion,	   and	   in	   turn	   this	   would	   be	   beneficial	   during	   the	   reperfusion	   phase.	   The	  principle	   of	   this	   modulation	   is	   a	   shift	   away	   from	   potentially	   harmful	   free	   fatty	   acid	  metabolism,	  towards	  a	  more	  efficient	  carbohydrate	  metabolism.	  (Taegtmeyer,	  Goodwin	  et	  al.	  1997).	  Maintaining	  a	  more	  efficient	  metabolic	  state	  whilst	  utilising	  carbohydrate	  substrates	   for	  metabolism,	  may	   reduce	   the	   insult	   of	   ischaemia,	  maintain	   high-­‐energy	  phosphate	   concentrations	   and	   therefore	   allow	  an	  enhanced	   recovery	   from	   ischaemia-­‐reperfusion	  injury.	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1.7.1 Glucose-­‐Insulin-­‐Potassium	  
An	  intravenous	  infusion	  of	  glucose-­‐insulin-­‐potassium	  (GIK)	  was	  first	  used	  in	  1962	  in	  a	  study	   evaluating	   the	   role	   of	   GIK	   in	   myocardial	   ischaemia,	   which	   showed	   a	   reduced	  infarction	  size,	  reduced	  electrocardiographic	  signs	  of	  ischaemia	  and	  prolonged	  survival	  (Sodi-­‐Pallares,	   Testelli	   et	   al.	   1962).	   Later,	   GIK	   infusion	   was	   used	   in	   stunned,	   failing	  myocardium	   not	   responding	   to	   other	   therapies	   (Braimbridge,	   Clement	   et	   al.	   1969;	  Sheldon,	  Braimbridge	  et	  al.	  1969).	  The	  mechanism	  of	  action	  of	  GIK	  on	  the	  myocardium	  during	  cardiac	  surgery	  is	  multifactorial.	  	  
The	   administration	   of	   GIK	   prior	   to	   the	   onset	   of	   ischaemia	   can	   improve	   myocardial	  glycogen	   content	   allowing	   for	   greater	   ATP	   and	   phosphocreatine	   production,	   via	  glycolysis	  during	  the	  period	  of	  ischaemia	  (Iyengar,	  Charrette	  et	  al.	  1976;	  Haider,	  Schutz	  et	   al.	   1982).	   This	   should	   allow	   for	   greater	   ischaemic	   tolerance	   and	   recovery	   post	  reperfusion.	   Post	   cardiac	   surgery	   there	   is	   higher	   insulin	   resistance	   as	   part	   of	   the	  hormonal	  stress	  response	  (Rassias,	  Givan	  et	  al.	  2002),	  causing	  hyperglycaemia.	  This	  can	  be	  combated	  by	  the	  infusion	  of	  insulin	  as	  part	  of	  the	  GIK	  solution	  (Doenst,	  Bothe	  et	  al.	  2003).	  	  
A	  feature	  of	  GIK	  infusion	  is	  that	  it	  limits	  the	  extent	  of	  free	  fatty	  acid	  metabolism.	  Insulin	  reduces	  lipolysis	  thereby	  reducing	  free	  fatty	  acids	  in	  circulation.	  Furthermore	  it	  reduces	  the	  levels	  of	  acyl-­‐carnitine,	  reducing	  membrane	  injury.	  In	  addition	  to	  this	  it	   limits	  FFA	  metabolism	   by	   activation	   of	   acetyl-­‐CoA-­‐carboxylase	   (Gamble	   and	   Lopaschuk	   1997).	  Activation	  of	  acetyl-­‐CoA-­‐carboxylase	  increases	  malonyl-­‐CoA,	  which	  inhibits	  the	  uptake	  of	   acetyl-­‐CoA	   for	   β-­‐oxidation.	   This	   inhibition	   of	   FFA	   metabolism	   promotes	   coupled	  glycolysis	  and	  glucose	  oxidation	  and	  reduces	  the	  energy	  inefficient	  FFA	  metabolism.	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Insulin	   also	   increases	   the	   expression	   of	   glucose	   transporters,	   particularly	   GLUT4.	  GLUT4	  increases	  the	  uptake	  of	  glucose	  into	  cardiomyocytes	  hence	  promotes	  glycolysis	  (Morgan,	  Neely	  et	  al.	  1965).	  GIK	  also	  has	  a	  role	  during	  reperfusion.	  Through	  the	  process	  of	  anaplerosis,	  GIK	  is	  able	  to	  replenish	  the	  intermediates	  of	  the	  TCA	  cycle	  at	  a	  fast	  rate	  allowing	  for	  better	  energy	  production	  and	  greater	  turnover	  of	  the	  cycle	  (Simonsen	  and	  Kjekshus	  1978;	  Taegtmeyer,	  Goodwin	  et	  al.	  1997).	  The	  vasodilatory	  properties	  of	  GIK	  improves	   cardiac	   output,	   by	   reducing	   the	   afterload	   (Gradinac,	   Coleman	   et	   al.	   1989).	  Furthermore	  it	  has	  a	  direct	  inotropic	  effect	  on	  the	  heart	  (Doenst,	  Richwine	  et	  al.	  1999).	  	  
These	   multifactorial	   benefits	   of	   GIK	   have	   been	   studied	   in	   a	   clinical	   setting	   in	   both	  patients	   with	   ischaemic	   heart	   disease	   and	   those	   undergoing	   cardiac	   surgery.	   An	  overview	  of	  randomised	  placebo	  controlled	  trial	  in	  patients	  that	  sustained	  a	  myocardial	  infarction,	   showed	   a	   proportional	   mortality	   reduction	   of	   28%	   in	   those	   that	   received	  GIK;	   translated	   to	   49	   lives	   saved	   per	   1000	   treated	   (Fath-­‐Ordoubadi	   and	  Beatt	   1997).	  However	  Mehta	  and	  colleagues	  in	  the	  CREATE-­‐ECLA	  trial;	  randomised	  20,201	  patients	  in	  470	  centres	  to	  GIK	  therapy	  in	  patients	  presenting	  with	  STEMI,	  and	  showed	  no	  overall	  clinical	   benefit	   with	   no	   difference	   in	   mortality,	   cardiac	   arrest	   and	   cardiogenic	   shock	  (Mehta,	   Yusuf	   et	   al.	   2005).	   Furthermore	   another	   meta-­‐analysis	   looking	   at	   patients	  treated	   with	   GIK	   post	   MI;	   in	   16	   randomised	   trials	   spanning	   40	   years	   and	   including	  28,000	  patients	  showed	  no	  mortality	  benefit	   for	  patient	  with	  ST-­‐Elevation	  myocardial	  infarction	   (Mamas,	  Neyses	   et	   al.	   2010).	  However,	  GIK	   therapy	  and	   its	  uses	  have	  been	  further	  evaluated	  in	  patients	  undergoing	  cardiac	  surgery.	  	  
1.7.1.1 GIK	  and	  cardiac	  surgery	  	  	  	  Bothe	  and	  colleagues	  performed	  a	  meta-­‐analysis	  of	  all	   randomized	  trials,	  using	  GIK	   in	  cardiac	   surgery.	   Of	   35	   GIK	   trials	   identified,	   11	   were	   included	   in	   this	   analysis;	   468	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patients	  underwent	  coronary	  artery	  bypass	  grafting	  or	  valve	  replacement	  surgery.	  Six	  studies	   showed	   significant	   improvement	   in	   post-­‐operative	   recovery,	   with	   a	  weighted	  mean	  relative	   improvement	  of	   cardiac	   index	  of	  11.4%	   in	   those	   treated	  with	  GIK,	  with	  reduced	   inotrope	   usage.	   This	   study	   concluded	   that	   GIK	   therapy	   may	   considerably	  improve	   post-­‐operative	   recovery	   of	   contractile	   function	   post	   cardiac	   surgery	   (Bothe,	  Olschewski	  et	  al.	  2004).	  A	   subsequent	  met-­‐analysis	  of	   similar	   trials	   included	  33	  RCTS	  assessing	  2113	  patients	  and	  showed	  that	  GIK	  therapy	  was	  associated	  with	  significantly	  fewer	  perioperative	  myocardial	  infarctions	  (RR	  =	  0.63,	  95%	  CI	  0.42-­‐0.95),	  less	  inotropic	  support	  requirement	  (RR	  =	  0.66,	  95%	  CI	  0.45-­‐0.96),	  better	  postoperative	  cardiac	  index	  (weighted	  mean	   difference	   (WMD)	   =	   0.43,	   95%	   CI	   0.31-­‐0.55),	   and	   reduced	   length	   of	  stay	  in	  the	  intensive	  care	  unit	  (WMD	  =	  -­‐7.96,	  95%	  CI	  -­‐13.36	  to	  -­‐2.55)	  (Fan,	  Zhang	  et	  al.	  2011).	  	  
1.7.1.2 The	  Birmingham	  experience	  	  The	   Birmingham	   group	   has	   conducted	   a	   series	   of	   studies	   evaluating	   the	   role	   of	   GIK	  therapy	  in	  cardiac	  surgery.	  The	  first	  of	  a	  series	  of	  trials	  with	  GIK	  was	  reported	  in	  2006.	  This	   double-­‐blind	  placebo	   controlled	   trial	   randomised	  138	  patients	   to	   the	  GIK	   group,	  and	  recruited	  patients	  who	  were	  undergoing	  first	  time	  isolated	  coronary	  artery	  bypass	  graft	  surgery.	  GIK	  was	  used	  as	  an	  adjunct	  to	  standard	  cardioplegia	  solution.	  This	  study	  showed	   that	   the	   incidence	   of	   LCOE	  was	   lower	   in	   the	   GIK	   group	   (GIK	   group,	   22/138	  [15.9%];	   placebo	   group,	   39/142	   [27.5%];	   p=0.021).	   Furthermore	   there	   was	   reduced	  incidence	   of	   inotrope	   use	   in	   the	   GIK	   group.	   There	   was	   also	   a	   reduced	   incidence	   of	  myocardial	  injury	  in	  the	  GIK	  group	  (GIK	  group,	  16/133	  [12.3%];	  placebo	  group,	  32/137	  [23.4%];	   p=0.017).	   Therefore	   this	   study	   showed	   GIK	   improved	   early	   post-­‐operative	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myocardial	  performance	  and	   reduced	   the	   requirement	  of	   inotropes	  and	  may	   improve	  myocardial	  injury	  (Quinn,	  Pagano	  et	  al.	  2006).	  	  
These	  finding	  were	  supported	  by	  another	  double-­‐blind	  randomized	  placebo	  controlled	  trial	   looking	   at	   the	   role	   of	   GIK	   individually	   and	   in	   combination	  with	   triiodothyronine	  (T3)	   and	   reported	   on	   combined	   data	   from	   the	   previous	   study	   (both	   consisting	   of	  identical	   trial	   protocols).	   	   This	   too	   showed	   improved	   haemodynamic	   performance	  associated	  with	  GIK	  compared	  to	  placebo	  either	  individually	  or	  in	  combination	  with	  T3.	  Furthermore	   the	   use	   of	   inotropes	   and	   vasoconstrictor	   usage	   was	   similar	   to	   the	  previously	   reported	   trial;	   fewer	   patients	   in	   all	   treatment	   groups	   required	   inotropic	  support	   in	   the	   first	   6	   hours	   after	   aortic	   cross-­‐clamp	   removal	   compared	  with	   placebo	  (66/160,	   41.3%),	   GIK	   (28/157	   [17.8%];	   p<0.001),	   T3	   (14/63	   [21.0%]	   p=0.03),	   and	  GIK/T3	  (9/60	  [15.0%];	  p<0.001),	  and	  vasoconstrictor	  use	  was	  significantly	  higher	  with	  the	   GIK	   groups	   (p<0.001).	   Moreover	   the	   overall	   incidence	   of	   low	   cardiac	   output	  syndrome	  was	   lower	   in	   all	   treatment	   groups	   (GIK,	   33/157	   [21.0%]	  p=0.228;	   GIK/T3,	  10/60	   [16.7%]	  p=0.186;	   T3,	   13/63	   [20.6%]	  p=0.42;	   versus	   placebo	   50/160	   [31.3%])	  but	  did	  not	  reach	  significance	  on	  multiple	  comparison	  testing.	  This	  study	  also	  showed	  a	  reduced	  Troponin	  I	  release	  at	  6	  hours	  in	  all	  treatment	  groups	  (placebo,	  5.8	  [3.1	  to	  11.3]	  ng/mL;	  GIK,	  5.1	  [2.7	  to	  7.7]	  ng/mL	  p=0.19;	  T3,	  2.74	  [1.0	  to	  5.9]	  ng/mL	  p<0.001;	  GIK/T3,	  3.3	  [1.5	  to	  7.8]	  ng/mL	  p<0.01)	  (Ranasinghe,	  Quinn	  et	  al.	  2006).	  Hence	  Ranasinghe	  et	  al	  concluded	   that	   perioperative	   GIK	   can	   reduce	   myocardial	   injury	   and	   improve	  haemodynamics	  in	  patients	  undergoing	  on-­‐pump	  CABG;	  however	  it	  is	  unclear	  whether	  the	  effects	  seen	  with	  GIK	  are	  due	  changes	  in	  contractility	  or	  afterload.	  	  
The	  above	  trials	  and	  others	  described	  in	  the	  literature	  using	  GIK	  in	  cardiac	  surgery	  have	  assessed	  its	  effect	  in	  patients	  undergoing	  CABG	  only	  and	  have	  not	  examined	  the	  role	  of	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GIK	  in	  the	  presence	  of	  quantified	  left	  ventricular	  hypertrophy.	  This	  led	  to	  the	  next	  large	  trial	  randomizing	  patients	  with	  quantified	  LVH	  secondary	  to	  aortic	  stenosis	  undergoing	  aortic	  valve	  replacement	  surgery.	  This	  study	  recruited	  110	  patients	  to	  the	  GIK	  arm	  and	  of	   these,	   11	  patients	  were	  diagnosed	  with	   a	   low	  cardiac	  output	  episode	   showing	   that	  GIK	  was	  associated	  with	  a	  significant	  reduction	   in	  the	   incidence	  of	   low	  cardiac	  output	  state	  (odds	  ratio,	  0.22;	  95%	  confidence	  interval,	  0.10	  to	  0.47;	  p<0.0001).	  Analysis	  of	  the	  secondary	  end-­‐points	  showed	  that	  there	  was	  significantly	  reduced	  incidence	  of	  inotrope	  usage	  and	  the	  cardiac	  index	  was	  significantly	  higher	  in	  the	  GIK	  group	  from	  the	  start	  of	  treatment	  until	  12	  hours	   from	  removal	  of	   the	  aortic	   cross	   clamp.	   In	  keeping	  with	   the	  previous	   GIK	   trials,	   GIK	   was	   associated	   with	   high	   incidence	   of	   vasoconstrictor	  requirements	  (Howell,	  Ashrafian	  et	  al.	  2011).	  
The	  myocardial	   protective	   role	   of	   GIK	   is	   likely	   to	   be	   insulin	   dependent	   and	   previous	  studies	   have	   explored	   the	   more	   established	   benefits	   of	   metabolic	   modulation;	   shift	  towards	  the	  more	  efficient	  glucose	  metabolism.	  Howell	  and	  colleagues	  explored	  the	  role	  of	   insulin	   on	   antiapoptotic	   and	   cardioprotective	   signalling	   pathways	   in	   addition	   to	  protein	  O-­‐GlcNAcylation	  and	  its	  interaction	  with	  insulin.	  	  
Phosphorylation	   and	   activation	   of	   Akt	   (activated	   by	   PI3K	   and	   in	   turn	   mediated	   by	  phosphoinositide-­‐3,4,5	  triphosphate,	  by	  the	  action	  of	  insulin	  on	  PI3K)	  has	  been	  shown	  to	  protect	  against	  apoptosis	  after	   ischaemia/reperfusion	   in	  cardiomyocytes	  (Jonassen,	  Sack	   et	   al.	   2001).	   Furthermore,	   AMP-­‐activated	   protein	   kinase	   (AMPK);	   activated	   by	  phosphorylation,	  also	  has	  an	  established	  role	  in	  insulin	  signalling	  (Bertrand,	  Horman	  et	  al.	   2008)	   and	   is	   thought	   to	   have	   a	   role	   in	   cardioprotection.	   Protein	   O-­‐GlcNAcylation	  refers	   to	   modification	   of	   serine	   and	   threonine	   residues	   of	   nuclear	   and	   cytoplasmic	  proteins	   by	   O-­‐GlcNAc	   (O-­‐linked	   βN-­‐acetylglucosamine).	   Experimental	   studies	   have	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shown	   high	   levels	   of	   O-­‐GlcNAcylation	   post	   ischaemia	   in	   isolated	   perfused	   hearts,	  showing	  that	  this	  stress–activated	  pathway	  is	  active	  in	  the	  heart	  and	  higher	  levels	  of	  O-­‐GlcNAc	   improves	   contractile	   function	   and	   decrease	   tissue	   injury	   after	   reperfusion	  (Fulop,	  Zhang	  et	  al.	  2007;	  Liu,	  Marchase	  et	  al.	  2007;	  Liu,	  Marchase	  et	  al.	  2007)	  
In	  addition	  to	  the	  above	  positive	  clinical	  findings,	  Howell	  et	  al	  showed	  that	  GIK	  causes	  insulin	  signalling	  pathway	  activation	  of	  Akt	  and	  AMPK,	  which	  could	  be	  associated	  with	  improved	  myocardial	   protection;	   significant	   increase	   in	   the	   ratio	   of	   phosphor-­‐Akt	   to	  pan-­‐Akt	  and	  phopho-­‐AMPK	  to	  AMPK	  in	  the	  GIK	  group.	  There	  was	  also	  more	  prominent	  O-­‐GlcNAcylation	   in	   the	  GIK	   group	   (Howell,	   Ashrafian	   et	   al.	   2011).	   These	   findings	   add	  further	  evidence	  to	  the	  mechanisms	  of	  cardioprotection	  achieved	  with	  GIK,	  in	  addition	  to	  the	  existing	  evidence	  of	  metabolic	  enhancement.	  	  
Despite	  the	  vast	  amount	  of	  data	  supporting	  the	  cardioprotective	  nature	  of	  systemic	  GIK,	  GIK	   is	   not	   widely	   used	   as	   an	   adjunct	   to	   standard	   myocardial	   protection	   in	   cardiac	  surgery.	  The	  administration	  and	  peri-­‐operative	  management	  of	  GIK	  is	  a	  labour	  intensive	  process	   that	   requires	   medical	   supervision	   and	   input	   in	   the	   peri-­‐operative	   stage.	   It	  requires	   continuous	  monitoring	  and	   control	  of	  blood	  glucose	   levels	  due	   to	   the	   risk	  of	  hyperglycaemia	   (Quinn,	   Pagano	   et	   al.	   2006;	   Ranasinghe,	   Quinn	   et	   al.	   2006;	   Howell,	  Ashrafian	   et	   al.	   2011).	  Hyperglycaemia	   is	  well	   known	   to	   have	   a	   negative	   impact	   post	  cardiac	   surgery	   with	   increased	  morbidity	   and	  mortality	   (Doenst,	  Wijeysundera	   et	   al.	  2005).	  Furthermore	  hyperglycaemia	  has	  adverse	  outcomes	  post	  myocardial	   ischaemia	  (Ishihara,	  Inoue	  et	  al.	  2003;	  Ishihara,	  Kojima	  et	  al.	  2005).	  	  
Existing	   evidence	   in	   favour	   of	   GIK	   comes	   from	   small	   studies,	   some	   which	   are	  inadequately	  powered	  or	  not	  randomised.	  Moreover,	  differing	  study	  protocols,	  regimes	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of	   GIK	   administration	   and	   study	   populations	   examined,	   heighten	   the	   heterogeneous	  manner	  in	  which	  positive	  cardioprotective	  conclusions	  with	  GIK	  have	  been	  reached.	  The	  multiple	  modalities	  of	  action	  of	  GIK	  add	  to	  the	  confusion	  and	  debate.	  Therefore	  there	  is	  a	  call	  for	  multi-­‐centre	  trials	  with	  GIK	  in	  patients	  at	  risk	  of	  low	  cardiac	  output	  syndrome	  including	   further	   examination	   into	   the	   underlying	  mechanism	   of	   actions	   (Vlasselaers	  2011).	   In	   the	  meantime	   the	  debate	   regarding	   the	  best	  myocardial	  protection	   strategy	  continues	   and	   other	   modalities	   of	   metabolic	   modulation,	   to	   be	   used	   as	   adjuncts	   to	  standard	  cardioplegia	  need	  to	  be	  considered.	  	  
1.7.2 Promoting	  pyruvate	  oxidation	  
Dichlorocetate	  (DCA)	  has	  been	  advocated	  as	  an	  agent	  for	  short-­‐term	  metabolic	  therapy	  in	   patients	   in	   early	   heart	   failure,	   where	   the	   substrate	   metabolism	   is	   near	   normal.	  Dichloroacetate	   inhibits	   pyruvate	   dehydrogenase	   kinase	   (PDH),	   in	   turn	   maintaining	  PDH	   in	   the	   dephosphorylated	   active	   form,	   thereby	   increasing	   pyruvate	   oxidation	  (Whitehouse,	   Cooper	   et	   al.	   1974).	   DCA	   has	   shown	   also	   to	   inhibit	   FFA	   oxidation	   by	  increasing	  malonyl	  CoA	  and	  inhibiting	  CPT1	  (Stanley,	  Hernandez	  et	  al.	  1996).	  Bersin	  et	  al	   showed	   that	   infusion	   of	   DCA	   increased	   stroke	   volume	   and	   stroke	   work	   and	   an	  increase	  in	  mechanical	  efficiency	  from	  15.3	  to	  20.6%	  (Bersin,	  Wolfe	  et	  al.	  1994;	  Bersin	  and	   Stacpoole	   1997).	   Similarly	   increasing	   the	   arterial	   load	   of	   pyruvate	   by	   infusing	  glycerol	  ester	  of	  pyruvate	  has	  been	  shown	  to	  reduce	  the	  myocardial	  infarct	  size	  during	  reperfusion	   in	   pigs	   (Stanley,	   Kivilo	   et	   al.	   2003).	   However	   these	   experimental	   studies	  have	   not	   translated	   to	   clinical	   practice	   and	   large-­‐scale	   clinical	   trials	   are	   required	   to	  comment	   on	   clinical	   benefit.	   Furthermore	   the	   beneficial	   effects	   of	   DCA	   appear	   to	   be	  linked	  to	  pyruvate	  oxidation	  and	  not	  glycolysis	  (Stanley,	  Lopaschuk	  et	  al.	  1997).	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L-­‐carnitine	  is	  involved	  in	  the	  transport	  of	  free	  fatty	  acids	  into	  the	  mitochondrial	  space,	  for	   fatty	   acid	   oxidation.	   In	   addition	   to	   this	   role,	   L-­‐carnitine	   is	   involved	   in	   regulating	  pyruvate	  oxidation	  (Stanley,	  Lopaschuk	  et	  al.	  1997).	  Administration	  of	  L-­‐carnitine	  and	  it’s	  analog	  propionyl	  L-­‐carnitine	  has	  shown	  to	  increase	  glucose	  oxidation	  by	  stimulating	  PDH	   activity	   (Schonekess,	   Allard	   et	   al.	   1995).	   Furthermore	   these	   compounds	   have	  shown	  to	  have	  cardioprotective	  benefits	  in	  early	  experimental	  studies	  due	  to	  their	  anti-­‐ischaemic	   properties	   (Iliceto,	   Scrutinio	   et	   al.	   1995;	   Stanley,	   Lopaschuk	   et	   al.	   1997).	  However,	  there	  use	  in	  cardiac	  surgery	  and	  their	  properties	  in	  clinical	  practice	  is	  limited.	  	  
1.7.3 Trimetazadine	  	  
Trimetazadine	  is	  a	  free	  fatty	  acid	  oxidation	  inhibitor	  hence	  has	  the	  potential	  to	  augment	  the	  more	   efficient	   glucose	  metabolism	   (Fantini,	  Demaison	   et	   al.	   1994).	  Trimetazadine	  has	   been	   clinically	   used	   as	   an	   anti-­‐anginal	   drug	   (Dalla-­‐Volta,	   Maraglino	   et	   al.	   1990;	  Lewandowski	  2000;	  Szwed,	  Sadowski	  et	  al.	  2001).	  Its	  action	  is	  by	  inhibiting	  long-­‐chain	  3-­‐ketoacyl-­‐CoA	  thiolase,	  (Lopaschuk,	  Barr	  et	  al.	  2003)	  a	  key	  enzyme	  in	  the	  β-­‐oxidation	  pathway.	   Trimetazadine	   has	   no	   impact	   on	   the	   rate	   of	   glycolysis	   during	   reperfusion	  (Boucher,	   Hearse	   et	   al.	   1994).	   In	   patients	  with	   ischaemic	   heart	   failure,	   trimetazadine	  significantly	   improved	   left	   ventricular	   ejection	   fraction	   and	   enhanced	   LV	  wall	  motion	  (Belardinelli	   and	  Purcaro	  2001).	  These	   findings	  have	  been	   supported	  by	  more	   recent	  clinical	   trials	   showing	   an	   improvement	   in	   systolic	   LV	   function	   (Rosano,	   Vitale	   et	   al.	  2003).	  	  
In	   animal	   models,	   trimetazadine	   has	   been	   beneficial	   in	   reducing	   injury	   following	  ischaemia/reperfusion	   thus	   could	   improve	   recovery	   of	   cardiac	   function.	   These	  cardioprotective	   effects	   appear	   to	   be	   through	   activation	   of	   Akt	   signalling	   pathways	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particularly	  when	  administered	  before	  reperfusion	  (Khan,	  Meduru	  et	  al.	  2010)	  and	  the	  anti-­‐apoptotic	   features	  post	   ischaemia/reperfusion	  evident	   in	  animal	  studies	  (Ruixing,	  Wenwu	  et	  al.	  2007).	  	  
However	   in	   June	   2012	   the	   European	  Medicines	   Agency	   recommended	   restricting	   the	  use	   of	   trimetazadine	   containing	   medicines	   due	   to	   concerns	   regarding	   the	   efficacy	   of	  trimetazadine.	   There	   were	   also	   concerns	   regarding	   movement	   disorders	   such	   as	  Parkinsonian	   symptoms	   (Agency	   2013).	   Therefore	   the	   Agency’s	   Committee	   for	  Medicinal	   Products	   for	   Human	   Use	   (CHMP)	   concluded	   that	   there	   was	   no	   positive	  beneficial	   balance	   that	   outweighed	   the	   risks	   associated	   with	   trimetazadine,	   and	  trimetazadine	  should	  only	  be	  used	  as	  an	  add-­‐on	   in	  patients	  with	  angina	  pectoris,	  who	  are	  inadequately	  controlled	  or	  intolerant	  to	  other	  medications.	  	  
1.7.4 Ranolazine	  	  
Ranolazine	  is	  also	  an	  oral	  anti-­‐ischaemic	  agent	  and	  has	  shown	  to	  be	  effective	  in	  patients	  with	  angina,	  restricting	  the	  extent	  of	  ischaemic	  damange	  (Iliceto,	  Scrutinio	  et	  al.	  1995).	  Its	   effects	   are	   most	   evident	   in	   low-­‐flow	   ischaemia	   or	   normoxia,	   with	   no	   protective	  benefits	   during	   complete	   cessation	   of	   flow	   (Black,	   Gralinski	   et	   al.	   1994).	   Despite	   the	  extensive	   experimental	   and	   animal	   studies	   that	   show	   significant	   increases	   in	   glucose	  oxidation	  and	  reduction	  in	  fatty	  acid	  oxidation,	  it’s	  limitation	  during	  no	  flow	  makes	  this	  unsuitable	  for	  practice	  during	  cardiac	  surgery	  (cessation	  of	  coronary	  perfusion).	  	  	  	  
1.7.5 Inhibition	  of	  free	  fatty	  acid	  oxidation	  
Inhibition	   of	   free	   fatty	   acid	   oxidation	   would	   promote	   the	   more	   efficient	   glucose	  oxidation	   pathway	   and	   would	   switch	   the	   substrates	   being	   utilized	   towards	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carbohydrates.	  Carnitine	  palmitoyltransferase	  1	  (CPT1)	  is	  a	  key	  enzyme	  involved	  in	  free	  fatty	   acid	  uptake	   into	   the	  mitochondrion.	  Therefore	   inhibition	  of	   this	  key	   step	   should	  inhibit	  FFA	  oxidation,	  thereby	  increasing	  the	  oxidation	  of	  glucose.	  	  
CPT1	  inhibition	  has	  shown	  to	  reduce	  fatty	  acid	  oxidation	  and	  increase	  glucose	  oxidation	  (Higgins,	   Morville	   et	   al.	   1980;	   Lopaschuk,	   Wall	   et	   al.	   1988;	   Schwartz,	   Greyson	   et	   al.	  1994).	  These	  studies	  used	  either	  etomoxir	  or	  oxfenicine	   for	  CPT1	   inhibition	  and	   their	  use	   in	   clinical	   practice	   is	   limited.	   Alternatively	   perhexiline	   has	   been	   used	   widely	   in	  clinical	  practice	  and	  has	  shown	  to	  be	  an	  effective	  CPT1	  inhibitor.	  Therefore	  there	  was	  potential	   to	   translate	   its	   cardioprotective	   benefits	   as	   an	   adjunct	   to	   standard	  cardioplegia	  for	  myocardial	  protection	  during	  cardiac	  surgery.	  	  
1.7.6 Clinical	  use	  of	  adjuncts	  in	  myocardial	  protection	  
GIK	   therapy	   in	   its	   role	   as	   a	   metabolic	   modulating	   adjunct	   to	   standard	   myocardial	  protection	  with	   cardioplegia	   during	   cardiac	   surgery	   has	   been	  widely	   and	   extensively	  evaluated.	   It	   has	   been	   found	   to	   be	   extremely	   beneficial.	   The	   other	   metabolic	   agents	  described	  above	  are	  less	  extensively	  evaluated	  particularly	  with	  cardiac	  surgery.	  	  
As	  a	  component	  of	  his	  thesis,	  Drury	  performed	  a	  systematic	  review	  of	  the	  literature	  to	  examine	  the	  extent	  of	  use	  of	  other	  metabolic	  agents	  as	  adjuncts	  to	  standard	  myocardial	  protection	   during	   cardiac	   surgery.	   Only	   eight	   studies	   were	   included,	   7	   using	  trimetazadine	   and	  1	   using	   trimetazadine	   and	  mildronate.	  None	   of	   the	   other	   potential	  agents	  have	  been	   tested	  clinically	   in	  cardiac	  surgery.	  He	  concluded	   that	  most	  of	   these	  trials	   were	   inadequately	   designed	   to	   effectively	   judge	   clinically	   important	   outcomes	  (Drury	  2012).	  The	  use	  of	  perhexiline	  as	  an	  adjunct	   to	  myocardial	  protection	  has	  only	  been	  studied	  recently,	  by	  our	  group,	  in	  patients	  undergoing	  CABG.	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1.8 Perhexiline	  
1.8.1 Overview	  	  
Perhexiline	  was	   initially	  developed	  by	  Richardson-­‐Merrell	  Pharmaceuticals	   in	   the	   late	  1960s.	  It	  was	  first	  marketed	  in	  France	  as	  an	  anti-­‐anginal	  agent	  and	  it	  was	  first	  marketed	  in	  the	  UK	  in	  1975.	  Although	  the	  exact	  mechanism	  of	  action	  was	  not	  elucidated	  until	  the	  mid	  1990s,	  perhexiline	  proved	  to	  improve	  symptoms	  by	  promoting	  an	  efficient	  cardiac	  metabolism.	  	  
However	   due	   to	   a	   number	   of	   reports	   related	   to	   hepatic	   and	   neurotoxicity	   caused	   by	  perhexiline,	   it	   fell	   out	   of	   favour	   and	  was	  withdrawn	   from	   the	  UK	  market	   in	   1985.	  By	  1988	  many	  other	  countries	  had	  followed	  the	  trend	  set	  by	  the	  UK;	  however	  in	  Australia	  and	   New	   Zealand	   perhexiline	   continued	   to	   be	   prescribed	   to	   patients	   who	   were	   on	  maximum	  alternative	  medical	  therapy.	  	  	  
Over	   time,	   the	   relation	   between	   perhexiline	   concentration	   and	   toxicity	   was	   better	  understood.	  Furthermore	  the	  pharmacokinetics	  and	  genetic	  basis	  for	  the	  metabolism	  of	  perhexiline	   became	   clearer.	   This	   prompted	   strict	   monitoring	   of	   plasma	   perhexiline	  concentrations	   and	   the	   identification	   of	   individuals	   who	   were	   poor	   metabolisers	   of	  perhexiline.	   Therefore	   at	   present	   in	   the	   UK,	   perhexiline	   is	   prescribed	   on	   a	   named	  patient	  basis	  with	  strict	  plasma	  concentration	  monitoring.	  	  
1.8.2 Composition	  and	  chemistry	  	  
Perhexiline	   is	  2-­‐(2,2-­‐dicyclohexylethyl)	  piperidine	   (Figure	  1-­‐7)	  and	  consists	  of	   a	   –CH-­‐CH2	   carbon	   chain	   backbone	   with	   three	   six	   membered	   rings	   and	   has	   the	   chemical	  
	  1-­‐61	  
formula	  C19H35N.	  Two	  of	   the	   rings	   are	   saturated	   cyclohexane	   rings	   and	   the	  other	   is	   a	  pyridine	  group.	  	  
	  
Figure	  1-­‐7	  Chemical	  structure	  of	  perhexiline	  
The	  molecule	  is	  amphiphilic	  in	  nature	  as	  the	  cyclohexane	  residues	  are	  hydrophobic	  and	  the	  pyridine	  group	  is	  hydrophilic,	  as	  it	  forms	  hydrogen	  bonds	  with	  the	  maleate	  oxygen	  atoms	  (Ashrafian,	  Horowitz	  et	  al.	  2007).	  	  
Perhexiline	   can	   be	   prepared	   through	   the	   catalytic	   hydration	   of	   2-­‐(2,2-­‐diphenylethyl)	  pyridine.	   Pharmaceutical	   preparations	   contain	   perhexiline’s	   maleate	   salts,	   although	  perhexiline	   hydrochloride	   is	   clinically	   effective.	   Perhexiline	   maleate	   salts	   contain	   a	  racemic	  mixture	  of	  (+)	  and	  (-­‐)	  enantiomers.	  Perhexiline	  salts	  have	  a	  white	  appearance	  and	   are	   odourless.	   They	   are	   aqueously	   soluble	   and	   form	   a	   crystalline	   powder,	  which	  melts	  at	  245	  °C.	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1.8.3 Early	  work	  with	  perhexiline	  
Over	   the	   last	   40	   years,	   efforts	  have	  been	  made	   to	  understand	   fully	   the	  mechanism	  of	  action	  of	  perhexiline.	  The	  development	  of	  perhexiline	  was	  based	  on	  the	  promise	  shown	  by	  a	  related	  compound,	  hexadylamine.	   In	  1962	  Rowe	  et	  al	   (Rowe,	  Afonso	  et	  al.	  1963)	  showed	   that	   hexadylamine	   increased	   cardiac	   oxygen	   efficiency;	   increasing	   coronary	  vasodilatory	   properties	   and	   cardiac	   output	  whilst	  maintaining	   constant	   cardiac	  work	  with	  a	  reduced	  cardiac	  oxygen	  extraction.	  	  
Perhexiline	  was	   found	   to	   improve	   cardiac	   efficiency,	   but	   the	  mode	   of	   action	   through	  which	  this	  was	  achieved	  has	  never	  been	  fully	  understood.	  A	  number	  of	   in-­‐vivo	  and	   in-­‐
vitro	  experiments	  in	  the	  1970s	  have	  tried	  to	  delineate	  the	  mechanism	  of	  action.	  Initially	  perhexiline	   was	   found	   to	   have	   vasodilatory	   properties	   in	   both	   the	   coronary	   and	  systemic	   circulation,	   without	   affecting	   the	   femoral	   blood	   flow	   despite	   a	   drop	   in	   the	  systemic	   blood	   pressure	   (Hudak,	   Lewis	   et	   al.	   1970).	   A	   canine	   right	   heart	   perfusion	  model	  employed	  by	  Cho	  and	  colleagues	  (Cho,	  Belej	  et	  al.	  1970)	  showed	  that	  perhexiline	  increased	   cardiac	  metabolic	   efficiency	  whist	   improving	   the	   parameters	   of	  mechanical	  cardiac	   function.	   Perhexiline	   given	   intravenously	   at	   1-­‐2mg/kg	   decreased	   the	   left	  ventricular	   work	   (blood	   pressure	   x	   cardiac	   output)	   and	   increased	   the	   index	   of	   left	  ventricular	   efficiency	   (change	   in	   left	   ventricular	   work/change	   in	   myocardial	   oxygen	  consumption).	  Similarly	  direct	   injection	  of	  perhexiline	   to	   the	  circumflex	  branch	  of	   the	  left	  coronary	  artery	  increased	  coronary	  blood	  flow	  in	  a	  dose	  dependent	  manner	  (Hudak,	  Lewis	   et	   al.	   1970).	   Thus	   far,	   animal	   models	   have	   shown	   that	   perhexiline	   improves	  cardiac	  efficiency,	  by	  improving	  coronary	  circulation	  and	  hence	  cardiac	  function.	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A	  human	  model	  to	  elucidate	  the	  effects	  of	  perhexiline	  was	  undertaken	  in	  patients	  with	  angina	  pectoris	  with	  angiographically	  proven	  coronary	  artery	  disease	  (Pepine,	  Schang	  et	  al.	  1974).	  Patients	  received	  200mg	  of	  perhexiline	  bd	  for	  2	  weeks.	  This	  study	  showed	  that	   perhexiline	   decreased	   heart	   rate	   and	   increased	   stroke	   volume	   and	   exercise	  tolerance	   with	   reduced	   angina.	   Furthermore	   perhexiline	   reduced	   myocardial	   lactate	  extraction	   and	   enhanced	   myocardial	   oxygen	   extraction.	   Coronary	   flow	   reflected	   by	  coronary	  sinus	  blood	  flow	  was	  unaltered	  whilst	   left	  ventricular	  oxygen	  utilisation	  was	  increased.	  	  At	  this	  stage	  it	  was	  only	  a	  hypothetical	  assumption	  that	  perhexiline	  induced	  an	  efficient	  cardiac	  metabolism	  by	  creating	  a	  shift	  towards	  carbohydrate	  utilisation.	  
1.8.4 Mechanism	  of	  action	  
This	   hypothesis	   that	   perhexiline	   promoted	   carbohydrate	   metabolism	   over	   fatty	   acid	  metabolism	  was	  evaluated	  in	  the	  early	  1990s.	  Free	  fatty	  acid	  metabolism	  would	  require	  more	   oxygen	   to	   generate	   the	   same	   number	   of	   ATP;	   therefore	   conversion	   to	  carbohydrate	  metabolism	  seemed	  a	  plausible	  explanation	  to	  achieve	  greater	  efficiency.	  Dechamps	  and	  colleagues	  treated	  ex-­‐vivo	   rat	  heart	  preparations	  and	  hepatocytes	  with	  perhexiline	   for	   72	   hours	   and	   showed	   a	   reduction	   in	   β-­‐oxidation	   of	   fatty	   acids	  (Deschamps,	  DeBeco	  et	  al.	  1994).	  Yet	  the	  exact	  mechanism	  of	  promoting	  carbohydrate	  metabolism	  was	  unclear.	  	  
Kennedy	  and	  colleagues	  hypothesised	  that	  the	  mechanism	  of	  action	  was	  likely	  to	  be	  by	  the	   inhibition	   of	   carnitine	   palminotyltransferase-­‐1	   (CPT-­‐1)	   (Kennedy,	   Unger	   et	   al.	  1996).	   The	   enzyme	   CPT-­‐1	   controls	   the	   access	   of	   long	   chain	   fatty	   acids	   to	   the	  mitochondrial	   site	   for	   β-­‐oxidation.	   Similarly	   other	   agents	   that	   promote	   carbohydrate	  metabolism	   have	   a	   similar	  mode	   of	   action.	   	   Kennedy	   et	   al,	   demonstrated	   perhexiline	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produced	   a	   concentration	   dependent	   inhibition	   of	   CPT-­‐1	   in	   rat	   cardiac	   and	   hepatic	  mitochondria	  in-­‐vitro.	  The	  experiments	  used	  homogenised	  cardiac	  and	  liver	  tissue	  from	  male	  Sprague-­‐Dawley	  rats	  treated	  with	  perhexiline.	  Furthermore	  there	  was	  competitive	  inhibition	  of	  cardiac	  and	  hepatic	  CPT-­‐1	  with	  perhexiline	  with	  respect	  to	  palmitoly-­‐CoA	  but	  non-­‐competitive	  inhibition	  with	  respect	  to	  carnitine.	  Perhexiline	  was	  found	  to	  be	  a	  competitive	   inhibitor	   of	   CPT-­‐1,	   with	   the	   endogenous	   CPT-­‐1	   inhibitor	   malonyl-­‐CoA.	  Treatment	   with	   the	   nargase	   protease,	   demonstrated	   that	   perhexiline	   acted	   at	   an	  independent	  mitochondrial	   site	   not	   amenable	   to	   proteolysis,	   unlike	  malonyl-­‐CoA	   and	  other	  CPT-­‐1	  inhibitors	  (Kennedy,	  Unger	  et	  al.	  1996).	  Moreover,	  there	  was	  also	  a	  greater	  inhibition	  to	  cardiac	  CPT-­‐1	  than	  hepatic	  CPT-­‐1	  with	  perhexiline.	  	  
Therefore	   perhexiline	   has	   been	   classified	   as	   a	   fatty	   acid	   oxidation	   inhibitor	   (FAOI),	  inhibiting	  fatty	  acid	  metabolism	  in	  the	  myocardium	  at	  CPT-­‐1	  level.	  Other	  FAOI	  include	  etomixir,	  oxfenicine	  and	  amiodarone.	  Beyond	  the	  scope	  of	   the	  myocardium,	  FAOI	  may	  have	   a	   systemic	   effect	   and	   may	   inhibit	   fatty	   acid	   metabolism	   in	   the	   liver;	   reducing	  systemic	  ketone	  body	  levels	  and	  mitigating	  detrimental	  mitochondrial	  lipid	  metabolism	  (Ashrafian,	   Horowitz	   et	   al.	   2007).	   Due	   to	   the	   competitive	   inhibition	   of	   CPT-­‐1,	  perhexiline	  is	  classified	  as	  a	  partial	  FAOI	  inhibitor.	  	  
Beyond	  CPT-­‐1	  inhibition,	  perhexiline	  has	  been	  found	  to	  have	  other	  mechanistic	  actions.	  Palmitate	  oxidation	  is	  inhibited	  in	  cardiomyocytes	  after	  48	  hours	  of	  pre-­‐exposure	  with	  perhexiline	   (Unger,	   Kennedy	   et	   al.	   2005).	   Therefore	   this	   study	   proposed	   that	   the	  increased	   myocardial	   efficiency	   observed	   in	   working	   non-­‐ischaemic	   rat	   hearts	   was	  independent	  of	  perhexiline’s	  effects	  on	  CPT-­‐inhibition.	  Furthermore,	  perhexiline	  has	  a	  number	   of	   electrophysiological	   effects,	   yet	   the	   relevance	   and	   significance	   is	   unclear.	  Barry	  et	  al	  demonstrated	  that	  perhexiline	  altered	  myocellular	  electrical	  activity	  through	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the	  blockade	  of	  voltage	  gated	  L-­‐type	  calcium	  channels	  (Barry,	  Horowitz	  et	  al.	  1985)	  and	  similarly,	  Grima	  et	  al	  demonstrated	  the	  blockade	  of	  Sodium	  channels	  (Grima,	  Velly	  et	  al.	  1988).	  These	   electrophysiological	   effects	  may	  demonstrate	   a	  negative	   inotropic	   effect	  depending	  on	   the	  degree	  of	   inhibition	  of	   calcium	   influx	   (Barry,	  Horowitz	  et	   al.	   1985).	  Perhexiline	   also	   blocks	   cardiac	   K+	   channels	   (Rampe,	  Wang	   et	   al.	   1995).	   Rampe	   et	   al	  found	   that	   perhexiline	   blocks	   both	   the	  K+	   channels	   in	   human	   embryonic	   kidney	   cells	  and	   the	   ultra-­‐rapid	   delayed	   rectifier	   in	   human	   atrial	   myocytes.	   Furthermore,	  perhexiline	   causes	   a	   blockade	   of	   the	   Human-­‐Ether-­‐a-­‐go-­‐go	   Related	   Gene	   (HERG),	   a	  subunit	  of	   the	  potassium	  ion	  channel,	  and	   is	   likely	   to	  be	  the	  cause	  of	  QT	  prolongation	  (Walker,	  Valenzuela	  et	  al.	  1999).	  	  	  
1.8.5 Metabolism	  and	  pharmacokinetics	  
During	   the	   early	   use	   of	   perhexiline	   as	   an	   anti-­‐anginal,	   the	   mechanism	   by	   which	  perhexiline	  was	  metabolised	  was	  not	  fully	  understood.	  Perhexiline	  metabolism	  is	  highly	  variable	  between	  individuals	  and	  those	  that	  did	  not	  metabolism	  perhexiline	  adequately	  developed	  perhexiline	  toxicity.	  This	  variability	  in	  metabolism	  and	  associated	  toxicity	  led	  to	   perhexiline’s	   unfavourable	   predisposition	   as	   an	   anti-­‐anginal	   agent.	   Patients	   who	  developed	  toxicity	  had	  neuropathy	  and	  liver	  damage.	  	  
Perhexiline	  is	  well	  absorbed	  orally,	  with	  absorption	  almost	  complete	  by	  12	  hours	  of	  the	  dose.	   Bioavailability	   studies	   in	   the	   1970s	   showed	   that	   perhexiline	   and	   metabolites	  continued	  to	  accumulate	  over	  time.	  Furthermore,	  perhexiline	   is	  metabolised	  primarily	  through	  oxidative	  pathways	  in	  the	  liver	  and	  the	  derivatives	  excreted	  by	  urine	  are	  either	  mono	   or	   dihydroxylated	   variants	   or	   their	   derivatives	   (Wright,	   Leeson	   et	   al.	   1973).	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Thus,	  perhexiline	  is	  predominately	  metabolised	  to	  cis-­‐monohydroxy	  derivative	  (cis-­‐OH-­‐perhexiline).	  	  
Singlas	  and	  colleagues	  further	  explored	  the	  variability	  to	  perhexiline	  metabolism.	  They	  found	   that	   patients	   with	   neuropathy	   exhibited	   higher	   plasma	   levels	   of	   perhexiline,	  slower	   hepatic	  metabolism	   and	   a	   longer	   plasma	   half-­‐life	   (Singlas,	   Goujet	   et	   al.	   1978;	  Singlas,	   Goujet	   et	   al.	   1978).	   Perhexiline	   to	  metabolite	   ratio	  was	   nine	   times	   greater	   in	  those	   with	   neuropathy	   than	   those	   without	   toxicity.	   Thus,	   patients	   can	   be	   broadly	  divided	  into	  2	  groups,	  those	  that	  have	  no	  evidence	  of	  toxicity	  and	  are	  able	  to	  metabolise	  perhexiline	  and	  those	  that	  have	  toxicity	  and	  hence	  poorer	  metabolisers	  of	  perhexiline.	  The	  reason	  for	  this	  variation	  in	  metabolism	  was	  yet	  to	  be	  identified	  and	  was	  thought	  to	  be	  genetic	  differences	  between	  individuals	  or	  hepatic	  damage	  caused	  by	  perhexiline.	  	  
Several	  drug	  oxidations	   in	  humans	  are	  controlled	  by	  a	  single	  gene	  and	  exhibit	  genetic	  polymorphism	   (Mahgoub,	   Idle	   et	   al.	   1977;	   Sloan,	   Mahgoub	   et	   al.	   1978).	   The	   anti-­‐hypertensive	  drug	  debrisoquine	  is	  extensively	  oxidised	  by	  most	  individuals	  and	  can	  be	  used	   to	   evaluate	   the	   genetic	   structure	   of	   a	   population	   with	   respect	   to	   oxidation.	  Oxidation	  is	  regulated	  by	  2	  alleles;	  one	  for	  rapid	  and	  extensive	  oxidation	  and	  the	  other	  for	   slow	   impaired	   oxidation.	   Those	   who	   are	   homozygous	   for	   the	   slow	   impaired	  oxidation	   are	   poor	   metabolisers	   and	   have	   impaired	   ability	   to	   oxidise	   several	   other	  drugs	   besides	   debrisoquine.	   Shah	   et	   al	   demonstrated	   a	   clear	   association	   between	  perhexiline	   induced	   neuropathy	   and	   diminished	   drug	   metabolic	   ability	   as	   shown	   by	  debrisoquine	   hydroxylation	   (Shah,	   Oates	   et	   al.	   1982).	   Those	   with	   poor	   metaboliser	  phenotype	   are	   at	   a	   higher	   risk	   of	   developing	   neuropathy	   from	   long-­‐term	   use	   of	  perhexiline	   and	   the	   risk	   is	   reduced	   in	   extensive	   metabolisers.	   Therefore	   perhexiline	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would	  tend	  to	  accumulate	  in	  individuals	  with	  an	  impaired	  drug	  oxidising	  ability	  due	  to	  defective	  metabolic	  elimination.	  	  
Following	  these	  initial	  studies,	  although	  the	  association	  between	  a	  poor	  metaboliser	  and	  high	   accumulation	   of	   perhexiline	   was	   known,	   the	   molecular	   substrate	   for	   the	  polymorphism	  was	   less	   clear.	   In	   a	   landmark	   study	   in	   1988,	   Gonzalez	   and	   colleagues	  identified	  the	  gene	  responsible	  for	  the	  polymorphic	  variation	  predisposing	  individuals	  to	   be	   poor	   metaboliser	   (Gonzalez,	   Skoda	   et	   al.	   1988).	   They	   showed	   that	   poor	  metabolisers	   have	   negligible	   amounts	   of	   the	   cytochrome	   P450	   enzyme	   P450db1.	  Furthermore	  they	  identified	  three	  variant	  messenger	  RNAs	  that	  are	  products	  of	  mutant	  genes	   producing	   incorrectly	   spliced	   db1	   pre-­‐mRNA.	   This	   provided	   a	   molecular	  explanation	   for	   the	   commonest	  defective	  gene	   in	  humans,	  which	   is	   represented	  as	  an	  autosomally	   inherited	   trait	   differentiating	   poor	   metabolisers	   from	   extensive	  metabolisers;	  deficiency	  in	  CYP2D6	  activity	  is	  inherited	  as	  an	  autosomal	  recessive	  trait.	  This	  study	  again	  was	  based	  on	  patients	  who	  had	  a	  defect	  on	  debrisoquine	  metabolism.	  However	   this	   same	  genetic	   defect	   predisposed	   individuals	   to	  poorly	  metabolise	  more	  than	  30	   commonly	  used	  medications	   in	  different	   categories.	  The	  gene	   responsible	   for	  this	  polymorphism	  is	  a	  member	  of	  the	  P450	  family	  and	  named	  CYP2D6.	  	  
The	  metabolism	  of	  perhexiline	   is	   thus	  dependent	  on	   the	  CYP2D6	   gene	  and	   its	   activity	  (Sorensen,	   Sorensen	   et	   al.	   2003).	   Furthermore,	   the	  metabolism	  within	   each	   group	   is	  highly	  variable	  with	  a	  100-­‐fold	  difference	  between	  the	  poor	  and	  extensive	  metaboliser	  groups.	   Individuals	   can	   be	   further	   classified	   into	   three	   categories:	   poor	  metabolisers,	  extensive	   metabolisers	   and	   ultra-­‐rapid	   metabolisers	   (Sallustio,	   Westley	   et	   al.	   2002).	  This	  categorisation	  was	  consistent	  with	  CYP2D6	  metabolism	  and	  those	  who	  were	  ultra-­‐rapid	  metabolisers	  required	  up	  to	  500	  mg/day	  of	  perhexiline	  compared	  to	  10-­‐25mg	  of	  
	  1-­‐68	  
perhexiline	   for	   the	   poor	   metabolisers.	   The	   ratio	   of	   cis-­‐OH-­‐perhexiline	  metabolite/parent	   plasma	   perhexiline	   concentration	   was	   used	   as	   an	   indication	   of	  perhexiline	  metabolism.	  Furthermore	  a	  study	  by	  Davies	  et	  al	  showed	  that	  patients	  with	  only	  1	  functional	  CYP2D6	  allele	  had	  a	  higher	  plasma	  concentration	  of	  perhexiline	  and	  a	  lower	  metabolic	  ratio	  compared	  to	  patients	  with	  2	  functional	  alleles	  and	  concluded	  that	  patients	   with	   one	   functional	   allele	   have	   diminished	   CYP2D6	   metabolic	   capacity	   for	  perhexiline	  (Davies,	  Coller	  et	  al.	  2006).	  	  
Therefore	   a	   direct	   correlation	   between	   CYP2D6	   activity	   and	   perhexiline	   metabolism	  (cis-­‐OH-­‐perhexiline	   metabolite/parent	   plasma	   perhexiline	   concentration)	   was	   made	  and	  could	  be	  used	  to	  assess	  the	  dosing	  requirements	  and	  identify	  those	  at	  greatest	  risk	  of	  developing	  side	  effects.	  	  
1.8.6 Side	  effects	  and	  toxicity	  	  
The	  poor	  metabolisers	  are	  most	  at	  risk	  of	  developing	  side	  effects	  and	  toxicity	  and	  the	  prevalence	  of	  poor	  metabolisers	  vary	  according	  to	  race.	  In	  European	  and	  US	  Caucasians	  poor	   metabolisers	   constitute	   7	   –	   10%	   of	   the	   population	   and	   harbour	   mutations	   of	  
CYP2D6.	   In	   African	   Americans	   however,	   only	   1.9%	   of	   the	   population	   are	   poor	  metabolisers	   (Evans,	   Relling	   et	   al.	   1993).	   In	   the	   Chinese,	   Japanese	   and	   Korean	  population,	  incidence	  is	  even	  lower	  at	  1%	  (Gardiner	  and	  Begg	  2006).	  	  	  
Side	   effects	   and	   toxicity	   associated	  with	   perhexiline	   is	   outline	   in	   (Table	   1-­‐4).	   Serious	  toxicity	   takes	   up	   to	   3	   months	   to	   develop.	   Minor	   side	   effects	   may	   improve	   with	   a	  reduction	   in	   the	   oral	   drug	   therapy	   regime	   and	   does	   not	   necessitate	   in	   drug	  discontinuation	  (Killalea	  and	  Krum	  2001).	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Minor	  side	  effect	   Major	  side	  effects	  and	  toxicity	  Dizziness	   Neurotoxicity/neuropathy	  Headache	   Hepatotoxicity/liver	  failure	  Nausea	   Hypoglycaemia	  	  Vomiting	   	  Diarrhea	   	  Tremor	   	  Lethargy	   	  Insomnia	   	  Loss	  of	  libido	   	  
Table	  1-­‐4	  Minor	  and	  major	  side	  effects	  of	  perhexiline	   	  
Major	   side	   effects	   and	   toxicity	   was	   observed	   in	   patients	   who	   were	   on	   long-­‐term	  perhexiline	   therapy.	   By	   August	   1983,	   80	   cases	   of	   hepatotoxicity	   and	   131	   cases	   of	  neuropathy	  had	  been	  reported	  in	  the	  United	  Kingdom	  (Shah	  2006).	  Similarly	  over	  a	  20-­‐year	   period	   from	   1974,	   46	   cases	   of	   hepatic	   adverse	   events	   due	   to	   perhexiline	   were	  reported	   in	   New	   Zealand	   (Pillans	   1996).	   The	   majority	   of	   reported	   adverse	   events	  occurred	   before	   the	   monitoring	   era.	   We	   are	   also	   now	   aware	   that	   the	   side	   effects	  observed	   are	   likely	   due	   to	   perhexiline	   accumulation	   amongst	   poor	   metabolisers	   and	  hence	  most	  evident	  in	  patients	  on	  long	  term	  therapy.	  	  
The	  molecular	  basis	  for	  the	  side	  effects	  observed	  with	  perhexiline	  accumulation	  is	  not	  very	  well	  understood.	  Speculation	  is	  that	  the	  adverse	  reactions	  are	  a	  result	  of	  excessive	  CPT-­‐1	   and	   hence	   fatty	   acid	   metabolism	   inhibition	   (Ashrafian,	   Horowitz	   et	   al.	   2007).	  Excessive	  CPT-­‐1	   inhibition	  would	   lead	   to	  upstream	   cytoplasmic	   accumulation	  of	   fatty	  acids	  and	   their	  derivatives	  and	  decreased	  downstream	  derivatives.	  Excess	  perhexiline	  may	  lead	  to	  a	  pathology	  termed	  pseudo-­‐alcoholic	  hepatitis;	  changes	  similar	  to	  alcoholic	  liver	  disease	  with	  cellular	  changes	  consistent	  with	  macro	  and	  microvascular	  steatosis,	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ballooning	   of	   hepatocytes	   and	   Mallory	   bodies.	   Furthermore	   phospolipidosis	   and	  accumulation	   of	   triglycerides	   and	   fatty	   acids	   were	   identified	   by	   studies	   using	  ultrastructure	   and	   histoenzymological	   techniques	   on	   cultured	   liver	   cells	   (Lageron,	  Scotto	  et	  al.	  1981).	  These	  changes	  were	  also	  evident	  in	  peripheral	  nerve	  Schwann	  cells.	  	  
These	  established	  cellular	  changes	   to	  perhexiline	  excess	  and	   the	  reported	  evidence	  of	  toxicity	   based	   on	   long-­‐term	   perhexiline	   use	   required	   a	   dose-­‐adjusted	   regime	   in	  perhexiline	  therapy.	  	  
1.8.7 Dosing	  regime	  with	  oral	  therapy	  	  
Poor	  metabolisers	  are	  at	  greatest	  risk	  of	  developing	  adverse	  events.	  Perhexiline	  plasma	  levels	  need	  to	  be	  monitored	  and	  early	  identification	  of	  poor	  metabolisers	  based	  on	  the	  perhexiline	  to	  metabolite	  ratio	  would	  allow	  appropriate	  dose	  adjustments	  in	  this	  group	  of	   individuals.	   Therefore	   ideally	   therapeutic	   monitoring	   should	   be	   carried	   out	  particularly	   in	   this	   group	   of	   individuals.	   Perhexiline	   is	   being	   used	   extensively	   in	  Australia	  and	  New	  Zealand	  with	  appropriate	  plasma	  monitoring	  and	  dose	  adjustments	  (Ashrafian,	   Horowitz	   et	   al.	   2007).	   Furthermore	   metabolic	   ratio	   of	   perhexiline	   to	  monohydroxyperhexiline	  may	  be	  used	   as	   a	   diagnostic	   tool	   to	  differentiate	  ultra-­‐rapid	  metabolisers,	  extensive	  metabolisers	  and	  poor	  metabolisers.	  	  
Horowitz	   et	   al	   pioneered	   a	   regime	   to	   appropriately	   manage	   the	   sub-­‐group	   of	   poor	  metabolisers.	   They	   recognised	   that	   patients	   who	   developed	   hepatic	   and	   neurological	  side	   effects	   had	   plasma	   perhexiline	   concentrations	   of	   720	   –	   2680	   µg/L	   on	   doses	   of	  perhexiline	   ranging	   from	   50	   –	   400	   mg/day.	   Furthermore,	   this	   study	   showed	   that	  patients	   with	   a	   plasma	   concentration	   of	   <	   600	   µg/L	   (mean	   dosage	   approximately	  160mg/day)	   had	   no	   side	   effects	   (Horowitz,	   Sia	   et	   al.	   1986).	   This	   maintenance	   of	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perhexiline	   concentrations	   could	   aid	   long-­‐term	   therapy	   with	   no	   adverse	   events.	  Similarly	   other	   studies	   have	   corroborated	   these	   finding	   (Pilcher,	   Cooper	   et	   al.	   1985;	  Cole,	  Beamer	  et	  al.	  1990;	  Stewart,	  Voss	  et	  al.	  1996).	  	  
A	  gradual	  loading	  regime	  and	  dose	  adjustment	  based	  on	  perhexiline	  to	  metabolite	  ratios	  is	  ideal	  to	  avoid	  an	  increase	  in	  plasma	  perhexiline	  levels.	  However	  a	  fast	  loading	  regime	  exists	   in	   patients	   treated	   for	   ACS	   and	  may	   incur	   side	   effects	   (Philpott,	   Chandy	   et	   al.	  2004).	  	  
We	   know	   that	   perhexiline	   is	   metabolised	   in	   the	   liver,	   and	   despite	   the	   known	  requirement	  for	  CYP2D6	  activity,	  extra	  caution	  should	  be	  taken	  in	  patients	  with	  existing	  liver	   disease;	   perhexiline	   metabolism	   may	   be	   impaired	   with	   underlying	   liver	  impairment.	   Furthermore	   as	   perhexiline	   is	   metabolized	   by	   CYP2D6	   activity,	  consideration	   should	   be	   made	   towards	   other	   drugs	   that	   interfere	   with	   this	   enzyme	  system	  i.e.	  SSRI	  such	  as	  fluoxetine	  (Alderman,	  Hundertmark	  et	  al.	  1997).	  
It	   is	   evident	   that	   adverse	   reactions	   to	   perhexiline	   are	   consistent	   with	   long-­‐term	  perhexiline	   therapy	   in	   conjunction	   with	   poor	   dose	   control,	   in	   relation	   to	   the	   rate	   at	  which	  perhexiline	  is	  metabolised	  on	  an	  individual	  basis.	  Therefore	  short-­‐term	  therapy	  without	   a	   fast	   loading	   regime	  may	   prove	   to	   be	   safe	   and	   effective	   particularly	   in	   the	  treatment	  of	  patients	  pre-­‐operatively	  (Horowitz,	  Sia	  et	  al.	  1986).	  	  
1.8.8 Pharmacogenetics	  
It	   is	   well	   established	   that	   perhexiline	   metabolism	   is	   controlled	   by	   CYP2D6	   activity.	  Individuals	  with	  2	  normal	  alleles	  are	  considered	  extensive	  metabolisers.	  Those	  with	  1	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normal	   allele	   are	   intermediate	   metabolisers	   but	   function	   as	   extensive	   metabolisers.	  Those	  with	  2	  poorly	  functioning	  alleles	  are	  poor	  metabolisers.	  	  
Barclay	  et	  al	  proposed	  that	  genotyping	  was	  able	  to	  identify	  poor	  metabolisers	  and	  the	  broad	  dose	  of	  these	  individuals	  could	  be	  predicted;	  yet	  therapeutic	  monitoring	  should	  not	   be	   avoided	   (Barclay,	   Sawyers	   et	   al.	   2003).	   Furthermore,	   perhexiline	   has	   been	  suggested	  as	  an	  ideal	  example	  for	  pharmacogenetic	  testing	  to	  rescue	  drugs	  withdrawn	  from	  the	  market	  (Shah	  2006).	  However,	   the	  use	  of	  pharmacogenetics	   is	  yet	   to	  be	  well	  established	  and	  would	  need	  appropriate	  ethical	  approvals	  and	   favourable	  cost-­‐benefit	  analysis	  before	  it	  is	  widely	  accepted	  for	  use.	  	  
1.8.9 Clinical	  benefits	  	  
Perhexiline	  is	  classed	  as	  a	  free	  fatty	  acid	  oxidation	  inhibitor	  and	  promotes	  carbohydrate	  metabolism	  through	  the	  mechanisms	  explained	  above.	  Carbohydrate	  metabolism	  is	  an	  energy	   efficient	   system	   utilising	   less	   oxygen	   and	   may	   improve	   cardiac	   energetics.	  Furthermore	   perhexiline	   may	   be	   able	   to	   ameliorate	   debt	   and	   improve	   coronary	  perfusion.	  Therefore	  perhexiline	  may	  be	  best	  suited	  in	  patients	  with	  myocardial	  oxygen	  deficiency	   such	   as	   ischaemic	   heart	   disease	   and	   aortic	   stenosis.	   Furthermore	   energy	  deficient	  pathologies	  such	  as	  heart	   failure	  and	  hypertrophic	  cardiomyopathy	  may	  also	  benefit	  from	  perhexiline’s	  efficient	  metabolic	  modulation.	  	  
1.8.9.1 Ischaemic	  heart	  disease	  
A	   systematic	   review	   was	   conducted	   to	   evaluate	   the	   efficacy	   and	   tolerability	   of	  perhexiline	  in	  the	  treatment	  of	  cardiac	  disease.	  Although	  the	  majority	  of	  the	  trials	  were	  of	  cross	  over	  design,	   this	  review	  found	  that	  perhexiline	   is	  considerably	  more	  effective	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than	   placebo	   when	   used	   as	   monotherapy.	   It	   further	   concludes	   that	   perhexiline	   adds	  further	   symptom	   relief	   in	   those	   patients	   on	   maximum	   conventional	   anti-­‐anginal	  therapy.	   Perhexiline	   also	   compared	   favourably	   with	   use	   of	   β-­‐blockers	   (Killalea	   and	  Krum	  2001).	   It	   has	  been	   shown	   that	  perhexiline	   is	  most	   efficacious	  when	   it’s	   used	   in	  patients	   with	   angina	   refractory	   to	   other	   medical	   and	   interventional	   therapies	  (Horowitz,	   Button	   et	   al.	   1995).	   Furthermore	   it	   has	   been	   used	   in	   acute	   coronary	  syndromes	  (ACS)	  and	  shown	  to	  be	  beneficial	  by	  potentiating	  platelet	  responsiveness	  to	  nitric	   oxide	   and	   was	   predictive	   of	   resolution	   of	   ischaemic	   symptoms	   in	   ACS	  (Willoughby,	  Stewart	  et	  al.	  2002).	  	  
1.8.9.2 Heart	  failure	  
Heart	  failure	  is	  considered	  a	  condition	  consistent	  with	  deranged	  substrate	  metabolism	  (Stanley,	   Recchia	   et	   al.	   2005).	   This	   deranged	   metabolism	   could	   lead	   to	   impaired	  myocardial	   energetics	   (Ingwall	   and	   Weiss	   2004).	   Therefore	   metabolic	   manipulation	  with	  perhexiline	  may	  prove	  to	  be	  beneficial	  in	  this	  group	  of	  patients.	  	  
In	  a	  double-­‐blind	  randomised	  placebo	  controlled	  trial,	  perhexiline	  was	  administered	  to	  patients	  with	  heart	  failure	  on	  maximum	  conservative	  medical	  therapy	  (Lee,	  Campbell	  et	  al.	   2005).	   This	   study	   showed	   a	   significant	   within	   group	   improvement	   in	   VO2max	   in	  patients	  administered	  perhexiline	  (16.1	  ±	  0.6	  to	  18.8	  ±	  1.1	  mL/kg/min;	  P<0.001),	  and	  similar	  changes	  between	  the	  groups.	  Perhexiline	  also	  improved	  the	  quality	  of	  life,	  based	  on	   the	  Minnesota	  score	   reduction.	  Furthermore	   there	  was	  significant	   improvement	   in	  left	   ventricular	   ejection	   fraction	   from	   24%	   ±	   1%	   to	   34%	   ±	   2%	   when	   treated	   with	  perhexiline.	  This	  proved	   to	  be	   a	  promising	  metabolic	   agent	   for	  patients	   on	  maximum	  medical	  therapy	  for	  heart	  failure.	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1.8.9.3 Aortic	  stenosis	  
With	   aortic	   stenosis,	   a	   state	   of	   relative	   oxygen	   debt	   may	   exist	   due	   to	   the	   decreased	  perfusion	   to	   an	   increasingly	   hypertrophied	   ventricle.	   In	   a	   study	   by	   Unger	   et	   al	   15	  elderly	   patients	   with	   severe	   aortic	   stenosis	   unsuitable	   for	   aortic	   valve	   replacement	  were	   treated	   with	   perhexiline	   (Unger,	   Robinson	   et	   al.	   1997).	   These	   patients	   were	  followed	  up	   for	  30	  months.	   In	  13	  patients,	   symptomatic	   status	   improved	   (in	   the	  1st	  3	  months)	  with	  5	  becoming	  asymptomatic.	  At	  12	  months	  actuarial	  survival	  was	  80%.	  This	  study	   has	   shown	   that	   in	   patients	   with	   aortic	   stenosis	   with	   likely	   left	   ventricular	  hypertrophy,	  perhexiline	  has	  been	  symptomatically	  beneficial.	  	  
1.8.9.4 Birmingham	  experience	  with	  perhexiline	  In	  a	  double-­‐blind	  placebo	  controlled	  RCT,	  Abozguia	  and	  colleagues	  recruited	  46	  patients	  with	   hypertrophic	   cardiomyopathy	   and	   administered	   oral	   perhexiline.	   Cardiac	  energetics	  were	  measured	   by	   evaluating	   the	   phosphocreatine	   to	  ATP	   (PCr:ATP)	   ratio	  using	  31P	  magnetic	  resonance	  spectroscopy	  at	  a	  mean	  follow	  up	  of	  4.6±1.8	  months.	  This	  study	  demonstrated	  an	  improved	  cardiac	  energetic	  state	  with	  perhexiline	  therapy,	  with	  an	   increase	   in	   PCr:ATP	   from	   1.27±0.02	   to	   1.73±0.02	   versus	   1.29±0.01	   to	   1.23±0.01;	  P<0.003.	  Furthermore,	   the	  primary	  end	  point	  of	  peak	  Vo2	   improved	   from	  22.2±0.2	   to	  24.3±0.2	   versus	   23.6±0.3	   to	   22.3±0.2	   mL/kg/min;	   P<0.003,	   with	   a	   significant	  improvement	   in	  NYHA	  class	  (Abozguia,	  Elliott	  et	  al.	  2010).	  This	  study	  in	  patients	  with	  hypertrophic	   cardiomyopathy	   demonstrated	   the	   clinical	   benefits	   of	   metabolic	  modulation	  with	   perhexiline,	   including	   increased	   cardiac	   energetics.	   These	   beneficial	  properties	   of	   perhexiline	   may	   render	   the	   ischaemic	   myocardium	   less	   susceptible	   to	  injury.	   The	   role	   of	   perhexiline	   as	   a	  metabolic	  modulator,	   to	   be	   used	   as	   an	   adjunct	   to	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standard	   myocardial	   protection	   during	   cardiac	   surgery	   (providing	   a	   controlled	  ischaemia/reperfusion	  phase)	  thus	  appeared	  worthy	  for	  further	  evaluation.	  	  
Therefore	  a	  randomised	  double-­‐blind	  placebo	  controlled	  trial	  was	  performed	  across	  2	  centres	  to	  evaluate	  the	  role	  of	  perhexiline	  in	  cardiac	  surgery.	  This	  study	  recruited	  286	  patients	  undergoing	  coronary	  artery	  bypass	  graft	  surgery	  only,	  over	  a	  3-­‐year	  period	  and	  randomised	   patients	   to	   receive	   oral	   perhexiline	   at	   least	   5	   days	   prior	   to	   surgery	   and	  assessed	  the	  outcome	  of	  low	  cardiac	  output	  episodes.	  This	  trial	  found	  the	  incidence	  of	  a	  low	  cardiac	  output	  episode	   in	   the	  perhexiline	  arm	  was	  36.7%	  (51/139)	  versus	  34.7%	  (51/147)	  in	  the	  control	  arm	  (odds	  ratio	  0.92	  [95%	  CI	  0.56–1.50];	  p=0.74).	  Furthermore	  there	  was	  no	  significant	  difference	  in	  the	  incidence	  of	  inotrope	  use	  or	  myocardial	  injury	  in	   addition	   to	   any	   other	   safety	   outcome	  measure	   i.e.	   reoperation,	   length	   of	   stay	   etc.	  Therefore	  in	  this	  large	  trial,	  oral	  perhexiline	  did	  not	  improve	  myocardial	  protection	  in	  patients	  undergoing	  CABG	  (Drury,	  Howell	  et	  al.	  2011;	  Drury	  2012).	  	  
The	   above	   study	   was	   conducted	   in	   patients	   with	   ischaemic	   heart	   disease	   requiring	  coronary	   artery	   bypass	   graft	   surgery.	   Although	   no	   formal	   left	   ventricular	   dimensions	  were	  measured	   in	   this	   study,	   some	   patients	   would	   have	   pathological	   left	   ventricular	  hypertrophy	   secondary	   to	   hypertension.	   Yet	   the	   majority	   would	   have	   normal	   left	  ventricular	   dimensions	  with	   normal	   left	   ventricular	  mass	   indices.	   The	   hypertrophied	  ventricle,	   as	  a	   result	  of	   the	  pathological	  processes	  of	  hypertrophy	  secondary	   to	  aortic	  stenosis,	  as	  explained	  earlier	  is	  more	  susceptible	  to	  ischaemic	  injury	  and	  the	  stressors	  of	   reperfusion.	   	   Furthermore	   the	   metabolic	   profile	   of	   the	   hypertrophied	   ventricle	   is	  vastly	  different	  to	  the	  non-­‐hypertrophied	  ventricle	  (Howell	  2010).	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In	   his	   thesis,	   Howell	   studied	   the	   metabolic	   profile	   of	   LVH	   versus	   non-­‐LVH,	   by	  performing	  an	  analysis	  of	  the	  key	  parts	  of	  the	  metabolic	  transcriptome,	  which	  included	  master	   transcriptional	   regulators	   PGC-­‐1α,	   PPARα	   and	   ERRα.	   The	   key	   fatty	   acid	  transport	   protein,	   CPT1	   and	   a	   key	   glucose	   uptake	   transporter,	   GLUT4	   were	   also	  analysed.	  Analyses	  of	  these	  elements	  were	  performed	  on	  left	  ventricular	  core	  biopsies	  taken	  from	  the	  anterior	  wall	  of	  the	  left	  ventricle	  on	  patients	  with	  LVH	  versus	  non-­‐LVH.	  A	   novel	  metabolomics	   analysis	   using	   Fourier	   transform	   ion	   cyclotron	   resonance	   (FT-­‐ICR)	  mass	  spectrometry	  was	  used	  to	  assess	  the	  metabolome	  and	  principal	  component	  analysis	  (PCA)	  was	  used	  to	  analyze	  the	  different	  metabolic	  profiles	  (Howell	  2010).	  	  This	  study	  showed	  that	  there	  was	  down	  regulation	  of	  the	  mRNA	  transcript	  levels	  of	  the	  key	  regulators	  mentioned	  above	  including	  key	  regulators	  of	  glucose	  and	  fatty	  acid	  oxidation	  GLUT4	  and	  CPT1	   respectively	   in	  LVH.	  Following	  PCA,	   it	  was	  evident	   that	   there	  was	  a	  clear	   significant	   separation	   between	   the	   2	   groups	   (Howell	   2010).	   There	  was	   a	   2-­‐fold	  decrease	  in	  the	  level	  of	  phosphocreatine	  and	  a	  2-­‐fold	  increase	  in	  the	  level	  of	  AMP	  and	  adenosine	  in	  the	  LVH	  group.	  	  
From	  this	  novel	  study	  looking	  at	  the	  metabolome	  of	  LVH,	  Howell	  has	  demonstrated	  that	  in	  LVH,	  there	  is	  not	  just	  down	  regulation	  of	  key	  master	  transcription	  regulators	  at	  key	  stages	  of	  both	  carbohydrate	  and	  FFA	  metabolism,	  but	  this	  down	  regulation	  may	  result	  in	  a	  reduced	  energetic	  state.	  This	  abnormal	  metabolomic	  profile	  may	  contribute	  to	  the	  poor	  prognosis	  associated	  with	  LVH	  secondary	  to	  aortic	  stenosis.	  Hence	  these	  patients	  with	   a	   hypertrophic	   myocardium	   may	   be	   more	   suited	   to	   metabolic	   modulation	   and	  therefore	  gain	  more	  from	  metabolic	  therapy.	  Metabolic	  modulation	  with	  perhexiline	  in	  patients	  with	  LVH	  secondary	  to	  AS	  has	  not	  been	  previously	  examined.	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1.9 Hypothesis	  
Patients	   diagnosed	   with	   aortic	   stenosis	   who	   become	   symptomatic,	   have	   a	   poor	  prognosis	   and	   quality	   of	   life,	  with	   an	   increased	   risk	   of	   developing	   heart	   failure	   if	   left	  untreated.	  Currently	  the	  most	  suitable	  form	  of	  treatment	  for	  severe	  symptomatic	  aortic	  stenosis	  is	  a	  conventional	  aortic	  valve	  replacement.	  	  
Aortic	   stenosis	   over	   time	   causes	   the	   ventricle	   to	   undergo	   an	   adaptive	   response	   of	  hypertrophy.	   Hypertrophy	   is	   associated	   with	   a	   lower	   energetic	   state	   and	   impaired	  cardiac	   metabolism.	   Therefore	   these	   patients	   with	   LVH	   secondary	   to	   longstanding	  aortic	   stenosis	   are	   at	   a	   greater	   risk	   of	   inadequate	   myocardial	   protection	   during	  conventional	  cardiac	  surgery.	  Morphological	  and	  functional	  changes	  due	  to	  hypertrophy	  make	  this	  risk	  greater.	  	  
Metabolic	   support	   through	   metabolic	   manipulation	   can	   improve	   the	   myocardial	  metabolic	  state.	  One	  method	  of	  metabolic	  manipulation	  is	  to	  try	  and	  promote	  the	  more	  efficient	   carbohydrate	  metabolic	   pathway	   and	   inhibit	   FFA	  metabolism.	   Perhexiline	   is	  known	  to	  be	  a	  suitable	  metabolic	  modulator,	  through	  its	  role	  in	  inhibiting	  CPT-­‐1,	  one	  of	  the	   key	   enzymes	   involved	   in	   inhibiting	   FFA	   metabolism.	   This	   inhibition	   of	   FFA	  metabolism	  could	  promote	  carbohydrate	  metabolism	  and	  increase	  glycogen	  stores	  to	  be	  utilised	  during	  the	  ischaemic	  and	  early	  reperfusion	  period.	  Furthermore	  promoting	  the	  more	   efficient	   glucose	   metabolism	   during	   the	   re-­‐perfusion	   phase,	   could	   improve	  myocardial	  performance.	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Therefore	  through	  this	  thesis	  I	  aim	  to	  elaborate	  on	  the	  following	  hypotheses:	  -­‐	  
1. That	  pre-­‐operative	  loading	  with	  perhexiline	  in	  patients	  with	  aortic	  stenosis	  and	  associated	  LVH	  undergoing	  AVR	  leads	  to	  improved	  myocardial	  protection.	  	  2. That	  pre-­‐operative	   improvement	   in	  energetic	  state	   leads	  to	  an	   improvement	   in	  cardiac	   performance	   following	   AVR,	   with	   an	   improved	   haemodynamic	  performance	  	  
These	  hypotheses	  are	  evaluated	  through	  a	  double-­‐blind	  placebo	  controlled	  multi-­‐centre	  randomised	  controlled	  trial	  evaluating	  the	  role	  of	  perhexiline	  as	  a	  myocardial	  protective	  adjunct.	   The	   methodology,	   results	   of	   the	   clinical	   trial	   and	   discussion	   are	   outlined	   in	  chapters	  2,	  3	  and	  8.	  	  
I	   then	   examine	   the	   energetic	   status	   of	   the	   heart.	   	  High-­‐energy	  phosphate	   ratios	   (PCr:	  ATP)	   in	   human	   myocardium	   can	   be	   measured	   through	   31P	   Magnetic	   Resonance	  Spectroscopy.	   To	   validate	   this	   and	   assess	   the	   reproducibility	   of	   our	   technique	   a	  validation	  study	  was	  performed	  in	  healthy	  volunteers	  to	  measure	  PCr:	  ATP	  ratios	  using	  
31P	   MRS	   and	   is	   outlined	   in	   chapter	   4.	   Having	   established	   this	   validation	   study,	   the	  following	  hypothesis	  is	  tested	  and	  is	  outlined	  in	  chapter	  5.	  	  
3. Metabolic	  manipulation	  with	  perhexiline	   in	  patients	  with	  LVH	  secondary	  to	  AS,	  leads	   to	   improvements	   in	   high-­‐energy	   phosphate	   (PCr:	   ATP)	   ratios	   and	   an	  improvement	  in	  their	  functional	  status.	  
Left	   ventricular	   hypertrophy	   secondary	   to	   AS,	   is	   a	   pathological	   adaptive	   process	  associated	   with	   increased	   morbidity	   post	   cardiac	   surgery.	   This	   pathological	  hypertrophy	  may	  result	   in	  chronic	  subendocardial	   ischaemia	  and	  this	  may	  change	  the	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metabolome	   of	   the	   myocardium.	   To	   understand	   the	   metabolome	   in	   LVH,	   I	   test	   the	  following	  hypothesis:	  -­‐	  
4. In	   LVH	   due	   to	   the	   pathological	   processes	   of	   hypertrophy,	   the	   epicardial	   and	  endocardial	  halves	  of	  the	  myocardium	  have	  different	  metabolomic	  profiles.	  	  	  	  
This	   hypothesis	   was	   examined	   through	   a	   novel	   metabolomics	   study	   to	   quantify	   the	  metabolomic	   profiles	   within	   the	   epicardium	   and	   endocardium	   and	   is	   outlined	   in	  chapter	  6.	  	  
Patients	  with	  LVH	  are	  more	  susceptible	  to	  myocardial	  injury	  particularly	  following	  the	  insults	   of	   ischaemia	   and	   reperfusion	   during	   cardiac	   surgery.	   This	   renders	   some	  individuals	   to	  develop	  a	   low	  cardiac	  output	  episode	   that	   requires	  additional	   inotropic	  support	   to	  maintain	   adequate	   haemodynamic	   parameters.	   The	   intrinsic	   role	   of	   some	  key	  master	  regulators	  within	  this	  group	  is	  less	  clear.	  To	  examine	  this	  further	  I	  test	  the	  following	  final	  hypothesis:	  -­‐	  	  
5. Patients	   with	   LVH	   that	   do	   not	   sustain	   a	   low	   cardiac	   output	   episode	   have	   an	  intrinsic	  upregulation	  of	  some	  key	  cardioprotective	  master	  regulators.	  	  
This	   hypothesis	   was	   examined	   through	   a	   basic	   science	   laboratory	   based	   study,	  evaluating	   the	   role	   of	   key	   transcriptional	   regulators,	  measured	  by	   the	   activity	   of	  ACC	  and	  GSK3β.	  This	  study	  is	  outlined	  in	  chapter	  7.	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2 CLINICAL	  TRIAL	  METHODOLOGY	  
2.1 Trial	  design	  
The	   trial	  was	  designed	  as	   a	  double-­‐blind	  placebo	   controlled	   randomised	   control	   trial,	  between	  pre-­‐operative	  oral	  loading	  of	  perhexiline	  versus	  placebo.	  Recruitment	  began	  at	  a	   single	   centre,	   the	   Queen	   Elizabeth	   Hospital,	   Birmingham.	   Due	   to	   slow	   recruitment	  concerns	   the	   trial	   was	   expanded	   to	   become	   a	   multi-­‐centre	   RCT	   to	   include	   2	   further	  centres	   in	   England,	   initially	   expanding	   to	   the	   Royal	   Sussex	   County	  Hospital,	   Brighton	  (RSCH)	  and	  then	  to	  University	  Hospital	  Coventry	  and	  Warwickshire,	  Coventry	  (UHCW).	  	  	  
2.2 Ethics	  and	  approvals	  
The	   trial	  protocol	  was	  approved	  by	   the	  Cambridgeshire	  1	  Research	  Ethics	  Committee	  (08/H0304/48)	   and	   the	   UK	   Medicines	   &	   Healthcare	   products	   Regulatory	   Authority	  (16719/0210/001-­‐0004).	   These	   authorities	   also	   approved	   subsequent	   substantial	  amendments	  to	  the	  protocol,	  which	  included	  expansion	  to	  other	  centres.	  The	  trial	  was	  registered	  with	  clinicaltrials.gov	  (NCT00989508),	  the	  European	  Clinical	  Trials	  Database	  (2008-­‐002376-­‐95)	  and	  the	  UK	  Clinical	  Research	  Network	  (5886).	  The	  trial	  was	  funded	  by	  grants	   from	   the	  British	  Heart	  Foundation	   (BHF:	  PG/08/040	  and	  BHF:	  PG/10/036)	  and	  University	  Hospitals	  Birmingham	  Charities	  (17-­‐3-­‐695).	  The	  trial	  was	  sponsored	  by	  University	  Hospital	  Birmingham	  NHS	  Foundation	  Trust	  (RRK3535).	  	  
2.3 Selection	  criteria	  	  
Patients	  diagnosed	  with	  aortic	  valve	  stenosis	  and	  awaiting	  an	  aortic	  valve	  replacement	  were	  suitable	  to	  be	  enrolled	  into	  the	  study.	  As	  left	  ventricular	  hypertrophy	  secondary	  to	  aortic	   stenosis	   was	   the	   primary	   pathology	   being	   studied,	   patients	   with	   concomitant	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coronary	   artery	   disease	   awaiting	   concomitant	   coronary	   artery	   bypass	   graft	   surgery	  were	  also	  eligible	  for	  enrolment.	  The	  presence	  of	  LVH	  secondary	  to	  AS	  was	  confirmed	  using	   pre-­‐operative	   echocardiographic	   data	   and	   had	   to	   meet	   the	   criteria	   for	  echocardiographic	  evidence	  of	  LVH.	  The	  echocardiograms	  were	  either	  transthoracic	  or	  trans-­‐oesophageal	  and	  were	  performed	  routinely	  during	  the	  work	  up	  towards	  cardiac	  surgery	  and	  in	  this	  patient	  population	  were	  also	  used	  to	  assess	  and	  quantify	  the	  extent	  of	   aortic	   valve	   stenosis	   and	   overall	   ventricular	   function.	   The	   inclusion	   and	   exclusion	  criteria	  are	  outlined	  in	  Table	  2-­‐1.	  	  	  
Around	   30%	   of	   patients	   with	   AS	   have	   concomitant	   CAD.	   Excluding	   this	   population	  would	  have	  provided	  a	  more	  homogenous	  patient	  sample,	  however	  these	  patients	  are	  likely	  to	  have	  a	  further	  reduced	  metabolic	  state	  and	  prone	  to	  have	  increased	  myocardial	  injury.	   Therefore	   inclusion	   of	   this	   group	   provided	   an	   opportunity	   to	   assess	   this	   sub-­‐group	  of	  patients	   further.	  Excluding	   them	  would	   increase	   the	   recruitment	  duration	   to	  meet	  the	  intended	  target.	  	  
Patients	   having	   extensive	   aortic	   surgery	   i.e.	   ascending	   and/or	  proximal	   and/or	   aortic	  arch	   replacement	   surgery	   were	   excluded,	   although	   this	   group	   may	   include	   some	  patients	   with	   LVH	   secondary	   to	   AS.	   These	   patients	   had	   different	   disease	  pathophysiology	  related	  to	  the	  aortic	  disease	  and	  the	  procedures	  undertaken	  to	  repair	  the	   aortic	   disease	   would	   require	   a	   more	   extensive	   period	   on	   the	   cardiopulmonary	  bypass	   machine,	   require	   deeper	   cooling	   strategies	   and	   other	   myocardial	   protection	  mechanisms	   to	   aid	   recovery	   following	   a	   more	   prolonged	   period	   of	   ischaemia	   which	  includes,	  at	  times	  complete	  full	  body	  circulatory	  arrest.	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Patients	   who	   were	   suitable	   but	   required	   emergency	   or	   salvage	   surgery	   due	   to	  catastrophic	  events	  were	  excluded	  due	  to	  the	  extensive	  repairs	  that	  are	  likely,	  requiring	  very	  different	  surgical	  and	  anaesthetic	  techniques.	  	  
Patients	   with	   diabetes	   were	   excluded.	   These	   patients	   have	   a	   different	   baseline	  metabolic	   and	   energetic	   state	   compared	   to	   non-­‐diabetics.	   Therefore	   regimes	   for	   drug	  intervention	  and	  metabolic	  therapy	  would	  be	  different.	  Furthermore	  these	  patients	  are	  likely	  to	  have	  a	  suppressed	  microvascular	  structure	  and	  uniquely	  different	  myocardial	  activity.	  	  
In	   patients	   with	   LVH,	   atrial	   contraction	   particularly	   aids	   ventricular	   filling	   during	  diastole	   and	   augments	   cardiac	   output.	   Therefore	   patients	   in	   atrial	   fibrillation	   were	  excluded.	   In	  addition,	   this	  study	  relies	  on	  the	  thermodilution	  principles	   for	  measuring	  cardiac	  function	  and	  this	  can	  be	  inconsistent	  in	  patients	  with	  AF.	  	  
Patients	  with	  mixed	  aortic	  valve	  disease;	  a	  combination	  of	  AS	  and	  aortic	  regurgitation	  were	  further	  evaluated	  to	  assess	  the	  degree	  of	  aortic	  regurgitation.	  If	  the	  AR	  was	  severe	  these	  patients	  were	  excluded.	  Severe	  AR	  over	   time	  changes	   the	  haemodynamic	  status	  with	  ventricular	  dilation	  and	  increased	  stroke	  volume	  leading	  to	  depressed	  ventricular	  function.	  Therefore	  patients	  with	  AR	  have	  a	  different	  disease	  pathophysiology.	  Similarly	  patients	  with	  other	  concomitant	  valvular	  pathologies	  would	  have	  even	  more	  different	  disease	  patterns	  and	  haemodynamics;	  hence	  were	  excluded.	  	  
Perhexiline	   is	   metabolised	   in	   the	   liver	   and	   due	   to	   its	   pharmacokinetic	   properties,	  patients	  with	  hepatic	  dysfunction,	   renal	   impairment	   (serum	  creatinine	  >	  200μmol/L),	  pregnancy	   and	   those	   on	   amiodarone	   therapy	   were	   excluded.	   Due	   to	   the	   toxicity	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associated	  with	  perhexiline	  leading	  to	  peripheral	  neuropathy,	  patients	  with	  pre-­‐existing	  peripheral	  neuropathy	  were	  excluded.	  	  
Inclusion	  criteria	   Exclusion	  criteria	  	  LVH	  secondary	  to	  AS	  awaiting	  AVR	   Patient	  choice	  AVR	  ±	  CABG	  with	  LVH	  secondary	  to	  AS	   Pregnancy	  	  Informed	  consent	  	   Renal	  impairment	  (creatinine	  >	  200μmol/L)	  	   Diabetes	  mellitus	  	   Hepatic	  impairment	  	   Atrial	  fibrillation	  	   Amiodarone	  therapy	  with	  last	  3	  months	  	   Peripheral	  neuropathy	  	  	   Intention	  to	  perform	  any	  other	  cardiac	  procedure	  	   Severe	  aortic	  regurgitation	  
Table	  2-­‐1	  Inclusion	  and	  Exclusion	  criteria	  
2.4 Sample	  size	  and	  power	  calculation	  
In	   ideal	  circumstances	  such	  a	  study	  could	  be	  powered	  on	  mortality	  and/or	  morbidity.	  However	   due	   to	   recent	   developments	   in	   operative	   technique	   and	   more	   so	   in	   post	  operative	   care,	  mortality	   post	   cardiac	   surgery	   has	   fallen.	   In	   2008,	   the	   post-­‐operative	  mortality	   in	   the	   UK	   for	   AVR	   and	   AVR	   ±	   CABG	   was	   2%	   and	   4-­‐5%	   respectively	  (Bridgewater	  B,	  Keogh	  B	  et	  al.	  2008).	  Therefore	  a	  trial	  based	  on	  mortality	  alone	  would	  require	   significant	   resource	   utilisation	   and	   costs,	   and	   would	   be	   premature.	  Alternatively,	   a	   surrogate	   marker	   of	   outcome	   such	   as	   low	   cardiac	   output	   episode	  (LCOE)	  was	  considered.	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In	  previous	   trials	   run	   in	   this	  department	   assessing	  myocardial	  protection	  using	  other	  metabolic	  therapies,	  LCOE	  was	  used	  as	  a	  primary	  end-­‐point	  (Quinn,	  Pagano	  et	  al.	  2006;	  Ranasinghe,	  Quinn	  et	  al.	  2006;	  Howell,	  Ashrafian	  et	  al.	  2011).	  LCOE	  post	  cardiac	  surgery	  is	  an	   indicator	  of	   inadequate	  myocardial	  protection	  and	  could	  contribute	  to	  morbidity	  and	  mortality	  (Hoffman,	  Wernovsky	  et	  al.	  2003).	   	  LCOE	  is	  associated	  with	  a	  depressed	  haemodynamic	   state	   and	   under	   these	   circumstances	   inotropic	   support	   is	   used	   to	  improve	   the	  patient’s	  haemodynamic	  condition	  and	  support	  myocardial	   function	  until	  no	   further	   artificial	   chemical	   or	   mechanical	   support	   is	   required.	   However	   inotropic	  support	  may	  be	   associated	  with	  permanent	  myocardial	   injury	   resulting	   in	   further	   re-­‐modelling	  and	  fibrosis	  (Fremes,	  Tamariz	  et	  al.	  2000).	  
The	   incidence	   of	   LCOE	   following	   coronary	   artery	   bypass	   graft	   surgery	   in	   the	   UK	   is	  approximately	   20	   –	   30%	   (Quinn,	   Pagano	   et	   al.	   2006;	   Ranasinghe,	   Quinn	   et	   al.	   2006;	  Howell,	  Ashrafian	  et	  al.	  2011).	  	  The	  incidence	  of	  LCOE	  post	  AVR	  at	  the	  Queen	  Elizabeth	  hospital	  recorded	  in	  the	  Patient	  Administration	  and	  Tracking	  System	  (PATS)	  database	  is	  approximately	  35%.	  	  
An	  estimated	  sample	  size	  of	  196	  patients	  was	  required	  based	  on	  a	  power	  of	  90%	  with	  a	  α	   of	   0.05	   randomising	   1:1	   between	   treatment	   and	   control	   arms.	   This	   was	   estimated	  based	  on	  the	  incidence	  of	  inotrope	  use	  observed	  on	  an	  earlier	  trial	  conducted	  within	  the	  department,	   assessing	   myocardial	   protection	   with	   GIK	   therapy	   versus	   placebo,	   in	  patients	  undergoing	  coronary	  artery	  bypass	  graft	  surgery;	  incidence	  of	  inotrope	  use	  in	  placebo	  was	  40%	  and	  in	  the	  GIK	  group	  was	  19%	  (Quinn,	  Pagano	  et	  al.	  2006).	  Assuming	  that	  perhexiline	  therapy	  may	  show	  a	  similar	  reduction	  in	  inotrope	  usage	  we	  intended	  to	  recruit	   220	   patients	   to	   provide	   an	   adequate	   power.	   This	   would	   also	   allow	   all	   the	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secondary	   end-­‐points	   to	   be	   analysed	   in	   an	   exploratory	   fashion	  with	   reference	   to	   the	  primary	  outcome.	  	  
2.5 Primary	  end-­‐point	  	  
The	  primary	  end	  point	  was	  the	  incidence	  of	  inotrope	  use	  ±	  comparison	  of	  cardiac	  index	  to	  show	  an	  increase	  >	  0.3L/min/m2	  within	  the	  first	  6	  hours	  from	  reperfusion	  (removal	  of	  the	  aortic	  cross	  clamp).	  The	  incidence	  of	  use	  was	  based	  on	  predetermined	  protocols	  outlined	  later	  in	  this	  chapter.	  	  
A	  blinded	  end-­‐points	  committee	  was	  convened	  at	  pre-­‐determined	  recruitment	  targets,	  to	  adjudicate	  on	  this	  end-­‐point	  (appropriate	  inotrope	  use	  in	  relation	  to	  the	  presence	  of	  low	   cardiac	   output	   episode	   outlined	   below).	   The	   meetings	   were	   set	   at	   a	   target	  recruitment	  of	  25,	  75,	  125,	  175	  and	  220	  patients.	  	  
2.6 Secondary	  end-­‐points	  	  
2.6.1 The	  incidence	  of	  low	  cardiac	  output	  episode	  (LCOE)	  
In	  this	  study	  LCOE	  was	  defined	  as	  hypotension	  with	  a	  cardiac	  index	  (CI)	  <	  2.2L/min/m2	  in	   the	   presence	   of	   adequate	   filling	   pressures	   and	   adequate	   heart	   rate	   (80-­‐110bpm),	  and/or	   inotropic	   support	   ±	   requirement	   of	   an	   intra-­‐aortic	   balloon	   pump	   for	   >	   60	  minutes	  to	  improve	  the	  haemodynamic	  status,	  within	  the	  first	  6	  hrs	  from	  removal	  of	  the	  aortic	   cross	   clamp.	   Adequate	   pre-­‐load	   was	   defined	   as	   a	   CVP	   8	   –	   12	   mmHg	   and/or	  Pulmonary	   Artery	  Wedge	   Pressure	   (PAWP)	   of	   12	   –	   16	   mmHg	   and	   hypotension	   was	  defined	  as	  a	  Mean	  Arterial	  Pressure	  (MAP)	  <	  60	  mmHg.	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2.6.2 The	  electrocardiographic	  (ECG)	  evidence	  of	  new	  myocardial	  injury	  
An	  independent	  blinded	  cardiologist	  assessed	  this	  outcome.	  New	  myocardial	  injury	  was	  defined	   as	   the	   presence	   of	   new	  Q	  waves	   (≥	   2mm	   in	   depth)	   in	   2	   or	  more	   contiguous	  leads,	  new	  bundle	  branch	  block	  or	  loss	  of	  R	  wave	  progression.	  	  
2.6.3 Cardiac	  troponin	  release	  	  
Cardiac	   troponin	   release	   was	   measured	   in	   the	   first	   24	   hrs	   from	   aortic	   cross	   clamp	  removal.	  Comparison	  of	  troponin	  release	  at	  6,	  12	  and	  24hrs	  of	  reperfusion	  to	  baseline,	  as	  an	  enzymatic	  marker	  of	  myocardial	  injury	  was	  made.	  	  
2.6.4 Incidence	  of	  inotrope	  and	  vasoconstrictor	  use	  	  
The	  overall	   incidence	  of	   inotrope	  use	  within	   the	   first	  6	  hours	  of	  reperfusion	  and	  6-­‐12	  hours	   of	   reperfusion	   was	   assessed.	   The	   dose	   per	   kilogram	   used	   for	   each	   group	   was	  assessed.	  Similarly	   the	   incidence	  and	  dose	  per	  kilogram	  of	  vasoconstrictor	  use	  during	  the	  same	  time	  periods	  for	  each	  group	  was	  assessed.	  	  
2.6.5 Use	  of	  volume	  expansion	  and	  blood	  products	  	  
The	   volume	   of	   colloids	   transfused	   to	   maintain	   ideal	   haemodynamics	   between	   the	  groups	  was	  assessed.	  The	  number	  of	  red	  blood	  cells	  transfused	  and	  the	  number	  of	  units	  of	  blood	  products	  used	  to	  control	  bleeding	  was	  assessed.	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2.6.6 Safety	  outcome	  measures	  
This	  included	  variable	  outcome	  measures	  such	  as	  length	  of	  ward	  and	  ITU	  stay,	  wound	  infection,	   and	   the	   incidence	   of	   systemic	   complications	   i.e.	   renal	   failure,	   stroke,	   GI	  complications	  etc.	  as	  outlined	  in	  the	  statistical	  analysis	  plan	  (Appendix	  9.3).	  	  
2.7 Statistical	  analysis	  
A	  statistical	  analysis	  plan	  was	  developed	  prior	  to	  starting	  the	  trial	  (Appendix	  9.3).	  The	  main	  outcome	  measures	  were	  analysed	  on	  an	  intension-­‐to-­‐treat	  basis.	  	  
Analysis	  was	  performed	  using	  SAS	  (version	  9.2,	  SAS	   Institute	   Inc.,	  Cary,	  NC)	  and	  SPSS	  software	  (version	  20.0,	  SPSS	  Inc.,	  Chicago,	  IL).	  Continuous	  data	  was	  assessed	  for	  normal	  distribution	   and	  presented	   as	  mean	  ±	   standard	  deviation	  of	   the	  mean	  or	  median	   and	  inter-­‐quartile	  range.	  Student’s	  t-­‐test	  was	  used	  to	  analyse	  normally	  distributed	  data	  and	  alternatively	   by	   analysis	   of	   variance	   (ANOVA).	   Skewed	   data	   was	   analysed	   by	   Mann-­‐Whitney	  U-­‐test.	  Categorical	  data	  was	  analysed	  by	  Fisher’s	  exact	  test.	  Paired	  non-­‐normal	  data	  was	  analysed	  using	  Wilcoxon	  signed	  rank	  test.	  Statistical	  significance	  was	  defined	  as	  a	  p	  <	  0.05.	  	  
Spearman’s	  rank	  correlation	  (a	  standardized	  non-­‐parametric	  measure	  of	  the	  strength	  of	  the	  relationship	  between	  two	  variables)	  was	  used	  to	  compare	  IMP	  concentration	  with	  duration	  of	  therapy.	  Kolmogorov-­‐Smirnov	  test	  was	  used	  to	  determine	  normality	  of	  data.	  	  
The	  analysis	   as	  per	   the	  analysis	  plan	  was	   intended	   to	  stratify	   for	  baseline	  ventricular	  function	  and	  priority	  (elective/urgent)	  status,	  accounting	  for	  surgeon	  as	  random	  effect.	  However,	   due	   to	   the	   small	   number	   of	   patients	   in	   these	   groups	   stratification	   by	  ventricular	   function	   and	   priority	   was	   not	   performed	   but	   surgeons	   were	   included	   as	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random	   effects.	   Missing	   data	   for	   outcomes	   were	   identified	   and	   excluded	   from	   the	  analysis.	  	  
All	   errors	   including	   errors	   to	   treatment	   and	   data	   entry	   errors	   were	   treated	   as	  measurement	  errors	  and	  therefore	  the	   locked	  database	  was	  analysed	  on	  an	   intention-­‐to-­‐treat	  basis.	  Hence	  if	  any	  error	  was	  found	  during	  the	  analysis	  no	  further	  new	  analyses	  were	  conducted	  on	   the	   locked	  database.	  Further	  analyses	  would	  be	  performed	  only	   if	  any	  supportive	  analyses	  could	  have	  led	  to	  qualitatively	  different	  results.	  	  	  	  
An	   assessment	   for	   futility	   was	   conducted.	   This	   was	   performed	   using	   the	   O’Brien	  Fleming	   alpha	   spending	   function	   plan,	   performed	   to	   examine	   the	   effect	   of	   primary	  outcome	   including	   futility;	   benefits	   are	  based	  upon	  Lan	  DeMets	  plan	   and	  harm	  based	  upon	  the	  power	  family	  spending	  function.	  
2.8 Investigational	  medicinal	  product	  	  
The	   investigational	  medicinal	  product	   (IMP)	  was	  perhexiline.	  Perhexiline	  and	  placebo	  tablets	   were	   manufactured	   by	   Sigma	   Pharmaceuticals	   (Baulkham	   Hills,	   Australia)	  according	   to	   the	   standards	  of	   good	  manufacturing	  practice	   and	  were	  provided	  with	  a	  certificate	  of	  analysis.	  They	  were	  ordered	   in	  batches	  (due	   to	   the	   limited	  shelf-­‐life	  of	  2	  years)	   through	   UDG	   Ltd	   (South	   Normanton,	   UK),	   a	   pharmaceutical	   supply	   chain	  specialist	  who	  imported	  perhexiline	  and	  placebo	  on	  request,	  into	  the	  UK	  and	  delivered	  the	  IMP	  to	  Bilcare	  GCS	  (Crickhowell,	  UK).	  Bilcare	  GCS	  provided	  the	  packaging,	  labelling	  and	  Qualified	  Person	  (QP)	  release	  on	  the	  perhexiline/placebo	  samples.	  	  
The	   tablets	   were	   bottled	   into	   pre-­‐defined	   bottle	   numbers	   (0-­‐560)	   according	   to	   the	  randomisation	  sequence.	  Each	  bottle	  had	  34	  tablets.	  Bilcare	  GCS	  delivered	  the	  packaged	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bottles	  to	  the	  UHB	  pharmacy.	  All	  tablets	  were	  identical	  (white/off-­‐white	  and	  8.5	  mm	  in	  diameter)	   and	   were	   labelled	   ‘PEXSIG’.	   UHB	   pharmacy	   then	   couriered	   the	   batches	  assigned	  to	  the	  other	  trial	  sites	  to	  their	  respective	  pharmacies.	  	  
2.9 Patient	  recruitment	  	  
Recruitment	   into	   the	   trial	   at	  UHB	  began	   in	  September	  2009.	  Following	  concerns	  with	  the	  rate	  of	  recruitment	  the	  trial	  expanded	  and	  started	  recruitment	  at	  RSCH	  and	  UHCW	  in	  October	  2011	  and	  January	  2012	  respectively.	  	  
2.9.1 Patient	  screening	  	  
Patients	  were	  identified	  from	  the	  cardiac	  surgery	  waiting	  list.	  At	  the	  QEH,	  this	  included	  patients	   from	   5	   cardiac	   surgeons.	   Patients	   listed	   as	   awaiting	   AVR	   ±	   CABG,	   were	  screened	   using	   the	   above	   outlined	   inclusion	   and	   exclusion	   criteria.	   An	   electronic	  screening	   log	   was	   maintained	   to	   track	   patients	   on	   the	   cardiac	   surgery	   waiting	   list.	  Screening	   involved	   reviewing	   the	   indications	   for	   referral	   and	  assessing	   the	   indication	  for	   surgery.	   This	   included	   an	   assessment	   of	   the	   patients’	   past	   medical	   history	   and	  echocardiographic	   findings.	   At	   UHCW	   and	   RSCH	   patients	   were	   recruited	   from	   two	  additional	   cardiac	   surgeons	   at	   each	   centre.	   This	   patient	   population	   comprised	   of	  patients	  awaiting	  elective	  cardiac	  surgery.	  	  Patients	  suitable	  for	  participation	  were	  sent	  an	   invitation	   letter	   (Appendix	   9.4)	   together	   with	   a	   Patient	   Information	   Sheet	   (PIS)	  (Appendix	  9.5)	  by	  post,	  at	  least	  2	  weeks	  before	  their	  pre-­‐operative	  assessment	  clinic.	  
At	  the	  QEH,	  patients	  awaiting	  urgent	  cardiac	  surgery	  for	  AVR	  ±	  CABG	  were	  screened	  as	  outlined	  above,	  having	  identified	  them	  on	  the	  urgent	  in-­‐patient	  waiting	  list.	  This	  group	  included	   in-­‐patients,	  who	  are	  admitted	   following	  an	  episode	  of	  unstable	  angina,	  acute	  
	  2-­‐90	  
coronary	   syndrome	   or	   exacerbation	   of	   their	   symptoms;	   unsafe	   to	   be	   discharged	   and	  require	  in-­‐patient	  definitive	  treatment.	  The	  number	  of	  patients	  awaiting	  urgent	  cardiac	  surgery	  at	  any	  given	  time	  is	  unpredictable.	  However	  inclusion	  of	  these	  patients	  allowed	  an	  opportunity	  to	  increase	  recruitment.	  Suitable	  in-­‐patients	  were	  met	  on	  the	  ward,	  an	  invitation	   letter	   and	   PIS	   were	   provided	   and	   the	   study	   was	   discussed	   with	   them.	   A	  period	   of	   at	   least	   24hrs	   was	   then	   given	   to	   the	   patient	   to	   reflect	   on	   this	   information	  before	   approaching	   them	   for	   written	   informed	   consent.	   Urgent	   in-­‐patients	   were	   not	  screened	   in	   the	   other	   2	   centres	   due	   to	   logistical	   difficulties	   and	   the	   unpredictable	  prevalence	  of	  these	  patients.	  	  
2.9.2 Enrolment	  	  	  	  
All	   elective	   patients	   for	   cardiac	   surgery	   routinely	   attend	   the	   cardiac	   pre-­‐operative	  assessment	   clinic	   approximately	   2	   weeks	   before	   their	   operation.	   Patients	   who	   were	  sent	  PIS	   regarding	   the	   study	  were	  approached	  at	   this	   clinic.	  The	   study	  was	  discussed	  with	   them	  and	  questions	  answered.	   If	   they	  were	  keen	  to	  participate	  written	   informed	  consent	  was	   obtained	   at	   this	   clinic	   (Appendix	   9.6).	   Those	  who	   provide	   consent	  were	  then	  randomised	  to	  a	  treatment	  group.	  	  
2.9.3 Randomisation	  	  
Patient	   randomisation	  was	  performed	  on	  a	  Microsoft	  Access	  database	  designed	  by	  Dr	  Melanie	   J.	   Calvert	   and	   Prof	   Nick	   Freemantle.	   This	   was	   password	   protected	   and	  encrypted.	   The	   randomisation	  was	   allocated	   on	   a	   1:1	   ratio	   to	   perhexiline	   or	   placebo	  using	  a	  blinded	  minimisation	  procedure	  stratified	  for	  surgeon	  and	  need	  for	  concomitant	  CABG	  surgery.	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The	  programme	  allocated	  a	  bottle	  number,	  which	  corresponded	  to	  the	  treatment	  group.	  If	  the	  patient	  needed	  a	  further	  supply	  of	  treatment	  at	  a	  later	  date,	  patients’	  details	  were	  entered	  a	  second	  time	   into	  the	  programme	  and	   it	  was	  able	  to	  provide	  a	  second	  bottle	  number	   in	   the	   same	   arm	   of	   treatment	  whilst	  maintaining	   allocation	   concealment.	   Dr	  Calvert	  maintained	  the	  allocation	  sequence	  and	  remained	  un-­‐blinded	  and	  reviewed	  the	  randomisation	   database	   at	   regular	   intervals	   to	   confirm	   the	   program	  was	   performing	  accurately.	  	  
2.9.4 Dispensing	  and	  dosing	  	  
Once	   the	   randomiser	   allocated	   a	   bottle	   number,	   a	   prescription	   was	   written	   for	   each	  patient	   and	   this	   was	   taken	   to	   pharmacy	   for	   dispensing.	   Pharmacy	   remained	   blinded	  throughout	   the	   study.	   The	   dispensed	   bottle	   was	   handed	   over	   or	   posted	   to	   each	  participant	  with	  a	  patient	  information	  sheet	  explaining	  the	  dosing	  schedule	  (Appendix	  9.7).	   The	   dosing	   schedule	   was	   explained	   in	   detail	   to	   participants	   during	   their	   pre-­‐operative	  assessment	  clinic	  visit.	  	  
Each	  bottle	  would	  contain	  34	  tablets	  of	  the	  Investigational	  Medicinal	  Product	  (IMP).	  The	  IMP	   was	   administered	   orally.	   Participants	   were	   dosed	   on	   a	   short	   loading	   regime	   of	  200mg	  bd	   (twice	   daily)	   for	   3	   days	   and	  maintained	   on	   a	   fixed	  maintenance	   regime	   of	  100mg	  bd	  thereafter	  until	  their	  surgery.	  IMP	  therapy	  was	  administered	  for	  a	  minimum	  of	   4	   days	   before	   surgery.	   Therapy	   was	   usually	   commenced	   1-­‐2	   weeks	   before	   their	  scheduled	  operation	  date.	  	  
If	   there	  was	  a	  delay	   in	   their	   initially	   scheduled	  operation	  date	  and	  more	   therapy	  was	  required,	   a	   second	   bottle	   was	   provided	   and	   participants	   would	   continue	   on	   their	  maintenance	   dose	   until	   surgery,	   unless	   features	   of	   side	   effects	   were	   observed.	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Participants	   were	   allowed	   to	   self-­‐administer	   the	   tablets	   as	   most	   patients	   were	   only	  admitted	  the	  night	  before	  the	  surgery.	  Patients	  were	  routinely	  followed	  up	  by	  telephone	  enquiry	   to	  assess	  compliance	  and	  side	  effects.	  For	   in-­‐patients	   the	   IMP	  was	  prescribed	  and	  administered	  as	  outlined	  above.	  	  
2.10 Admission	  	  
Elective	   patients	  were	   routinely	   admitted	   the	   night	   before	   their	   surgery.	   Participants	  were	  met	   on	   admission	   and	   compliance	  with	  medication	  was	   checked.	   Patients	  were	  also	  asked	   if	   they	  experienced	  any	  side	  effects	  or	   if	   there	  was	  any	  deviation	   from	   the	  dosing	  regime.	  The	  IMP	  therapy	  for	  the	  night	  before	  and	  the	  morning	  of	  their	  surgery	  was	  prescribed.	  Thereafter	  the	  period	  leading	  up	  to	  and	  including	  anaesthetic	  induction,	  the	  operative	  procedure	  and	  the	  peri	  and	  post-­‐operative	  management	  was	  in	  line	  with	  the	  HYPER	  trial	  protocol.	  	  
2.11 Trial	  protocols	  	  	  
The	   anaesthetic,	   surgical	   and	   post-­‐operative	   management	   protocols	   were	   pre-­‐determined	   and	   agreed	   amongst	   all	   the	   consultants	   in	   the	   department.	   The	  management	  of	  patients	  requiring	  inotropic	  support,	  the	  management	  of	  LCOE	  and	  the	  trial	  guidelines	  recommending	  inotropic	  support	  were	  standardised	  for	  all	  patients.	  An	  extensive	  description	  of	  these	  procedures	  and	  protocols	  are	  outlined	  in	  Appendix	  9.8.	  
2.12 Trial	  measurements	  	  
All	   data	   for	   the	   trial	   was	   collected	   prospectively	   for	   each	   patient	   and	   recorded	   on	   a	  patient	  specific	  data	  collection	  sheet.	  Data	  collected	  included:	  -­‐	  
	  2-­‐93	  
- Baseline	  demographics	  including	  medications	  and	  risk	  factors	  	  
- Trial	  therapy	  duration,	  compliance	  and	  side	  effects	  
- Pre-­‐operative	  echocardiographic	  measurement	  data	  
- Operative	  data	  	  
- Intra-­‐operative	  and	  peri-­‐operative	  haemodynamic	  studies	  as	  outlined	  below	  
- Incidence	  and	  volume	  of	  inotropic	  and	  vasoconstrictor	  support	  required	  
- Incidence	  and	  volume	  of	  fluid	  administration	  
- All	  post	  operative	  complications	  including	  arrhythmias	  	  
- Post	  operative	  blood	  results	  	  
- Deviations	  from	  trial	  protocol	  	  
All	   data	  was	   recorded	   prospectively	   onto	   a	   data	   collection	   sheet.	   This	   data	  was	   then	  entered	  into	  a	  specifically	  designed	  Microsoft	  Access	  Database	  and	  stored.	  In	  addition	  to	  the	   above,	   the	   following	   trial	  measurements	  were	   undertaken	   and	   recorded	   for	   each	  patient	  and	  included	  baseline	  blood	  samples,	  serial	  haemodynamic	  studies,	  serial	  blood	  samples,	  and	  TOE	  assessment	  as	  outline	  in	  Appendix	  9.9.	  
2.12.1 Quality	  of	  life	  questionnaire	  	  
A	  quality	  of	  life	  questionnaire	  was	  introduced	  into	  the	  trial	  at	  the	  time	  of	  a	  substantial	  amendment	   to	   the	   REC	   when	   including	   another	   trial	   centre.	   This	   would	   allow	  measurement	  of	  quality	  of	  life	  markers	  with	  the	  IMP.	  	  Hence	  approximately	  half	  of	  the	  patients	   completed	   a	   quality	   of	   life	   questionnaire	   (EQ-­‐5D)	   (Appendix	   9.10)	   prior	   to	  starting	   trial	   therapy.	   This	   was	   then	   repeated	   at	   approximately	   6-­‐8	   weeks	   post-­‐operatively	  either	  in	  person	  at	  their	  follow	  up	  visit	  or	  by	  telephone	  interview.	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The	  EQ-­‐5D	  questionnaire	  was	  used	  to	  calculate	  a	  single	  utility	  at	  each	  time	  point	  (pre	  trial	   therapy	   and	   after	   surgery).	   Utilities	   were	   calculated	   using	   the	   following	  methodology.	  	  
A	   score	   is	   calculated	   by	   subtracting	   the	   relevant	   coefficients	   from	  1	   (co-­‐efficients	   are	  outlined	  in	  Table	  2-­‐2).	  The	  constant	  term	  is	  used	  once	  if	  there	  is	  any	  dysfunction	  at	  all	  (a	  response	  of	  2	  or	  3	  on	  the	  questionnaire).	  The	  N3	  term	  is	  used	  once	  if	  any	  dimension	  has	  a	  response	  of	  3.	  	  
For	  example,	  if	  you	  scored	  1,	  1,	  3,	  2,	  2,	  then	  your	  QoL	  would	  be:	  
𝑄𝑜𝐿   =   1  −   0.081  −   0  −   0  −   0.094  −   0.123  −   0.071  −   0.269   =   0.362  
Dimension/Level	   Coefficient	  Constant	  	   0.081	  Mobility	  -­‐	  Level	  2	  -­‐	  Level	  3	   	  0.069	  0.314	  	  Self-­‐care	  -­‐	  Level	  2	  -­‐	  Level	  3	  
	  	  0.104	  0.214	  	  Usual	  activity:	  -­‐	  Level	  2	  -­‐	  Level	  3	  
	  	  0.036	  0.094	  	  Pain/discomfort:	  -­‐	  Level	  2	  -­‐	  Level	  3	  
	  	  0.123	  0.386	  	  Anxiety/depression:	  -­‐	  Level	  2	  -­‐	  Level	  3	  
	  	  0.071	  0.236	  	  N3	   	  0.269	  
Table	  2-­‐2	  Co-­‐efficients	  used	  to	  calculate	  EQ-­‐5D	  utilities	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2.12.2 Perhexiline	  and	  hydroxyl-­‐perhexiline	  analysis	  	  	  
The	   baseline	   arterial	   samples	   collected	   in	   the	   plain	   vacuette	   bottles,	   that	   were	  centrifuged	   and	   stored	   at	   -­‐80°C	   for	   the	   analysis	   of	   serum	   perhexiline	   concentration	  were	   sent	   in	   one	   batch	   to	   the	   Cardiff	   and	   Valve	   University	   Health	   Board,	   Analytical	  Toxicology	  Department	  for	  the	  analysis	  of	  serum	  perhexiline	  concentrations.	  	  
Cardiff	   toxicology	   laboratories	   obtained	   the	   perhexiline	   and	   hydroxy-­‐perhexiline	  concentrations	   through	   gas	   chromatographic	   analysis	   using	   a	   Varian	   3800	   Gas	  Chromatograph	  fitted	  with	  a	  CP	  Sil-­‐8CB	  column	  (30Mx0.25mm)	  and	  the	  detection	  of	  the	  compounds	  was	  achieved	  with	  a	  Varian	  4000	  ion-­‐trap	  mass	  spectrometer.	  Analysis	  was	  done	  in	  batches	  of	  approximately	  30	  samples	  per	  batch.	  	  
2.12.3 Troponin	  analysis	  	  
Baseline	  troponin	  and	  serial	  troponin	  measurement	  were	  performed.	  The	  Z	  Serum	  Sep	  Clot	  Activator	   bottles	   collected	  were	   sent	   to	   the	  Department	   of	   Clinical	  Biochemistry,	  Queen	   Elizabeth	   Hospital,	   Birmingham.	   Troponin	   analysis	   was	   performed	   using	   the	  Elecsys	  Troponin-­‐T	  assay	  (Roche	  Diagnostics,	  Burgess	  Hill,	  UK).	  	  
In	  March	  2011,	  troponin	  analysis	  at	  the	  Queen	  Elizabeth	  Hospital,	  Birmingham	  changed	  to	   using	   the	   High	   Sensitivity	   Troponin	   T	   analysis	   using	   the	   Cobas	   immunoassay	   and	  Elecsys	  analyzers	  (Roche	  Diagnostics,	  Burgess	  Hill,	  UK).	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2.13 Haemodynamic	  management	  procedures	  	  
2.13.1 Early	  inotropic	  support	  	  
Inotrope	   administration	   was	   withheld	   until	   post	   CPB	   haemodynamic	   measurements	  were	   complete.	   However,	   sometimes	   this	   was	   not	   possible	   due	   to	   haemodynamic	  instability	   and	   clinical	   circumstances	   based	   on	   the	   subjective	   features	   (observational	  assessment	   by	   the	   operating	   surgeon)	   of	   cardiac	   performance.	   If	   inotropes	   were	  required	  before	  discontinuation	  of	   CPB	  or	   soon	   after	   separation	   from	  CPB,	   dopamine	  was	   used	   as	   a	   first	   line	   agent.	   At	   times	   (rarely)	   based	   on	   surgical	   assessment	   of	  contractility,	  adrenaline	  was	  used	  for	  inotropic	  support.	  The	  decision	  to	  insert	  an	  IABP	  electively	  before	  separation	  from	  CPB	  or	  immediately	  after	  was	  at	  the	  discretion	  of	  the	  clinical	   team.	   These	   events	   were	   adjudicated	   at	   the	   blinded	   end	   points	   review	  committee	  meetings.	  	  
2.13.2 Management	  of	  a	  LCOE	  and	  institution	  of	  inotropic	  support	  	  
A	   low	   cardiac	   output	   episode	   (LCOE)	  was	   defined	   as	   hypotension	   (MAP	   <60)	  with	   a	  cardiac	  index	  <	  2.2	  L/min/m2,	   in	  the	  presence	  of	  adequate	  filling	  pressures	  (CVP	  8-­‐12	  mmHg,	   PCWP	  12–16	  mmHg)	   and	  heart	   rate	   of	   70-­‐110bpm;	   refractory	   to	   appropriate	  intra-­‐vascular	   volume	   expansion	   and	   following	   correction	   or	   attempted	   correction	   of	  any	  dysrhythmias.	  	  
If	  these	  criteria	  for	  LCOE	  were	  met	  inotropic	  support	  was	  initiated	  to	  improve	  cardiac	  output.	  Therefore	  once	  a	  LCOE	  is	  reached	  inotropic	  support	  is	  required	  to	  improve	  the	  haemodynamic	   status	   of	   the	   patient.	   The	   appropriate	   arrival	   at	   this	   end	   point	   was	  adjudicated	  at	  a	  blinded	  end	  points	  review	  committee	  meeting,	  which	  took	  place	  at	  pre-­‐defined	  recruitment	  intervals.	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Dopamine	   (200mg	   in	   50ml	   5%	   dextrose)	   was	   used	   as	   a	   1st	   line	   inotropic	   agent	   and	  instituted	   at	   a	   dose	   of	   5-­‐10	   µg/kg/min.	   Further	   inotropic	   escalations	   were	   at	   the	  discretion	  of	  the	  clinical	   team	  but	  usually	   involved	  the	  addition	  of	  Adrenaline	  (2mg	  in	  50ml	  5%	  dextrose)	  and/or	  Enoximone.	  	  	  
2.14 Adverse	  events	  reporting	  and	  trial	  safety	  	  
Adverse	   events	   that	   occurred	   to	   participants	   were	   reported	   using	   pre-­‐determined	  standard	   operating	   procedures	   for	   reporting	   such	   events	   (Appendix	   9.11).	   A	   serious	  adverse	   event	   form	   was	   completed	   for	   each	   event	   and	   the	   sponsor	   was	   informed	  through	  the	  sponsor’s	  online	  incident	  reporting	  system.	  The	  necessary	  authorities	  such	  as	  the	  MHRA	  and	  the	  ethics	  committee	  were	  also	  informed.	  	  
Initially	   the	   CI/PI	   was	   informed	   of	   any	   adverse	   events	   (AE),	   serious	   adverse	   events	  (SAE),	  adverse	  drug	  reactions	  (ADR)	  or	  suspected	  unexpected	  serious	  adverse	  reaction	  (SUSAR).	   	   Following	   this	   the	   sponsor	   was	   informed	   of	   the	   event.	   The	   MHRA	   were	  informed	  if	  required	  through	  the	  MHRA’s	  online	  eSUSAR	  reporting	  system	  as	  per	  their	  reporting	  timeframes.	  The	  ethics	  committee	  and	  the	  MHRA	  were	  provided	  with	  annual	  safety	   reports.	   In	   the	   event	   that	   code	   breaking	  was	   required,	   the	   code	   breaking	   SOP	  would	   be	   followed.	   To	   avoid	   reporting	   of	   adverse	   events	   for	   known	   complications	  associated	  with	  cardiac	  surgery,	  a	  separate	  SOP	  was	  written	  that	  listed	  events	  that	  did	  not	  require	  reporting	  (Appendix	  9.11).	  
2.15 Sponsor’s	  internal	  audit	  and	  MHRA	  inspection	  	  
The	  sponsor	  for	  this	  clinical	  trial	  was	  University	  Hospitals	  Birmingham	  NHS	  Foundation	  Trust.	   The	   HYPER	   trial	   was	   randomly	   selected	   as	   one	   of	   the	   IMP	   clinical	   trials	   to	   be	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audited	  internally.	  This	  audit	  evaluated	  the	  overall	  running	  of	  the	  trial	  and	  compliance	  with	  the	  current	  GCP	  guidelines	  for	  the	  conduct	  of	  a	  clinical	  trial	  (ICH	  1996;	  ICH	  1997).	  	  This	  audit	  concluded	  that	  the	  trial	  was	  running	  in	  accordance	  with	  the	  GCP	  guidelines,	  however	   recommended	   improving	   the	   SOPs	   and	   making	   it	   more	   robust	   for	  interpretation	  by	  anyone	  other	  than	  the	  research	  fellow	  running	  the	  trial.	  
Following	   this	  audit	   the	  regulatory	  authority,	  MHRA	  carried	  out	  an	   inspection	  at	  UHB	  and	  selected	  the	  HYPER	  trial	  as	  one	  of	  the	  studies	  they	  would	  like	  to	  inspect.	  This	  again	  included	  a	  thorough	  assessment	  and	  inspection	  into	  the	  running	  of	  the	  trial,	   including	  interviews	  with	  the	  Principle	  investigator	  and	  the	  trial	  research	  fellow.	  Furthermore	  the	  MHRA	   reviewed	   the	   practice	   of	   SOPs,	   which	   included	   recruitment,	   randomisation,	  handing	  and	  procurement	  of	  the	  IMP,	  data	  collection,	  and	  data	  analysis.	  The	  MHRA	  also	  assessed	  the	  maintenance	  of	  the	  trial	  master	  file	  and	  reviewed	  the	  paper	  trail	  associated	  to	  each	  participant.	  In	  addition	  to	  this,	  the	  MHRA	  conducted	  a	  thorough	  assessment	  of	  randomisation.	  This	   included	  a	  detailed	   inspection	   into	   the	  practices	  of	   IMP	  handling,	  dispensing	  and	  later	  destruction	  of	  the	  IMP	  by	  the	  pharmacy	  at	  UHB.	  	  
The	  MHRA	  concluded	  that	  the	  HYPER	  trial	  could	  continue	  in	  accordance	  with	  the	  GCP	  guidelines	   without	   restriction	   or	   further	   review,	   but	   raised	   concerns	   with	   UHB	  pharmacy	  and	  the	  handling	  of	  IMP.	  Therefore,	  a	  review	  of	  the	  SOPs	  for	  handling	  of	  IMP	  by	  pharmacy	  was	  reviewed	  and	  updated.	  Furthermore,	   the	  sponsor	  and	  myself	  as	   the	  trial	   research	   fellow	   conducted	   internal	   audits	   on	   pharmacy’s	   documentation,	  dispensing	  and	  handling	  of	  IMP	  following	  the	  MHRA	  inspection.	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2.16 Trial	  expansion	  	  
The	  rate	  of	  recruitment	  was	  always	  a	  concern	  (outlined	  in	  the	  results	  chapter)	  and	  due	  to	   under-­‐recruitment	   avenues	   to	   improve	   recruitment	   were	   considered.	   	   One	   of	   the	  main	  reasons	  for	  declining	  participation	  in	  the	  trial	  was	  the	  requirement	  to	  take	  an	  IMP.	  Measures	   to	   improve	   recruitment	   at	  UHB,	  where	   the	   trial	   started	  were	   initially	  made	  and	  included	  the	  following:	  -­‐	  	  
- Optimise	  the	  screening	  log	  to	  ensure	  that	  all	  patients	  listed	  for	  AVR	  ±	  CABG	  were	  being	  screened	  and	  not	  missed	  	  
- Adequate	  provision	  of	  information	  by	  way	  of	  an	  invitation	  and	  PIS	  was	  sent	  to	  all	  suitable	  patients	  well	  in	  advance	  of	  the	  PAC	  appointment	  
- All	   suitable	   patients	   were	   met	   at	   the	   PAC	   and	   the	   study	   discussed	   in	   detail	  including	  answering	  any	  questions	  regarding	  the	  trial	  
- Patients	  that	  needed	  more	  time	  to	  consider	  their	  decision,	  were	  given	  a	  contact	  telephone	  number	  in	  the	  instance	  they	  needed	  to	  discuss	  the	  trial	  at	  a	  later	  date	  
- All	  patients	  that	  were	  uncertain	  during	  their	  PAC	  consultation	  were	  followed	  up	  by	  telephone	  	  
- The	   time	   required	   to	   wait	   for	   the	   dispensing	   of	   their	   IMP	   was	   reduced	   to	   a	  minimum	  and	  if	  the	  patient	  was	  unable	  to	  wait,	  this	  was	  delivered	  to	  them	  
However,	  despite	  maximum	  measures	  to	  improve	  recruitment	  at	  UHB,	  the	  recruitment	  targets	  set	  internally	  were	  not	  being	  met	  to	  complete	  the	  trial	  within	  3	  years.	  Therefore	  in	  an	  attempt	  to	  increase	  recruitment	  the	  trial	  was	  expanded	  to	  2	  other	  centres;	  initially	  Royal	   Sussex	   County	   Hospital,	   Brighton	   (RSCH)	   and	   then	   to	   University	   Hospital	  Coventry	  and	  Warwickshire,	  Coventry	  (UHCW).	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2.16.1 Initial	  setup	  	  
An	   introductory	   presentation	   was	   made	   to	   the	   cardiothoracic	   department	   of	   each	  centre.	   This	   included	   the	   background	   and	   the	   aims	   of	   the	   trial,	   scope	   of	   the	   trial	   and	  intention	   to	   collaborate	  with	   the	  department.	   The	   trial	   protocol	  was	   reviewed	  by	   the	  surgical,	   anaesthetic	   and	   perfusion	   departments	   and	   disseminated	   to	   the	   nursing	  department	  at	  each	  centre.	  The	  protocol	  was	  vetted,	  queries	  clarified	  and	  rectified	  and	  eventually	   approved	   once	   a	   collective	   decision	   was	   made	   to	   collaborate	   and	   allow	  expansion	   of	   the	  HYPER	   trial	   to	   the	   respective	   centres.	   A	   local	   PI	  was	   appointed	   and	  local	  and	  national	  approvals	  were	  sought.	  
2.16.2 Additional	  approvals	  	  
The	  sponsor	  was	  informed	  of	  the	  intention	  to	  expand	  the	  trial	  and	  their	  approval	  was	  sought.	  Following	  this,	  local	  R&D	  approval	  from	  each	  trust	  was	  obtained.	  This	  included	  a	  review	  of	  the	  protocol,	  ethics,	  standard	  operating	  procedures,	  funding	  and	  systems	  for	  recruitment	  and	  running	  of	  the	  trial.	  SOPs	  were	  tailored	  to	  suit	  each	  trust,	  as	  were	  the	  PIS	   and	   consent	   forms.	   The	   REC	   was	   informed	   and	   a	   substantial	   amendment	   to	   the	  original	   ethics	   was	   obtained.	   The	   MHRA	   was	   informed	   of	   the	   trial	   expansion	   and	  approval	   sought.	  These	  approvals	  were	  obtained	   for	  each	   trust	  on	   separate	  occasions	  due	  to	  the	  staggered	  timing	  of	  the	  expansion.	  	  
2.16.3 Local	  education	  
Each	  department	  involved	  in	  the	  trial	  were	  familiarised	  with	  the	  HYPER	  trial.	  The	  trial	  procedures	  pertaining	  to	  each	  department	  were	  discussed	  as	  per	  the	  trial	  protocol	  and	  relevant	  queries	  clarified.	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2.16.4 Local	  running	  of	  the	  trial	  	  
Each	  centre	  excluding	  UHB	  had	  a	  clinical	  research	  nurse	  assigned	  to	  the	  trial.	  Their	  role	  was	   to	   screen	   patients,	   send	   out	   PIS	   and	   coordinate	  with	   the	   clinical	   research	   fellow	  regarding	   trial	   recruitment.	   Initial	   patient	   screening	   was	   performed	   by	   the	   clinical	  research	  nurse.	   	  This	  was	   then	  checked	  periodically	  by	  myself	  as	   the	  clinical	   research	  fellow	   before	   invitations	   and	   PIS	   were	   sent	   out.	   Consenting,	   randomisation	   and	   IMP	  dispensing	   was	   conducted	   on	   a	   pre-­‐arranged	   date.	   The	   remainder	   of	   the	   trial	   was	  conducted	   as	   described	   above	   allowing	   for	   the	   exceptions	   outlined	   below	   (section	  2.16.5).	  	  	  
2.16.5 Deviations	  to	  the	  protocol	  	  
Due	   to	   differences	   in	   surgical	   practice	   and	   postoperative	   management	   between	  surgeons	  at	  RSCH	  and	  UHCW,	   recruitment	  of	  patients	  was	   restricted	   to	  2	   surgeons	  at	  each	   centre.	   This	   was	   accounted	   for	   during	   randomisation	   and	   the	   randomisation	  programme	  was	  set	  up	  similar	   to	   that	  used	  at	  UHB.	  Due	   to	   logistical	   reasons	  of	  being	  unable	   to	   consent	   and	   start	   IMP	   therapy	   on	   an	   ad-­‐hoc	   basis	   for	   urgent	   patients,	   only	  elective	  surgical	  candidates	  were	  approached	  at	  the	  other	  centres.	  	  
Although	   blood	  was	   collected	   and	   prepared	   in	   the	   same	  manner	   as	   described	   above,	  there	  was	  no	  facility	  for	  liquid	  nitrogen.	  Therefore	  biopsies	  were	  not	  taken	  from	  these	  patients	  due	  to	  the	  inability	  to	  snap	  freeze	  these	  samples	  prior	  to	  freezing.	  	  
In	  addition	   to	   screening	  and	  recruitment	   the	   research	  nurse	  was	   involved	   in	   the	  data	  collection	  and	  acquisition	  of	  blood	  samples	  from	  beyond	  the	  1st	  6	  hrs	  from	  XC	  removal.	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Serum	  samples	  were	  stored	  locally	  in	  a	  -­‐80°C	  freezer	  and	  couriered	  to	  UHB	  at	  the	  end	  of	  the	  trial.	  
2.17 Data	  safety	  monitoring	  and	  futility	  assessment	  	  
An	   independent	   data	   safety	   monitoring	   board	   (DSMB)	   was	   appointed	   and	   a	   DSMB	  meeting	  was	   held	   on	   the	   22nd	   June	   2012	   once	   a	   predetermined	   target	   of	   99	   patients	  (45%	   recruitment)	   had	   been	   recruited	   and	   discharged	   (allowing	   for	   all	   outcome	  measures	  to	  be	  collected)	  from	  the	  hospital.	  The	  DSMB	  was	  requested	  to	  assess	  the	  trial	  for	   safety	   and	  efficacy	   and	  also	   assess	   the	   trial	   for	   futility	  based	  on	   the	   results	  of	   the	  CASPER	  trial	  that	  had	  concluded	  earlier.	  The	  CASPER	  trial	  is	  discussed	  in	  more	  detail	  in	  the	  following	  discussion	  chapters.	  	  
The	   meeting	   concluded	   that	   recruitment	   has	   proved	   to	   be	   difficult	   yet	   they	   had	   no	  further	   suggestions	   to	   improve	   recruitment	   and	   the	   recruitment	   objective	   would	  unlikely	  be	  achieved	   in	   less	   than	  20	  months.	  With	  regard	   to	   the	  assessment	  of	   futility	  using	  the	  O’Brien	  Fleming	  alpha	  Spending	  approach	  the	  board	  concluded	  that	  the	  trial	  was	  unlikely	  to	  achieve	  its	  scientific	  objective	  and	  was	  content	  for	  the	  trial	  to	  be	  halted	  and	   recommended	   the	   trials	   steering	   committee	   to	   halt	   recruitment	   to	   the	   trial	  (Appendix	  9.12).	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3 RESULTS	  OF	  THE	  CLINICAL	  TRIAL	  
3.1 Patient	  recruitment	  
Recruitment	   into	   the	   trial	   started	   in	   September	   2009	   and	  was	   initially	   from	   a	   single	  centre,	   the	   University	   Hospitals	   Birmingham	   NHS	   FT	   (UHB);	   patients	   were	   recruited	  from	   5	   surgeons	   at	   this	   centre.	   The	   first	   patient	   was	   operated	   on,	   in	   October	   2009.	  Subsequently	  the	  mean	  rate	  of	  recruitment	  at	  this	  centre	  was	  3	  cases	  per	  month	  (Figure	  3-­‐1).	  	  This	  fell	  severely	  below	  the	  initial	  predicted	  rate	  of	  recruitment,	  to	  complete	  the	  trial	  well	  within	  three	  years	  (figure	  3-­‐2)	  
	  
Figure	  3-­‐1	  Number	  of	  cases	  per	  month	  -­‐	  HYPER	  trial	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a	  3rd	  centre,	  the	  University	  Hospital	  Coventry	  and	  Warwickshire,	  Coventry.	  Recruitment	  in	   Coventry	   started	   in	   January	   2012	   and	   the	   first	   patient	  was	   operated	   on,	   in	  March	  2012.	  	  
	  
Figure	  3-­‐2	  Rate	  of	  recruitment	  compared	  to	  predicted	  rate	  of	  recruitment	  















3.2 Consort	  flow	  diagram	  	  
The	   consort	   flow	   diagram	   (Figure	   3-­‐3)	   outlines	   the	   number	   of	   patients	   screened	   for	  eligibility,	   the	  reasons	   for	   their	  exclusion	  and	  pathway	  of	  patients	  post	  randomisation	  as	  based	  on	  the	  locked	  database.	  	  
	  
Figure	  3-­‐3	  CONSORT	  flow	  diagram	  of	  the	  HYPER	  trial	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During	   the	   period	   of	   trial	   recruitment	   (Sept	   2009	   –	   June	   2012),	   489	   patients	   were	  screened	   for	  suitability	   to	  enter	   the	   trial.	  Of	   these,	  339	  were	  excluded,	  majority	  being	  patients	  with	  diabetes	  (n=110)	  who	  otherwise	  met	  the	  exclusion	  criteria.	  In	  addition	  to	  the	  diabetic	  patients,	  patients	  with	  atrial	  fibrillation	  (AF)	  or	  those	  planned	  to	  have	  atrial	  ablation	   therapy	   (AFA)	   (n=58),	   and	   those	   patients	   with	   moderate	   to	   severe	   aortic	  regurgitation	  (n=54)	  met	  the	  exclusion	  criteria.	  A	  smaller	  number	  of	  patients	  n=7,	  had	  echocardiographic	  confirmation	  that	  there	  was	  no	  LVH	  and	  a	  similar	  number	  had	  renal	  dysfunction	   and	   were	   on	   amiodarone	   therapy.	   A	   total	   of	   49	   patients	   declined	   to	  participate	  in	  the	  trial.	  Another	  large	  portion	  of	  patients	  (n=54)	  fell	  into	  a	  group	  where	  it	  was	  logistically	  difficult	  to	  recruit	  them	  into	  the	  trial	  outlined	  in	  (Table	  3-­‐1).	  	  
Logistical	  reason	  for	  exclusion	   Number	  Operation	  too	  soon	  for	  intervention	   33	  Other	  concomitant	  procedure	   5	  Operation	  in	  another	  hospital	   3	  Unable	  to	  contact	  patient	   7	  Patient	  unable	  to	  travel	  for	  recruitment	   3	  Other	  medical	  reason	   3	  
	  
Table	  3-­‐1	  Logistical	  reasons	  for	  trial	  exclusion	  
Patients	   required	   a	  minimum	   period	   of	   4	   days	   of	   trial	   therapy	   and	   this	   included	   the	  loading	  regime	  of	  3	  days.	  Although	  efforts	  were	  made	  to	  identify	  all	  suitable	  patients,	  an	  important	   number	   (n=33),	   did	   not	   have	   enough	   time	   before	   surgery	   to	   take	   the	   trial	  therapy.	  Concomitant	  procedures	  (initially	  unplanned)	   included	  aortic	  root	  surgery	  or	  other	   valve	   surgery	   i.e.	   mitral	   or	   tricuspid	   valve	   surgery.	   Other	   medical	   reasons	  included;	   patients	   too	   high	   risk	   or	   had	   co-­‐existing	  medical	   conditions	   that	   precluded	  them	  from	  entering	  the	  trial	  i.e.	  metal	  health	  illness.	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At	   the	   time	   of	   trial	   closure,	   23	   patients	   had	   been	   identified	   who	   were	   suitable	   for	  enrolment	   and	   had	   been	   sent	   the	   patient	   information	   leaflets.	   If	   the	   trial	   continued	  these	   patients	  would	   have	   been	   seen	   in	   the	   pre-­‐assessment	   clinic	   to	   discuss	   the	   trial	  further.	  	  
In	  the	  locked	  final	  database,	  a	  total	  of	  62	  patients	  were	  randomised	  to	  the	  perhexiline	  arm	   and	   65	   to	   the	   placebo	   arm.	   Of	   these	   57	   and	   60	   patients	   received	   and	   self-­‐administered	   the	   trial	   therapy	   in	   the	  perhexiline	   and	   control	   arm	   respectively.	   In	   the	  perhexiline	   arm,	   1	   patient	   died	   whilst	   awaiting	   surgery	   and	   wasn’t	   started	   on	   trial	  therapy.	  In	  the	  placebo	  arm,	  1	  patient	  had	  their	  operation	  in	  another	  hospital	  and	  one	  was	   operated	   on	   too	   soon,	   hence	   trial	   therapy	   was	   not	   started.	   One	   patient	   in	   the	  perhexiline	   arm	   and	   2	   in	   the	   placebo	   arm	   were	   randomised	   but	   didn’t	   receive	   trial	  therapy	  prior	  to	  trial	  closure.	  Therefore	  of	  57	  patients	  who	  received	  the	  trial	  therapy	  in	  the	  perhexiline	  arm,	  54	  underwent	  an	  operation.	  Similarly	  of	  60	  patients	  who	  received	  trial	  therapy	  in	  the	  placebo	  arm,	  58	  underwent	  an	  operation.	  	  
3.2.1 Withdrawals	  	  
Five	  patients	  withdrew	  consent;	  four	  from	  the	  perhexiline	  arm	  and	  1	  from	  the	  placebo	  arm.	  Of	   these	  patients,	  3	  had	  started	   trial	   therapy	  before	   they	  withdrew	  consent;	  2	   in	  the	  perhexiline	  arm	  and	  1	  in	  the	  placebo	  arm	  and	  hence	  although	  these	  patients	  were	  followed	  up	  as	  per	  the	  trial	  protocol	  due	  to	  being	  exposed	  to	  the	  trial	  therapy,	  they	  have	  been	  excluded	  from	  all	  analysis.	  	  	  
A	  total	  of	  3	  patients	  were	  withdrawn	  from	  the	  trial.	  	  Of	  these,	  2	  were	  randomised,	  didn’t	  receive	  the	  intervention	  but	  met	  the	  exclusion	  criteria;	  one	  had	  atrial	  fibrillation	  and	  the	  other	  post	  randomisation	  was	  scheduled	  for	  a	  Trans-­‐catheter	  Aortic	  Valve	  Implantation	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(TAVI),	  a	  procedure	  that	  doesn’t	  arrest	  the	  heart.	  The	  third	  patient	  was	  withdrawn	  due	  to	  pre-­‐existing	  renal	   impairment	  (creatinine	  >	  200),	  but	  had	   inadvertently	  started	  the	  trial	  therapy;	  although	  followed	  up	  due	  to	  exposure	  to	  the	  trial	  therapy	  this	  patient	  was	  not	  included	  in	  the	  analysis.	  	  
3.2.2 Patients	  excluded	  from	  the	  analysis	  	  
In	   the	   perhexiline	   arm,	   3	   patients	   were	   excluded	   from	   the	   final	   analysis	   due	   to	  withdrawal	   of	   consent	   and	   being	   withdrawn	   from	   the	   trial	   as	   outlined	   above.	   In	  addition	   to	   this,	   2	   patients	   in	   the	   perhexiline	   arm	   did	   not	   have	   pulmonary	   artery	  flotation	  catheter	  (PAFC)	  inserted	  at	  the	  time	  of	  the	  operation	  during	  the	  majority	  of	  the	  initial	  6	  hours	  post	  cross	  clamp	  removal	  (required	  to	  make	  haemodynamic	  assessment	  of	   cardiac	   output	   and	   index).	   Therefore	   a	   blinded-­‐end	   points	   committee	   decided	   to	  exclude	  these	  2	  patients	  from	  the	  primary	  end-­‐point,	  as	  there	  was	  insufficient	  evidence	  to	  reach	  a	  decision	  on	  the	  primary	  end-­‐point.	  	  
In	   the	  placebo	  arm,	  2	  patients	  were	   excluded;	   one	   for	  withdrawal	  of	   consent	   and	   the	  other	   patient	   had	   the	   operation	   postponed	   due	   to	   ill	   health	   and	   later	   died	   of	  disseminated	  malignancy	  before	  the	  operation	  could	  be	  re-­‐scheduled.	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3.3 Demographics	  	  
3.3.1 Pre-­‐operative	  demographics	  	  
Patient	   demographics	   are	   outlined	   in	   Table	   3-­‐2	   and	   outlines	   the	   pre-­‐operative	  demographics	  between	  the	  groups.	  	  
Variable	  (IQR)/(%)	   Placebo	  (n=58)	   Perhexiline	  (n=54)	  
Age	   72	  (66	  –	  76)	   73	  (63	  –	  78)	  
BSA	  	   1.88	  (1.75	  –	  2.07)	   1.7	  (1.86	  –	  1.97)	  
Male:	  Female	  	   38:20	  (65.5:34.5)	   37:17	  (68.5:31.5)	  
Caucasian	   56	  (96.6)	   52	  (96.3)	  
Status	   	   	  -­‐	  Elective	   54	  (93.1)	   53	  (98.1)	  -­‐	  Urgent	   4	  (6.9%)	   1	  (1.9)	  
EuroSCORE	   6	  (4	  –	  7)	   6	  (4	  –	  7)	  
Logistic	  EuroSCORE	   4.5	  (2.4	  –	  7.25)	   3.75	  (2.6	  –	  7.24)	  
CCS	  	   	   	  -­‐	  1	   24	  (58.6)	   38	  (70.4)	  -­‐	  2	   20	  (34.5)	   12	  (22.2)	  -­‐	  3	   3	  (5.2)	   4	  (7.4)	  
NYHA	   	   	  -­‐	  1	   14	  (24.1)	   12	  (22.2)	  -­‐	  2	   26	  (44.8)	   29	  (53.7)	  -­‐	  3	   16	  (27.6)	   11	  (20.4)	  -­‐	  4	   1	  (1.7)	   2	  (3.7)	  
Previous	  MI	   4	  (6.9)	   3	  (5.6)	  
Risk	  factors	   	   	  -­‐	  Hypercholesterolemia	  	   10	  (17.2)	   18	  (33.3)	  -­‐	  Hypertension	   23	  (39.7)	   22	  (40.7)	  -­‐	  FHx	  IHD	   6	  (10.3)	   2	  (2.7)	  -­‐	  Previous	  TIA	   4	  (6.9)	   2	  (3.7)	  -­‐	  Previous	  CVA	   1	  (1.7)	   3	  (5.6)	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-­‐	  PVD	   1	  (1.7)	   0	  (0)	  -­‐	  CEA	   0	  (0)	   0	  (0)	  -­‐	  Smoking	   	   	  	  	  	  -­‐	  Never	  smoked	   13	  (22.4)	   11	  (20.4)	  	  	  	  -­‐	  Ex-­‐smoker	   22	  (37.9)	   18	  (33.3)	  	  	  	  -­‐	  Current	  smoker	   3	  (5.2)	   4	  (7.4)	  -­‐	  Asthma	   4	  (6.9)	   4	  (7.4)	  -­‐	  COPD	   3	  (3.4)	   6	  (11.1)	  
Medication	   	   	  -­‐	  Aspirin	   30	  (51.1)	   31	  (57.4)	  -­‐	  Clopidogrel	   5	  (8.6)	   2	  (3.7)	  -­‐	  ACE	   13	  (22.4)	   12	  (22.2)	  -­‐	  A2	   8	  (13.8)	   5	  (9.3)	  -­‐	  Statin	   32	  (55.2)	   37	  (68.5)	  -­‐	  β	  blocker	   15	  (25.9)	   16	  (29.6)	  -­‐	  Ca	  channel	  blocker	   15	  (25.9)	   13	  (24.1)	  -­‐	  Nitrate	   3	  (5.2)	   3	  (5.6)	  -­‐	  Nicorandil	   1	  (1.7)	   2	  (3.7)	  
IABP	  pre	  surgery	   0	  (0)	   0	  (0)	  
Pre-­‐op	  Haemoglobin	   13.4	  (12.5	  –	  145)	   14.1	  (12.8	  –	  14.8)	  
Pre-­‐op	  Creatinine	   83	  (70.5	  –	  104.5)	   87.5	  (75.3	  -­‐101.8)	  	  
Table	  3-­‐2	  Pre-­‐operative	  demographics	  
3.3.2 Echocardiographic	  demographics	  	  
The	   pre	   IMP	   therapy	   echocardiographic	   findings	   including	   left	   ventricular	   wall	  dimensions	   and	   valve	   haemodynamics	   are	   outlined	   in	   Table	   3-­‐3.	   There	   was	   no	  significant	  difference	   in	   the	  ventricular	  dimensions	  or	  valve	  haemodynamics	  between	  the	  groups.	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Variable	  (IQR/%)	   Placebo	   Perhexiline	   P	  value	  
Ventricular	  Function	   	   	   0.42	  -­‐	  Good	   54	  (93.1)	   47(87.0)	   	  -­‐	  Moderate	   4	  (6.9)	   6	  (11.1)	   	  -­‐	  Poor	   0	  (0)	   1	  (1.9)	   	  
LVEDV	   95.7	  (73.4	  –	  113.5)	   98.5	  (69.9	  –	  132.8)	   1.0	  
LVID	   4.35	  (3.83	  –	  4.72)	   4.6	  (4.1	  –	  4.8)	   0.35	  
IVSd	   1.4	  (1.2	  –	  1.6)	   1.4	  (1.3	  –	  1.6)	   0.99	  
PWd	   1.18	  (1.0	  –	  1.4)	   1.3	  (1.1	  –	  1.5)	   0.20	  
Valve	  Vmax	   4.23	  (3.9	  –	  4.8)	   4.4	  (3.7	  –	  5.0)	   0.68	  
LVOT	  Vmax	   0.9	  (0.7	  –	  1.2)	   0.9	  (0.9	  –	  1.2)	   0.45	  
Valve	  area	  (m2)	   0.79	  (0.6	  –	  0.9)	   0.7	  (0.6	  –	  0.9)	   0.61	  
Peak	  gradient	   76	  (63.8	  –	  94.0)	   77	  (62.0	  –	  94.5)	   0.77	  
Mean	  gradient	  	   43.5	  (35.8	  –	  59.5)	   48.5	  (34.5	  –	  56.5)	   0.98	  
Aortic	  regurgitation	   	   	   	  -­‐	  Mild	   8	  (13.8)	   8	  (19.8)	   	  -­‐	  Moderate	   3	  (5.2)	   6	  (11.1)	   	  
Table	  3-­‐3	  Echocardiographic	  variables	  
3.3.3 Operative	  demographics	  	  
The	   operative	   variables	   between	   the	   groups	   are	   outlined	   in	   Table	   3-­‐4.	   There	  was	   no	  statistical	  significance	  between	  the	  groups	   in	  each	  of	  the	  variable.	   In	  each	  group,	  44%	  underwent	   concomitant	   CABG	   and	   the	   majority	   of	   patients	   had	   a	   biological	   valve	  implanted.	  There	  were	  4	  IABP	  inserted	  and	  of	  these,	  3	  patients	  were	  in	  the	  perhexiline	  arm.	   All	   balloon	   pumps	   were	   inserted	   to	   aid	   weaning	   off	   CPB;	   either	   poor	  haemodynamic	   performance	  with	   low	   cardiac	   output	   or	   right	   ventricular	   dysfunction	  and/or	  dilatation	  on	  weaning	  from	  CPB.	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In	   some	   patients	   who	   underwent	   CABG,	   a	   side-­‐biting	   aortic	   occlusion	   technique	  was	  used	  for	  the	  proximal	  anastomosis	  of	   the	  vein	  grafts.	  This	  was	  at	   the	  discretion	  of	   the	  operating	   surgeon	   and	   was	   equal	   in	   proportion	   in	   each	   group.	   The	   additional	  procedures	  were	  unplanned	  at	  the	  time	  of	  listing	  for	  surgery	  and	  hence	  decided	  intra-­‐operatively	   based	   on	   intra-­‐operative	   TOE	   assessment.	   One	   patient	   in	   the	   perhexiline	  arm	   underwent	   unplanned	   grafting	   of	   the	   left	   coronary	   system	   due	   to	   untoward	  complications	  intra-­‐operatively.	  	  
Variable	  (IQR/%)	   Placebo	   Perhexiline	   P	  Value	  
Procedure	   	   	   1.0	  -­‐	  AVR	   32	  (55.2)	   30	  (55.6)	   	  -­‐	  AVR	  +	  CABG	   26	  (44.8)	   24	  (44.4)	   	  
Additional	  procedure	   	   	   	  -­‐	  MV	  repair	   2	  (3.4)	   1	  (1.9)	   	  -­‐	  TV	  repair	   1	  (3.4)	   	   	  -­‐	  MV	  replacement	   	   1	  (1.9)	   	  -­‐	  Unintended	  CABG	   	   1	  (1.9)	   	  
Valve	  type	   	   	   1.0	  -­‐	  Biological	   50	  (86.2)	   47	  (87)	   	  -­‐	  Mechanical	   8	  (13.8)	   7	  (13)	   	  
Valve	  size	   23	  (21	  –	  24)	   22.5	  (21	  –	  23)	   	  
Technique	   	   	   0.68	  -­‐	  Side-­‐biting	  cross	  clamp	   18	  (31)	   14	  (26)	   	  -­‐	  Single	  clamp	   40	  (69)	   40	  (74.1)	   	  
Cumulative	  CPB	  time	   129	  (103	  –	  165)	   135	  (106	  –	  192)	   0.48	  
Cumulative	  cross	  clamp	  time	   95	  (65	  –	  116)	   89	  (71	  –	  120)	   0.92	  
Hot	  shot	  administered	   28	  (48.3)	   31	  (37.4)	   0.35	  
Tranaexamic	  acid	  used	   21	  (36)	   22	  (40.7)	   0.70	  
Aprotinin	  used	   9	  (15.5)	   8	  (14.8)	   1.0	  
IABP	   1	  (1.7)	   3	  (5.6)	   0.35	  
Table	  3-­‐4	  Operative	  variables	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3.4 Duration	  of	  trial	  therapy	  	  
All	  patients	  were	  required	  to	  have	  a	  minimum	  duration	  of	  trial	  therapy	  of	  4	  days,	  which	  consisted	  of	  a	  loading	  regime	  in	  the	  initial	  3	  days.	  Each	  bottle	  of	  trial	  therapy	  consisted	  of	  34	  IMP	  tablets	  and	  would	  last	  a	  patient	  14	  days,	  which	  included	  the	  loading	  regime.	  If	  the	  surgery	  was	  postponed	  a	  second	  bottle	  was	  issued	  and	  this	  would	  last	  17	  days	  on	  the	  maintenance	  regime.	  A	  second	  bottle	  was	  issued	  to	  43	  patients	  and	  this	  was	  usually	  due	  to	  the	  surgery	  being	  postponed	  hence	  the	  requirement	  to	  continue	  trial	  therapy.	  If	  the	   surgery	  was	  postponed	   to	   a	  date	  beyond	   the	  duration	  of	   therapy	  possible	  by	  one	  bottle	  (over	  2	  weeks)	  then	  the	  trial	  therapy	  was	  stopped	  and	  then	  re-­‐started	  nearer	  the	  new	  re-­‐scheduled	  date	  following	  the	  initial	  loading	  and	  maintenance	  regimes.	  	  
The	  median	  duration	  of	  trial	  therapy	  was	  8.5	  days	  (IQR	  5	  –	  17.5)	  for	  all	  trial	  participants	  in	   the	   final	  analysis.	   In	   the	  perhexiline	  arm	  median	  duration	  was	  8	  days	   (IQR	  5	  –	  11)	  and	  in	  the	  placebo	  arm	  median	  duration	  was	  8	  days	  (IQR	  6	  –	  14),	  p=	  0.41	  and	  did	  not	  meet	  a	  normal	  distribution	  on	  a	  Kolmogorov-­‐Smirnov	  test	  of	  normality	  (p<0.005)	  The	  distribution	  and	  frequency	  of	  trial	  therapy	  for	  each	  arm	  is	  outlined	  in	  figures	  3-­‐4	  and	  3-­‐5.	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Figure	  3-­‐4	  Distribution	  and	  frequency	  of	  placebo	  therapy	  
 
 
Figure	  3-­‐5	  Distribution	  and	  frequency	  of	  perhexiline	  therapy 
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Of	  the	  112	  patients	  that	  received	  trial	  therapy,	  ten	  patients	  were	  not	  on	  trial	  therapy	  at	  the	   time	   of	   their	   operation;	   four	   ran	   out	   of	   tablets	   before	   their	   operation	   and	   six	  stopped	  therapy	  due	  to	  side	  effects;	  of	  the	  six,	  five	  were	  in	  the	  treatment	  group.	  Of	  the	  four	  that	  ran	  out	  of	  tables,	  three	  were	  on	  placebo	  and	  one	  on	  perhexiline.	  	  	  
3.5 Serum	  perhexiline	  levels	  	  
Serum	   for	   perhexiline	   concentration	   analysis	   was	   available	   in	   106	   patients,	   51/54	  (94.4%)	  in	  the	  treatment	  group	  and	  55/58	  (94.8%)	  in	  the	  placebo	  group.	  These	  were	  all	  analysed	  for	  perhexiline	  and	  hydroxy-­‐perhexiline	  concentrations.	  All	  but	  one	  patient	  in	  the	  placebo	  arm	  had	  a	  serum	  perhexiline	  concentration	  of	  zero	  mg/L.	  This	  patient	  had	  perhexiline	   and	   hydroxyl-­‐perhexiline	   concentrations	   of	   0.09mg/L	   and	   0.74mg/L	  respectively.	   This	   patient	   had	   been	  wrongly	   allocated	   into	   the	   placebo	   arm	   as	   a	   data	  entry	  error	  prior	   to	   locking	   the	  database;	  was	  analysed	  within	   the	  placebo	  arm	  on	  an	  intension-­‐to-­‐treat	  basis	  without	  any	  further	  analyses	  thereafter	  and	  therefore	  treated	  as	  a	   unbiased	   measurement	   error.	   	   Had	   the	   results	   been	   potentially	   sensitive	   to	   the	  misallocation	  of	  this	  subject	  a	  supportive	  analysis	  would	  have	  been	  conducted,	  but	  this	  was	  judged	  not	  to	  be	  the	  case.	  
In	  the	  perhexiline	  group	  the	  median	  perhexiline	  concentration	  was	  0.22mg/L	  (IQR	  0.09	  –	  0.43),	  ranging	  from	  0	  –	  1.2mg/L.	  	  Twenty	  patients	  (39.2%)	  in	  the	  perhexiline	  arm	  had	  a	  perhexiline	   level	  below	   the	   therapeutic	   range	   (0.15	  –	  0.6mg/L).	  Of	   these,	  2	  patients	  had	  no	  detectable	  perhexiline	  concentration	  in	  the	  serum;	  one	  stopped	  therapy	  due	  to	  side	   effects	   of	   diarrhoea	   after	   one	   day	   of	   therapy	   and	   the	   other	   ran	   out	   of	   tablets	   1	  month	   before	   the	   operation.	   Hence	   24	   patients	   (47%)	   were	   within	   the	   therapeutic	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range	   (0.16	   –	   0.6mg/L)	   with	   7	   of	   these	   patients	   being	   above	   the	   therapeutic	   range	  (Figure	  3-­‐6).	  	  	  
	  
Figure	  3-­‐6	  Distribution	  of	  perhexiline	  concentrations	  
The	   median	   hydroxy-­‐perhexiline	   concentration	   was	   1.02	   mg/L	   (IQR	   0.72	   –	   1.22),	  ranging	  0	  –	  1.67mg/L.	  Of	  the	  20	  patients	  below	  the	  lower	  therapeutic	  range,	  17	  patients	  had	  a	  hydroxy-­‐perhexiline	  to	  perhexiline	  ratio	  of	  >	  6mg/L	  and	  the	  other	  had	  a	  ratio	  of	  5.92mg/L.	  These	  18	  patients	  fell	  within	  the	  extensive	  metabolisers	  group.	  	  
There	  was	  one	  ultra-­‐rapid	  metaboliser	  in	  whole	  cohort	  and	  four	  patients	  had	  hydroxy-­‐perhexiline:perhexiline	  ratio	  of	  	  ≤	  0.3	  and	  fell	  within	  the	  poor	  metaboliser	  group.	  There	  was	  10	   and	  34	   intermediate	   and	  extensive	  metaboliser	   respectively.	  Both	  perhexiline	  and	   hydroxyl-­‐perhexiline	   concentration	   ranges	   did	   not	   show	   a	   normal	   distribution	  pattern	  on	  a	  Kolmogorov-­‐Smirnov	  test	  of	  normality,	  p=0.01	  and	  p=0.02	  respectively.	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All	  patients	  appear	  to	  be	  compliant	  with	  trial	  therapy,	  yet	  it	  is	  difficult	  to	  comment	  on	  the	   level	   of	   compliance.	   Although	   all	   patients	   in	   the	   perhexiline	   arm	   had	   detectable	  levels	  of	  perhexiline	  and	  hydroxyl-­‐perhexiline,	  compliance	  with	  the	  strict	  dosing	  regime	  is	  not	  measurable.	  Looking	  at	  those	  who	  were	  sub-­‐therapeutic	  (n=20),	  median	  duration	  of	   trial	   therapy	   in	   this	   group	  was	   7	   days	   (IQR	   4.25	   –	   7.25);	   there	  was	   no	   significant	  correlation	   between	   the	   length	   of	   therapy,	   and	   perhexiline	   concentration	   using	  Spearman’s	  rank	  correlation	  with	  a	  co-­‐efficient	  of	  0.42	  (p	  =	  0.63).	  	  Similarly	  analysis	  of	  the	   whole	   perhexiline	   arm	   for	   correlation	   between	   perhexiline	   concentration	   and	  duration	  of	  therapy,	  showed	  a	  Spearman’s	  rank	  correlation	  co-­‐efficient	  of	  0.15	  (p=0.23).	  
3.6 Side	  effects	  to	  trial	  therapy	  
Of	  127	  patients	  that	  receive	  trial	  therapy,	  11	  patients	  reported	  side	  effects	  outlined	  in	  Table	   3-­‐5.	   All	   but	   one	   patient	  with	   side	   effects	  were	   in	   the	   perhexiline	   arm	   and	   side	  effects	  consisted	  of	  dizziness	  with	  a	  combination	  of	  nausea.	  Other	  side	  effects	  reported	  included	   diarrhoea	   and	   itching.	   The	   patient	   in	   the	   placebo	   arm	   reported	   a	   tingling	  sensation	  down	  the	  arm.	  	  
Side	  effects	  reported	   Perhexiline	   Placebo	  Dizziness	  and	  nausea	   3	   	  Dizziness	  alone	   4	   	  Diarrhoea	  	   2	   	  Rash	  and	  itching	  	   1	   	  Tingling	   	   1	  
Table	  3-­‐5	  Side-­‐effects	  after	  starting	  trial	  therapy	  
One	  patient	   that	  had	  dizziness	  and	  nausea	  halved	   the	  maintenance	   regime	   to	  1	   tablet	  daily	  with	   resolution	   of	   side	   effects.	   Two	   patients	  with	   dizziness,	   one	  with	   diarrhoea	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and	  one	  with	  itching	  had	  side	  effects	  associated	  to	  the	  loading	  regime,	  which	  settled	  by	  day	  4.	  One	  patient	  with	  nausea	  and	  dizziness	  had	  no	  benefit	  with	  a	  halved	  regime	  and	  stopped	   trial	   therapy.	   Another	   5	   patients	   did	   not	  want	   to	   trial	   a	   reduced	   regime	   and	  stopped	  trial	  therapy	  after	  noticing	  the	  side	  effects.	  	  
At	   the	   time	   of	   surgery,	   of	   the	   6	   patients	   who	   stopped	   trial	   therapy	   and	   were	   in	   the	  perhexiline	  arm,	  one	  patient	  didn’t	  have	   serum	   for	  perhexiline	   concentration	  analysis	  and	   one	   was	   sub-­‐therapeutic	   (serum	   concentration	   of	   perhexiline	   <	   0.16mg/L);	   all	  others	  were	  within	  the	  therapeutic	  range.	  	  
3.7 Primary	  outcome	  	  
The	  primary	   end-­‐point	  was	  defined	   as	   the	   incidence	  of	   inotrope	  use	  ±	   comparison	  of	  cardiac	   index	   to	  baseline	   to	   show	  an	   increase	  >	  0.3L/min/m2	  within	   the	   first	  6	  hours	  from	  reperfusion.	  This	  was	  adjudicated	  by	  a	  blinded	  end-­‐point	  committee	  based	  on	  the	  haemodynamic	   studies	   conducted	   in	   the	   1st	   6	   hours	   from	   removal	   of	   the	   aortic	   cross	  clamp.	  These	  haemodynamic	  studies	  included	  data	  on	  the	  heart	  rate	  and	  rhythm	  (paced	  or	   native),	   cardiac	   output,	   cardiac	   index,	   mean	   systemic	   and	   pulmonary	   artery	  pressures,	  filling	  pressure	  (central	  venous	  and	  pulmonary	  artery	  wedge	  pressure),	  and	  temperature.	   This	   information	   was	   evaluated	   in	   conjunction	   with	   metabolic	   status	  including	  lactate	  and	  base	  deficit.	  	  
This	   committee	   judged	   if	   an	   inotrope	  was	  started	  appropriately	  based	  on	  pre-­‐defined	  criteria	   (outlined	   in	   the	  methodology).	   The	   presence	   of	   a	   low	   cardiac	   output	   episode	  inevitably	   results	   in	   an	   inotrope	   being	   initiated	   to	   improve	   haemodynamic	  performance.	  	  
	  3-­‐119	  
Of	  112	  patients	  that	  underwent	  surgery,	  110	  patients	  had	  a	  PAFC	  in	  place	  to	  obtain	  the	  haemodynamic	  measurement	  needed	  to	  adjudicate	  on	  the	  primary	  end	  point.	  Therefore	  2	  patients	  who	  were	  both	  in	  perhexiline	  arm	  were	  excluded	  from	  this	  analysis.	  	  
Of	  110	  patients,	  the	  blinded	  end-­‐points	  committee	  judged	  that	  30	  patients	  in	  total	  had	  inotropes	  started	  appropriately	  and	  hence	  had	  achieved	  a	  low	  cardiac	  episode,	  to	  have	  the	  inotropes	  started.	  Of	  the	  30,	  16	  were	  in	  the	  perhexiline	  arm	  and	  14	  in	  the	  placebo	  arm.	   This	   primary	   end-­‐point	   showed	   no	   statistical	   significance	   in	   the	   incidence	   of	  appropriate	  inotrope	  usage	  OR	  1.65	  (CI	  0.67	  –	  4.06)	  p=0.28.	  	  	  
3.8 Haemodynamic	  assessments	  	  
Haemodynamic	   assessments	  were	  measured	   at	   baseline	   (prior	   to	   institution	   of	   CPB),	  prior	   to	   administration	   of	   protamine,	   approximately	   10	   minutes	   after	   protamine	  administration	   and	   then	   at	   2	   hourly	   intervals	   for	   6	   hours	   after	   aortic	   cross	   clamp	  release	  (2,	  4,	  6	  hours)	  and	  finally	  at	  9	  and	  12	  hours	  after	  aortic	  cross	  clamp	  release.	  
3.8.1 Heart	  rate	  and	  filling	  pressure	  	  
The	  heart	  rate	  pre	  CPB	  was	  based	  on	  the	  native	  heart	  rate	  of	  the	  patient.	  To	  attain	  an	  ideal	  constant	  heart	  rate	  prior	  to	  CPB	  discontinuation	  and	  during	  the	  early	  reperfusion	  stage,	   patients	   are	   paced	   either	   atrially	   or	   have	   dual	   chamber	   pacing.	   There	   was	   no	  significant	   difference	   in	   the	   mean	   heart	   rate	   between	   the	   groups	   at	   any	   time	   point	  (Figure	  3-­‐7).	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Figure	  3-­‐7	  Mean	  heart	  rate	  between	  groups	  at	  each	  time	  point 
Right	   and	   left	   heart	   filling	   pressures	   are	   assessed	   by	   the	   measurement	   of	   CVP	   and	  PAWP	  respectively	  and	  are	  maintained	  at	  an	  optimum,	  on	  an	  individual	  patient	  basis	  to	  achieve	  the	  optimum	  overall	  hemodynamic	  status.	  	  




Figure	  3-­‐8	  Mean	  CVP	  between	  groups	  at	  each	  time	  point	  
	  	  	  
 
 
Figure	  3-­‐9	  Mean	  PAWP	  between	  groups	  at	  each	  time	  point 
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3.8.2 Mean	  arterial	  pressures	  	  
There	  was	  no	  statistical	  difference	  in	  the	  MAP	  between	  groups	  at	  any	  of	  the	  time	  points	  except	   at	   4	   hours	   post	   removal	   of	   the	   aortic	   cross	   clamp,	   with	  marginal	   significance	  (p=0.04).	  	  The	  trend	  in	  MAP	  between	  groups	  is	  shown	  below	  (Figure	  3-­‐10).	  	  
 
 
Figure	  3-­‐10	  Mean	  arterial	  pressure	  between	  groups	  at	  each	  time	  point	  
In	   the	   assessment	   of	   mean	   PAP	   between	   groups,	   there	   were	   marginal	   statistical	  significant	   differences	   at	   time	   points;	   pre	   protamine	   (p=0.04),	   and	   reperfusion	   at	   4	  hours	  (p=0.03),	  6	  hours	  (p=0.048)	  and	  12	  hours	  (p=0.02).	  However	  application	  of	   the	  Bonferroni	   correction	  would	  make	   this	  not	   significant.	  Mean	  PAPs	  were	  higher	   in	   the	  perhexiline	  arm	  after	  2	  hours	  of	  reperfusion	  (Figure	  3-­‐11).	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Figure	  3-­‐11	  Mean	  pulmonary	  artery	  pressures	  between	  groups	  at	  each	  time	  point	  
3.8.3 Cardiac	  index	  assessments	  	  
The	   mean	   cardiac	   index	   (standard	   deviation)	   at	   each	   of	   the	   time	   points	   is	   depicted	  below	   (Figure	   3-­‐12)	   and	   shows	   no	   significant	   difference	   between	   perhexiline	   and	  placebo	  at	  all	  time	  points	  except	  at	  12	  hours	  where	  the	  placebo	  arm	  has	  a	  higher	  cardiac	  index	  (Table	  3-­‐6).	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Measured	  cardiac	  











Pre	  CPB	   1.99	  (0.51)	   2.15	  (0.46)	   0.66	  (-­‐0.35	  –	  0.024)	   0.66	  
Pre	  protamine	   2.48	  (0.46)	   2.51	  (0.54)	   0.10	  (-­‐0.23	  –	  0.18)	   0.48	  
Post	  protamine	   2.57	  (0.67)	   2.58	  (0.56)	   0.004	  (-­‐0.24	  –	  0.25)	  	   0.97	  
2	  hours	   2.61	  (0.69)	   2.52	  (0.47)	   0.12	  (-­‐0.10	  –	  0.27)	   0.27	  
4	  hours	   2.53	  (0.71)	   2.62	  (0.54)	   -­‐0.04	  (-­‐0.27	  –	  0.18)	   0.69	  
6	  hours	   2.57	  (0.60)	   2.75	  (0.69)	   -­‐0.18	  (-­‐0.43	  –	  0.08)	   0.17	  
9	  hours	   2.74	  (0.56)	   2.85	  (0.61)	   -­‐0.11	  (-­‐0.33	  –	  0.12)	   0.36	  
12	  hours	   2.68	  (0.51)	   2.90	  (0.52)	   -­‐0.23	  (-­‐0.44	  –	  -­‐0.02)	  	   0.03	  
Table	  3-­‐6	  Cardiac	  index	  at	  each	  time	  point	  
There	   is	   a	   trend	  of	   consistently	  higher	   cardiac	   indices	   throughout	   the	  measured	   time	  within	  the	  placebo	  arm,	  particularly	  beyond	  2	  hours	  post	  reperfusion.	  	  	  
	  
 
Figure	  3-­‐12	  Mean	  cardiac	  index	  (L/min/m2)	  at	  each	  time	  point 
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3.9 Inotrope	  usage	  	  
The	  use	  of	  all	   inotropes	  was	  assessed	  between	  removal	  of	   the	  aortic	  cross	  clamp	  to	  6	  hours	  and	  then	  for	  the	  6	  –	  12	  hrs	  of	  reperfusion	  (Table	  3-­‐7).	  There	  was	  no	  difference	  in	  the	  usage	  of	  inotropes	  between	  groups	  during	  0	  –	  6	  hrs	  of	  reperfusion.	  	  




Estimate	  	  (95%	  
confidence	  interval)	  
P	  value	  
Inotrope	  use	  in	  
first	  6	  hours	  
22	  (40.1%)	   15	  (25.9%)	   2.31	  (0.99	  –	  5.74)	   0.053	  
Inotrope	  use	  	  	  	  	  	  	  	  	  	  	  	  	  
6	  -­‐	  12	  hours	  
26	  (48.1%)	   15	  (25.9%)	   3.11	  (1.34	  –	  7.23)	   0.009	  
Table	  3-­‐7	  Inotrope	  use	  in	  the	  1st	  6	  and	  6-­‐12	  hours	  of	  reperfusion	  
Statistical	  significance	  was	  present	  in	  inotrope	  usage	  6	  –	  12	  hours	  of	  reperfusion,	  with	  48%	   of	   patients	   in	   the	   perhexiline	   arm	   requiring	   inotropes	   compared	   with	   26%	   of	  control	  subjects	  in	  the	  same	  time	  frame.	  	  
The	  mean	  dose	  per	  kilogram	  of	  Dopamine	  and	  Adrenaline	  used	   in	   the	  1st	  6	  hours	  and	  then	   from	  6	  –	  12	  hours	  of	  reperfusion,	  between	  the	  groups	   is	  depicted	   in	  Figure	  3-­‐13	  and	  Figure	  3-­‐14	  respectively,	  and	  shows	  no	  significant	  difference	  between	   the	  groups	  for	  each	  time	  point.	  However,	  there	  is	  a	  rise	  in	  the	  mean	  dose	  per	  kilogram	  of	  Dopamine	  and	  Adrenaline	  used	  in	  the	  perhexiline	  group	  by	  6	  –	  12	  hrs	  of	  reperfusion,	  reflective	  of	  the	  significant	  difference	   in	  the	  total	   incidence	  of	   inotropes	  used,	  as	  depicted	   in	  Table	  3-­‐7.	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Figure	  3-­‐13	  Mean	  dose	  (mg/kg)	  of	  Dopamine	  at	  each	  time	  point 
 
 
Figure	  3-­‐14	  Mean	  dose	  (mg/kg)	  of	  Adrenaline	  at	  each	  time	  point 
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3.10 Vasoconstrictor	  use	  	  
Phenylephrine	  was	  the	  used	  as	  the	  1st	   line	  vasoconstrictor	  to	  maintain	  haemodynamic	  parameters	   as	   outlined	   in	   the	  methods.	   The	   2nd	   line	   vasoconstrictor	  was	   vasopressin	  and	   lastly	   noradrenaline	   at	   the	   discretion	   of	   the	   clinical	   team	   if	   the	   aforementioned	  agents	  did	  not	  show	  a	  benefit.	  	  
Within	  0-­‐6	  hours	  of	  reperfusion	  overall	  (phenylephrine	  and	  noradrenaline)	  constrictor	  use	  was	  53/58	  in	  the	  placebo	  arm	  and	  48/54	  in	  the	  perhexiline	  arm	  (p=0.76).	  Within	  6-­‐12	  hours	  of	  reperfusion	  overall	  vasoconstrictor	  use	  was	  37/58	  in	  the	  placebo	  arm	  and	  43/54	   in	   the	   perhexiline	   arm	   (p=0.09).	   Use	   of	   phenylephrine	   and	   noradrenaline	  individually	  at	  each	  time	  point	  was	  not	  significant	  between	  the	  groups	  (Table	  3-­‐8).	  





0	  –	  6	  hours	  	   	   	   	  
Phenylephrine	   43	  (79.6%)	   52	  (89.7%)	   0.19	  
Noradrenaline	   11	  (20.4%)	   7	  (12.1%)	   0.31	  
Both	   48	  (88.9)	   53	  (91.4%)	   0.76	  
	   	   	   	  
6	  –	  12	  hours	   	   	   	  
Phenylephrine	   35	  (64.8%)	   31	  (53.4%)	   0.25	  
Noradrenaline	   11	  (20.4%)	   10	  (17.2%)	   0.81	  
Both	   43	  (79.6%)	   37	  (63.7%)	   0.09	  
Table	  3-­‐8	  Vasoconstrictor	  use	  in	  the	  first	  6	  hrs	  and	  6-­‐12hrs	  of	  reperfusion	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Dose	  per	  kilogram	  of	  phenylephrine	  was	  calculated	  for	  the	  time	  period	  up	  to	  6	  hours	  of	  reperfusion	   and	   then	   from	   6	   to	   12	   hours	   of	   reperfusion;	   there	   was	   no	   statistically	  significant	   difference	   between	   the	   groups	   at	   each	   of	   these	   time	   points	   p=0.83	   and	  p=0.55	   respectively	   (Figure	   3-­‐15).	   Similarly	   there	   was	   no	   difference	   in	   the	   use	   of	  noradrenaline	  between	   groups	   at	   each	   time	  point	   (Figure	  3-­‐16).	  However,	  within	   the	  placebo	  arm	  there	  was	  no	  vasopressin	  used	  as	  a	  2nd	  line	  vasoconstrictor	  at	  either	  time	  point;	  compared	  to	  a	  mean	  dose	  per	  kilogram	  of	  0.015	  and	  0.016	  at	  0-­‐6	  hrs	  (n=8)	  and	  6-­‐12	   hrs	   (n=7)	   respectively	   in	   the	   perhexiline	   arm,	   making	   this	   statistically	   significant	  p=0.002	  and	  0.005	  respectively.	  	  
 
 




Figure	  3-­‐16	  Mean	  dose	  of	  Noradrenaline	  at	  each	  time	  point 
3.11 Myocardial	  injury	  	  
3.11.1 Electrocardiographic	  evaluation	  	  
New	  myocardial	  injury	  was	  defined	  as	  outlined	  in	  the	  methods	  and	  was	  reviewed	  by	  an	  independent	  cardiologist.	  New	  myocardial	  injury	  was	  identified	  in	  2/54	  patients	  in	  the	  perhexiline	   arm	   and	   6/58	   patients	   in	   the	   placebo	   arm	   and	   showed	   no	   statistical	  significant	  difference	  OR	  0.36	  (CI	  0.07	  –	  1.97)	  p=0.24.	  	  
3.11.2 Cardiac	  troponin	  release	  	  
In	   March	   2011,	   the	   method	   of	   troponin	   analysis	   within	   University	   Hospitals	  Birmingham	   changed.	   Therefore	   troponin	   analysis	   between	   perhexiline	   and	   placebo	  outlined	  below	  is	  as	  per	  the	  new	  and	  older	  method	  of	  troponin	  analysis.	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1431.33	  (709.30)	   1114.61	  (1137.44)	   334.37	  (-­‐446.86	  –	  1115.60)	   0.39	  
Old	  method	  
(ng/ml)	  
0.78	  (0.37)	   0.85	  (0.38)	   -­‐0.08	  (-­‐0.30	  –	  0.15)	   0.50	  
Table	  3-­‐9	  Troponin	  analysis	  








Figure	  3-­‐18	  Mean	  Troponin	  concentration	  (new	  method)	  for	  each	  time	  point 
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3.12 Use	  of	  volume	  expansion	  	  
3.12.1 Administration	  of	  colloids	  	  
Volume	   in	   the	   form	   of	   colloids	   and	   blood	   were	   transfused	   to	   maintain	   the	   optimum	  parameters	  as	  outlined	  in	  the	  methods.	  The	  preferred	  colloid	  was	  Gelofusin	  initially	  and	  then	  Human	  Albumin	  Solution	  (HAS)	  once	  >	  2L	  of	  Gelofusin	  had	  been	  transfused.	  There	  was	   no	   difference	   between	   the	   groups	   in	   the	   mean	   volume	   of	   Gelofusin	   or	   HAS	  administered	  at	  either	  0	  –	  6	  hrs	  of	  reperfusion	  or	  6	  –	  12	  hours	  of	  reperfusion	  (Figure	  3-­‐19	  and	  Figure	  3-­‐20).	  	  
 
 






Figure	  3-­‐20	  Mean	  volume	  of	  HAS	  administered	  for	  each	  time	  point 
3.12.2 Administration	  of	  blood	  and	  blood	  products	  	  
Packed	   red	   blood	   cells	   were	   transfused	   to	   maintain	   the	   haemodynamics	   and	  Haemoglobin	   concentrations	   as	   outlined	   in	   the	  methods.	   A	   total	   of	   41/58	   (75%)	   and	  34/58	  (59%)	  of	  patients	  in	  the	  perhexiline	  and	  placebo	  arms	  respectively	  had	  received	  packed	   red	   cells	   within	   0	   –	   6	   hrs	   of	   reperfusion.	   	   However	   there	   was	   no	   difference	  between	  groups	  in	  the	  mean	  number	  of	  packed	  red	  blood	  cell	  units	  transfused	  at	  0	  –	  6	  hours	  (p=0.06)	  and	  6	  -­‐12	  hours	  (p=0.63)	  of	  reperfusion	  (Figure	  3-­‐21).	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Figure	  3-­‐21	  Mean	  packed	  red	  blood	  cells	  transfused	  at	  each	  time	  point	  




Figure	  3-­‐22	  Mean	  number	  of	  blood	  products	  transfused	  0-­‐6	  hrs	  of	  reperfusion	  	  
3.13 New	  reperfusion	  and	  post	  operative	  arrhythmias	  	  
Data	   on	   arrhythmias	   post	   intial	   reperfusion	   and	   in	   the	   post-­‐operative	   period	   was	  collected	   and	   analysed.	   There	   was	   no	   significant	   difference	   in	   the	   number	   of	  arrhythmias	   in	   any	   of	   the	   categories	   (Table	   3-­‐10).	   There	   was	   no	   incidence	   of	   post-­‐operative	   ventricular	   fibrillation	   in	   either	   arm.	   Three	   patients	   (5.2%)	   in	   the	   placebo	  arm	  required	  a	  permanent	  pace	  maker	  with	  none	  in	  the	  perhexiline	  arm	  (p=0.24).	  	  
Arrhythmias	  (%)	   Placebo	  (n-­‐58)	   Perhexiline	  (n=54)	   P	  value	  
Reperfusion	  VF	   11	  (19.0)	   9	  (16.7)	   0.81	  
Reperfusion	  VT	   0	  (0)	   3	  (5.2)	   0.11	  
Post	  op	  AF	   28	  (48.3)	   33	  (55.6)	   0.45	  
Post	  op	  VT	   1	  (1.9)	   1	  (1.8)	   1.0	  
Table	  3-­‐10	  Reperfusion	  and	  post-­‐operative	  arrhythmias	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3.14 Time	  to	  warm,	  extubate	  and	  discharge	  	  
All	  patients	  were	  admitted	  to	  the	  ITU	  and	  actively	  warmed	  to	  36°C.	  The	  time	  taken	  to	  warm	  to	  36°C	  for	  each	  group,	  time	  for	  extubation	  and	  time	  to	  discharge	  from	  the	  ITU	  to	  the	  ward	  and	  total	   in-­‐hospital	  stay	  are	  outlined	  in	  Table	  3-­‐11	  (represented	  by	  median	  and	   IQR).	   There	   was	   no	   statistical	   difference	   between	   the	   groups	   in	   any	   of	   these	  outcomes.	  The	  total	  blood	  loss	  via	  the	  drains	  was	  evaluated	  at	  12	  hrs	  (median	  and	  IQR)	  from	  reperfusion	  and	  showed	  no	  difference	  between	  the	  groups.	  
An	  intra-­‐aortic	  balloon	  pump	  was	  inserted	  in	  2	  and	  5	  patients	  in	  total	  in	  the	  placebo	  and	  perhexiline	  arm	  (Table	  3-­‐11).	  This	  is	  inclusive	  of	  those	  inserted	  in	  theatre	  as	  illustrated	  in	  Table	  3-­‐4.	  	  
	   Placebo	  (n-­‐58)	   Perhexiline	  (n=54)	   P	  value	  
Time	  to	  36°C	  (hrs)	   3:00	  (0:56	  –	  4:41)	   2:30	  (0:00	  –	  5:41)	   0.11	  
Total	  drain	  losses	  at	  12	  hrs	  	   475	  (317	  –	  810)	   510	  (345	  –	  940)	   0.51	  
Intubation	  time	  (hrs)	   11.39	  (7:54	  –	  16:21)	   13:29	  (7:33	  –	  17:47)	   0.51	  
Days	  on	  ITU	   3	  (2	  –	  5)	   3	  (2	  –	  6)	   0.22	  
In-­‐hospital	  stay	  	   10	  (7	  –	  14)	   9	  (7	  –	  15)	   0.53	  
IABP	  (%)	   2	  (3.4)	   5	  (9.4)	   0.26	  
Table	  3-­‐11	  Duration	  to	  warm,	  extubate	  and	  discharge	  
The	  total	  mean	  length	  of	  hospital	  stay	  for	  the	  perhexiline	  and	  placebo	  arms	  were	  15.11	  ±	  13.54	  and	  11.84	  ±	  6.95	  days	  respectively	  and	  showed	  no	  statistical	  significance	  DiM	  3.17	  (CI	  -­‐0.82	  –	  7.17)	  p=0.12.	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3.15 Safety	  outcome	  measures	  and	  other	  postoperative	  complications	  	  
Safety	  outcome	  measures	  included	  postoperative	  mortality,	  stroke	  with	  residual	  deficit,	  requirement	   for	   renal	   replacement	   therapy,	   re-­‐operation,	   and	   treated	   infective	  episodes.	  These	  are	  illustrated	  in	  Table	  3-­‐12.	  	  
Overall	  mortality	  for	  the	  trial	  was	  1.9%;	  a	  patient	  who	  was	  in	  the	  perhexiline	  arm	  and	  died	   after	   protracted	   course	   on	   the	   ITU,	   secondary	   to	  multi-­‐organ	   failure	   following	   a	  cerebral	  infarct.	  There	  was	  no	  statistical	  significant	  difference	  between	  groups	  for	  any	  of	   the	   safety	   outcome	   measures	   except	   for	   renal	   impairment	   (creatinine	   >	   200);	   6	  patients	  in	  the	  perhexiline	  arm.	  	  	  
All	   other	   complications	  are	   listed	   in	  Table	  3-­‐12	  and	  were	   found	   to	  have	  no	   statistical	  significant	  differences	  between	  the	  groups.	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   Placebo	  (n=58)	   Perhexiline	  (n=54)	   P	  Value	  
Mortality	  (%)	   0	   1	  (1.9)	   0.48	  
Re-­‐operation	   	   	   	  -­‐	  Bleeding	  (%)	   2	  (3.4)	   1	  (1.9)	   0.23	  -­‐	  Tamponade	  (%)	   1	  (1.7)	   0	   1.0	  -­‐	  Arrest	   0	   1(1.9)	   0.48	  
Infective	  episodes	   	   	   	  -­‐	  Pneumonia	  (%)	   4	  (6.9)	   3	  (5.5)	   1.0	  -­‐	  Leg	  wound	  infection	  (%)	   1	  (1.7)	   1	  (1.9)	   1.0	  -­‐	  Leg	  dehiscence	  (%)	   0	   1	  (1.9)	   0.48	  
Requirement	  for	  CPAP	  (%)	   4	  (6.9)	   3	  (5.5)	   1.0	  
Re-­‐intubation	  (%)	   3	  (5.2)	   2	  (3.4)	   1.0	  
Tracheostomy	  	  (%)	   2	  (3.4)	   6	  (11.1)	   0.15	  
Renal	  impairment	   	   	   	  -­‐	  Creatine	  >	  200	  (%)	   0	   6	  (11.1)	   0.01	  -­‐	  Haemofiltration	  (%)	   0	   2	  (3.4)	   0.23	  -­‐	  Dialysis	  (%)	   0	   1	  (1.9)	   0.48	  
Neurological	   	   	   	  -­‐	  Difficulty	  waking	  (%)	   0	   1	  (1.9)	   0.48	  -­‐	  Focal	  CVA	   0	   1	  (1.9)	   0.48	  -­‐	  Type	  II	  (%)	   1	  (1.7)	   1	  (1.9)	   1.0	  
Table	  3-­‐12	  Safety	  outcome	  measure	  and	  postoperative	  complications	  
3.16 Quality	  of	  life	  analysis	  	  
Quality	   of	   life	   was	   assessed	   using	   the	   EQ-­‐5D	   (version	   3L)	   questionnaire.	   This	   is	   a	  standard	  questionnaire	  used	  to	  assess	  health	  outcomes.	  The	  EQ-­‐5D	  assessed	  the	  health	  state	   in	   5	   health	   state	   categories;	  mobility,	   self	   care,	   usual	   activities,	   pain/discomfort	  and	  anxiety/depression	  and	  allowed	  the	  participant	   to	  rank	  each	  on	  3	   levels,	  1	  –	  3	  (1	  indicating	   no	   problems	   and	   3	   indicating	   extreme	   problems).	   	   In	   addition	   the	  questionnaire	  allowed	  the	  patient	  to	  rank	  their	  overall	  health	  sate	  on	  a	  visual	  analogue	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scale	   (VAS)	   of	   0	   –	   100	   (100	   being	   the	   best	   health	   state	   imaginable,	   and	   0	   being	   the	  worst).	  	  
The	  results	  from	  this	  questionnaire	  was	  analysed	  to	  assess	  the	  pre	  and	  post-­‐operative	  differences.	  Forty-­‐four	  patients	  completed	  the	  questionnaire	  pre	  and	  post	  surgery.	  The	  number	  of	  patients	  reporting	  ≥	  3	  for	  each	  health	  state	  was	  small,	   therefore	  those	  who	  reported	  1	  are	  classified	  as	  having	  ‘no	  problem’	  and	  those	  reporting	  >	  1	  are	  classified	  as	  having	  a	  problem	  (Table	  3-­‐13).	  	  
Health	  state	   Pre	  surgery	  (%)	   Post	  surgery	  (%)	   P	  value	  
	   Problem	   No	  problem	   Problem	   No	  problem	   	  
Mobility	   22	  (50)	   22	  (50	   6	  (13.1)	   38	  (86)	   <	  0.001	  
Self	  care	   2	  (5)	   42	  (95)	   1	  (2)	   43	  (98)	   0.32	  
Activities	   18	  (41)	   26	  (59)	   4	  (9)	   40	  (91)	   0.001	  
Pain	   25	  (57)	   19	  (43)	   5	  (11)	   39	  (89)	   <	  0.001	  
Anxiety	  	   20	  (46)	   24	  (55)	   11	  (25)	   33	  (75)	   0.03	  
VAS	  (IQR)	   69.5	  (56	  –	  80)	   90	  (80	  –	  95)	   <	  0.001	  
Table	  3-­‐13	  EQ-­‐5D	  analysis	  pre	  and	  post	  surgery	  
There	  was	  a	  significant	  improvement	  in	  the	  mobility,	  ability	  to	  perform	  activities,	  pain	  and	  marginal	  significance	  with	  anxiety,	  after	  the	  operation	  compared	  to	  before.	  The	  VAS	  score	  also	  showed	  statistical	  significance	  with	  a	  median	  score	  of	  90	  after	  the	  operation	  compared	  to	  60.5	  before	  the	  operation.	  	  
The	   table	   below	   (Table	   3-­‐14)	   summaries	   the	   overall	   utility	   score	   (median	   and	   inter-­‐quartile	   range)	   for	   each	   group	   at	   both	   time	   points	   of	   the	   questionnaire.	   The	  median	  utility	  score	  in	  each	  group	  is	  greater	  at	  follow-­‐up	  as	  is	  the	  inter-­‐quartile	  range	  for	  both	  groups.	   Analysis	   of	   the	   utilities	   between	   perhexiline	   and	   placebo	   groups	   showed	   no	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statistical	  difference	  between	  the	  groups	  (p=0.17).	  Generalised	   liner	  model	  analysis	  of	  baseline	   utilities	   versus	   the	   end-­‐point	   utility	   (score	   at	   FU),	   showed	   that	   the	   baseline	  measure	  does	  not	  contribute	  towards	  the	  follow	  up	  measure.	  	  
Health	  state	   Pre	  surgery	  	   Post	  surgery	  
	   Median	   IQR	   Median	   IQR	  
Perhexiline	  (n=17)	   0.79	   0.62	  –	  0.92	   1	   0.78	  -­‐	  1	  
Placebo	  (n=27)	  	   0.72	   0.69	  –	  0.80	   1	   0.85	  -­‐	  1	  
Table	  3-­‐14	  Summary	  of	  utilities	  at	  each	  time	  point	  
3.17 Futility	  analysis	  	  
The	  DSMB	  were	  requested	  to	  assess	  the	  trial	  for	  safety	  and	  efficacy	  and	  also	  assess	  the	  trial	  for	  futility	  based	  on	  the	  results	  (based	  on	  the	  clinical	  and	  metabolic	  findings)	  of	  the	  CASPER	   trial	   (using	   perhexiline	   as	   an	   adjunct	   to	   myocardial	   protection	   in	   patients	  undergoing	  CABG).	  	  
An	   Alpha	   Spending	   plan	   was	   performed	   to	   examine	   the	   effect	   of	   primary	   outcome	  including	   futility.	   The	   benefits	   are	   based	   upon	   the	   Lan	   DeMets	   plan	   and	   the	   harm	   is	  based	  upon	  a	  power	  family	  spending	  function.	  The	  table	  below	  (Table	  3-­‐15)	  shows	  the	  bounds	  for	  efficacy,	  futility	  and	  harm	  accompanied	  by	  the	  p	  value	  (alpha(i)	  –	  alpha(i-­‐1))	  at	   each	   planned	   look	   at	   45%,	   73%	   and	   100%	   completed	   patients.	   This	   is	   graphically	  represented	  by	  Figure	  3-­‐23,	  that	  illustrates	  the	  stopping	  boundaries	  for	  efficacy,	  futility	  and	   harm	   for	   the	   primary	   outcome.	   The	   figure	   depicts	   the	   standard	   errors	   for	   each	  boundary	   (efficacy,	   futility	   and	   harm)	   versus	   the	   number	   of	   patients	   that	   would	  complete	   the	   trial	   at	   45%,	   73%	   and	   100%	   completed	   patients.	   Harm	   is	   much	   less	  steeply	  pitched	  (enabling	  an	  earlier	  stop	  for	  evidence	  of	  harm).	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The	   DSMB	   performed	   a	   planned	   observation	   at	   45%	   recruitment	   (99	   patients)	   and	  analysis	   of	   the	  primary	  outcome	   showed	  a	   significance	  of	   0.823.	  This	   significance	   fell	  below	  the	  line	  of	  futility	  and	  above	  the	  line	  of	  harm,	  demonstrating	  overall	  futility	  of	  the	  trial.	  	  
If	  the	  significance	  at	  45%	  fell	  below	  the	  line	  of	  efficacy	  and	  above	  the	  line	  of	  futility,	  then	  the	   trial	  was	  on	   target	   to	   achieve	  a	  positive	  outcome.	   Similarly,	   if	   the	   significance	   fell	  below	  the	  line	  of	  harm,	  then	  the	  trial	  would	  be	  halted	  early	  for	  the	  risk	  of	  harm	  or	  be	  modified	  to	  reduce	  harm	  to	  the	  patients.	  Alternatively	  if	  the	  significance	  fell	  above	  the	  line	  of	  efficacy,	  the	  trial	  would	  be	  halted	  early	  for	  efficacy.	  	  




Table	  3-­‐15	  Tables	  illustrating	  the	  alpha	  spending	  plan	  analysis	  	  
	  
Figure	  3-­‐23	  Stopping	  boundaries	  for	  efficacy,	  harm	  and	  futility	  
Hyper Trial DSMB Alpha Spending Plan 
Examining effect on Primary Outcome, and Safety 
Alpha Spending Plan for Primary Outcome, including futility 
Lan DeMets superiority and futility curve 
Power Family Safety Curve 
Planned Looks at 100 (45%) completed patients and 160 (73%) completed patients 
Efficacy 
Time Bounds alpha(i)-alpha(i-1) Cum alpha 
0.45 3.1438 0.00083 0.00083 
0.73 2.3896 0.00787 0.00871 
1.00 2.0081 0.01629 0.02500 
 
Futility 
Time Bounds alpha(i)-alpha(i-1) 
0.45 0.8724 0.383 
0.73 1.6266 0.104 
1.00 2.0081  
 
Harm 
Time Bounds alpha(i)-alpha(i-1) Cumulative alpha 
0.45 2.4301 0.00755 0.00755 
0.73 2.2813 0.00805 0.01559 
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3.18 Summary	  of	  the	  HYPER	  results	  	  
The	  median	  duration	  of	  trial	  therapy	  was	  8.5	  days	  (IQR	  5	  –	  17.5)	  for	  all	  trial	  participants	  in	   the	   final	   analysis,	   and	   was	   8	   days	   (IQR	   5	   –	   11)	   and	   8	   days	   (IQR	   6	   –	   14),	   in	   the	  perhexiline	  and	  placebo	  groups	  respectively	  (p=	  0.41).	   In	  the	  treatment	  group	  median	  perhexiline	  concentration	  was	  0.22mg/L	  (IQR	  0.09	  –	  0.43).	  The	  majority	  of	  side	  effects	  were	  consistent	  with	  the	  known	  side	  effects	  of	  perhexiline.	  	  
The	   trial	  was	  halted	  early	   for	   futility	  on	   the	  advice	  of	   the	  DSMB.	  Of	  110	  patients	  who	  achieved	  the	  primary	  end	  point,	  30	  patients	  (16	  perhexiline,	  14	  placebo)	  had	  inotropes	  started	   appropriately;	   there	  was	   no	   difference	   in	   the	   incidence	   of	   inotrope	   usage	   OR	  1.65	  (CI	  0.67	  –	  4.06)	  p=0.28.	  	  	  
There	   was	   a	   significant	   increase	   in	   the	   overall	   incidence	   of	   inotrope	   use	   in	   the	  perhexiline	   group	   from	   six	   to	   12	   hours	   of	   reperfusion;	   26	   (48%)	   and	   15	   (26%)	   of	  patients	  in	  the	  perhexiline	  and	  placebo	  groups	  respectively	  requiring	  inotropes,	  OR	  3.11	  (1.34	  –	  7.23),	  p=0.009.	  All	  longitudinal	  haemodynamic	  measurements	  were	  comparable	  between	  the	  groups.	  Mean	  CI	  was	  not	  significant	  at	  each	  time	  point	  until	  at	  12	  hours	  of	  reperfusion,	   when	   the	   perhexiline	   group	   had	   a	   lower	   CI.	   There	   was	   no	   difference	   in	  myocardial	  injury	  as	  evidenced	  by	  electrocardiogram	  OR	  0.36	  (CI	  0.07	  –	  1.97)	  p=0.24	  or	  post-­‐operative	  troponin	  release.	  	  
All	   other	   safety-­‐outcome	   measures	   were	   comparable	   between	   the	   groups	   except	   for	  renal	  impairment	  (Creatinine	  >	  200),	  with	  six	  patients	  developing	  renal	  impairment	  in	  the	   perhexiline	   group	   and	   none	   in	   the	   placebo	   group	   (p=0.01),	   two	   requiring	  haemofiltration	  and	  one	  requiring	  dialysis.	  	  
	  4-­‐144	  
4 MAGNETIC	  RESONANCE	  SPECTROSCOPY	  TO	  ASSESS	  	  	  	  	  	  	  	  	  	  
CARDIAC	  ENERGETICS	  –	  A	  VALIDATION	  STUDY	  
4.1 Introduction	  	  
Magnetic	   resonance	   spectroscopy	   is	   a	   non-­‐invasive,	   radiation	   free	   investigation	   to	  acquire	   information	   about	   metabolites	   in	   a	   given	   tissue,	   using	   some	   of	   the	   standard	  magnetic	   resonance	   imaging	   techniques.	   	  Standard	  magnetic	   resonance	   imaging	  relies	  on	   the	   detection,	   signals	   and	   spin	   of	   hydrogen	   protons	   to	   create	   a	   two-­‐dimensional	  image.	  However	  magnetic	  resonance	  spectroscopy	  (MRS)	  can	  detect	  other	  metabolites	  such	  as	  carbon,	  nitrogen,	  fluorine,	  sodium	  and	  also	  phosphorus	  and	  create	  a	  spectra	  of	  these	   metabolites	   for	   analysis	   (Holloway,	   Suttie	   et	   al.	   2011).	   Evaluating	   31Phosporus	  through	  MRS	   allows	   the	   detection	   of	   phosphocreatine	   and	   ATP	   in	   cardiac	   tissue	   and	  thereby	  can	  be	  used	  to	  study	  cardiac	  energetics.	  	  
4.1.1 Cardiac	  magnetic	  resonance	  spectroscopy	  	  
Cardiac	  MRS	   investigates	   the	   spectrum	   for	   31Phosporus	   nucleus.	   	   Examination	   of	   this	  nucleus	  for	  a	  normal	  healthy	  subject	  should	  provide	  six	  resonances,	  which	  include	  the	  3	  
31Phosporus	   atoms	   of	   ATP	   (alpha,	   beta	   and	   gamma),	   phosphocreatine	   (PCr),	  diphosphoglycerate	   (from	   erythrocytes)	   and	   phosphodiesters	   (from	   membrane	   and	  serum	  phospholipids)	  (Hudsmith	  and	  Neubauer	  2009;	  Beadle	  and	  Frenneaux	  2010).	  	  	  	  
Cardiac	  MRS	  was	  first	  performed	  in	  the	  1980s	  (Bottomley	  1985).	  In	  current	  practice	  a	  1.5	   –	   3.0	   T	  magnet	   is	   used	   with	   a	   31Phosporus	   nucleus	   specific	   coil,	   together	   with	   a	  broadband	   radiofrequency	   transmitter	   to	   excite	   non-­‐proton	   nuclei.	   	   More	   recently	   a	  3.0T	   field	   strength	  has	  been	  used,	  which	  provides	  a	  greater	   signal	   strength,	   improves	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temporal	   resolution	   and	   spectral	   signal	   to	   noise	   ratio	   (Tyler,	   Hudsmith	   et	   al.	   2008;	  Abozguia,	   Elliott	   et	   al.	   2010;	   Shivu,	   Abozguia	   et	   al.	   2010)	   In	   addition	   to	   this,	   MRS	  acquisition	  sequence	  post	  processing	  data	  analysis	  software	  is	  also	  required	  (Hudsmith	  and	   Neubauer	   2009).	   The	   setup	   for	   data	   acquisition	   therefore	   consists	   of	   a	  superconducting	   magnet,	   interfaced	   with	   a	   computer	   and	   a	   radiofrequency	   (RF)	  transmitter	   and	   receiver.	   The	   transmitter	   and	   receiver	   is	   combined	   into	   a	   single	   disk	  shaped	   device	   that	   is	   placed	   onto	   the	   chest	  wall,	  with	   the	   patient	   in	   supine	   or	   prone	  position,	   to	   allow	   close	   approximation	   of	   the	   coil	   to	   the	   heart.	   The	  RF	   generator	   and	  workstation	  create	  a	  RF	  impulse,	  which	  is	  sent	  to	  the	  31Phosporus	  nucleus	  specific	  coil.	  This	   impulse	   creates	   the	   nuclear	   spin	   excitation	   in	   the	   heart.	   The	   response	   to	   this	  impulse	  (the	  resulting	  magnetic	  resonance	  signal)	   is	  also	  detected	  by	  the	  31Phosporus	  nucleus	  specific	  coil	  and	  is	  relayed	  to	  the	  computer.	  The	  data	  that	  is	  relayed	  is	  stored	  as	  free	  induction	  decay	  (FID),	  represented	  as	  the	  relationship	  between	  signal	  intensity	  and	  time.	   The	   FID	   is	   then	   converted	   to	   a	   magnetic	   resonance	   spectrum	   by	   Fourier	  transformation.	  The	  spectrum	  relates	  resonance	   frequency	  (on	  the	  x	  axis)	   to	   intensity	  (on	  the	  y	  axis).	  The	  area	  under	  each	  resonance	  frequency	  is	  proportional	  to	  the	  amount	  of	  each	  31Phosporus	  nucleus	  species	  in	  the	  heart	  and	  hence	  the	  relative	  concentrations	  of	  each	  metabolite	  can	  be	  calculated	  and	  quantified	  (Arad,	  Moskowitz	  et	  al.	  2003).	  The	  acquisitions	   are	   performed	   with	   ECG	   gating	   (surface	   ECG),	   which	   allows	   for	   the	  acquisition	   to	   be	   obtained	   during	   diastole	   when	   the	   heart	  motion	   is	   least.	   To	   obtain	  absolute	  quantification	  of	  the	  metabolites,	  further	  calibration	  of	  the	  31Phosporus	  signal	  is	   required	   to	   accommodate	   for	   the	   1Hydrogen	  water	   signal	   and	   this	   process	   is	  more	  complex.	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For	   spectral	   acquisition,	   a	   specific	   area	   of	   the	   heart	   is	   identified	   using	   1Hydrogen	  magnetic	  resonance	  imaging.	  This	  allows	  confirmation	  of	  coil	  position	  and	  identification	  of	  an	  anatomical	  voxel	  selection	  for	  spectral	  acquisition	  and	  under	  ideal	  circumstances	  includes	   the	   myocardial	   inter-­‐ventricular	   septum.	   There	   are	   several	   localisation	  sequences	  to	  position	  the	  voxel.	  These	  include	  depth	  resolves	  surface	  coil	  spectroscopy,	  image-­‐selected	  in	  vivo	  spectroscopy	  or	  3-­‐dimentional	  chemical	  shift	  imaging	  (CSI)	  using	  a	  selection	  of	  multiple	  voxel	  in	  3	  dimensions	  (Bottomley	  1994).	  Care	  should	  be	  taken	  to	  exclude	  signal	  from	  overlapping	  skeletal	  muscle.	  	  
Analysis	   of	   the	   acquired	   spectra	   can	   provide	   the	   phosphocreatine	   to	   ATP	   ratio	   and	  through	   this	   the	   energetic	   state	   of	   the	   heart	   can	   be	   assessed.	   The	   analysis	   of	   the	  acquired	  spectra	  can	  be	  performed	  offline.	  	  
4.1.2 MRS	  spectral	  analysis	  	  
Spectral	   analysis	   can	   be	   performed	   using	   the	   Java	   based	   Magnetic	   Resonance	   User	  Interface	  (JMRUI),	  a	  software	  package	  which	  is	  a	  graphical	  user	  interface	  and	  allows	  for	  time-­‐domain	   analysis	   of	   the	   MRS	   data	   (Beadle	   and	   Frenneaux	   2010).	   This	   software	  allows	  accurate	   analysis	  of	   the	   frequency	  peaks	   and	  hence	   calculation	  of	   the	  PCr:ATP	  ratios.	   To	   help	   with	   this,	   the	   Advanced	   Method	   for	   Accurate,	   Robust	   and	   Efficient	  Spectral	  (AMARES)	  fitting	  can	  be	  performed,	  which	  allows	  non-­‐linear	  fitting	  in	  the	  time	  domain.	   In	   addition,	   JMRUI	   includes	   algorithms	   for	   frequency	   selective	   filtering	   of	  signals.	  In	  combination	  and	  adapting	  these	  methods,	  accurate	  quantification	  of	  the	  area	  under	  the	  peaks	  can	  be	  calculated	  and	  PCr:ATP	  ratio	  obtained	  (Hudsmith	  and	  Neubauer	  2009;	  Beadle	  and	  Frenneaux	  2010).	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For	   further	   accuracy,	   blood	   contamination	   can	  be	  minimized.	  Blood	   contains	  ATP	  but	  not	  PCr.	  	  Therefore	  calculation	  of	  the	  2,3-­‐diphosphoglycerate	  peak	  and	  exclusion	  of	  this	  can	  avoid	  under	  estimation	  of	  the	  PCr:ATP	  ratio,	  particularly	  when	  the	  2,3-­‐DPG	  peak	  is	  greater	  than	  the	  γ-­‐ATP	  peak.	  	  
4.1.3 Cardiac	  energetics	  and	  metabolism	  	  
Cardiac	  energetics	  refers	  to	  the	  study	  of	  high-­‐energy	  phosphates	  and	  their	  metabolism	  in	   the	   myocardium.	   High-­‐energy	   phosphates	   such	   as	   phosphocreatine	   allow	   energy	  storage	  and	  rapid	  utilisation	  when	  required.	  Phosphocreatine	  functions	  as	  a	  reserve	  of	  energy	   and	   provides	   ATP	   when	   required	   for	   contraction	   and	   other	   ATP	   dependent	  enzyme	   reactions	   and	   shuttles.	   The	   process	   of	   PCr	   to	   ATP	   conversion	   is	   outlined	   in	  Figure	   4-­‐1	   below.	   Therefore	   the	   real	   end	   product	   of	   oxidative	   phosphorylation	   is	   the	  formation	  of	  PCr.	  	  
	  
Figure	  4-­‐1	  Phosphocreatine	  and	  ATP	  energy	  transfer	  
The	   equilibrium	   shown	   above	   favours	   the	   production	   of	   ATP	   by	   approximately	   50	  times.	   The	   amount	   of	  ATP	   is	  maintained	   for	   utilisation	   and	   therefore	   during	   times	   of	  greater	  demand	  PCr	   is	  converted	  to	  ATP	  and	  therefore	   the	  overall	  PCr:ATP	  ratio	   falls.	  	  ATP	  is	  subsequently	  hydrolysed	  to	  form	  ADP	  to	  create	  energy	  and	  then	  reformed	  from	  the	   interaction	  with	   PCr.	   Therefore	   ATP	   levels	  may	   eventually	   fall,	   only	  when	   PCr	   is	  substantially	  depleted.	  A	  total	  decrease	  in	  the	  creatine	  pool	  may	  also	  eventually	  reduce	  the	  PCr:ATP	  ratio.	  	  
	  4-­‐148	  
The	  creatine	  phosphokinase	  (CK)	  shuttle	  is	  involved	  in	  providing	  ATP	  to	  the	  sites	  that	  most	   require	   it.	   The	   mitochondrial	   CK	   isoenzyme	   is	   situated	   between	   the	   inner	   and	  outer	  mitochondrial	  membrane	  and	  therefore	  able	  to	  form	  PCr	  from	  creatine.	  The	  PCr	  formed	  this	  way,	  is	  transferred	  to	  the	  cytosol,	  where	  it	  can	  be	  transferred	  to	  other	  sites	  within	  the	  cytosol	  and	  utilised.	  The	  outer	  mitochondrial	  membrane	  is	  freely	  permeable	  to	   PCr.	   The	   CK	   shuttle	   provides	   ATP	   to	   sites	   that	   require	   ATP	   other	   than	   the	  mitochondrion,	  such	  as	  the	  myosin	  ATPase,	  sarcoplasmic	  reticulum	  Ca-­‐ATPase	  and	  the	  Na-­‐K	  exchanger	  and	  therefore	  plays	  a	  role	   in	   functional	  compartmentalisation	  of	  ATP.	  To	  allow	  this	  process,	  CK	  is	  present	  in	  different	  extra	  mitochondrial	  sites,	  with	  a	  larger	  proportion	   of	   the	  MB	   isoenzyme	   in	   the	   cytosol	   and	  MM	   isoenzyme	   in	   the	  myofibrils.	  This	   forms	   the	   CK	   shuttle,	   where	   energy	   is	   transferred	   from	   one	   site	   in	   cytosol	   to	  another.	  	  	  
The	   ratio	   of	   PCr:ATP	   is	   an	   indicator	   of	   the	   energetic	   state	   of	   the	   heart	   and	   can	   be	  affected	   in	   certain	   heart	   disorders.	   It	   is	   this	   ratio	   that	   is	   commonly	   measured	   by	  
31Phosporus	   MRS	   with	   a	   normal	   ratio	   in	   a	   healthy	   individual	   measured	   at	  approximately	   1.8	   (Bottomley	   1994),	   with	   a	   range	   of	   1.1	   to	   2.5	   (Hudsmith	   and	  Neubauer	   2009)	   and	   a	   likely	   decrease	   in	   PCr:ATP	   ratio	  with	   increasing	   age	   (Kostler,	  Landschutz	  et	  al.	  2006).	  This	  large	  variability	  is	  mostly	  due	  to	  methodological	  variation,	  due	   to	   differences	   in	   acquisition	   protocols,	   localisation	   techniques,	   spectral	   analysis,	  spectral	  selection	  criteria	  and	  correction	  calculations.	  	  
The	  aim	  of	  this	  study	  was	  to	  validate	  the	  method	  and	  techniques	  in	  acquiring	  a	  magnetic	  resonance	  spectrum,	  using	  31Phospurous	  MRS	  on	  a	  3-­‐Tesla	  Philips	  Achieva	  whole-­‐body	  magnet,	  to	  measure	  high-­‐energy	  phosphates	  and	  evaluate	  the	  ratio	  of	  phosphocreatine	  to	  ATP	   in	   healthy	   cardiac	   tissue.	   Thereby	   assess	   the	   reproducibility	   of	   the	   technique,	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acquisition	  protocols	  and	  spectral	  analysis	   in	  acquiring	  phosphocreatine	  to	  ATP	  ratios	  by	  our	  group,	  and	  hence	  its	  applicability	  to	  other	  research	  areas	  within	  the	  department.	  	  
4.2 Methods	  	  
4.2.1 Patient	  selection	  	  
Ethical	  approval	  was	  sought	  and	  obtained	  from	  the	  University	  of	  Birmingham.	  All	  work	  was	   carried	   out	   according	   to	   the	   principles	   of	   the	   declaration	   of	   Helsinki.	   Healthy	  volunteers	  with	  no	  history	  of	  cardiovascular	  disease	  over	  the	  age	  of	  18	  were	  recruited	  into	   the	  study.	  Each	  participant	  gave	  written	   informed	  consent.	  Following	  consent,	  all	  participants	   underwent	   a	   detailed	   history	   to	   review	   and	   confirm	   they	   had	   no	  cardiovascular	   disease,	   confirm	   their	   drug	   history	   and	   smoking	   status.	   All	   patients’	  height	  and	  weight	  were	  measured.	  
4.2.2 Equipment	  and	  MRS	  scanning	  	  
All	   31Phosphorous	   MRS	   scans	   were	   performed	   on	   a	   on	   a	   3-­‐Tesla	   Philips	   (Philips	  Healthcare,	   Reigate,	   Surrey)	   Achieva	   whole-­‐body	   magnet,	   using	   a	   commercially	  available	  ‘all	  purpose’	  linearly	  polarized	  transmit	  and	  receive	  31Phospurous	  coil	  with	  a	  diameter	  of	  14	  cm.	  	  	  
The	   scan	   was	   performed	   with	   the	   participants	   in	   the	   supine	   position,	   with	   the	   coil	  directly	  over	  the	  precordium	  (ideally	  over	  the	  left	  ventricle).	  	  All	  scans	  were	  performed	  between	  08:00	  and	  10:00	  after	  an	  overnight	   fast.	   In	   this	  validation	  study,	   two	  cardiac	  MRS	   scans	   were	   performed	   per	   participant	   in	   one	   sitting.	   The	   second	   scan	   was	  performed	   after	   a	   period	   of	   rest	   following	   their	   1st	   scan,	   but	   after	   repositioning	   the	  participant	  and	  coil.	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4.2.2.1 Acquisition	  protocol	  	  The	   coil	   was	   secured	   in	   place	   by	   straps	   around	   the	   upper	   body	   and	   coil.	   The	  participants	  were	   then	  positioned	   inside	   the	  magnet	  with	   the	  centre	  of	   the	  coil	  at	   the	  isocenter	  of	  the	  magnet.	  	  The	  coil	  has	  a	  small	  disk	  buried	  in	  the	  centre	  containing	  both	  water	  and	  methylphosphonic	  acid	  that	  can	  be	  seen	  with	  the	  use	  of	  proton	  localisation	  images.	  Localization	  was	  achieved	  by	  image	  selected	  in-­‐vivo	  spectroscopy	  (ISIS)	  volume	  selection.	  The	  position	  of	  the	  coil	  was	  checked	  with	  a	  survey	  image.	  The	  subjects	  and/or	  the	   coil	   was	   repositioned	   if	   required	   to	   ensure	   that	   the	   distance	   between	   coil	   to	   the	  cardiac	  septum	  and	  apex	  of	  the	  heart	  is	  minimized	  to	  allow	  for	  maximize	  signal	  strength	  and	   to	   maintain	   consistency.	   These	   surveys	   were	   repeated	   to	   achieve	   an	   optimum	  placement.	  	  
Localized	   iterative	   1st	   order	   shimming	   was	   performed	   with	   an	   image	   guided	   shim	  volume	   that	   included	   the	   entire	   heart,	   using	   the	   unsuppressed	  water	   signal	   acquired	  with	   the	   body	   coil	   as	   reference.	   The	   shimming	   process	   involves	   an	   automated	  Hydrogen-­‐1	  spectral	  acquisition	  to	  test	  the	  quality	  of	  the	  shim	  that	  is	  expressed	  as	  a	  full	  width	  at	  half	  maximum	  (FWHM).	   	  This	   is	  repeated	  until	  a	  FWHM	  of	   less	  than	  40	  Hz	  is	  achieved	   to	   maintain	   consistency	   and	   achieve	   a	   good	   quality	   shim.	   The	   process	   of	  shimming	  reduces	  the	  infield	  inhomogeneties	  in	  the	  region	  of	  interest	  and	  the	  narrower	  the	  FWHM	  peak	  the	  better	  the	  achieved	  shim	  in	  the	  region	  of	  interest.	  	  
A	  short	  axis	  cine	  scan	  was	  acquired	  to	  calculate	  the	  trigger	  delay	  for	  ECG	  triggering	  and	  to	   check	  quality	  of	   shimming	  and	  F0	  determination.	   	  The	   trigger	  delay	  was	   calculated	  such	  that	  the	  spectrum	  was	  acquired	  in	  the	  diastolic	  period	  when	  the	  heart	  is	  as	  still	  as	  possible,	  hence	  spectral	  acquisition	  was	  ECG	  gated.	  To	  allow	  for	  an	  acquisition	  time	  of	  170ms,	   250-­‐300ms	  were	   deducted	   from	   the	   R-­‐R	   interval	   of	   the	   cardiac	   cycle.	   The	   3-­‐
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dimensional	   ISIS	   voxel	   of	   acquisition	  was	  planned	   to	   include	  most	   of	   the	   septum	  and	  apex	   of	   the	   heart	   within	   the	   shimmed	   area.	   Care	   was	   taken	   to	   minimize	   blood	  contamination	   from	   the	   right	  ventricle,	   liver	  and	  skeletal	  muscle	  as	  much	  as	  possible.	  	  The	   voxel	   size	   was	   kept	   constant	   at	   89.54ml	   (44x55x37mm3)	   to	   allow	   comparisons	  between	  different	  subjects	  and	  scans.	  A	  screen	  shot	  was	  taken	  of	  the	  voxel	  during	  the	  1st	  scan,	  which	  helped	  with	  accurate	  re-­‐positioning	  of	  the	  voxel	  during	  the	  2nd	  scan.	  	  
Following	   this	   the	   31Phospurous	   spectrum	   was	   acquired	   with	   a	   repetition	   time	   of	  10,000ms,	  136	  averages	  and	  512	  samples.	  	  A	  repetition	  time	  of	  10,000ms	  was	  found	  to	  be	  optimal	  for	  adequate	  reduction	  of	  saturation	  effects	  without	  increasing	  the	  scan	  time	  greatly.	   	  The	  total	  scan	  time	  was	  approximately	  23	  minutes.	  The	  total	  time	  the	  patient	  was	  in	  the	  scanner	  including	  set	  up	  time	  was	  approximately	  48	  minutes.	  	  
A	  standard	  phosphorus	  spectroscopy	  sequence	  provided	  by	  the	  manufacturer	  was	  used.	  	  It	  was	  based	  on	  hyperbolic	  secant	  pulses	  for	  slice	  selective	  inversion	  and	  adiabatic	  half	  passage	  radio	  frequency	  (RF)	  pulses	   for	  non-­‐selective	  excitation.	   In	  order	  to	  minimize	  increased	  chemical	  shift	  artefacts	  at	  3T,	  slice	  selective	  inversion	  for	  ISIS	  encoding	  was	  based	  on	  adiabatic	  hyperbolic	  secant	  pulses	  which	  achieved	  a	  pulse	  bandwidth	  between	  1300Hz	  (at	  a	  distance	  of	  9cm	  from	  the	  surface	  coil)	  and	  2000Hz	  (at	  a	  distance	  of	  3cm	  from	  the	  surface	  coil).	  	  This	  corresponds	  to	  a	  chemical	  shift	  displacement	  of	  6-­‐10%	  for	  the	  investigated	  metabolites	  PCr	  and	  γ-­‐ATP	  for	  volumes	  of	  interest	  that	  were	  between	  3	  and	  9cm	  from	  the	  coil	  (Shivu,	  Abozguia	  et	  al.	  2010).	  	  
4.2.2.2 Analysis	  of	  the	  spectra	  	  The	  spectra	  were	  analysed	  and	  quantified	  on	  the	  Java	  based	  Magnetic	  Resonance	  User	  Interface	   (JMRUI)	   software.	   	   Post-­‐processing	   of	   the	   acquired	   spectra	   was	   performed	  
	  4-­‐152	  
with	   15Hz	   Gaussian	   line	   broadening	   filter	   and	   subsequent	   Fourier	   transformation.	  Phase	   correction	  was	   performed	  with	   PCr	   peak	   as	   the	   reference	   peak.	   Quantification	  was	   performed	   with	   Advanced	   Method	   for	   Accurate,	   Robust	   and	   Efficient	   Spectral	  (AMARES)	   fitting	   time	   domain	   fitting	   program.	   This	   allows	   for	   and	   involves	   selecting	  peaks	  and	  defining	  their	  line	  width	  (Vanhamme,	  Sundin	  et	  al.	  2001).	  The	  concentrations	  of	  PCr,	  ATP	  (γ,	  α	  and	  β)	  and	  2,3-­‐Diphosphoglycerate	  (2,3-­‐DPG)	  were	  calculated	  as	  the	  area	   under	   the	   peaks.	   The	   PCr/ATP	   ratio	  was	   determined	   after	   correcting	   the	   γ	   ATP	  peak	  for	  blood	  contamination	  as	  described	  previously	  based	  on	  the	  quantity	  of	  2,3-­‐DPG	  in	  the	  derived	  spectrum	  (Conway,	  Bottomley	  et	  al.	  1998).	  	  	  
Cramer	   Rao	   lower	   bounds	   (CRLBs)	  were	   then	   calculated	   to	   assess	   the	   quality	   of	   the	  spectral	  fit.	  	  The	  CRLB	  is	  the	  lower	  bound	  on	  the	  variance	  of	  any	  unbiased	  estimator.	  In	  other	  terms	  it	  is	  the	  lowest	  possible	  standard	  deviation	  of	  all	  unbiased	  model	  parameter	  estimates	   obtained	   from	   the	   data.	   CRLBs	   are	  widely	   used	   as	   a	  measure	   of	   attainable	  precision	  of	  parameter	  estimates	   (Cavassila,	  Deval	  et	  al.	  2001).	  The	  software	  used	   for	  the	  analysis	  (JMRUI)	  generates	  a	  standard	  deviation	  for	  each	  measured	  peak.	  Using	  this,	  participants	   that	   had	   a	  CRLB	  greater	   than	  20%	   for	   the	  PCr	  peak	  were	   excluded	   from	  further	  analysis.	   	  The	  20%	  threshold	  has	  been	  previously	  used	  with	   this	   technique	   in	  clinical	   studies	   and	   in	   published	   validation	   reports	   (Lamb,	   Doornbos	   et	   al.	   1996;	  Abozguia,	  Elliott	  et	  al.	  2010).	  
4.2.3 Analyses	  for	  validation	  
Analysis	   of	   the	   PCr:ATP	   ratio	   prior	   knowledge,	   which	   is	   an	   automated	   peak	  identification	  process	  (an	  option	  that	  is	  available	  within	  JMURI	  and	  AMARES	  software),	  was	   compared	   to	   manual	   peak	   selection	   (manual	   identification	   of	   the	   peak	   by	   the	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operator).	  	  The	  PCr:ATP	  ratio	  was	  measured	  in	  two	  forms;	  using	  an	  average	  of	  the	  ATP	  peaks	  (γ,	  α	  and	  β)	  and	  using	  the	  γ-­‐ATP	  peak	  alone	  to	  calculate	  PCr:γ-­‐ATP	  ratio,	  for	  the	  1st	  scan	  only.	  	  
Intra-­‐subject	  variability	  was	  assessed	  by	   the	  absolute	  difference	  between	   the	  value	  of	  the	  PCr:ATP	  ratio	  measured	  at	  the	  1st	  and	  2nd	  scans	  for	  each	  subject.	  The	  co-­‐efficient	  of	  repeatability	  was	  calculated	  and	  the	  data	  plotted	  in	  the	  form	  of	  a	  Bland	  and	  Altman	  plot.	  Inter-­‐subject	   variability	   was	   assessed	   by	   calculating	   the	   co-­‐efficient	   of	   variation	   of	  PCr:ATP	   values	   across	   the	   1st	   scans	   of	   all	   subjects.	   Intra-­‐observer	   variability	   was	  assessed	  by	  one	  of	  the	  observers	  assessing	  all	  scans	  twice,	  with	  each	  analysis	  separated	  by	  more	  than	  one	  week.	  	  
4.2.4 Statistical	  analysis	  	  
Analysis	   was	   performed	   using	   SPSS	   software	   (version	   20.0,	   SPSS	   Inc.,	   Chicago,	   IL).	  Continuous	   data	   was	   assessed	   for	   normal	   distribution	   and	   presented	   as	   mean	   ±	  standard	  deviation	  of	  the	  mean	  or	  median	  and	  inter-­‐quartile	  range.	  Student’s	  t-­‐test	  was	  used	  to	  analyse	  normally	  distributed	  data.	  Difference	  between	  measurements	  between	  the	   same	  participant	  was	   analysed	  using	   the	  paired	   students	   t-­‐test.	   Skewed	  data	  was	  analysed	  by	  Mann-­‐Whitney	  U-­‐test.	  Categorical	  data	  was	  analysed	  by	  Fisher’s	  exact	  test.	  Paired	   non-­‐normal	   data	   was	   analysed	   using	   Wilcoxon	   signed	   rank	   test.	   Statistical	  significance	  was	  defined	  as	  a	  p	  <	  0.05.	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4.3 Results	  	  
4.3.1 Basic	  demographics	  	  
The	  study	  recruited	  16	  subjects,	  of	  which	  4	  were	  excluded	  due	  to	  poor	  spectral	  quality.	  A	   poor	   spectral	   quality	   prevented	   accurate	   quantification	   of	   spectral	   analysis.	   These	  patients	  were	  also	   identified	  by	  CRLBs	  greater	  than	  20%.	  Therefore	  24	  scans	   from	  12	  participants	  were	  suitable	  for	  analysis.	  Patient	  characteristics	  are	  outlined	  in	  Table	  4-­‐1.	  
Patient	  characteristics	   N=12	  Age	  (mean,	  SD)	   28	  ±	  10	  Weight	  (mean,	  SD)	   83	  ±	  9.7	  Height	  (mean,	  SD)	   178.5	  ±	  7.1	  BMI	  (mean,	  SD)	   24.2	  ±	  8.2	  
Table	  4-­‐1	  Patient	  characteristics	  for	  MRS	  validation	  
The	  mean	  CRLBs	  for	  the	  PCr	  and	  γ	  –ATP	  peak	  for	  the	   included	  participants	   for	  the	  1st	  and	  2nd	  scans	  are	  outline	  in	  Table	  4-­‐2.	  	  
	   CRLBs	  Scan	  1	   CRLBs	  Scan	  2	  
PCr	  peak	   7.66	  ±	  6.79	   5.96	  ±	  1.63	  	  
γ	  ATP	  	   10.68	  ±	  5.49	   9.34	  ±	  2.51	  
Table	  4-­‐2	  CRLBs	  for	  PCr	  and	  ATP	  peaks	  




Figure	  4-­‐2	  Typical	  MRS	  spectra	  with	  measured	  peaks	  labelled	  	  DPG,	  diphosphoglycerate;	  PDE,	  Phosphodiesters,	  PCr,	  phosphocreatine;	  ATP,	  adenosine	  triphosphate	  
4.3.2 Validation	  analysis	  	  
4.3.2.1 Assessment	  of	  analysis	  method	  Analysis	  of	   the	  PCr:	  ATP	   ratio	  using	  prior	  knowledge	  gave	  a	  higher	  PCr:ATP	   ratio	   for	  both	  the	  1st	  and	  2nd	  scans	  compared	  to	  the	  manual	  peak	  defining	  approach	  as	  shown	  in	  Figure	   4-­‐3.	   This	   was	   statistically	   significant	   for	   both	   the	   1st	   (p=0.004)	   and	   2nd	   scans	  (p=0.002).	   The	   standard	   deviation	   was	   higher	   with	   prior	   knowledge	   compared	   to	  manual	   selection	   for	   the	   1st	   and	   2nd	   scans,	   0.50	   and	   0.34	   versus	   0.33	   and	   0.28	  respectively.	  
2,3	  -­‐	  DPG 
PDE 
PCr 
γ	  -­‐ATP α-­‐ATP β-­‐ATP 
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Figure	  4-­‐3	  PCr:ATP	  ratios	  between	  manual	  defined	  and	  prior	  knowledge	  defined	  peak	  identification 
Analysis of the PCr:ATP ratio by the average of the ATP peaks gave a lower PCr:ATP ratio 
compared to using the γ-­‐ATP	  alone	  and	  was	  statistically	  significant	  (p=0.005)	  as	  shown	  in	  Figure	  4-­‐4.	  	  	  
	  
Figure	  4-­‐4	  PCr:ATP	  ratios	  using	  Gamma	  ATP	  versus	  Average	  ATP	  measurements	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4.3.2.2 Assessment	  of	  reproducibility	  	  The	  following	  assessments	  of	  reproducibility	  were	  performed	  using	  a	  manually	  selected	  peak	  technique	  and	  using	  the	  γ-­‐ATP	  alone	  for	  calculating	  the	  PCr:ATP	  ratio.	  	  
The	  intra-­‐subject	  variability	  was	  the	  absolute	  difference	  between	  the	  1st	  and	  2nd	  scans	  for	  each	  subject.	  The	  mean	  PCr:ATP	  ratio	  for	  the	  1st	  and	  2nd	  scans	  were	  1.72	  ±	  0.33	  and	  1.59	   ±	   0.28	   respectively,	   producing	   a	   mean	   difference	   of	   0.13	   with	   a	   percentage	  difference	   of	   7.6%.	   The	  mean	   difference	   between	   the	  measurements	  was	   0.13	   ±	   0.26	  (95%	   confidence	   interval	   -­‐0.4	   –	   0.29,	  p=0.12).	   This	   is	   graphically	   represented	   by	   the	  Bland-­‐Altman	   plot	   of	   the	   data	   (Figure	   4-­‐5).	   The	   intraclass	   correlation	   coefficient	  was	  0.71	  (p=0.10).	  This	  correlation	  is	  further	  represented	  by	  Figure	  4-­‐6.	  
	  
Figure	  4-­‐5	  Bland-­‐Altman	  plot	  of	  the	  intra-­‐subject	  variability	  	  






















Figure	  4-­‐6	  Scatter	  plot	  of	  Scan	  1	  versus	  Scan	  2	  with	  a	  regression	  line	  and	  95%	  confidence	  intervals	   
The	   inter-­‐subject	   variability	  was	   assessed	   using	   the	   average	   of	   the	   1st	   scans	   and	  was	  1.72	   ±	   0.33	   and	   showed	   an	   inter-­‐subject	   coefficient	   of	   variation	   of	   19.3%.	   The	   intra-­‐observer	  variability	  was	  calculated	  by	  assessing	   the	  absolute	  difference	  between	  each	  scan	  analysed	  twice	  and	  was	  0.001	  ±	  0.005,	  showing	  no	  significant	  difference	  (p=0.34).	  
4.4 Discussion	  	  
This	   study	   illustrates	   the	   feasibility	   of	   performing	   31P	   cardiac	   Magnetic	   Resonance	  Spectroscopy.	   	   Using	   the	   methodology	   and	   spectral	   analysis	   techniques	   described	  above,	   this	   study	  has	   demonstrated	   a	   normal	   PCr:	  ATP	   ratio	   of	   1.72	  ±	   0.33	  using	   the	  manual	  selected	  peak	  technique	  and	  using	  the	  γ-­‐ATP	  peak	  alone,	  to	  calculate	  the	  ratio.	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The	  acquisition	  protocol	  and	  spectral	  analysis	  has	  proven	  to	  be	  both	  reproducible	  and	  reliable.	  The	  CRLBs	  for	  this	  cohort	  was	  relatively	  low	  at	  <	  11%	  for	  both	  PCr	  and	  γ-­‐ATP	  measurements	   on	   both	   scan	   sittings.	   Intra-­‐subject	   variability	   was	   low	   with	   a	   mean	  difference	   and	   percentage	   difference	   of	   0.13	   and	   7.6%	   respectively.	   In	   addition	   the	  inter-­‐subject	  variability	  and	  intra-­‐observer	  variability	  were	  also	  low	  with	  no	  significant	  differences,	   confirming	   reproducibility	   and	   hence	   affirming	   the	   validity	   of	   this	  methodology.	  	  
A	   number	   of	   other	   groups	   have	   performed	   validation	   studies	   of	   31P	   cardiac	   MRS,	  however	   each	   groups’	   acquisition	   protocols,	   techniques	   and	   methods	   of	   spectral	  analysis	   remains	   different,	   and	   is	   governed	   by	   departmental	   procedures	   and	   type	   of	  scanning	   equipment	   available	   (Lamb,	   Doornbos	   et	   al.	   1996;	   Tyler,	   Emmanuel	   et	   al.	  2009).	  	  This	  study	  concentrated	  on	  reproducibility	  of	  31P	  Cardiac	  MRS	  at	  3-­‐Tesla	  using	  a	  Philips	  magnet.	  The	  PCr:	  ATP	  ratios	  obtained	  in	  this	  study	  are	  as	  expected	  different	  to	  those	  reported	  by	  other	  validation	  studies.	  Tyler	  et	  al	  report	  a	  ratio	  of	  2.07	  –	  2.14	  in	  a	  group	   of	   healthy	   young	   males;	   key	   differences	   being	   their	   subjects	   were	   positioned	  prone	   lying	   on	   the	   surface	   coil,	   a	   Siemens	   magnet	   and	   multi-­‐voxel	   chemical	   shift	  imaging	   acquisition	   protocol	   (Tyler,	   Emmanuel	   et	   al.	   2009).	   In	   contrast	   Lamb	   et	   al	  report	  a	  PCr:	  ATP	  ratio	  of	  between	  1.41	  –	  1.31	  using	  either	  3D	   image	  selected	   in-­‐vivo	  spectroscopy	  (ISIS)	  or	  a	  combination	  of	  1D	  spectroscopic	   imaging	  and	  2D	  ISIS	  (Lamb,	  Doornbos	   et	   al.	   1996).	   This	   underscores	   the	   importance	   of	   validating	   your	   own	  MRS	  protocol	  particularly	  when	  these	  protocols	  are	  used	   for	  other	  cardiovascular	  research	  within	   the	   department,	   given	   that	   the	   differing	   techniques	   and	   complexity	   of	   the	  measurement	  may	  result	  in	  highly	  variable	  high-­‐energy	  phosphate	  ratios.	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The	   acquisition	   and	   analysis	   protocols	   used	   in	   this	   study	   have	   been	   developed	   and	  optimised	   over	   the	   years.	   This	   study	   has	   demonstrated	   that	   using	   prior	   knowledge	  during	  spectral	  analysis	  gave	  higher	  PCr:ATP	  ratio	  with	  larger	  standard	  deviation,	  than	  if	   it	   was	   measured	   using	   manual	   peak	   selection.	   Prior	   knowledge	   can	   make	   an	  inaccurate	   assessment	   of	   the	   2,3	   DPG	   peak	   leading	   to	   an	   over	   correction	   for	   blood,	  resulting	  in	  an	  over	  estimation	  of	  the	  PCr:ATP	  ratio.	  In	  addition	  using	  prior	  knowledge	  resulted	   in	   greater	   CRLBs	   and	   at	   times	   some	   peaks	   were	   missed	   entirely	   leading	   to	  inconsistency	   during	   spectral	   analysis.	   When	   the	   multiple	   splitting	   of	   ATP	   into	   its	  relative	  components	  does	  not	  occur	  due	  to	  poor	  shim	  quality	  or	   it	   is	   less	  obvious,	   the	  prior	  knowledge	  algorithm	  fails	  to	  define	  some	  of	  these	  peaks	  and	  underestimates	  the	  γ-­‐ATP	  peak,	  once	  again	  leading	  to	  over	  estimation	  of	  the	  PCr:	  ATP	  ratio.	  	  
In	   addition	   this	   study	   demonstrated	   that	   using	   the	   γ-­‐ATP	   peak	   alone	   to	   measure	  PCr:ATP	  ratios	  resulted	  in	  a	  higher	  ratio	  in	  comparison	  to	  using	  the	  average	  of	  the	  ATP	  peaks	   in	   combination.	   The	   use	   of	   the	   β-­‐ATP	   peak	   can	   lead	   to	   errors	   due	   to	   an	  inhomogeneous	  RF	  excitation	  pulse	  profile.	  The	  use	  of	  γ-­‐ATP	  peak	  alone	  can	  be	  limited	  by	   spectral	   overlap	  with	   the	   PCr	   peak	   (Tyler,	   Emmanuel	   et	   al.	   2009).	   At	   3-­‐Tesla	   the	  issue	   of	   spectral	   overlap	   should	   be	   reduced	   due	   to	   the	   field	   dependent	   increase	   in	  spectral	  separation.	  The	  higher	  ratios	  obtained	  in	  this	  study	  using	  the	  γ-­‐ATP	  alone	  can	  be	  attributed	  to	  the	  decreased	  intensity	  of	  the	  β-­‐ATP	  and	  α-­‐ATP	  peaks.	  The	  band	  with	  of	  the	   excitation	   pulse	   may	   have	   been	   limited	   and	   insufficient	   to	   excite	   the	   whole	  frequency	  range	  of	   interest;	   the	  β-­‐ATP	  and	  α-­‐ATP	  peaks	  have	  a	   large	   frequency	  offset	  compared	  to	  the	  PCr	  peak	  therefore	  the	  intensity	  of	  these	  peaks	  are	  decreased	  or	  lost	  in	  some	   spectra.	   This	   is	   in	   contrast	   to	   the	   study	   by	   Tyler	   at	   el	   where	   an	   average	   ATP	  measurement	  resulted	  in	  greater	  PCr:ATP	  ratios	  than	  using	  the	  γ-­‐ATP	  alone.	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Other	   validation	   studies	   have	   shown	   similar	   levels	   of	   reproducibility.	   Lamb	   et	   al	  demonstrated	  PCr:ATP	  ratio	  percentage	  difference	  of	  18-­‐21%	  using	  either	  1D-­‐CSI	  with	  2D	   ISIS	   or	   3D-­‐CSI	   acquisition	   methods.	   	   (Lamb,	   Doornbos	   et	   al.	   1996).	   Tyler	   et	   al	  demonstrated	   a	   percentage	   difference	   of	   20%	   in	   PCr:ATP	   ratio	   using	   3D-­‐CSI	   (Tyler,	  Emmanuel	   et	   al.	   2009).	  This	   study	   shows	  an	   improved	   level	   of	   reproducibility	  with	   a	  percentage	   difference	   of	   7.6%.	   Inter-­‐subject	   variability	   reported	   here	   is	   19.3%	  comparable	  to	  other	  studies,	  ranging	  between	  14	  –	  18%	  (Lamb,	  Doornbos	  et	  al.	  1996;	  Tyler,	  Emmanuel	  et	  al.	  2009).	  	  
The	  sequence	  used	   in	   this	  study	   is	  one	  that	  has	  been	  optimized	   following	  preliminary	  work	   carried	   out	   by	   our	   group	   (Shivu,	   Abozguia	   et	   al.	   2010),	   which	   obtained	   a	  percentage	   difference	   of	   12%	   in	   PCr:ATP	   ratios	   in	   one	   subject	  measured	   eight	   times.	  During	   this	   preliminary	   work,	   the	   use	   of	   volume	   suppression	   bands	   to	   avoid	  contamination	   from	   adjacent	   structures,	   proton	   decoupling	   and	   the	   use	   of	   Nuclear	  Overhauser	  Enhancement	  (NOE)	  had	  been	  addressed	  and	  found	  no	  added	  advantages	  to	  the	   quality	   of	   the	   spectra	   using	   the	   acquisition	   sequence	   described	   here.	   NOE	   can	  increase	  the	  SNR,	  but	  this	  can	  impart	  different	  amounts	  of	  energy	  to	  ATP	  and	  PCr	  and	  hence	  alter	  the	  PCr:ATP	  ratio	  which	  would	  need	  additional	  correction	  (Shivu,	  Abozguia	  et	   al.	   2010).	   Therefore	   the	   additional	   techniques	   that	   may	   improve	   spectral	   quality	  were	  not	  evaluated	  in	  this	  validation	  study.	  	  
In	  this	  validation	  study	  four	  participants	  were	  excluded	  due	  to	  poor	  spectra	  quality	  and	  CRLBs	  being	  >20%.	  These	  participants	  were	  recruited	  at	  the	  initial	  stages	  of	  the	  study	  and	  at	  that	  stage	  the	  shimming	  process	  had	  just	  been	  optimised.	  Poor	  shimming	  leads	  to	  broader	   and	   ill-­‐defined	   peaks,	  which	   are	   difficult	   to	   analyse	   and	   hence	   less	   accurate.	  The	  ISIS	  process	  used	  in	  this	  study	  uses	  a	   larger	  shimming	  volume	  of	   interest,	  using	  a	  
	  4-­‐162	  
large	   voxel	   that	   covers	   most	   of	   the	   myocardium.	   This	   larger	   area	   increases	   the	  heterogeneity	   (significant	   blood	   contamination)	   and	   the	   increased	   movement	   of	   the	  myocardium	   makes	   it	   more	   difficult	   to	   achieve	   satisfactory	   results.	   The	   3D	   CSI	  technique	   using	   a	   smaller	   voxel	   may	   improve	   these	   results	   (Tyler,	   Emmanuel	   et	   al.	  2009)	  
The	   cohort	   of	   subjects	   consisted	   of	   a	   younger	   aged	   population	   and	   this	   can	   be	  considered	   a	   limitation	   of	   this	   study,	   in	   particular	   for	   the	   assessment	   of	   normal	   PCr:	  ATP	   ratio.	   However,	  we	   intended	   to	   assess	   the	   reproducibility	   of	   our	   techniques	   and	  therefore	  it	  is	  accepted	  that	  the	  PCr:	  ATP	  ratio	  of	  this	  study	  may	  reflect	  that	  of	  a	  younger	  aged	   population.	   Other	   limitations	   of	   this	   study	   remain	   those	   that	   exist	   of	   any	   study	  performing	   cardiac	   MRS.	   These	   include	   high	   signal	   to	   noise	   ratio,	   large	   voxel	   size	  (greater	  with	   ISIS;	   technique	   used	   here)	   and	   the	   distance	   of	   the	   transmitter/receiver	  coil	  placed	  on	  the	  chest	  wall	  to	  the	  targeted	  area	  of	  acquisition	  (variable	  depending	  on	  body	  habitus).	  The	  limitation	  in	  signal	  to	  noise	  ratio	  (SNR)	  impacts	  on	  the	  temporal	  and	  spatial	   resolution	   and	   spectral	   quality,	   such	   that	   there	   is	   a	   compromise	   between	  spectral	  quality	  and	  length	  of	  scanning	  time.	  The	  advent	  of	  the	  3-­‐Tesla	  MRI	  scanning	  is	  thought	  to	  improve	  SNR	  and	  hence	  temporal	  and	  spatial	  resolution	  (Tyler,	  Emmanuel	  et	  al.	  2009).	  	  
Spectroscopy	   has	   an	   inherent	   limitation,	   where	   the	   magnetic	   resonance	   has	   a	   low	  sensitivity	   to	   the	   phosphorus	   signal.	   This	   is	  made	  worse	   by	  motion	   of	   the	   heart	   and	  during	  respiration.	  Furthermore,	  although	  absolute	  measurement	  of	  the	  metabolites	  is	  preferable,	  this	  is	  difficult	  to	  perform	  and	  requires	  calibration	  of	  the	  31P	  signal	  to	  the	  1H	  water	  signal	  of	  the	  voxel	  (Bottomley,	  Atalar	  et	  al.	  1996).	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5 A	  STUDY	  TO	  ASSESS	  CARDIAC	  ENERGETICS	  AND	  	  	  	  	  	  	  	  	  	  	  	  
FUNCTIONAL	  STATUS	  IN	  PATIENTS	  WITH	  LEFT	  VENTRICULAR	  
HYPERTROPHY	  TREATED	  WITH	  PERHEXILINE	  
5.1 Introduction	  
Left	  ventricular	  hypertrophy	   is	  an	  adaptive	  response	  to	  physiological	  stressors	  placed	  on	   the	   left	   ventricle	   and	   therefore	   can	   initially	   be	   a	   normal	   physiological	   response	  (Lorell	   and	   Carabello	   2000).	   However,	   over	   time	   in	   patients	  with	   aortic	   stenosis	   this	  initial	  adaptive	  response	  to	  pressure	  overload	  results	   in	  an	  abnormal	  myocardium.	  As	  the	  degenerative	  aortic	  stenosis	  worsens,	  the	  left	  ventricle	  is	  subjected	  to	  a	  progressive	  increase	   in	   pressure	   overload.	   Therefore	   the	   initial	   adaptive	   response	   of	   the	  myocardium	   to	   become	   hypertrophied,	   renders	   itself	   to	   a	   sub-­‐normal	   state	   with	  deleterious	   consequences;	   diastolic	   dysfunction,	   impaired	   energetic	   state,	   gene	  reprogramming	   and	   metabolic	   derangement.	   These	   changes	   and	   consequences	   have	  been	  discussed	  in	  detail	  in	  the	  preceding	  introductory	  chapters.	  If	  LVH	  secondary	  to	  AS	  is	   left	   untreated	   by	   eliminating	   the	   cause	   for	   pathological	   LVH	   (aortic	   stenosis),	   the	  heart	   begins	   to	   fail	   and	   patients	   succumb	   to	   heart	   failure.	   It	   is	   suspected	   that	   the	  transition	   into	   heart	   failure	   in	   patients	   with	   LVH	   is	   dependent	   on	   the	   underlying	  energetic	   state	   (Neubauer	   2007)	   and	   that	   in	   LVH	   there	   is	   reduced	   high-­‐energy	  phosphates	  to	  supplement	  cardiac	  function	  (Conway,	  Allis	  et	  al.	  1991;	  Beer,	  Seyfarth	  et	  al.	  2002).	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5.1.1 Left	  ventricular	  hypertrophy	  and	  cardiac	  energetics	  	  
Measurement	  of	  cardiac	  energetics	  as	  described	  in	  the	  previous	  chapter	  can	  be	  used	  to	  evaluate	  the	  ratio	  of	  Phosphocreatine	  to	  ATP,	  which	  is	  an	  index	  of	  the	  energetic	  state	  of	  the	  heart	   (Neubauer	  2007).	   31P	  MRS	  has	  been	  used	   in	   a	  number	  of	   clinical	   studies	   to	  investigate	  the	  cardiac	  energetic	  state	  (Hudsmith	  and	  Neubauer	  2009).	  In	  patients	  with	  heart	  failure	  there	  is	  a	  reduction	  in	  PCr:ATP	  with	  an	  overall	  reduction	  in	  creatine	  levels,	  which	  reduces	  the	  ratio	  of	  PCr:ATP	  further	  (Neubauer,	  Krahe	  et	  al.	  1992).	  This	  reduced	  PCr:ATP	   ratio	   is	   associated	  with	   other	  markers	   of	   functional	   status	   such	   as	   the	   New	  York	   Heart	   Association	   classes	   of	   dyspnoea	   (Neubauer,	   Krahe	   et	   al.	   1992)	   and	  echocardiographic	   assessment	   of	   ventricular	   function:	   associated	   with	   systolic	   and	  diastolic	  dysfunction	  (Neubauer,	  Horn	  et	  al.	  1995;	  Lamb,	  Beyerbacht	  et	  al.	  1999).	  	  
There	   is	   ample	   evidence	   to	   suggest	   that	   the	   cardiac	   energetic	   state	   is	   diminished	   in	  patients	  with	  hypertrophic	  cardiomyopathy	  (Jung,	  Sieverding	  et	  al.	  1998;	  Crilley,	  Boehm	  et	  al.	  2003).	   It	   is	   further	  suggested	   that	   this	  energetic	  derangement	   is	   independent	  of	  the	   degree	   of	   hypertrophy	   in	   patients	   with	   hypertrophic	   cardiomyopathy	   (Crilley,	  Boehm	  et	  al.	  2003).	  However	  hypertrophic	  cardiomyopathy	  is	  an	  inherited	  disorder	  and	  although	  a	  decreased	  energetic	  state	  exists	  it	  is	  unclear	  how	  much	  the	  hypertrophy	  per	  
se	  contributes	  towards	  this.	  In	  LVH	  there	  appears	  to	  be	  a	  down	  regulation	  of	  both	  free	  fatty	  acid	  and	  carbohydrate	  utilisation.	  This	  is	  reflected	  as	  a	  low	  energy	  state	  reflected	  by	   impaired	  cardiac	  energetics,	   in	  the	  presence	  of	   increased	  cardiac	  energy	  utilisation	  and	  reduced	  oxygen	  delivery.	  	  
A	  study	  by	  Neubauer	  and	  colleagues	  demonstrated	  that	  in	  patients	  with	  aortic	  stenosis	  the	  PCr:	  ATP	  ratio	  was	   reduced	  at	  1.55	  ±	  0.12	  and	   the	   ratio	  was	  particularly	   reduced	  
	  5-­‐166	  
further	   to	   1.13	   ±	   0.03	   in	   a	   select	   group	   of	   patients	   who	   had	   a	   left	   ventricular	   end-­‐diastolic	  pressure	  of	  >	  15	  mmHg	  or	  when	  LV	  diastolic	  stress	  was	  >	  20	  kdyne/cm2.	  This	  led	  Neubauer	  et	  al	  to	  conclude	  that	  pressure	  overload	  induces	  significant	  impairment	  in	  cardiac	  energetics	  and	  this	  is	  related	  to	  the	  degree	  of	  heart	  failure	  (Neubauer,	  Horn	  et	  al.	   1997).	   In	   another	   study	   Conway	   et	   al	   demonstrated	   a	   PCr:ATP	   ratio	   of	   1.56	   	   in	  patients	  with	  LVH	  and	  in	  those	  that	  had	  heart	  failure,	  the	  ratio	  was	  reduced	  further	  to	  1.1	   (Conway,	   Allis	   et	   al.	   1991).	   	   This	   deranged	   energetic	   state	   seems	   to	   improve	   in	  patients	  that	  undergo	  an	  aortic	  valve	  replacement	  for	  aortic	  stenosis,	  from	  1.28	  ±	  0.17	  to	   1.47	   ±	   0.14	   at	   9	  months	   post	   surgery	   (Beyerbacht,	   Lamb	   et	   al.	   2001).	   Lamb	   et	   al	  demonstrated	   that	   with	   myocardial	   hypertrophy	   there	   is	   a	   reduced	   energetic	   state	  without	  heart	   failure	  with	  a	  PCr:	  ATP	  ratio	  of	  1.2	  ±	  0.18	  and	   further	  showed	  that	   this	  energetic	   deficiency	   correlated	   with	   a	   diastolic	   dysfunction	   (Lamb,	   Beyerbacht	   et	   al.	  1999).	   	  Furthermore	  Smith	  et	  al	  showed	  that	  there	  is	  a	  35%	  reduction	  in	  PCr	  levels	  in	  patients	  with	  pressure	  overload	  LVH	  and	  that	   there	   is	  a	   further	  65%	  reduction	   in	   the	  net	  ATP	  flux	  through	  CK	  in	  patients	  with	  LVH	  and	  heart	  failure,	  compared	  to	  those	  with	  LVH	  alone	  (30%	  reduction	   in	  ATP	  flux)	  when	  compared	  to	  normal	  subjects;	   therefore	  stipulates	   that	   it	   is	   the	  ATP	   turnover	   that	   distinguishes	   between	   the	   failing	   and	   non-­‐failing	  hypertrophic	  hearts	  (Smith,	  Bottomley	  et	  al.	  2006).	  	  
5.1.2 Metabolic	  modulation	  to	  improve	  cardiac	  energetics	  	  	  
The	   role	   and	   use	   of	  metabolic	  modulation	   using	  metabolic	   therapies	   such	   as	   GIK	   has	  been	   extensively	   discussed	   in	   the	  preceding	   introductory	   chapters.	   In	   LVH,	  metabolic	  therapies	  to	  improve	  substrate	  utilisation	  may	  prove	  an	  added	  benefit	  especially	  in	  the	  early	   post	   ischaemic	   period	   following	   cardiac	   surgery.	   There	   is	   further	   evidence	   that	  
	  5-­‐167	  
metabolic	  modulation	  through	  manipulating	  substrate	  utilisation,	  can	   improve	  cardiac	  energetics	  as	  measured	  by	  31P	  MRS.	  	  
Perhexiline	  is	  an	  anti-­‐anginal	  agent	  and	  thought	  to	  modulate	  metabolism	  by	  promoting	  glucose	  substrate	  utilisation	  (Ashrafian,	  Horowitz	  et	  al.	  2007).	  This	  is	  achieved	  through	  inhibition	   of	   mitochondrial	   free	   fatty	   acid	   uptake	   enzyme	   carnitine	   palmitoyl	  transferase-­‐1	   (CPT-­‐1)	   and	   CPT-­‐2	   (Kennedy,	   Unger	   et	   al.	   1996;	   Yellon	   and	   Hausenloy	  2007).	   A	   recent	   study	   by	   Lee	   and	   colleagues	   demonstrated	   that	   treatment	   with	  perhexiline	   therapy	   shortened	   phosphocreatine	   recovery	   in	   skeletal	   muscle	   after	  exercise	  by	  34%	  compared	  to	  a	  placebo	  group	  that	  remained	  unchanged	  (Lee,	  Campbell	  et	  al.	  2005).	  This	  impact	  on	  energetics	  has	  subsequently	  been	  tested	  in	  cardiac	  muscle.	  Abozguia	   et	   al	   demonstrated	   that	   perhexiline	   therapy	   improved	   cardiac	   energetics	  (PCr:ATP	   ratios)	   from	   1.23	   ±	   0.02	   to	   1.73	   ±	   0.02	   in	   patients	   with	   hypertrophic	  cardiomyopathy	  compared	  to	  controls	  (Abozguia,	  Elliott	  et	  al.	  2010).	  	  
5.1.3 Functional	  assessment	  of	  metabolic	  modulation	  	  
In	  addition	   to	   improvements	   in	  cardiac	  energetics,	  Abozguia	  and	  colleagues	  showed	  a	  significant	   improvement	   in	   exercise	   capacity	   and	   oxygen	   consumption	   measured	   by	  peak	  VO2	  and	  improvement	  in	  symptomatic	  status	  in	  NYHA	  class	  (Abozguia,	  Elliott	  et	  al.	  2010).	   These	   findings	   corroborate	   a	   study	   by	   Lee	   et	   al	   showing	   similar	   functional	  improvements	  with	  perhexiline	  therapy	  in	  patients	  with	  moderate	  to	  severe	  congestive	  heart	   failure;	  VO2	  max	   increased	  by	  17%	  and	   improvement	   in	   left	  ventricular	  ejection	  fraction	  (LVEF)	  by	  42%,	  long	  axis	  systolic	  function	  by	  20%	  and	  myocardial	  function	  at	  rest	   by	   15%	   (Lee,	   Campbell	   et	   al.	   2005).	   Furthermore	   Lee	   et	   al	   demonstrated	   a	   24%	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reduction	   in	   E/E’	   ratio	   (a	   non	   invasive	   marker	   of	   LV	   end-­‐diastolic	   pressure)	   with	  perhexiline	  therapy.	  	  	  
Speckle	   tracking	   using	   standard	   transthoracic	   echocardiography	   can	   provide	   another	  dimension	  to	  the	  assessment	  of	  ventricular	  function	  in	  longitudinal,	  circumferential	  and	  radial	   planes	   (Amundsen,	  Helle-­‐Valle	   et	   al.	   2006;	  Bertini,	  Nucifora	   et	   al.	   2009;	  Chang,	  Kim	  et	  al.	  2010;	  Kearney,	  Lu	  et	  al.	  2012).	  There	  is	  evidence	  to	  suggest	  that	  LV	  twist	   is	  preferable	   to	   LVEF	   in	   assessing	   ventricular	   function.	   A	   study	   by	  Bertini	   et	   al	   showed	  that	  LV	  twist	  and	  untwisting	  rates	  determined	  by	  speckle	  tracking	  are	  strongly	  related	  to	  the	  systolic	  and	  diastolic	  functions	  respectively	  with	  a	  strong	  correlation	  of	  LVEF	  to	  LV	   twist	   (Bertini,	  Nucifora	   et	   al.	   2009).	   Torsion	   is	   a	  measure	   of	   systolic	   function	   and	  untwisting	  is	  a	  measure	  of	  diastolic	  function.	  In	  patients	  with	  hypertrophy	  secondary	  to	  hypertension	  there	  is	  a	  delay	  in	  early	  diastolic	  untwisting	  and	  untwisting	  rate,	  which	  is	  reduced	   in	   parallel	   to	   the	   degree	   of	   LVH	   (Takeuchi,	   Borden	   et	   al.	   2007),	   and	   may	  contribute	   towards	   LV	   relaxation	   abnormalities.	   In	   patients	   with	   apical	   hypertrophy	  secondary	  to	  hypertrophic	  cardiomyopathy,	  there	  is	  a	  marked	  reduction	  in	  overall	  twist	  due	   to	   a	   reduction	   in	   apical	   rotation	   (Chang,	   Kim	   et	   al.	   2010).	   A	   further	   study	   by	  Takamura	   et	   al	   has	   shown	   a	   reduced	  peak	   systolic	   strain	   and	  peak	   relaxation	   rate	   in	  patients	  with	  hypertensive	  LVH	  (Takamura,	  Dohi	  et	  al.	  2010).	  	  
It	   is	   believed	   that	   longitudinal	   strain	   is	   governed	   by	   the	   subendocardial	   layer	   and	   is	  most	   sensitive	   to	  myocardial	   disease	   (Bertini,	   Nucifora	   et	   al.	   2009).	   In	   patients	   with	  aortic	   stenosis,	   there	   is	   a	   stepwise	   progressive	   impairment	   in	   longitudinal,	  circumferential	   and	   radial	   strain	   and	   strain	   rate	   with	   increasing	   AS	   severity	   despite	  normal	  ejection	  fractions	  (EF	  >	  50%)	  (Ng,	  Delgado	  et	  al.	  2011).	  	  Furthermore	  this	  study	  showed	   that	   the	   dysfunction	   started	   in	   the	   subendocardium	   and	   progressed	   to	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transmural	  dysfunction	  with	  increasing	  AS	  severity.	  	  The	  most	  useful	  measurement	  as	  a	  prognostic	   indicator	   is	   global	   longitudinal	   strain	   (GLS)	   (Mignot,	   Donal	   et	   al.	   2010).	  Kousa	   et	   al	   demonstrated	   reduced	   longitudinal	   strain	   in	  patients	  with	   concentric	   and	  eccentric	   hypertrophy	   compared	   to	   control	   (Kouzu,	   Yuda	   et	   al.	   2011).	  Miyazaki	   et	   al	  showed	  that	  GLS	  progressively	  decreased	  with	  an	  increase	  in	  aortic	  stenosis	  and	  there	  is	  a	  strong	  correlation	  between	  GLS	  and	  aortic	  valve	  area,	  mean	  pressure	  gradient,	  LV	  mass	   index	   and	   early	   diastolic	   mitral	   annular	   velocity	   (e’)	   (Miyazaki,	   Daimon	   et	   al.	  2011).	  The	  extent	   and	   impact	  of	  LVH	   in	   these	  patients	  warrants	   further	   investigation	  and	   examination	   of	   these	   parameters	   may	   help	   elucidate	   the	   impact	   of	   metabolic	  therapy	  on	  this	  vulnerable	  group	  of	  patients.	  	  
The	  role	  of	  perhexiline	  therapy	  as	  a	  metabolic	  modulator	  on	  myocardial	  energetics	  and	  ventricular	   function	   on	   LVH	   secondary	   to	   AS	   has	   not	   been	   previously	   examined.	   The	  aim	  of	   this	  study	   is	   to	  measure	   the	  cardiac	  energetic	  status	  using	  magnetic	  resonance	  spectroscopy,	   in	  patients	  with	  only	   left	  ventricular	  hypertrophy	  (without	  concomitant	  IHD)	  secondary	  to	  aortic	  stenosis	  and	  evaluate	  the	  impact	  of	  metabolic	  modulation	  with	  perhexiline	  on	  their	  high	  energy	  phosphates	  and	  energetic	  status.	  In	  addition	  this	  study	  aimed	   to	   look	   at	   the	   effect	   of	   longer	   perhexiline	   therapy	   on	   left	   ventricular	   function	  using	  speckle	  tracking	  and	  evaluate	  the	  functional	  capacity	  of	  these	  individuals.	  	  
5.2 Methods	  	  
5.2.1 Study	  design	  	  
This	   study	   constituted	   a	   sub-­‐study	   to	   the	   main	   HYPER	   trial	   (Methodology	   outlined	  earlier	   in	   Chapter	   2).	   	   Therefore	   this	   sub-­‐study	   was	   consistent	   with	   a	   double-­‐blind	  placebo	  controlled	  randomised	  controlled	   trial	  design.	  Study	  participant	  received	  pre-­‐
	  5-­‐170	  
operative	  oral	  loading	  of	  perhexiline	  or	  placebo.	  Recruitment	  into	  this	  sub-­‐study	  was	  at	  a	  single	  centre	  (University	  Hospitals	  Birmingham).	  	  
All	  ethics	  and	  approvals	  were	  as	  per	  the	  main	  HYPER	  trial	  outlined	  in	  Chapter	  2	  section	  2.2	  and	  were	  approved	  as	  a	  substantial	  amendment	  to	  the	  main	  trial	  ethics	  and	  MHRA	  approvals.	  	  
5.2.2 Patient	  selection,	  recruitment	  and	  randomisation	  
Patients	   listed	   for	   an	   isolated	   AVR	   only,	   were	   included	   into	   this	   study.	   Those	   with	  concomitant	   IHD	   needing	   a	   concomitant	   CABG	   were	   not	   eligible,	   in	   addition	   to	   the	  inclusion/exclusion	  criteria	  outlined	  in	  Table	  2-­‐1.	  	  
Patient	   screening,	   enrolment	   and	   randomisation	   were	   as	   per	   the	   main	   HYPER	   trial	  procedures	   outlined	   in	   sections	   2.9.1	   to	   2.9.3.	   Those	   patients	   who	   were	   willing	   to	  undertake	  a	  prolonged	  period	  of	  trial	  therapy	  as	  outlined	  below	  and	  were	  clinically	  able	  to	  await	  surgery	  until	  follow-­‐up	  investigations	  were	  completed,	  were	  recruited	  into	  this	  trial.	   Those	   who	   didn’t	   want	   to	   undertake	   a	   prolonged	   course	   of	   IMP	   but	   agreed	   to	  participate	  in	  the	  main	  trial	  were	  managed	  along	  the	  main	  trial	  protocols.	  	  
5.2.3 Sample	  size	  and	  primary	  outcome	  measure	  	  
The	  primary	  outcome	  is	  to	  detect	  a	  20%	  improvement	  in	  PCr:ATP	  ratio	  with	  metabolic	  manipulation	   from	   baseline.	   PCr:ATP	   ratio	   in	   patients	   with	   LVH	   is	   1.3±0.3,	   with	   a	  difference	   between	  means	   of	   0.26;	   SD	   0.3	   (Beer,	   Seyfarth	   et	   al.	   2002).	   To	   achieve	   an	  improvement	   of	   20%,	   with	   a	   α	   0.05	   and	   β	   0.9	   would	   require	   34	   patients.	   An	  improvement	  of	  20%	  in	  PCr:ATP	  ratio	  would	  mean	  a	  near	  normalisation	  of	  this	  index.	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5.2.4 Baseline	  studies	  	  
All	   patients	   had	   their	   height	   and	   weight	   recorded	   on	   arrival	   before	   their	   baseline	  investigations.	   Venous	   blood	   was	   taken	   for	   baseline	   full	   blood	   count,	   urea	   and	  electrolytes	   and	   liver	   function	   tests.	  Additional	   venous	  blood	  was	   taken	   into	  Z	   Serum	  Sep	  Clot	  Activator,	  K3E	  K3EDTA	  and	  Z	  Serum	  clot	  Activator	  (plain)	  vacuette	  bottles	  and	  immediately	   centrifuged	   at	   3000g	   for	   5	  mins.	   The	   supernatant	  was	   pipetted	   out	   into	  NUNC	  cryotubes	  and	  frozen	  at	  -­‐80	  °C	  for	  later	  analysis.	  	  
In	   addition	   to	   the	   above	   baseline	   blood	   samples	   a	   transthoracic	   echocardiography,	  Cardiac	  MRS	  and	  a	  6-­‐minute	  walk	  test	  were	  also	  performed	  in	  that	  sequence	  at	  baseline,	  before	   administration	   of	   trial	   therapy.	   These	   tests	  were	   then	   repeated	   4	  weeks	   after	  trial	  therapy	  (placebo/perhexiline),	  before	  their	  cardiac	  operation.	  	  
5.2.5 Transthoracic	  echocardiography	  
5.2.5.1 2-­‐Dimentional	  echocardiography	  	  A	  standard	  TTE	  (Vivid	  7,	  GE	  Vingmed	  Ultrasound,	  Horten,	  Norway)	  was	  performed	  with	  subjects	   in	   the	   left	   lateral	   decubitus	   position	   by	   an	   experienced	   blinded	  echocardiographer	   using	   second	   harmonic	   imaging	   and	   an	   M3S	   multi-­‐frequency	  transducer.	   	   All	   parameters	   were	   measured	   in	   triplicate	   and	   averaged	   as	   per	   the	  recommendations	   of	   the	   American	   Society	   of	   Echocardiography	   (Schiller,	   Shah	   et	   al.	  1989).	  	  
Analysis	   was	   performed	   offline	   by	   a	   single	   blinded	   observer	   using	   an	   EchoPAC	  workstation	   (GE	  Vingmed	  Ultrasound,	  Horten,	  Norway).	   	  Ventricular	  dimensions,	  wall	  thickness,	   chamber	   volume,	   stroke	   volume	   and	   ejection	   fraction	  were	   determined	   by	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standard	  methods	   (Lang,	  Bierig	  et	  al.	  2005).	  Resting	   left	  ventricular	  diastolic	   function	  was	   determined	   using	   standard	   techniques	   (Nagueh,	   Appleton	   et	   al.	   2009).	   Tissue	  Doppler	  assessment	  of	  ventricular	  function	  was	  measured	  using	  peak	  systolic	  (S’),	  early	  diastolic	   (E’)	   and	   late	   diastolic	   (A’)	  mitral	   annular	   velocities	   at	   end	   expiration	   at	   the	  anterolateral,	   inferioseptal,	   inferior	   and	   anterior	   left	   ventricular	   walls	   with	   real	   time	  pulsed	  wave	  tissue	  Doppler	  (Alam,	  Wardell	  et	  al.	  1999).	  
5.2.5.2 Speckle	  tracking	  echocardiography	  	  Greyscale	   images	   for	   2-­‐dimensional	   left	   ventricular	   strain	   was	   acquired	   in	   cine-­‐loop	  format	   in	   triplicate	   from	   the	  apical	  4-­‐,	   2-­‐	   and	  3-­‐chamber	  views	  and	  parasternal	   short	  axis	   views	   at	   basal,	   papillary	   and	   apical	   ventricular	   levels	   at	   end	   expiration	   at	   frame	  rates	  >70Hz	  for	  offline	  analysis	  using	  commercially	  available	  software	  (Speqle	  Tracking,	  GE	  Healthcare,	  United	  Kingdom).	  	  	  
The	   endocardial	   border	   was	   manually	   tracked	   at	   end-­‐systole	   and	   the	   software	  generated	   a	   region	   of	   interest	   over	   the	  myocardium.	   This	   generated	   region	  was	   then	  adjusted	   and	   optimised	  manually.	   This	   enables	   frame-­‐to-­‐frame	   tracking	   of	   ultrasonic	  speckles	   that	   change	  position	   according	   to	   surrounding	   tissue	  motion	   throughout	   the	  length	  of	  the	  cardiac	  cycle.	  	  Peak	  systolic	  velocities,	  strain,	  strain	  rate,	  rotation	  and	  twist	  were	  measured	   for	   each	  myocardial	   segment	   in	   triplicate	   and	  averaged.	  Peak	   systolic	  longitudinal	   strain	   was	   calculated	   by	   averaging	   the	   peak	   systolic	   values	   of	   the	   six	  segments	  in	  the	  four-­‐chamber	  view	  and	  expressed	  as	  Global	  Longitudinal	  Strain	  (GLS)	  and	  integrated	  from	  time	  to	  give	  global	  longitudinal	  strain	  rate	  (GLSR).	  
Rotation	   of	   the	   heart	   refers	   to	   the	   rotation	   of	   the	   short	   axis	   segments	   of	   the	   left	  ventricle.	  The	  left	  ventricle	  has	  a	  spiral	  architecture	  formed	  by	  the	  myofibrils.	  Therefore	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when	  viewed	  from	  the	  apex,	  the	  base	  of	  the	  LV	  rotates	  in	  a	  clockwise	  direction	  and	  the	  apex	   rotates	   in	   a	   counter-­‐clockwise	   direction.	   This	   opposing	   motion	   leads	   to	   a	   left	  ventricular	  wringing	  motion	  during	  systole	  and	  is	  referred	  to	  as	  twist.	  Left	  ventricular	  twist	  is	  the	  net	  difference	  at	  isochronal	  time	  points	  between	  apex	  and	  base	  along	  the	  left	  ventricular	   longitudinal	   axis.	   Left	   ventricular	   torsion	   is	   the	   twist	   corrected	   by	   the	  distance	  between	  the	  apex	  and	  the	  base.	  These	  results	  are	  integrated	  over	  time	  to	  give	  torsion	  and	  untwist	  rates.	  	  
5.2.6 Cardiac	  Magnetic	  Resonance	  Spectroscopy	  
Cardiac	   MRS	   was	   performed	   according	   to	   the	   acquisition	   and	   analysis	   protocols	  outlined	   in	   the	   chapter	   sections	   4.2.2.1	   and	   4.2.2.2	   respectively.	   This	   technique	   was	  subjected	  to	  a	  validation	  study	  performed	  to	  assess	  the	  reproducibility	  and	  reliability	  of	  cardiac	  MRS	  outlined	   in	  Chapter	  4.	  Therefore	  the	  techniques	  used	   in	  this	  study	  follow	  the	  principles	  outlined	  in	  the	  preceding	  chapter.	  	  
5.2.7 6-­‐minutue	  walk	  test	  	  
All	   patients	   performed	   a	   6-­‐mintue	   walk	   test	   as	   per	   the	   American	   Thoracic	   Society	  guidelines	   (ATS	   Committee	   on	   Proficiency	   Standards	   for	   Clinical	   Pulmonary	   Function	  Laboratories	  2002)	  This	   involved	  walking	  between	  2	  set	  points,	  54	  meters	  apart.	  The	  total	  distance	  walked	  in	  6	  minutes	  was	  calculated.	  The	  resting	  and	  post	  6-­‐minute	  walk	  symptoms	  of	  dyspnoea	  and	   fatigue	  were	   recorded	  as	  per	   the	  Borg	   scale	   (Borg	  1982),	  outlined	  in	  Appendix	  9.13.	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5.2.8 Trial	  therapy	  dose	  adjustment	  	  
Patients	  who	  entered	  this	  sub-­‐study	  were	  given	  an	  extended	  period	  of	  trial	  therapy	  for	  4	  weeks.	  Hence	  these	  patients	  did	  not	  have	  an	  initial	  loading	  dose,	  but	  were	  started	  on	  100mg	  bd	  of	  perhexiline/placebo	  after	  the	  base	  line	  investigation.	  	  
Trial	  therapy	  levels	  were	  monitored	  between	  1-­‐2	  weeks	  after	  starting	  the	  IMP	  to	  avoid	  toxicity	  related	   to	  perhexiline	   therapy;	  a	  venous	  blood	  sample	  was	   taken	  and	  sent	   for	  perhexiline	  level	  analysis.	  An	  unblinded	  contact	  was	  informed	  of	  the	  perhexiline	  levels	  and	   they	   individually	   contacted	   the	   participant	   to	   optimise	   the	   dosage	   requirements.	  Dose	  adjustments	  were	  made	  according	  to	  the	  dosing	  regime	  in	  Appendix	  9.14.	  	  
5.2.9 Study	  management	  protocols	  	  
After	  undergoing	  the	  above	  studies	  at	  baseline	  and	  four	  weeks	  post	  randomisation	  and	  trial	   therapy	   administration,	   these	   patients	   were	   included	   into	   the	   main	   trial	   and	  followed	  the	  methodology	  as	  outlined	  in	  Chapter	  2.	  Therefore	  patients	  enrolled	  into	  this	  sub-­‐study	   were	   operated	   when	   they	   were	   on	   the	   4th	   week	   of	   their	   trial	   therapy.	   All	  methodology	  and	  trial	  protocols	  as	  per	  the	  main	  HYPER	  trial	  were	  followed	  thereafter	  as	  outlined	  in	  sections	  2.11	  to	  2.15.	  	  
5.2.10 Statistical	  analysis	  	  
Analysis	   was	   performed	   using	   SPSS	   software	   (version	   20.0,	   SPSS	   Inc.,	   Chicago,	   IL).	  Continuous	   data	   was	   assessed	   for	   normal	   distribution	   and	   presented	   as	   mean	   ±	  standard	  deviation	  of	  the	  mean	  or	  median	  and	  inter-­‐quartile	  range.	  Student’s	  t-­‐test	  was	  used	   to	   analyse	   normally	   distributed	   data.	   Difference	   in	   measurements	   between	   the	  same	   participants	   was	   analysed	   using	   the	   paired	   students	   t-­‐test.	   Skewed	   data	   was	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analysed	  by	  Mann-­‐Whitney	  U-­‐test.	  Categorical	  data	  was	  analysed	  by	  Fisher’s	  exact	  test.	  Paired	   non-­‐normal	   data	   was	   analysed	   using	   Wilcoxon	   signed	   rank	   test.	   Statistical	  significance	  was	  defined	  as	  p	  <	  0.05.	  
5.3 Results	  	  
5.3.1 Consort	  flow	  diagram	  	  
Recruitment	   into	   this	   sub-­‐study	   started	   in	   October	   2010.	   The	   consort	   flow	   diagram	  (Figure	   5-­‐1)	   outlines	   the	   number	   of	   patients	   screened	   for	   eligibility,	   the	   reasons	   for	  their	   exclusion	   and	   pathway	   of	   patients	   post	   randomisation	   as	   based	   on	   the	   locked	  database.	  Based	  on	   the	  exclusion	  criteria	  as	  per	   the	  main	  HYPER	  trial,	   the	  majority	  of	  patients	   (n=20)	   had	   aortic	   regurgitation	   and	   the	   remainder	   had	   diabetes	   or	   atrial	  fibrillation.	  Of	  those	  eligible	  to	  enter	  this	  sub-­‐study,	  18	  patients	  did	  not	  want	  to	  take	  a	  prolonged	  period	  of	   IMP	  or	  have	   the	  additional	  baseline	  and	   follow-­‐up	   investigations.	  These	  patient,	  were	  enrolled	  into	  the	  main	  HYPER	  trial.	  	  
Following	   randomisation	   into	   this	   sub-­‐study,	   one	   patient	   in	   the	   control	   group	   was	  excluded	   from	   the	   sub-­‐study;	   a	   baseline	   magnetic	   resonance	   spectroscopy	   was	   of	  inadequate	   quality	   for	   subsequent	   analysis	   despite	   multiple	   attempts	   to	   acquire	   an	  analysable	   spectrum.	   This	   patient	   therefore	   didn’t	   undergo	   any	   other	   baseline	  investigations	   and	   entered	   the	  main	  HYPER	   trial	   instead.	   Two	  patients	   in	   the	   control	  group	  after	  randomisation	   into	   the	  sub-­‐study	  were	  brought	   forward	   for	  early	  surgery	  on	  clinical	  grounds	  of	  urgency.	  These	  patients	  therefore	  did	  not	  complete	  baseline	  or	  FU	  tests	  for	  this	  sub-­‐study	  and	  hence	  entered	  the	  main	  HYPER	  trial.	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Figure	  5-­‐1	  Consort	  flow	  diagram	  for	  patients	  included	  into	  the	  MRS	  sub-­‐study	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5.3.2 Sample	  group	  
The	  patient	  demographics	  and	  pre-­‐operative	  echocardiographic	  data	  and	  are	  outlined	  in	   Table	   5-­‐1	   and	   Table	   5-­‐2	   respectively.	   The	   echocardiographic	   data	   represents	   the	  measurements	   at	   the	   time	   of	   randomisation	   prior	   to	   trial	   administration	   of	   IMP.	   Ten	  patients	  entered	  this	  study.	  	  
Variable	  (Median,	  IQR)/(%)	   Control	  (n=6)	   Perhexiline	  (n=4)	  
Age	   64.2	  (50	  –	  77)	   79	  (73	  –	  82)	  
BSA	  	   1.81	  (1.28	  –	  2.20)	  	   1.82	  (1.59	  –	  2.06)	  	  
Male:	  Female	  	   4:2	  (67:33)	   2:2	  (50:50)	  
Caucasian	   6	  (100)	   5	  (85)	  
Status	   	   	  -­‐	  Elective	   6	  (100)	   4	  (100)	  
EuroSCORE	   3	  (2	  –	  7)	   7	  (6.00	  –	  8.75)	  
Logistic	  EuroSCORE	   2.12	  (1.67	  –	  7.50)	   7.29	  (4.80	  –	  12.66)	  
CCS	  	   	   	  -­‐	  1	   3	  (50)	   3	  (75)	  -­‐	  2	   3	  (40)	   0	  -­‐	  3	   0	  	   1	  (25)	  
NYHA	   	   	  -­‐	  1	   0	   1	  (25)	  -­‐	  2	   4	  (67)	   1	  (25)	  -­‐	  3	   2	  (33)	   2	  (50)	  -­‐	  4	   0	   0	  
Previous	  MI	   0	  	   0	  
Risk	  factors	   	   	  -­‐	  Hypercholesterolemia	  	   0	  	   1	  (25)	  -­‐	  Hypertension	   1	  (17)	   2	  (50)	  
Medication	   	   	  -­‐	  ACE	   0	   0	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-­‐	  A2	   1	  (17)	   0	  -­‐	  Statin	   3	  (50)	   3	  (65)	  -­‐	  β	  blocker	   1	  (17)	   1	  (20)	  
IABP	  pre	  surgery	   0	  	   0	  
Coronary	  artery	  disease	   0	   0	  
Table	  5-­‐1	  Baseline	  demographics	  characteristics	  of	  the	  patient	  sample	  	  	  
	  
Variable	  (Median,	  IQR/%)	   Control	  (n=6)	   Perhexiline	  (n=4)	  
Ejection	  fraction	  (%)	   57	  (46	  –	  61)	   59	  (52	  –	  64)	  
LVID	  	  (cm)	   4.45	  (2.70	  –	  4.72)	  	   4.7	  (3.75	  –	  5.36)	  
IVSd	  (cm)	   1.65	  (1.50	  –	  1.72)	   1.23	  (1.01	  –	  1.70)	  
PWd	  (cm)	   1.46	  (1.10	  –	  1.55)	   1.4	  (1.2	  –	  1.4)	  
Aortic	  valve	  Vmax	  (m/s)	   4.30	  (3.81	  –	  5.30)	   4.55	  (4.17-­‐	  4.85)	  
Valve	  area	  (m2)	   0.70	  (0.58	  –	  0.95)	   0.50	  (0.40	  –	  0.50)	  
Peak	  Aortic	  Valve	  Gradient	  (m/s)	   74.0	  (65.3	  –	  112.5)	   82	  (63.3	  –	  101.5)	  
Mean	  Aortic	  Valve	  Gradient	  (m/s)	   46.0	  (38.8	  –	  62.8)	   47.5	  (35.5	  –	  53.5)	  
Table	  5-­‐2	  Baseline	  echocardiographic	  data	  of	  the	  patient	  cohort	  
5.3.3 Perhexiline	  concentrations	  	  
Of	  the	  10	  patients	  entered	  into	  the	  study,	  four	  patients	  were	  in	  the	  perhexiline	  arm	  at	  the	   time	   of	   the	   baseline	   investigations.	   After	   administration	   of	   the	   investigation	  medicinal	  product	  (IMP),	  only	  three	  completed	  the	  follow-­‐up	  investigations;	  one	  patient	  developed	  side	  effects	  (diarrhoea	  and	  vomiting)	  after	  the	  initial	  3	  days	  and	  declined	  to	  continue	   with	   IMP	   despite	   halving	   the	   regime.	   The	   mean	   perhexiline	   and	   hydroxyl-­‐perhexiline	  concentrations	  of	  those	  in	  the	  treatment	  group	  (n=3)	  were	  0.20	  ±	  0.07	  and	  1.31	   ±0.73	   (μg/L)	   respectively.	   Of	   the	   three,	   one	   patient	   was	   sub-­‐therapeutic	   with	   a	  perhexiline	  concentration	  of	  0.14	  at	  follow-­‐up.	  	  
	  5-­‐179	  
5.3.4 Echocardiographic	  analysis	  	  
Of	   the	   10	   patients	   who	   entered	   this	   study,	   echocardiographic	   data	   was	   available	   for	  nine	  patients	  (one	  declined	  follow-­‐up	  testing	  after	  stopping	  IMP	  for	  SEs)	  at	  follow-­‐up	  (4	  weeks	   after	   intervention,	   before	   their	   cardiac	   surgery).	   The	   data	   presented	   below	  applies	  to	  those	  that	  completed	  the	  follow-­‐up	  investigations.	  	  	  
Due	  to	  the	  small	  number	  of	  patients	  in	  the	  treatment	  arm,	  normal	  distribution	  was	  not	  possible	  even	  after	  log	  transformation.	  Therefore	  all	  analyses	  are	  performed	  using	  non-­‐parametric	  testing	  as	  outlined	  above.	  	  
5.3.4.1 2-­‐Dimentional	  echocardiography	  analysis	  	  The	   two-­‐dimensional	   echocardiography	   data	   is	   outline	   in	   Table	   5-­‐3	   for	   this	   patient	  cohort	   at	   baseline	   and	   at	   follow-­‐up,	   between	   the	   groups.	   There	   was	   no	   significant	  difference	   in	   any	   of	   the	   ventricular	   dimensions,	   wall	   thickness,	   chamber	   volumes	   or	  function	  at	  baseline	  or	  at	  follow-­‐up	  with	  the	  IMP.	  Furthermore,	  there	  was	  no	  difference	  in	  tissue	  Doppler	  assessments	  of	  ventricular	  function	  at	  either	  of	  the	  measured	  points	  with	  the	  IMP.	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Table	  5-­‐3	  2D	  Echocardiographic	  data	  at	  baseline	  and	  follow-­‐up	  
	   Baseline	   Follow-­‐up	  
	   Control	  (n=6)	   Perhexiline	  (n=3)	   P	  	   Control	  (n=6)	   Perhexiline	  (n=3)	   P	  	  
EF	   69.5	  (52.3	  –77.8)	   71.0	  (60	  –	  71.0)	  	   0.71	   67.5	  (58.8	  –	  76.3)	   77.0	  (71.0	  –	  77.0)	   0.26	  
IVSd	   1.25	  (1.0	  –	  1.78)	   1.5	  (0.7	  –	  1.5)	   1.0	   1.3	  (1.3	  –	  1.4)	   1.4	  (1.1	  –	  1.4)	   0.71	  
PWd	   0.95	  (0.8	  –	  1.2)	   1.3	  (1.1	  –	  1.3)	   0.10	   1.4	  (1.4	  –	  2.0)	   1.5	  (1.1	  –	  1.5)	   0.90	  
LVIDd	   4.9	  (4.5	  –	  5.5)	   4.8	  (4.7	  –	  4.8)	   0.91	   5.35	  (4.72	  –	  6.2)	   4.9	  (4.6	  –	  4.9)	   0.17	  
LVEDV	   113	  (96	  –	  153)	   107	  (102	  –	  107)	   0.91	   139	  (106	  –	  195)	   114	  (98	  –	  114)	   0.17	  
SV	   66	  (58	  –	  93)	   73	  (72	  –	  73)	   0.38	   100	  (63	  –	  128)	   85	  (48	  -­‐85)	   0.38	  
MV	  E	   0.81	  (0.57	  –	  1.02)	   0.83	  (0.79	  –	  0.83)	   1.0	   0.83	  (0.65	  –	  0.94)	   0.68	  (0.65	  –	  0.68)	   0.38	  
MV	  A	   0.90	  (0.71	  –	  0.96)	   1.12	  (0.81	  –	  1.12)	   0.26	   0.92	  (0.60	  –	  1.03)	   0.88	  (0.66	  –	  0.88)	   0.74	  
E/A	   0.89	  (0.67	  –	  1.19)	   0.74	  (0.59	  0.74)	   0.91	   0.94	  (0.73	  –	  1.33)	   0.75	  (0.53	  –	  0.75)	   0.38	  
MV	  DT	   423.8	  	  	  	  	  	  	  	  	  	  	  	  	  	  (375.5	  –	  490.9)	   457	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (393.0	  –	  457.0)	   1.0	   403.3	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (357.3	  –	  478.7)	   411.5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (387.5	  –	  411.5)	   1.0	  
IVRT	   87.3	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (59.9	  –	  109.1)	   109.3	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (67.0	  –	  109.3)	   0.26	   119.2	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (89.3	  –	  139.4)	   145.0	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (84.3	  –	  145.0)	   0.71	  
CI	   2.41(2.07	  –	  3.18)	   3.87	  (0.93	  –	  3.87)	   0.55	   2.49	  (1.2–	  2.6)	   3.01	  (3.01	  –	  3.01)	   0.29	  
E/E1	   12.3	  (7.6	  –	  15.6)	   13.7	  (11.3	  –	  13.7)	   0.38	   13.7	  (9.2	  –	  15.4)	   9.62	  (9.28	  –	  9.62)	   0.26	  
TDi	  AL	  S	  	   6	  (5	  –	  7)	   6	  (3	  –	  6)	  	   0.91	   7	  (4.75	  –	  8.25)	   7	  (5	  –	  7)	   1.0	  
TDi	  AL	  E	   6.5	  (5.75	  –	  8.25)	   6	  (4	  –	  6)	   0.38	   6.5	  (5.75	  –	  7.25)	   7	  (6	  –	  7)	   0.55	  
TDi	  AL	  A	   9.5	  (8	  –	  10.25)	   8	  (8	  –	  8)	   0.26	   9.5	  (6.75	  –	  12.0)	   8	  (8	  –	  8)	   1.0	  
TDi	  IS	  S	   6	  (4.75	  –	  7)	   5	  (5	  –	  5)	   0.55	   6	  (4.75	  –	  8)	   6	  (5	  –	  6)	   0.71	  
TDi	  IS	  E	   4.5	  (4	  –	  6)	   5	  (4	  –	  5)	   0.71	   5.5	  (4.75	  –	  10.25)	   5	  (5	  –	  5)	   0.71	  
TDi	  IS	  A	   7	  (5.5	  –	  8.25)	   8	  (7	  –	  8)	   0.38	   8.5	  (7.75	  –	  12.0)	   9	  (7	  –	  9)	   1.0	  
TDi	  A	  S	   6.5	  (5	  –	  7)	   8	  (5	  –	  8)	  	   0.38	   6.5	  (5.75	  –	  7.75)	   7	  (5	  –	  7)	   1.0	  
TDi	  A	  E	   6.5	  (4.75	  –	  8.25)	   6	  (6	  –	  6)	   0.91	   6.5	  (5.75	  –	  8.25)	   5	  (4	  –	  5)	   0.10	  
TDi	  A	  A	   9	  (8.75	  –	  11)	   10	  (9	  –	  10)	   0.38	   10.5	  (6.5	  –	  14)	   8	  (8	  –	  8)	   0.55	  
TDi	  IN	  S	   6	  (5	  –	  6.5)	   7	  (7	  –	  7)	   0.38	   7	  (5.75	  –	  9)	   6	  (6	  -­‐6)	   0.71	  
TDi	  IN	  E	   6	  (5-­‐	  7.25)	   6	  (5	  -­‐6)	   0.17	   5.5	  (4	  –	  6)	   6	  (5	  –	  6)	   0.55	  
TDi	  IN	  A	   10.5	  (8.75-­‐	  11.5)	   10	  (8	  -­‐10)	   0.71	   10	  (9.5	  –	  12.25)	   8	  (8	  –	  8)	   0.55	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EF,	   ejection	   fraction;	   IVSd,	   Inter-­‐ventricular	   septum	   diameter	   in	   diastole;	   PWd,	  Posterior	  wall	  diameter	  in	  diastole;	  LVID,	  Left	  Ventricular	  Internal	  Diameter	  in	  diastole;	  LVEDV,	  left	  ventricular	  diastolic	  volume	  (mL);	  SV,	  Stroke	  volume;	  MV	  E,	  mitral	  valve	  E	  wave	  velocity	  (cm/s);	  MV	  A,	  mitral	  valve	  A	  wave	  velocity	  (cm/s);	  E/A,	  mitral	  valve	  E	  to	  A	   ratio;	  MV	  DT,	  mitral	  E	  wave	  deceleration	   time	   (ms);	   IVRT,	   isovolumetric	   relaxation	  time	  (ms);	  CI,	  cardiac	  index	  (l/min/m2);	  TDi,	  tissue	  Doppler	  imaging	  during	  systolic	  (S),	  and	  passive	   (E)	   and	   active	   (A)	   relaxation	   from	  AL	   (anterolateral),	   IS	   (inferoseptal),	   A	  (anterior)	  and	  IN	  (inferior)	  wall	  peak	  annular	  velocities.	  	  	  
5.3.4.2 Speckle	  tracking	  echocardiography	  	  The	   speckle	   tracking	   echocardiography	   data	   is	   outline	   in	   Table	   5-­‐4.	   The	   baseline	  characteristics	   between	   the	   groups	   are	   not	   comparable.	   Through	   non-­‐parametric	  testing,	   characteristics	   of	   basal	   rotation,	   twist,	   torsion,	   peak	   twist,	   systolic	   twist	   rates	  and	   untwist	   rates	   were	   not	   comparable	   albeit	   with	   small	   statistical	   significance.	  However	  post	  IMP	  therapy	  speckle	  tracking	  echocardiography	  failed	  to	  demonstrate	  a	  change	   in	   any	   of	   the	   measurements	   including	   twist,	   twist	   rates,	   torsion	   or	   in	   left	  ventricular	  strain	  between	  the	  groups.	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Table	  5-­‐4	  Speckle	  tracking	  echocardiography	  data	  
	  
Baseline	   Follow-­‐up	  
	   Control	  	  	  	  	  	  (n=6)	   Perhexiline	  (n=3)	   P	  value	   Control	  	  	  	  	  	  	  	  	  	  	  	  	  	  (n=6)	   Perhexiline	  (n=3)	   P	  value	  
Apical	  
rotation	  
14.0	  	  	  	  	  	  	  	  	  	  	  	  	  (10.2	  –	  117.5)	   15.0	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (14.3	  –	  15.0)	   0.55	   15.0	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (7.8	  –	  18.4)	   14.8	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (8.1	  –	  14.8)	   1.0	  
Basal	  
Rotation	  	  
-­‐6.5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐7.8	  –	  -­‐3.8)	  	   -­‐11.9	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐16.9	  –	  	  -­‐11.9)	   0.02	   -­‐9.8	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐11.3	  –	  -­‐3.3)	   -­‐8.4	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐8.7	  –	  -­‐8.4)	   0.55	  
Twist	   19.3	  	  	  	  	  	  	  	  	  	  	  	  	  (14.6	  –	  25.7)	   30.1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (26.8	  –	  30.1)	   0.02	   22.4	  	  	  	  	  	  	  	  	  	  	  	  	  	  (12.3	  –	  27.6)	   23.3	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (5.4	  –	  23.3)	   1.0	  
Torsion	   2.3	  (1.7	  –	  3.2)	   4.2	  (3.8	  –	  4.2)	   0.02	   2.9	  (1.6	  –	  3.7)	   3.5	  (0.8	  –	  3.5)	   0.71	  
Peak	  Twist	   16.5	  	  	  	  	  	  	  	  	  	  	  	  	  	  (12.0	  –	  24.0)	   27.3	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (25.6	  –	  27.3)	   0.02	   20.9	  	  	  	  	  	  	  	  	  	  	  	  	  (12.8	  –	  26.8)	   21.9	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (12.1	  –	  21.9)	   1.0	  
Time	  to	  peak	  
twist	  
559	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (519	  –	  597)	   508	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (413	  –	  508)	   0.17	   510	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (454	  –	  540)	   466	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (78	  –	  466)	   0.26	  
Peak	  Untwist	   4.0	  (1.1	  –	  5.8)	   7.6	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐0.02	  –	  7.6)	   0.39	   4.9	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐1.0	  –	  108.7)	   95.4	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (6.6	  –	  95.4)	   0.26	  
Time	  to	  peak	  
untwist	  
843	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (708	  –	  932)	   778	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (704	  –	  778)	   0.79	   740	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (524	  –	  875)	   551	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (300	  –	  551)	   0.71	  
Systolic	   twist	  
rate	  S	  
97.5	  	  	  	  	  	  	  	  	  	  	  	  	  	  (69.5	  –	  116.6)	   169.2	  	  	  	  	  	  	  	  	  	  	  	  (145.1	  –	  169.2)	   0.02	   64.4	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐63.7	  –	  117)	   131.5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐61.3	  –	  131)	   0.71	  
Untwist	  rate	  E	   -­‐91.2	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐144.5	  –	  -­‐76.6)	   -­‐120.5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐180.4	  –	  -­‐120.5)	   0.91	   -­‐	  125.0	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐170.0	  –	  -­‐92.1)	   -­‐148.5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐207.8	  –	  148.5)	   0.91	  
Untwist	  rate	  A	   -­‐59.1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐84.1	  –	  -­‐45.8)	   -­‐120.1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐127.4	  –	  -­‐120.1)	   0.05	   -­‐79.8	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐95.8	  –	  -­‐74.8)	   -­‐83.3	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐107.0	  –	  -­‐83.3)	   1.0	  
GLS	   -­‐13.1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (15.8	  –	  -­‐10.8)	   -­‐14.4	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐17.2	  –	  -­‐14.4)	   0.55	   -­‐14.1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐15.2	  –	  -­‐9.6)	   -­‐14.5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐15.5	  –	  -­‐14.5)	   0.38	  
GLSR	  S	   -­‐0.73	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐1.03	  –	  -­‐0.63)	   -­‐1.04	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐1.04	  –	  -­‐1.04)	   0.10	   -­‐1.01	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐1.18	  –	  -­‐0.63)	   -­‐1.3	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (-­‐1.58	  –	  -­‐1.3)	   0.17	  
GLSR	  E	   0.88	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (0.78	  –	  1.13)	   1.22	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (1.0	  –	  1.22)	   0.17	   1.21	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (0.65	  –	  1.31)	   1.28	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (1.14	  –	  1.28)	   0.71	  
GLSR	  A	   1.11	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (0.87	  –	  1.43)	   1.06	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (0.95	  –	  1.06)	   1.0	   1.23	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (0.61	  –	  1.39)	   1.46	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (1.42	  –	  1.46)	   0.17	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Rotation,	  Peak	  twist	  and	  Peak	  untwist	  expressed	  in	  degrees	  (°);	  Torsion	  (°/cm);	  Time	  to	  peak	  twist	  and	  untwist	  (s);	  Twist	  rate	  (°/s);	  GLS,	  Global	  Longitudinal	  Strain	  (%);	  GLSR,	  Global	   Longitudinal	   Strain	   Rate	   (%/s)	   at	   systolic	   (S),	   passive	   (E)	   and	   active	   (A)	  relaxation.	  	  
5.3.5 MRS	  analysis	  	  
Of	   the	   10	   patients	   who	   entered	   this	   study,	   all	   patients	   underwent	   baseline	   MRS	  assessment.	  Of	  these,	  eight	  patients	  had	  both	  baseline	  and	  follow-­‐up	  scans	  performed,	  prior	  to	  their	  cardiac	  surgery	  for	  subsequent	  analysis.	  One	  patient	  was	  unable	  to	  attend	  for	  their	  second	  scan	  in	  time,	  and	  the	  other	  discontinued	  follow-­‐up	  testing	  (stopped	  IMP	  due	  to	  side-­‐effects).	  The	  PCr:ATP	  ratio	   for	  each	  of	   the	  eight	  participants	   is	  outlined	   in	  Figure	  5-­‐2.	  Subject	  number	  7	  shows	  a	  relatively	  greater	  increase	  in	  PCr:ATP	  ratio	  on	  the	  follow-­‐up	  scan.	  The	  other	   subjects	   show	  a	  consistent	  difference	   in	   ratios	  between	   the	  baseline	  and	  follow-­‐up	  scans.	  	  
	  








1	   2	   3	   4	   5	   6	   7	   8	  
Baseline	  FU	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The	  PCr:ATP	  ratios	   for	   the	  baseline	  and	   follow-­‐up	  scans	   for	  each	  treatment	  group	  did	  not	  show	  a	  normal	  distribution	  and	  this	  was	  consistent	  even	  after	   log	  transformation.	  Therefore	   analysis	  was	   performed	   using	   non-­‐parametric	   tests	   as	   outlined	   above.	   The	  median	   and	   interquartile	   range	   for	   PCr:ATP	   ratios	   at	   baseline	   and	   at	   follow-­‐up	   are	  outlined	  in	  Table	  5-­‐5.	  
	   Control	  (n=5)	   Perhexiline	  (n=3)	   P	  value	  
Baseline	  (median/IQR)	   1.17	  (1.07	  –	  1.45)	   0.78	  (0.74	  –	  0.78)	   0.571	  
Follow-­‐up	  (median/IQR)	   1.21	  (0.99	  –	  2.01)	   1.28	  (1.18	  –	  1.38)	   0.786	  
Table	  5-­‐5	  PCr:ATP	  ratios	  at	  baseline	  and	  follow-­‐up	  
Statistical	  analyses	  showed	  no	  difference	   in	  PCr:ATP	  ratios	  at	  baseline	  or	  at	   follow	  up	  between	  the	  groups.	  Subject	  7	  may	  have	  had	  a	  spurious	  result	   in	   their	  PCr:ATP	  ratios	  however,	  their	  spectra	  was	  within	  the	  parameters	  of	  CRLBs	  and	  hence	  analysable.	  	  	  
5.3.6 	  Six	  minute	  walk	  test	  	  




Table	  5-­‐6	  Baseline	  and	  follow-­‐up	  6-­‐mintue	  walk	  test	  	  
Statistical	  analysis	  showed	  no	  difference	  between	  the	  treatment	  and	  control	  groups	  at	  baseline.	  An	  expected	  increase	  in	  HR	  at	  the	  end	  of	  the	  6-­‐mintue-­‐walk	  test	  is	  evident	  as	  is	  a	  slight	  increase	  in	  the	  dyspnoea	  and	  fatigue	  status	  (measured	  using	  the	  Borg	  scale)	  at	  the	  end	  of	  the	  test	  compared	  to	  these	  findings	  before	  starting	  the	  walk	  test.	  Statistical	  analysis	   at	   follow-­‐up	  was	   futile	   due	   to	   the	   small	   sample	   size	   in	   the	   treatment	   arm	   at	  follow-­‐up.	  	  
5.4 Discussion	  	  
This	  study	  was	  designed	  to	  assess	  the	  impact	  of	  metabolic	  modulation	  with	  perhexiline	  on	   a	   homogenous	   group	   of	   patients	  with	   LVH	   secondary	   to	  AS	   by	   evaluation	   of	   their	  cardiac	   energetic	   status	   and	   functional	   capacity	   after	   an	   extended	   duration	   of	   IMP	  therapy.	  	  Perhexiline	  did	  not	  improve	  the	  cardiac	  energetic	  status	  and	  therefore	  showed	  no	  added	  benefit.	  Furthermore,	  through	  standard	  echocardiographic	  assessment,	  tissue	  Doppler	   imaging	  and	  speckle	   tracking	  echocardiography,	  perhexiline	   therapy	   failed	   to	  
	   	   	   	   	  
	   Baseline	   Follow-­‐up	  
	   Control	  	  	  	  	  	  	  	  (n=6)	   Perhexiline	  (n=3)	   Control	  	  	  	  	  	  	  	  	  (n=5)	   Perhexiline	  (n=1)	  
Baseline	  	  	  	  	  	  	  	  	  	  
Dyspnoea	  	  
0	  (0	  –	  3)	   0	  (0	  –	  0)	   0	  (0	  –	  1.25)	   1	  
End	  dyspnoea	   1.75	  (0	  –	  3.25)	   5	  (0.5	  –	  5)	   3	  (1	  –	  3.5)	   4	  
Baseline	  
Fatigue	  	  
0	  (0	  –	  3.25)	   0	  (0	  –	  2)	   0	  (0	  –	  1)	   2	  
End	  fatigue	   1	  (0	  –	  3.25)	   6	  (0	  –	  6)	   0	  (0	  –	  3.5)	   3	  
Baseline	  HR	   66	  (60	  –	  77)	   80	  (68	  –	  80)	   80	  (65	  –	  80)	   92	  
End	  HR	   89	  (75	  –	  109)	   104	  (88	  –	  104)	   88	  (76	  –	  102)	   92	  
Total	  distance	  	   450	  (396	  –	  468)	   324	  (324	  –	  324)	   403	  (350	  –	  438)	   364	  
	  5-­‐186	  
demonstrate	   an	   improvement	   in	   overall	   systolic	   and	   diastolic	   ventricular	   function.	  Functional	   exercise	   capacity	   assessment	  was	   inadequate	   to	   comment	   on	   the	   value	   of	  perhexiline	  therapy	  in	  this	  cohort.	  	  	  
In	   this	   study,	   the	   sample	   groups	   were	   disproportionate	   from	   the	   outset	   dictated	   by	  clinical	  urgency.	  There	  was	  limited	  tolerance	  to	  purse	  clinical	  experimentation	  when	  a	  subjects’	   clinical	   condition	   necessitated	   early	   surgery;	   symptomatic	   severe	   aortic	  stenosis	  which	  would	  otherwise	  be	  operated	  on	  urgently	  without	  delaying	  4	  weeks	  i.e.	  for	   trial	   therapy.	   	  However,	   this	  reflects	   the	  demands	  of	  a	  real	  world	  trial.	  These	  real-­‐world	   difficulties	   continued	   throughout	   this	   sub-­‐study;	   patients	   reluctant	   to	   attend	  follow-­‐up	   investigations,	   unwilling	   to	   continue	   taking	   IMP	  due	   to	   side	   effects	   and	   the	  inability	  to	  acquire	  an	  analysable	  spectrum	  despite	  multiple	  attempts.	  Recruitment	  was	  made	  more	  challenging	  as	  most	  subjects	  although	  being	  suitable,	  preferred	  to	  enter	  the	  main	   HYPER	   trial,	   which	   negated	   the	   need	   to	   take	   a	   prolonged	   duration	   of	   IMP	   (4	  weeks)	   or	   undergo	   any	   further	   experimental	   investigations.	   Furthermore	   the	   main	  HYPER	  trial	  was	  intrinsically	   linked	  to	  this	  sub-­‐study	  due	  to	  the	  same	  IMP	  and	  dosing	  regimes;	  therefore	  under	  the	  recommendation	  of	  the	  DSMB	  of	  the	  HYPER	  trial,	  this	  sub-­‐study	   too	   had	   to	   be	   halted	   due	   to	   the	   futility	   of	   the	   IMP	   being	   tested.	   This	   futility	  analysis	  is	  discussed	  in	  greater	  detail	  in	  the	  discussion	  chapter	  later	  in	  this	  thesis.	  	  
The	   three	  subjects	   in	   the	   treatment	  group	   that	  completed	   the	  FU	   investigations	  had	  a	  mean	  perhexiline	  concentration	  of	  0.20	  ±	  0.07,	  which	  fell	  within	  the	  therapeutic	  range	  albeit	   by	   a	   marginal	   0.05	   md/dL.	   It	   is	   possible	   that	   despite	   therapeutic	   levels,	   the	  duration	   of	   trial	   therapy	  was	   insufficient	   to	  maintain	   the	   patients	  within	   therapeutic	  levels	   for	   long	   enough	   for	   perhexiline	   to	   impart	   any	   change	   on	   the	   energetic	   or	  functional	   status.	   Lee	   at	   al	   who	   showed	   an	   improvement	   in	   functional	   status	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administered	   perhexiline	   for	   up	   to	   8	   weeks	   (Lee,	   Campbell	   et	   al.	   2005).	   Similarly	  Abozguia	  et	  al	  administered	  perhexiline	  for	  a	  prolonged	  duration	  with	  a	  mean	  follow-­‐up	  duration	   of	   4.6	   months	   and	   showed	   significant	   improvements	   in	   energetics	   and	  functional	   status	   in	   hypertrophic	   cardiomyopathy	   patients	   (Abozguia,	   Elliott	   et	   al.	  2010).	  	  
The	  GLS	  for	  patients	  with	  severe	  aortic	  stenosis	  in	  this	  study	  was	  calculated	  at	  between	  -­‐13.1	  and	  -­‐14.4,	  which	  is	  comparable	  to	  an	  earlier	  study	  assessing	  GLS	  in	  patients	  with	  aortic	   stenosis	   (Lafitte,	   Perlant	   et	   al.	   2009)	   and	   is	   also	   comparable	   to	   a	  more	   recent	  study	   examining	   GLS	   in	   asymptomatic	   AS	   patients	   (Donal,	   Thebault	   et	   al.	   2011).	  Kearney	   et	   al	   demonstrated	   that	   GLS	   deteriorated	   with	   increasing	   severity	   in	   aortic	  stenosis	  in	  patients	  with	  normal	  LV	  ejection	  fraction	  and	  correlated	  with	  LV	  mass	  index	  and	  symptom	  class.	  Furthermore,	  GLS	  was	  a	  strong	  independent	  predictor	  of	  all-­‐cause	  mortality	   (HR:	   1.38,	   p<0.001),	   supporting	   the	   value	   of	   GLS	   in	   identifying	   subclinical	  dysfunction	   (Kearney,	   Lu	   et	   al.	   2012).	   This	   may	   help	   identify	   optimal	   timing	   in	  operative	   intervention,	   not	   just	   in	   patients	   with	   aortic	   stenosis	   but	   even	   other	   heart	  pathologies.	   However	   the	   value	   of	   GLS	   and	   GLS	   rate	   to	   evaluate	   the	   change	   in	  ventricular	  function	  towards	  metabolic	  therapies	  is	  still	  novel	  and	  although	  perhexiline	  modulation	  in	  this	  study	  has	  not	  shown	  any	  change	  in	  this	  subtle	  marker	  of	  myocardial	  function,	  further	  experimental	  studies	  using	  GLS	  is	  warranted.	  	  
Previous	  work	   that	  has	  shown	   improvements	   in	  myocardial	  energetics	  and	   functional	  status	   using	   perhexiline	   as	   a	   metabolic	   modulator	   have	   been	   on	   subjects	   either	   in	  chronic	  heart	   failure	  or	   those	  with	  hypertrophic	  cardiomyopathy	  (Lee,	  Campbell	  et	  al.	  2005;	   Abozguia,	   Elliott	   et	   al.	   2010).	   In	   the	   study	   by	   Lee	   et	   al	   the	   baseline	   ejection	  fraction	   in	   patients	   with	   chronic	   heart	   failure	   was	   between	   20	   –	   30%,	   hence	   these	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patients	   may	   benefit	   most	   from	   metabolic	   modulation	   to	   improve	   their	   energetics,	  compared	  to	  the	  subjects	  in	  this	  cohort	  who	  despite	  having	  severe	  AS	  had	  near	  normal	  ventricular	   function.	   In	   a	   RCT	   conducted	   in	   our	   department,	   evaluating	   the	   role	   of	  perhexiline	   in	  patients	  with	  dilated	  cardiomyopathy	  (known	  to	  have	  severe	  metabolic	  derangement)	   with	   moderate	   to	   severe	   LV	   impairment,	   perhexiline	   showed	   an	  improvement	   in	   cardiac	   energetics;	   myocardial	   PCr/γATP	   ratio	   increased	   following	  treatment	  in	  the	  perhexiline	  group	  versus	  placebo	  from	  1.16±0.08	  to	  1.51±0.11	  versus	  1.38±0.07	  to	  1.34±0.07	  in	  the	  control	  P<0.0005	  (Beadle	  2013).	  However	  the	  anticipated	  improvements	   in	   cardiac	   function	   using	   2D	   and	   STE,	   including	   cardiac	   efficiency	   by	  invasive	   monitoring	   were	   not	   demonstrated.	   This	   study	   too	   followed	   a	   one-­‐month	  regime	  of	  perhexiline	  therapy,	  and	  this	  may	  have	  dictated	  the	  efficacy	  of	  perhexiline	  in	  showing	  benefit	  towards	  cardiac	  energetics.	  	  
This	  study	  further	  demonstrates	  the	  correlation	  between	  the	  metabolic	  and	  functional	  status	  of	  the	  heart	  to	  the	  clinical	  outcomes	  as	  evident	   from	  the	  main	  HYPER	  trial.	  The	  clinical	  outcomes	  as	  outlined	  in	  the	  main	  results	  chapter	  demonstrate	  no	  added	  clinical	  benefit	   with	   perhexiline	   in	   patients	   with	   LVH	   secondary	   to	   AS	   (discussed	   in	   further	  detail	  in	  the	  main	  discussion	  chapter).	  Similarly,	  given	  the	  limitations	  of	  this	  sub-­‐study,	  the	   energetic	   and	   functional	   assessments	   of	   these	   patients	   substantiate	   the	   clinical	  outcomes	  of	  perhexiline	  therapy.	  	  
This	   study	   is	   inherently	   limited	   by	   the	   sample	   size	   of	   the	   cohort	   studied.	   The	  recruitment	  target	  was	  34	  participants	  randomised	  1:1	  to	  perhexiline	  and	  control.	  This	  poor	  recruitment	  is	  in	  part,	  due	  to	  participants’	  being	  reluctant	  to	  undertake	  prolonged	  administration	   of	   trial	   therapy	   (4	   weeks)	   and	   attend	   baseline	   and	   follow-­‐up	  investigations	  prior	  to	  their	  surgery	  and	  also	  due	  to	  the	  main	  HYPER	  trial	  being	  halted	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due	  to	  futility,	  which	  prevented	  any	  further	  recruitment	  into	  this	  sub-­‐study	  due	  to	  the	  same	   IMP	  being	   used	   in	   both	   studies.	   	   Therefore	   this	   study	   lacks	   statistical	   power	   to	  infer	  strong	  conclusions	  on	  these	  end-­‐points.	  	  
In	   conclusion,	   MRS	   is	   a	   feasible	   mode	   of	   experimental	   investigation	   to	   assess	  myocardial	   energetics;	   in	   particular	   for	   those	   patients	   who	   are	   vulnerable	   and	   are	  known	   to	   have	   a	   diminished	   myocardial	   metabolic	   state	   and	   warrant	   metabolic	  modulation.	  Speckle	  tracking	  echocardiography	  remains	  a	   feasible	  and	  subtle	  mode	  of	  functional	   assessment.	   Perhexiline	   may	   remain	   a	   potential	   metabolic	   modulator	   in	  patients	  who	  are	  in	  heart	  failure	  refractory	  to	  standard	  medical	  therapy,	  and	  only	  in	  this	  group	  would	  it	  show	  maximum	  metabolic	  and	  clinical	  benefit.	  Cardiac	  energetic	  studies	  will	   help	   extrapolate	   cardiac	   function	   based	   on	   other	   clinical	   outcomes,	   in	   patients	  treated	  with	  an	  investigational	  medicinal	  product	  during	  clinical	  trials.	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6 A	  STUDY	  LOOKING	  AT	  METABOLOMIC	  ANALYSIS	  OF	  THE	  
MYOCARDIUM	  IN	  LEFT	  VENTRICULAR	  HYPERTROPHY	  
SECONDARY	  TO	  AORTIC	  STENOSIS	  
6.1 Introduction	  	  
The	   heart	   is	   a	   unique	   arrangement	   of	  muscular	   tissue	   that	   creates	   four	   chambers:	   2	  atria	  and	  2	  ventricles	   that	  are	  separated	  by	   the	  atrioventricular	  valves.	  The	  ventricles	  empty	   blood	   into	   the	   ventricular	   outflow	   tracts	   via	   the	   outflow	   tract	   valves.	   The	  pathophysiology	   of	   left	   ventricular	   hypertrophy	   is	   discussed	   in	   detail	   in	   the	  introductory	  chapter.	  In	  brief,	  obstruction	  of	  the	  left	  ventricular	  outflow	  tract	  by	  aortic	  stenosis	  exerts	  pressure	  overload	  on	  the	  left	  ventricle.	  In	  order	  to	  combat	  the	  excessive	  pressure	   the	   LV	   responds	   by	   hypertrophy,	   thereby	   changing	   the	   normal	   muscular	  structure	  of	  the	  heart.	  	  
6.1.1 Muscular	  structure	  of	  the	  heart	  	  
The	   muscular	   structure	   of	   the	   heart	   consists	   of	   three	   distinct	   layers:	   epicardium,	  myocardium	  and	  endocardium	  (Stevens	  and	  Lowe	  2001).	  The	  epicardium	  is	  the	  visceral	  pericardium	   of	   the	   heart	   and	   is	   a	   thin	   layer	   covered	   with	   flat	   mesothelial	   cells	   that	  produce	  a	  smooth	  outer	  surface.	  These	  cells	  lie	  on	  a	  stroma	  of	  fibrocollagenous	  support	  tissue	   that	  contains	  elastic	   fibres.	   In	  addition	   this	   layer	  contains	   the	  coronary	  arteries	  that	  provide	  blood	   to	   the	  heart	  wall	   and	   the	  venous	   tributaries	   that	   carry	  blood	   from	  the	  heart	  wall.	  The	  coronary	  arteries	  send	  branches	  deep	  into	  the	  myocardium.	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The	   myocardium	   makes	   up	   the	   bulk	   of	   the	   heart	   and	   is	   the	   contractile	   component	  composed	  of	  specialised	  striated	  skeletal	  muscle,	  which	  form	  a	  interconnecting	  network	  of	  myocardial	  fibres	  separated	  by	  loose	  fibrocollagenous	  tissue.	  The	  left	  ventricle	  deals	  with	   the	   majority	   of	   the	   workload,	   pumping	   blood	   into	   the	   high-­‐pressure	   systemic	  circulation	   and	   therefore	   the	   myocardial	   diameter	   of	   the	   LV	   is	   greater	   than	   other	  chambers	  of	  the	  heart.	  The	  outer	  surface	  of	  the	  myocardium	  beneath	  the	  epicardium	  is	  smooth	  however	   the	   internal	   surface	  beneath	   the	  endocardium	   is	   trebeculated	  and	   is	  most	   marked	   in	   the	   ventricle.	   	   These	   trabeculations	   are	   covered	   by	   the	   smooth	  endocardium.	  	  
The	   endocardium	   lines	   the	   internal	   surface	   of	   the	   heart	   and	   is	   composed	   of	   three	  separate	  layers;	  layer	  in	  direct	  contact	  with	  the	  myocardium,	  the	  middle	  layer	  and	  the	  innermost	   layer.	  The	   layer	   in	  contact	  with	  the	  myocardium	  is	  composed	  of	   irregularly	  arranged	   collagen	   fibres	   that	  merge	  with	   the	   collagen	   surrounding	   the	  muscle	   fibres	  within	  the	  myocardium.	  The	  middle	  layer	  is	  the	  thickest	  layer	  and	  is	  composed	  of	  more	  regularly	  arranged	  collagen	  fibres	  containing	  variable	  number	  of	  elastic	  fibres	  (compact	  and	  arranged	  in	  parallel).	  The	  innermost	  layer	  is	  composed	  of	  flat	  endothelial	  cells.	  The	  endocardium	  is	  the	  thinnest	  layer	  in	  the	  ventricle.	  	  
In	  hypertrophy	  there	  is	  an	  increase	  in	  the	  thickness	  of	  the	  myocardium.	  This	  occurs	  as	  a	  result	  of	  an	   increase	   in	   the	  number	  of	   sarcomeres	   in	   the	  cardiomyocyte.	  A	  sarcomere	  consists	   of	   a	   number	   of	   myofibrils	   that	   run	   in	   parallel,	   held	   in	   place	   by	   plates	   of	  accessory	   proteins;	   sarcomeres	   are	   the	   force	   generating	   units	   in	   the	   myocyte.	  	  Myofibrils	  are	  the	  contracting	  elements	  within	  the	  cardiomyocyte	  and	  are	  composed	  of	  overlapping	  thick	  myosin	  and	  thin	  actin	  filaments.	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6.1.2 Left	  ventricular	  hypertrophy	  and	  clinical	  implications	  	  
The	   clinical	   implications	   of	   LVH	   have	   been	   described	   extensively	   in	   the	   introductory	  chapter.	  LVH	  and	  concentric	  remodelling	  are	  well	  known	  risk	  factors	  for	  peri-­‐operative	  and	  midterm	  mortality	  (Orsinelli,	  Aurigemma	  et	  al.	  1993;	  Mehta,	  Bruckman	  et	  al.	  2001).	  In	  an	  editorial	  on	  LVH	  in	  aortic	  stenosis,	  Yotti	  and	  Bermejo	  conclude	  the	  LVH	  should	  no	  longer	  be	  considered	  only	  as	  a	  favourable	  adaptive	  mechanism	  to	  AS	  (Yotti	  and	  Bermejo	  2011).	   This	   editorial	   raises	   the	   controversial	   question	   on	   how	   and	   if	   the	   degree	   of	  hypertrophy	  should	   influence	   the	   timing	  of	   surgery	  and	   if	   so	  how	  should	   this	  be	  best	  measured.	   In	   a	   study	   by	   Cioffi	   et	   al,	   multivariate	   analysis	   proved	   that	   inappropriate	  increase	   in	   left	   ventricular	   mass	   was	   an	   independent	   predictor	   of	   outcome	   in	  asymptomatic	   patients	   with	   severe	   AS	   (Cioffi,	   Faggiano	   et	   al.	   2011)	   and	   this	  consolidates	  previous	   findings	  of	   a	  maladaptive	   response	  with	   systolic	   dysfunction	   in	  patients	  with	  LVH	  in	  AS	  (Kupari,	  Turto	  et	  al.	  2005).	  	  	  
In	   recent	   years	   LVH	   has	   been	   studied	   at	   a	   cellular	   level	   and	   Selvetella	   et	   al	   describe	  separate	   intracellular	   pathways	   for	   an	   adaptive	   and	   maladaptive	   response	   to	  hypertrophy	  (Selvetella,	  Hirsch	  et	  al.	  2004).	  Furthermore,	  there	   is	  evidence	  to	  suggest	  that	   in	  hypertrophy	   there	   is	   a	   less	  dense	   capillary	  bed	   (Tomanek,	  Palmer	  et	   al.	   1986;	  Weber	  and	  Brilla	  1991)	  and	  an	  increased	  diffusion	  distance	  for	  oxygen	  and	  metabolites	  from	   the	   capillaries	   to	   the	   myocyte	   (Bache,	   Vrobel	   et	   al.	   1981;	   Gosse	   and	   Clementy	  1995).	   These	   changes	   may	   in	   part,	   increase	   the	   susceptibility	   of	   the	   hypertrophic	  ventricle	   to	   the	   ischaemic	   insults	   during	   cardiac	   surgery.	   Fundamentally	   there	   is	   an	  increase	   in	   myocardial	   muscle	   mass	   with	   a	   thicker	   myocardium	   which	   is	   capable	   of	  dealing	  with	  pressure	  overload	  (Lorell	  and	  Carabello	  2000).	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Despite	   numerous	   evidence	   associating	   LVH	   to	   poor	   clinical	   consequences	   and	  outcomes	  (prior	  to	  or	  after	  cardiac	  surgery)	  there	  has	  yet	  been	  no	  study	  evaluating	  the	  molecular	   basis	   or	  metabolome	   of	   the	   hypertrophied	   heart	   muscle	   per	   se.	   Given	   the	  extent	   of	   hypertrophy	   and	   the	   pathophysiological	   changes	   the	   ventricle	   undergoes,	   it	  may	   be	   plausible	   that	   the	   metabolome	   may	   differ	   within	   the	   ventricle,	   from	   the	  epicardial	  to	  the	  endocardial	  surface.	  	  
6.1.3 Metabolomics	  	  
Metabolomics	   is	   the	   scientific	   study	   of	   the	   chemical	   processes	   that	   involve	   the	  metabolites	   of	   a	   cell	   or	   tissue	   and	   allows	   the	   study	   of	   the	   fingerprint	   that	   specific	  cellular	  processes	   leave	  behind	  (Griffin,	  Atherton	  et	  al.	  2011).	  A	  metabolome	  refers	  to	  the	  collection	  of	  all	   the	  metabolites	  within	  a	  specific	   tissue.	   	  Detection	  and	  analysis	  of	  these	   complex	   metabolites	   requires	   specific	   research	   tools.	   Mass	   Spectrometry	   and	  Nuclear	   Magnetic	   Resonance	   Spectroscopy	   (NMR)	   based	   metabolomics	   are	   the	   two	  main	  forms	  of	  metabolomic	  study.	  	  
NMR	   relies	   on	   the	   spin	   properties	   of	   the	   nuclei	   within	   a	   magnetic	   field,	   and	   the	  frequency	   at	   which	   a	   nucleus	   resonates	   is	   used	   to	   identify	   a	   particular	   chemical	  structure.	   	   Despite	   its	   advantages	   of	   being	   fast	   and	   reproducible	   mass	   spectrometry	  (MS)	  is	  more	  sensitive	  at	  identifying	  metabolites	  wth	  low	  biological	  concentrations.	  	  
There	  are	  two	  main	  forms	  of	  mass	  spectrometer	  based	  metabolomic	  analysis:	  Fournier	  Transform	  Ion	  Cyclotron	  Resonance	  (FT-­‐ICR)	  mass	  spectrometer	  and	  the	  Orbitrap	  mass	  spectrometer	   analysis.	   Mass	   spectrometry	   provides	   a	   spectrum	   of	   the	   metabolites	  within	   a	   tissue	   sample	   by	   identifying	   the	  mass	   to	   charge	   ratio	   (m/z)	   of	   positively	   or	  negatively	  charged	  ions	  and	  measures	  the	  abundance	  of	  these	  metabolites	  (Figure	  6-­‐1);	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each	   peak	   representative	   of	   a	  metabolite	   at	   a	   given	  m/z	   and	   the	   height	   of	   each	   peak	  reflective	  of	  the	  abundance	  of	  the	  metabolite	  (Southam,	  Payne	  et	  al.	  2007).	  	  	  
	  
Figure	  6-­‐1	  An	  example	  spectrum	  using	  FT-­‐ICR	  MS	  	  
The	   principle	   of	   achieving	   an	   optimum	   metabolomic	   analysis	   relies	   on	   high	   mass	  resolution	  and	  high	  mass	  accuracy;	  mass	  resolution	  refers	   to	   the	  ability	   to	  distinguish	  specific	  metabolites	  with	  a	  specific	  mass	  to	  charge	  ratio	  and	  mass	  accuracy	  refers	  to	  the	  approximation	   of	   the	  mass	  measured	   to	   the	   actual	  mass	   of	   the	  metabolite	   (Southam,	  Payne	  et	  al.	  2007).	  FT-­‐ICR	  offers	  a	  greater	  resolution	  of	  metabolites	  and	  an	  accuracy	  of	  <	  1ppm,	  hence	  superior	  to	  other	  forms	  of	  metabolomic	  analyses.	  This	  therefore	  narrows	  down	   the	   number	   of	   metabolites	   that	   can	   be	   identified	   at	   a	   given	   m/z,	   thereby	  increasing	  the	  metabolite	  identification	  rate.	  	  	  
“SIM-stitching” FT-ICR MS of liver extract
>3000 reproducible peaks measured in 5 min
• Maximum ass error 0.48 ppm
• Root mean square mass error 0.18 ppm
• Equivalent to ¼ mas  of a single electron
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With	   FT-­‐ICR	   mass	   spectrometry,	   mass	   is	   measured	   by	   detecting	   the	   image	   current	  produced	   by	   negatively	   or	   positively	   charged	   metabolites,	   cyclotroning	   within	   a	  magnetic	   field.	   	  Detectors	  at	   fixed	   locations	  measure	   the	  electrical	   signals	  of	   ions	   that	  pass	  near	  them	  over	  time,	  forming	  a	  periodic	  signal.	  The	  m/z	  ratio	  of	  an	  ion	  determines	  the	   frequency	  of	   the	   ion’s	  cycling.	  This	  allows	  each	   ion	   to	  be	  counted	  more	   than	  once	  and	   this	   increases	   the	   resolution	   of	   FT-­‐ICR	   MS.	   Extensive	   data	   processing	   is	   then	  required	  to	  analyse	  the	  spectra	  obtained.	  	  
With	  complex	  biological	  samples	  there	  are	  a	  large	  number	  of	  ions	  to	  be	  analysed,	  hence	  mass	  accuracy	  can	  be	  reduced.	  An	  analysis	  technique	  that	  uses	  selected	  ion	  monitoring	  (SIM),	  which	  records	  a	  series	  of	  spectrum	  with	  small	  mass	  ranges	  and	  then	  stiches	  these	  multiple	   SIM	   spectra,	   to	   generate	   a	   SIM	   stitched	   spectrum	   improves	   the	   overall	  sensitivity	   (Southam,	   Payne	   et	   al.	   2007).	   	   Further	   data	   processing	   and	   analysis	   takes	  place	   and	   this	   includes	   noise	   filtration,	   normalisation,	   generalized	   log-­‐transformation	  and	  application	  of	  false	  discovery	  rate	  during	  statistical	  analysis.	  	  
6.1.4 Metabolomics	  with	  cardiac	  tissue	  	  
Our	  group	  have	  conducted	  a	  number	  of	  preliminary	  unpublished	  studies	  to	  optimise	  the	  methodology	   and	   the	   technical	   aspects	   in	   tissue	   preparation	   of	   small	   cardiac	   tissue	  samples,	   and	   the	   subsequent	   data	   analysis.	   Following	   this,	   our	   group	   studied	   the	  metabolomic	  profile	  of	  LVH	  compared	   to	  non-­‐LVH	  cardiac	   tissue	   in	  humans	  and	  have	  shown	  a	  significant	  difference	  in	  the	  metabolomic	  profile	  between	  these	  groups	  p=7.91	  x	  105	  and	  0.0053	  in	  the	  positive	  and	  negative	  ion	  modes	  respectively	  (Howell	  2010).	  A	  subsequent	   study	   evaluated	   the	   metabolomic	   profile	   of	   human	   left	   ventricular	  myocardium	   and	   the	   impact	   on	   the	   metabolome	   after	   metabolic	   modulation	   with	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perhexiline.	   This	   latter	   study	   showed	   no	   difference	   in	   the	   metabolome	   following	  perhexiline	   therapy	   and	   concluded	   that	   perhexiline	   has	   no	   effect	   on	   the	   myocardial	  metabolome	  (Drury	  2012)	  
The	   aim	   of	   this	   study	  was	   to	   examine	   the	  metabolomic	   profile	   of	   the	  myocardium	   in	  LVH	  secondary	  to	  aortic	  stenosis	  by	  comparing	  the	  epicardial	  and	  endocardial	  halves	  of	  the	  left	  ventricle.	  Thereby	  distinguishing	  if	  there	  is	  an	  inherent	  metabolomic	  difference	  within	   the	   myocardium	   of	   the	   left	   ventricle,	   which	   could	   contribute	   towards	   the	  susceptibility	  to	  injury	  following	  cardiac	  surgery	  and	  its	  associated	  clinical	  outcomes.	  	  	  
6.2 Methods	  	  
6.2.1 Patient	  sample	  
Patients	  recruited	  into	  the	  HYPER	  trial	  were	  the	  subjects	  of	  this	  study	  and	  the	  patient	  cohort	  used	   in	   this	   study	  was	  a	   randomly	   selected	   sample.	  These	  patients	  underwent	  aortic	  valve	  replacement	  ±	  CABG	  for	  aortic	  stenosis	  and/or	  coronary	  artery	  disease.	  Left	  ventricular	  hypertrophy	  was	  a	  co-­‐existing	  pathophysiological	  response	  in	  these	  patients	  to	  long-­‐standing	  aortic	  stenosis.	  	  
6.2.2 Tissue	  extraction	  and	  preparation	  
Left	   ventricle	   (LV)	   free	   wall	   full	   thickness	   biopsies	   were	   obtained	   from	   non-­‐fibrotic	  areas	  between	  the	  left	  anterior	  descending	  artery	  and	  the	  first	  diagonal	  artery.	  This	  was	  performed	   using	   a	   Trucut	   biopsy	   needle	   (Allegiance	   Healthcare,	   McGaw	   Park,	   IL),	  immediately	   after	   institution	   of	   cardiopulmonary	   bypass	   and	   before	   the	   onset	   of	  ischaemia	  (placement	  of	  the	  aortic	  cross	  clamp).	  These	  biopsies	  were	  immediately	  split	  into	  equal	  endocardial	  and	  epicardial	  halves	  using	  a	  scalpel	  and	  placed	  into	  individual	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NUNC	  cryotubes	  and	  immediately	  snap	  frozen	  in	  liquid	  nitrogen	  and	  then	  stored	  in	  a	  -­‐80°C	  freezer	  until	  analysis.	  	  
6.2.3 Laboratory	  methodology	  	  
A	   detailed	   protocol	   for	   sample	   preparation	   and	   subsequent	   mass	   spectroscopy	   is	  outlined	   in	   Appendix	   9.15.	   This	   protocol	   has	   been	   optimised	   for	   extraction	   of	  metabolites	  from	  small	  LV	  biopsies	  (<	  10mg)	  and	  is	  a	  result	  of	  a	  number	  of	  preliminary	  studies	   designed	   to	   extract	   such	   metabolites.	   This	   methodology	   has	   been	   used	   in	  previous	   studies	   from	   our	   group	   for	  mass	   spectrometry	   based	  metabolomic	   analysis	  (Howell	  2010;	  Drury	  2012).	  	  	  
6.2.3.1 Sample	  preparation	  	  Metabolites	   were	   extracted	   from	   the	   cardiac	   tissue	   biopsies	   using	   a	  methanol:water:chloroform	   solvent	   system	   (Wu,	   Southam	   et	   al.	   2008).	   The	   polar	  fractions	   from	   each	   biphasic	   mixture	   were	   removed,	   dried	   using	   a	   centrifugal	  concentrator	   and	   stored	   at	   -­‐80°C	   for	   analysis.	   Subsequently,	   each	   dried	   polar	   extract	  was	   re-­‐dissolved	   in	   80:20	   methanol:water	   containing	   20mM	   ammonium	   acetate	   (for	  negative	  ion	  analysis),	  vortexed	  and	  centrifuged	  at	  10,000g	  prior	  to	  mass	  spectrometry	  (MS).	  Quality	  control	  (QC)	  samples	  were	  prepared	  by	  pooling	  an	  aliquot	  of	  each	  sample.	  
6.2.3.2 Mass	  spectroscopy	  	  MS	  analyses	  were	  conducted	  using	  a	  hybrid	  7-­‐Tesla	   linear	   ion	   trap	  Fourier	   transform	  ion	   cyclotron	   resonance	   (FT-­‐ICR)	   mass	   spectrometer	   (LTQ	   FT	   Ultra,	   Thermo	   Fisher	  Scientific,	  Germany)	  equipped	  with	  a	  Triversa	  chip-­‐based	  nanoelectrospray	  ion	  source	  (Advion	  Biosciences,	  NY)	  using	  conditions	  as	  described	  previously	  (Weber,	  Southam	  et	  al.	  2011).	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Three	   mass	   spectra	   for	   each	   sample	   were	   collected	   using	   a	   selected-­‐ion-­‐monitoring	  (SIM)	  stitching	  method	   from	  mass-­‐to-­‐charge	  ratio	   (m/z)	  70-­‐740	   in	  negative	   ion	  mode	  (Southam,	  Payne	  et	   al.	   2007;	  Weber,	   Southam	  et	   al.	   2011)	  processed,	  normalized	  and	  generalized-­‐log	   transformed	   as	   reported	   previously	   (Payne,	   Southam	   et	   al.	   2009;	  Hrydziuszko	  and	  Viant	  2011).	  This	  produced	  a	  peak	   intensity	  matrix	  representing	   the	  metabolic	  profile	  of	  each	  extracted	  biopsy.	  Using	  MI-­‐Pack	  software,	  m/z	  measurements	  were	  putatively	  annotated	  (Weber	  and	  Viant	  2010).	  
6.2.4 Statistical	  analysis	  
Student’s	  t-­‐tests	  were	  conducted	  on	  the	  non-­‐generalized	  log-­‐transformed	  peak	  intensity	  matrix,	   using	   a	   false	   discovery	   rate	   (FDR)	   of	   5%,	   to	   determine	   if	   individual	   peaks	  changed	   significantly	   between	   groups	   (Benjamini	   and	   Hochberg	   1995).	   In	   addition,	  principal	  components	  analyses	  (PCA)	  were	  conducted	  to	  discover	  metabolic	  differences	  between	  the	  sample	  groups.	  	  
6.3 Results	  	  
6.3.1 Sample	  group	  	  
Pre-­‐ischaemic	   left	   ventricular	   biopsies	   from	   10	   randomly	   selected	   patients	   were	  included	   in	   this	   study.	   The	   demographics	   and	   echocardiographic	   data	   of	   this	   patient	  cohort	   are	   outline	   in	   Table	   6-­‐1	   and	   Table	   6-­‐2	   respectively.	   Of	   the	   10	   patients,	   three	  patients	  were	   in	   the	  perhexiline	  group	  with	  perhexiline	   levels	  of	  0,	  0.08	  and	  0.27	  and	  hydroxy-­‐perhexiline	   levels	   of	  0,	   1.59	   and	  1.6	   respectively.	  Hence	   just	   one	  patient	  had	  therapeutic	   levels	   of	   perhexiline	   in	   their	   serum.	   	   Two	   patients	   had	   coronary	   artery	  disease	  and	  underwent	  concomitant	  AVR	  +	  CABG	  surgery.	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Variable	  (IQR)/(%)	   Sample	  size	  (n=10)	  
Age	   73	  (69	  –	  75)	  
BSA	  	   1.83	  (1.79	  –	  1.93)	  
Male:	  Female	  	   5:5	  (50:50)	  
Caucasian	   8	  (80)	  
Status	   	  -­‐	  Elective	   10	  (100)	  
EuroSCORE	   6	  (5.3	  –	  6.8)	  
Logistic	  EuroSCORE	   4.5	  (4.1	  –	  75.9)	  
CCS	  	   	  -­‐	  1	   6	  (60)	  -­‐	  2	   3	  (30)	  -­‐	  3	   1	  (10)	  
NYHA	   	  -­‐	  1	   2(20)	  -­‐	  2	   4	  (40)	  -­‐	  3	   3	  (30)	  -­‐	  4	   1	  (10)	  
Previous	  MI	   0	  (0)	  
Risk	  factors	   	  -­‐	  Hypercholesterolemia	  	   2	  (20)	  -­‐	  Hypertension	   4	  (40)	  
Medication	   	  -­‐	  ACE	   1	  (10)	  -­‐	  A2	   1	  (10)	  -­‐	  Statin	   5	  (50)	  -­‐	  β	  blocker	   0	  (0)	  
IABP	  pre	  surgery	   0	  (0)	  
Coronary	  artery	  disease	   2	  (20)	  
Table	  6-­‐1	  Demographic	  characteristics	  of	  the	  patient	  sample	  
Data	  are	  median	  (interquartile	  range)	  or	  N	  (%).	  BSA,	  Body	  surface	  area;	  CCS,	  Canadian	  Cardiovascular	  Society;	  NYHA,	  New	  York	  Heart	  Association;	  MI,	  Myocardial	   Infarction;	  ACE,	   Angiotensin	   Converting	   enzyme	   inhibitor;	   A2,	   Angiotensin	   II	   antagonist;	   IABP,	  Intra-­‐aortic	  Balloon	  Pump	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Variable	  (IQR/%)	   N	  =	  10	  
Ejection	  fraction	   63	  (60	  –	  68)	  
LVID	   3.6	  (3.5	  –	  4.1)	  
IVSd	   1.45	  (1.30	  –	  1.70)	  
PWd	   1.37	  (1.31	  –	  1.48)	  
Aortic	  valve	  Vmax	   4.43	  (4.11	  –	  5.08)	  
Valve	  area	   0.7	  (0.60-­‐	  0.79)	  
Peak	  Aortic	  Valve	  Gradient	  	   94	  (72	  –	  103)	  
Mean	  Aortic	  Valve	  Gradient	   45	  (40-­‐	  67)	  
Table	  6-­‐2	  Echocardiographic	  characteristics	  of	  the	  patient	  sample	  
Data	  are	  median	   (interquartile	   range)	  or	  N	   (%).	  LVEDV,	  Left	   ventricular	  end-­‐diastolic	  volume;	   LVID,	   Left	   ventricular	   internal	   diameter;	   IVSd,	   Intra-­‐ventricular	   septum	  thickness	   in	   diastole;	   PWd,	   Posterior	   wall	   diameter	   thickness	   in	   diastole;	   Vmax,	  Maximum	  velocity	  	  	  
Each	   epicardial	   and	   endocardial	   halve	   was	   normalised	   to	   achieve	   the	   least	   mass	  difference	  between	  them.	  This	  was	  achieved	  by	  shaving	  fractions	  of	  tissue	  to	  achieve	  an	  optimal	   mass.	   The	   mass	   of	   each	   epicardial	   and	   endocardial	   half,	   pre	   and	   post	  normalisation	  is	  outlined	  in	  Table	  6-­‐3.	  
	   	  
	  6-­‐201	  
	   LV	  mass	  
Before	  normalisation	  
	   LV	  mass	  
After	  normalisation	  
	  	   Epi	   Endo	   Delta	   	   Epi	   Endo	   Delta	  
1	   4.80	   3.00	   1.80	   	   4.80	   3.00	   1.80	  
2	   4.00	   3.10	   0.90	   	   4.00	   3.10	   0.90	  
3	   2.50	   2.80	   -­‐0.30	   	   2.50	   2.80	   -­‐0.30	  
4	   4.30	   4.20	   0.10	   	   4.30	   4.20	   0.10	  
5	   5.80	   7.30	   -­‐1.50	   	   5.80	   5.48	   0.33	  
6	   4.40	   7.20	   -­‐2.80	   	   4.40	   4.80	   -­‐0.40	  
7	   2.80	   3.00	   -­‐0.20	   	   2.80	   3.00	   -­‐0.20	  
8	   2.50	   7.00	   -­‐4.50	   	   2.50	   2.31	   0.19	  
9	   4.00	   9.00	   -­‐5.00	   	   4.00	   4.50	   -­‐0.50	  
10	   2.00*	   2.20	   -­‐0.20	   	   2.00*	   2.20	   -­‐0.20	  
	   	   	   	   	   	   	   	  Min	   2.00	   2.20	   -­‐5.00	   	   2.00	   2.20	   -­‐0.50	  
Max	   5.80	   9.00	   1.80	   	   5.80	   5.48	   1.80	  
Mean	   3.71	   4.88	   -­‐1.17	   	   3.71	   3.54	   0.17	  
Median	   4.00	   3.65	   -­‐0.25	   	   4.00	   3.05	   -­‐0.05	  
*Mass	  spectrometry	  analysis	  failed	  	  
Table	  6-­‐3	  LV	  mass	  of	  epicardial	  and	  endocardial	  halves	  before	  and	  after	  normalisation	  
6.3.2 Metabolomic	  analysis	  
Polar	   extracts	   from	   pre-­‐ischemia	   left	   ventricular	   biopsies	   were	   analysed	   from	   10	  patients.	  Epicardial	  and	  endocardial	  halves	  suitable	  for	  analysis	  were	  available	  in	  9	  and	  10	  patients	  respectively.	  	  
The	   final	   intensity	  matrix	  of	   the	  complete	  spectrum	  after	  data	  processing	  consisted	  of	  2020	  peak	  intensity	  measurements	  for	  each	  sample	  having	  incorporated	  a	  80%	  samples	  filter.	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All	   peaks	   were	   examined	   using	   univariate	   statistics	   to	   determine	   if	   any	   changed	  intensity	   significantly	   in	   response	   to	   perhexiline	   treatment.	   No	   significant	   peak	  intensity	   changes	   were	   found	   (FDR	   5%).	   In	   addition,	   there	   was	   no	   significant	   peak	  intensity	  changes	  found	  between	  the	  endocardial	  and	  epicardial	  halves	  with	  either	  un-­‐paired	  or	  paired	  student’s	  t-­‐tests	  with	  a	  5%	  FDR	  correction,	  as	  outlined	  in	  Table	  6-­‐4	  and	  Table	  6-­‐5	  respectively.	  	  
	   P-­‐value	  criteria	  
Number	  of	  m/z	  measurements	   <	  0.01	   <	  0.05	   <	  0.5	  
Before	  FDR	  correction	  at	  5%	   1	   12	   55	  
After	  FDR	  correction	  at	  5%	   0	   0	   0	  
Table	  6-­‐4	  Summary	  of	  m/z	  measurements	  changing	  significantly	  following	  unpaired	  Student’s	  t-­‐tests	  	  
	  
	   P-­‐value	  criteria	  
Number	  of	  m/z	  measurements	   <	  0.01	   <	  0.05	   <	  0.5	  
Before	  FDR	  correction	  at	  5%	   3	   30	   145	  
After	  FDR	  correction	  at	  5%	   0	   0	   0	  
Table	  6-­‐5	  Summary	  of	  m/z	  measurements	  changing	  significantly	  following	  paired	  Student’s	  t-­‐tests	  	  
m/z	  indicates	  mass-­‐to-­‐charge	  ratio;	  FDR,	  false	  discovery	  rate.	  
Multivariate	  PCA	  was	  used	   to	   reduce	   the	  dimensionality	  of	   the	  data	   and	  visualize	   the	  metabolic	  similarities	  and	  differences	  between	  the	  two	  groups.	  The	  PCA	  scores	  plot	  did	  not	  show	  any	  separation	  due	  to	  the	  difference	  in	  tissue	  location	  as	  illustrated	  in	  Figure	  6-­‐2.	  More	  than	  500	  m/z	  measurements	  in	  the	  FT-­‐ICR	  MS	  dataset	  were	  assigned	  (within	  ≤	   1.5	   ppm)	   and	   the	   following	   ion	   forms	   were	   used:	   [M-­‐H]-­‐,	   [M+K-­‐H2]-­‐,	   [M+Na-­‐H2]-­‐,	  [M+35Cl]-­‐,	  [M+37Cl]-­‐)	  to	  at	  least	  one	  putative	  named	  metabolite.	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6.3.3 Quality	  control	  	  
The	  median	  spectral	  relative	  standard	  deviation	  (RSD),	  which	  is	  a	  benchmark	  to	  assess	  the	  reproducibility	  in	  metabolomics	  (Tian,	  Musi	  et	  al.	  2001)	  was	  assessed.	  	  Each	  sample	  was	  analysed	  in	  triplicate	  by	  MS	  and	  the	  median	  spectral	  RSD	  was	  relatively	  small	  and	  consistent	  across	  all	  samples	  (mean	  10.8%,	  SD	  1.3%).	  The	  clustering	  of	  the	  QC	  samples	  in	   the	  PCA	  plot	  (Figure	  6-­‐2)	  demonstrates	   the	  consistency	   in	   instrument	  performance	  over	  time.	  	  
	  
Figure	  6-­‐2	  PCA	  scores	  plot	  from	  analysis	  of	  negative	  ion	  FT-­‐ICR	  mass	  spectra	  of	  left	  ventricular	  extracts	  	  
9	  epicardial	  samples	  (●)	  and	  10	  endocardial	  samples	  samples	  (●),	  show	  no	  separation	  along	  PC1	  and	  PC2	  axes.	  All	  five	  QC	  samples	  (●)	  are	  in	  a	  narrow	  cluster,	  confirming	  the	  consistency	  in	  MS	  instrument	  performance	  over	  time.	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6.4 Discussion	  	  
This	   study	   is	   a	  novel	  metabolomics	   analysis	  of	   the	  human	  myocardium	   that	  has	  been	  subjected	  to	  pressure	  overload	  hypertrophy	  secondary	  to	  aortic	  stenosis,	  and	  is	  the	  only	  study	   to	   evaluate	   the	   human	  myocardium	   using	  metabolomics	   to	   assess	   a	   change	   in	  metabolites	  based	  on	  location.	  This	  study	  has	  demonstrated	  that	  there	  is	  no	  difference	  in	   the	   metabolome	   of	   the	   hypertrophied	   myocardium	   between	   the	   epicardial	   and	  endocardial	  halves	  hence	  there	  is	  no	  difference	  in	  metabolome	  in	  the	  subendocardium.	  	  
Hypertrophy	  initially	  is	  a	  normal	  physiological	  response	  to	  deal	  with	  pressure	  overload	  i.e.	   allows	   for	   a	   reduction	   in	   systolic	   wall	   stress	   and	   maintains	   ejection	   fraction	  (Sasayama,	   Ross	   et	   al.	   1976;	   Grossman	   1980).	   However	   there	   is	   ample	   evidence	   to	  implicate	   hypertrophy	   with	   poor	   clinical	   outcomes.	   Poor	   clinical	   outcomes	   include	  greater	   risk	   of	   cardiac	   morbidity	   and	   mortality	   (Levy	   D,	   Salomon	   M	   et	   al.	   1994),	  increased	   ventricular	   ectopic	   activity	   (Messerli,	   Ventura	   et	   al.	   1984;	   McLenachan,	  Henderson	  et	  al.	  1987),	  and	  increased	  infarct	  size	  and	  greater	  mortality	  post	  myocardial	  infarction	   (Koyanagi,	   Eastham	   et	   al.	   1982).	   	   The	   underlying	  molecular	   basis	   for	   poor	  prognosis	  associated	  with	  LVH	  is	  unclear.	  	  
More	  pertinent	  to	  cardiac	  surgery,	  is	  the	  increased	  susceptibility	  of	  hypertrophic	  hearts	  to	   ischaemic	   injury	   and	   reperfusion	   (Kohya,	   Kimura	   et	   al.	   1988;	   Zhang	   and	   Xu	   1995;	  Minami,	  Gohra	  et	  al.	  2000).	  This	  might	  be	  in	  part	  due	  to	  hypertrophied	  hearts	  exhibiting	  a	   limited	   vasodilatory	   coronary	   reserve	   (Marcus,	   Doty	   et	   al.	   1982)	   and	   reduced	  subendocardial	   blood	   flow	   resulting	   in	   a	   transmural	   maldistribution	   of	   blood	   flow	  causing	  subendocardial	  ischaemia	  (Bache,	  Vrobel	  et	  al.	  1981;	  Bache,	  Vrobel	  et	  al.	  1981).	  Therefore	   the	  hypertrophic	  myocardium	  with	   these	   inherent	   limitations	  consequently	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has	  an	  altered	  metabolism	  (Sambandam,	  Lopaschuk	  et	  al.	  2002)	  with	  a	   	   reduced	   fatty	  acid	   metabolism,	   uncoupling	   of	   glycolysis	   and	   glucose	   metabolism	   and	   accelerated	  glycogen	  metabolism	  during	  ischaemia.	  	  
With	   hypertrophy,	   there	   is	   not	   only	   an	   increase	   in	   the	   number	   of	   sarcomeres	   per	  cardiomyocyte	   but	   also	   an	   increase	   in	   the	   extracellular	   matrix	   and	   surrounding	  architecture	   including	   the	  connective	   tissue,	   capillary	  and	  nerve	  networks	   (Lorell	  and	  Carabello	  2000).	  The	  connective	  tissue	  is	  mainly	  composed	  of	  collagen	  and	  this	  collagen	  network	  between	   the	  cardiomyocytes	   is	   responsible	   for	   the	   force	  generation	  between	  cardiomyocytes	   resulting	   in	   ventricular	   contraction	   and	   is	   also	   responsible	   for	   the	  passive	  diastolic	   stiffness	   (Weber,	   Sun	  et	  al.	  1994).	  However	  despite	   the	  changes	   that	  occur	  within	  the	  myocardium,	  coronary	  blood	  supply	  arises	  from	  the	  coronary	  arteries,	  which	  sit	  on	  the	  epicardium,	  with	  its	  branches	  and	  capillary	  networks	  flowing	  towards	  the	   endocardium.	   Canine	   studies	   have	   shown	   a	   reduction	   in	   both	   capillary	   numeric	  density	  and	  capillary	  volume	  density	  towards	  the	  endocardium	  (Tomanek,	  Palmer	  et	  al.	  1986).	   Moreover	   there	   is	   evidence	   for	   raised	   minimal	   coronary	   resistance	   with	  reduction	   in	   vascular	   density,	   reduced	   lumen	   size	   due	   to	   concentric	   vessel	   wall	  hypertrophy	   and	   extrinsic	   compression	   due	   to	   LVH	   (Gosse	   and	   Clementy	   1995)	  particularly	   affecting	   the	   endocardium.	   These	   features	   support	   the	   hypothesis	   that	  there	   is	   reduced	   oxygen	   delivery	   hence	   an	   impaired	   metabolism	   towards	   the	  endocardium	  and	  therefore	  the	  endocardial	  metabolome	  should	  be	  distinctly	  different	  from	  the	  epicardial	  metabolome.	  	  
A	   preliminary	   review	   on	   coronary	   blood	   flow	   in	   LVH,	   concluded	   that	   the	   transmural	  coronary	   blood	   flow	  was	   diminished	   particularly	   during	   exercise	   (Wicker	   and	   Tarazi	  1982)	  and	  these	  findings	  may	  be	  consist	  with	  subendocardial	  ischaemia	  on	  ECG,	  evident	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in	   patients	   with	   LVH	   exposed	   to	   stress.	   This	   alone	   may	   explain	   the	   neutral	   findings	  reported	   in	   this	   study,	   as	   the	   tissue	   analysed	   was	   obtained	   prior	   to	   the	   insult	   of	  ischaemia	   and	  without	   imposing	   any	   additional	   stress	   on	   the	  myocardium.	   Therefore	  the	  metabolism	  within	  the	  myocardial	  halves	  may	  not	  have	  changed	  enough	  to	  project	  a	  difference	   in	   their	  metabolome.	   Furthermore	   this	   cohort	   of	   patients	   had	   no	   previous	  myocardial	   infarction	   and	   had	   good	   ventricular	   function,	   hence	   was	   less	   vulnerable	  even	  prior	  to	  ischaemia.	  	  
Another	  paradigm	  in	  LVH	  is	  the	  extent	  and	  impact	  of	  ventricular	  fibrosis	  (Weber,	  Janicki	  et	  al.	  1990;	  Weber	  and	  Brilla	  1991),	  a	  feature	  that	  is	  part	  of	  the	  pathological	  process	  of	  hypertrophy	   and	   implicated	   in	   the	   failing	   hypertrophic	   heart	   (Villari,	   Campbell	   et	   al.	  1993).	  This	   is	   evident	   initially	   as	  diastolic	  dysfunction	  and	   subsequently	  manifests	   as	  systolic	  dysfunction	  (Lorell	  and	  Carabello	  2000;	  Hein,	  Arnon	  et	  al.	  2003)	  and	  eventually	  heart	   failure.	   Although	   these	   features	   may	   well	   have	   been	   present	   in	   this	   cohort,	  assessment	  of	  myocardial	  fibrosis	  was	  not	  conducted;	  hence	  its	  impact	  on	  the	  epicardial	  and	  endocardial	  metabolome	  cannot	  be	  assessed.	  	  
This	   sample	   group	   was	   selected	   randomly	   to	   avoid	   any	   selection	   bias	   towards	   the	  degree	   of	   hypertrophy.	   Echocardiographic	   quantification	   of	   this	   cohort	   shows	   a	  moderate	  degree	  of	  LVH.	  Due	  to	  the	  random	  selection,	  there	  were	  three	  patients	  from	  within	   the	   treatment	   arm	   of	   the	   HYPER	   trial	   and	   had	   received	   perhexiline	   therapy,	  however	   only	   one	   patient	   was	   marginally	   within	   the	   therapeutic	   range.	   Drury	   et	   al	  demonstrated	  in	  patients	  with	  ischaemic	  heart	  disease,	  that	  perhexiline	  therapy	  has	  no	  impact	  on	  the	  metabolome	  (Drury	  NE,	  Howell	  NJ	  et	  al.	  2014),	  hence	  perhexiline	  therapy	  should	   not	   impact	   on	   the	   evaluation	   of	   the	   metabolome	   between	   epicardial	   and	  endocardial	  halves.	  Furthermore	  this	  cohort	  had	  two	  patients	  with	  IHD	  who	  underwent	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concomitant	   AVR+CABG	   surgery.	   Patients	   with	   IHD	   in	   the	   setting	   of	   LVH	   should	  theoretically	   have	   a	   more	   deranged	   metabolism	   in	   comparison	   to	   LVH	   alone;	   these	  patients	  have	  made	  the	  epicardial	  and	  endocardial	  metabolome	  heterogeneous	  and	  its	  impact	  is	  difficult	  to	  quantify	  through	  this	  study	  alone.	  	  
This	  study	  is	  limited	  by	  the	  small	  sample	  size	  and	  although	  there	  is	  no	  statistical	  test	  or	  power	   calculation	   to	   infer	   an	   adequate	   sample	   size	   for	   such	   a	   study	   (Nyamundanda,	  Gormley	   et	   al.	   2013),	   further	   evaluation	   with	   a	   larger	   sample	   size	   may	   prove	   more	  reassuring.	  The	  laboratory	  methodology	  used	  in	  the	  study	  to	  deal	  with	  small	  ventricular	  biopsies	   and	   tissue	   samples	   had	   been	   previously	   optimised.	   However,	   this	   is	   an	  inherent	   limitation	   and	   dealing	   with	   such	   small	   tissue	   samples	   can	   prove	   to	   be	  technically	  challenging	  albeit	   the	  quality	  control	  analysis	  shows	  consistency.	  Although	  the	   intension	   is	   to	   obtain	   a	   full	   thickness	   left	   ventricular	   biopsy	   this	   too	   can	   be	  technically	   challenging	   on	   a	   beating	   heart	   pre	   ischaemia	   and	   as	   a	   consequence	   the	  epicardial	  and	  endocardial	  portions	  may	  not	  be	  split	  exactly	  in	  half.	  	  
This	   study	   examined	   the	   hypertrophic	   myocardium	   prior	   to	   an	   ischaemic	   insult	  (placement	   of	   the	   aortic	   cross	   clamp).	   Further	   assessment	   of	   the	  myocardium	  after	   a	  period	  of	   ischaemia	  and	  subsequent	  reperfusion	  with	  comparison	  between	  these	  time	  points	   may	   give	   insight	   into	   the	   metabolomic	   changes	   that	   take	   place	   with	  ischaemia/reperfusion	   and	   could	  help	   elucidate	   the	   susceptibility	   of	   the	  hypertrophic	  heart	   to	   these	   insults.	   Furthermore	  metabolomic	   studies	   on	   different	   heart	   chambers	  and	   other	   pathological	   settings	   i.e.	   volume	   overload	   hypertrophy	   can	   help	   create	   a	  metabolome	  for	  the	  spectrum	  of	  heart	  disease.	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In	   conclusion	  metabolomic	   assessment	   of	   the	   human	  pressure	   overload	   hypertrophic	  myocardium	   does	   not	   show	   a	   change	   in	   metabolome	   between	   the	   epicardial	   and	  endocardial	   portions.	   The	   metabolomic	   differences	   that	   may	   exist	   are	   subtle	   hence	  further	   studies	   are	   warranted	   to	   examine	   the	   metabolome	   of	   the	   hypertrophic	  myocardium.	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7 A	  STUDY	  OF	  KEY	  REGULATORS	  INVOLVED	  IN	  CARDIAC	  
METABOLISM	  AND	  THEIR	  ROLE	  IN	  LOW	  CARDIAC	  OUTPUT	  
EPISODES	  DURING	  CARDIAC	  SURGERY	  
7.1 Introduction	  
Cardiac	  metabolism	  is	  controlled	  by	  a	  host	  of	  different	  mechanisms	  of	  which	  some	  are	  affected	  by	  the	  process	  of	  ischaemia	  and	  reperfusion.	  During	  cardiac	  surgery	  the	  insults	  of	   ischaemia-­‐reperfusion	   are	   inevitable	   due	   to	   the	   nature	   of	   the	   procedural	  requirements	   such	   as	   elective	   myocardial	   arrest.	   This	   renders	   some	   individuals	  susceptible	   to	   myocardial	   injury	   that	   is	   clinically	   projected	   as	   a	   low	   cardiac	   output	  episode.	   Key	   regulators	   of	   myocardial	   metabolism	   may	   be	   involved	   in	   this	   clinical	  outcome.	  	  
7.1.1 Acetyl	  CoA	  carboxylase	  	  
Acetyl	  CoA	  Carboxylase	  (ACC)	  is	  a	  critical	  enzyme	  that	  regulates	  fatty	  acid	  synthesis	  and	  degradation	  (Berg,	  Tymoczko	  et	  al.	  2012)	  and	  is	  subjected	  to	  both	  local	  and	  hormonal	  regulation.	  Phosphorylation	  by	  AMP-­‐activated	  protein	  kinase	   (AMPK)	   inactivates	  ACC,	  while	  dephosphorylation	  by	  protein	  phosphatase	  1	   (PP1)	   activates	   it	   (Figure	  7-­‐1).	  As	  the	  activity	  of	  AMPK	  is	  modulated	  by	  AMP	  and	  ATP,	  cellular	  energy	  levels	  can	  directly	  influence	   the	   activity	   of	   ACC	   (Figure	   7-­‐2).	   The	   extent	   of	   ACC	   phosphorylation	   can	  therefore	   act	   as	   a	   surrogate	   marker	   for	   AMPK	   activity	   and	   therefore	   the	   cellular	  response	  to	  energy	  stress.	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Figure	  7-­‐1	  ACC	  activation	  and	  inactivation	  
The	   acetyl-­‐CoA	   carboxylase	   reaction	   forms	  malonyl-­‐CoA	   through	   the	   carboxylation	   of	  acetyl-­‐coA.	   Malonyl-­‐CoA	   is	   a	   potent	   endogenous	   inhibitor	   of	   carnitine	   palmitoyl	  transferase	  (CPT),	  a	  key	  regulator	  of	  free	  fatty	  acid	  (FFA)	  uptake	  into	  the	  mitochondrion	  (Stanley,	   Recchia	   et	   al.	   2005).	   It	   follows	   therefore	   that,	   through	   the	   production	   of	  malonyl-­‐CoA,	   ACC	   acts	   as	   a	   regulator	   of	  mitochondrial	   FFA	   degradation.	  Hence	  when	  energy	   levels	  are	  high,	  FFA	  oxidation	   is	   inhibited	  by	  malonyl-­‐CoA.	  ACC	  activity	   is	  also	  stimulated	   by	   insulin	   and	   inhibited	   by	   glucagon	   and	   adrenaline.	   The	   latter	   hormonal	  control	   is	  a	   response	   to	  allow	   fatty	  acid	  degradation	  rather	   than	  synthesis	   in	   times	  of	  need.	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Figure	  7-­‐2	  Control	  mechanisms	  of	  ACC	  
Activation	  of	  AMPK	  will	   inhibit	  ACC,	   in	   turn	   reducing	  malonyl-­‐CoA	  production,	  which	  results	  in	  increased	  FFA	  oxidation	  (Stanley,	  Recchia	  et	  al.	  2005).	  A	  rat	  animal	  model	  has	  shown	   a	   chronic	   increase	   in	   AMPK	   activity	   with	   LV	   hypertrophy	   produced	   by	   aortic	  banding	   (Tian,	   Musi	   et	   al.	   2001)	   and	   suggested	   that	   AMPK	   activity	   may	   play	   an	  important	   role	   in	   respiratory	   substrate	   utilisation.	   Furthermore,	   mutations	   in	   AMPK	  that	   lead	   to	   its	   constitutive	   activation	   has	   been	   shown	   to	   result	   in	   abnormalities	   in	  carbohydrate	   utilisation	   causing	   glycogen	   storage,	   consistent	   with	   hypertrophic	  cardiomyopathy	   (Arad,	   Benson	   et	   al.	   2002),	   making	   the	   myocardium	  more	   prone	   to	  arrhythmias	   such	   as	  Wolff-­‐Parkinson-­‐White	   syndrome	   (Arad,	  Moskowitz	   et	   al.	   2003).	  AMPK	  activity	  is	  also	  known	  to	  influence	  glucose	  transporter	  translocation	  and	  glucose	  uptake	  (Stanley,	  Recchia	  et	  al.	  2005),	  therefore	  giving	  it	  a	  central	  role	  through	  its	  ability	  to	   control	   both	   carbohydrate	   and	   FFA	   metabolism	   in	   order	   to	   meet	   the	   metabolic	  demands	  of	  the	  heart.	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7.1.2 Glycogen	  synthase	  kinase-­‐3	  
Glycogen	  synthase	  kinase-­‐3	  (GSK-­‐3)	  belongs	  to	  a	  family	  of	  serine/threonine	  kinases	  and	  in	  humans	  2	   isoforms	  of	  GSK-­‐3	  exist:	  GSK3α	  and	  GSK3β	  (Hardt	  and	  Sadoshima	  2002).	  GSK3β	   is	  ubiquitously	  expressed,	  and	   is	   therefore	  present	   in	  cardiomyocytes,	  and	  has	  been	  more	   extensively	   studied.	   This	   enzyme	  was	   initially	   identified	   as	   a	   regulator	   of	  glycogen	  synthesis	  by	  phosphorylating	  glycogen	  synthase,	   thereby	   inhibiting	  glycogen	  synthesis	   (Embi,	   Rylatt	   et	   al.	   1980;	   Parker,	   Caudwell	   et	   al.	   1983).	   However	   more	  recently	  there	  is	  evidence	  for	  the	  multifaceted	  roles	  of	  GSK3β	  which	  include	  other	  areas	  of	  metabolism,	   as	  well	   as	   the	   regulation	  of	   gene	  expression	  and	   cytoskeletal	   integrity	  (Grimes	  and	  Jope	  2001)	  
In	   general,	   the	   result	   of	   GSK3β	   phosphorylation	   of	   its	   substrates	   is	   their	   inhibition.	  Therefore	   inactivation	   of	  GSK3β	   results	   in	   upregulation	   of	   the	  downstream	   signalling	  mechanisms	   (Hardt	   and	   Sadoshima	   2002).	   Inactivation	   of	   GSK3β	   is	   through	  phosphorylation	  by	  upstream	  protein	  kinases,	  of	  which	  protein	  kinase	  B	  (AKT)	   is	  one	  that	   is	   most	   thoroughly	   studied.	   AKT	   is	   a	   major	   protein	   kinase	   downstream	   from	  phosphatidylinositol	   3-­‐kinase	   (PI3K).	   Therefore	   any	   stimuli	   that	   activate	   PI3K	   will	  inactivate	  GSK3β	  through	  AKT	  (Figure	  7-­‐3).	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Figure	  7-­‐3	  Mechanism	  for	  GSKβ	  inactivation	  
Stimuli	   known	   to	   activate	   the	   PI3K-­‐AKT	   pathway	   include	   β-­‐adrenergic	   stimulation	  (Morisco,	  Zebrowski	  et	  al.	  2000)	  and	  other	  cardiac	  hypertrophic	  stimuli	  (endothelin-­‐1,	  Fas,	   pressure	   overload)	   (Haq,	   Choukroun	   et	   al.	   2000;	   Badorff,	   Ruetten	   et	   al.	   2002).	  	  Apart	  from	  the	  PI3K-­‐AKT	  pathway,	  other	  pathways	  known	  to	  inactivate	  GSK3β	  include	  the	  Wnt	  signalling	  pathway	  (Hardt	  and	  Sadoshima	  2002).	  In	  addition	  insulin	  signalling	  through	  the	  PI3K	  pathway	  is	  also	  thought	  to	  inactive	  GSK3β	  (Jonassen,	  Sack	  et	  al.	  2001)	  and	   inactivation	   via	   the	   Wnt	   pathway	   is	   thought	   to	   act	   distinctly	   differently	   to	  inactivation	  by	  insulin.	  	  
Furthermore	   GSK3β	   has	   shown	   to	   play	   a	   crucial	   role	   in	   the	   development	   of	   cardiac	  hypertrophy	  by	  imparting	  a	  negative	  influence	  towards	  hypertrophy.	  (Haq,	  Choukroun	  et	   al.	   2000;	  Antos,	  McKinsey	   et	   al.	   2002;	  Badorff,	  Ruetten	   et	   al.	   2002).	   Inactivation	  of	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GSK3β	  by	  phosphorylation	  of	  Ser9	  via	  the	  PI3K/AKT	  pathway	  due	  to	  activation	  of	   the	  hypertrophic	  program	  (stimulation	  of	  β-­‐adrenergic	  receptors,	  Gq-­‐coupled	  receptors	  and	  Fas	   receptors)	   leads	   to	   hypertrophy.	   Hardt	   and	   Sadoshima	   in	   their	   review	   of	   GSK3β	  speculate	   on	   the	   evidence	   of	   transcription	   signalling	   mechanisms,	   and	   that	   the	  PI3K/PKB/AKT/GSK3β	  pathway	  may	  be	  as	  important	  as	  the	  Mitogen	  Activated	  Protein	  Kinase	  (MAPK)	  signalling	  pathway	   in	  some	  types	  of	  hypertrophy	  and	  can	  play	  a	  more	  dominant	   role	   in	   β-­‐adrenergic	   cardiac	   hypertrophy	   (Haq,	   Choukroun	   et	   al.	   2000;	  Badorff,	  Ruetten	  et	  al.	  2002;	  Hardt	  and	  Sadoshima	  2002).	  	  
Moreover,	  GSK3β	  may	  also	  have	  a	  role	  in	  protein	  synthesis	  during	  cardiac	  hypertrophy,	  working	   together	   with	   other	   molecules	   downstream	   from	   PI3K/AKT	   (Hardt	   and	  Sadoshima	   2002).	   GSK3β	   may	   also	   be	   involved	   in	   cell	   survival	   and	   regulation	   of	  apoptosis,	  whereby	  the	  degree	  of	   influence	  may	  depend	  on	  the	  cell	   type	  and	  extent	  of	  GSK3β	  inactivation.	  Activation	  of	  PI3K/Akt	  has	  shown	  to	  be	  cardioprotective	  (Matsui,	  Li	  et	  al.	  1999)	  and	  may	  be	  associated	  with	  GSK3β	  inactivation.	  Tong	  et	  al	  have	  shown	  that	  phosphorylation	  of	  GSK3β	  through	  the	  PI3K/Akt	  pathway	  during	  pre-­‐conditioning,	  has	  proven	  to	  have	  cardioprotective	  effects	  during	  ischaemia	  (Tong,	  Imahashi	  et	  al.	  2002).	  Despite	  these	  initial	  preliminary	  studies,	  there	  is	  no	  evidence	  that	  elucidates	  the	  distinct	  role	  of	  GSK3β	  in	  the	  human	  myocardium,	  in	  particular	  the	  role	  of	  GSK3β	  on	  growth	  and	  death	   of	   cardiac	   myocytes	   (Hardt	   and	   Sadoshima	   2002).	   However	   a	   review	   by	  Juhaszova	  and	  colleagues	  has	  elaborated	  on	  the	  distinct	  cardioprotective	  role	  of	  GSK3β	  (Juhaszova,	  Zorov	  et	  al.	  2009).	   It	   is	   thought	  that	  GSK3β	  acts	  as	  an	   integration	  point	  of	  many	  cardioprotective	  signalling	  pathways	  and	  signals	  downstream	  to	  GSK3β	  act	  at	  or	  near	  to	  the	  mitochondrial	  permeability	  transition	  pore	  (mPTP),	  a	  protein	  complex	  that	  has	  been	  highlighted	  as	  a	  key	  element	  in	  reperfusion	  injury.	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Insulin	  has	  been	  associated	  in	  playing	  a	  role	  in	  reperfusion	  injury	  salvage	  kinases	  such	  as phosphatidylinositol	   3-­‐kinase	   (PI3K)/protein	   kinase	   B	   (AKT)	   pathways	   (Bertrand,	  Horman	   et	   al.	   2008)	   and	   AMP-­‐activated	   protein	   kinase	   (AMPK),	   may	   have	   a	   role	   in	  cardioprotection	  (Hausenloy	  and	  Yellon	  2007).	   	  As	  part	  of	  a	  clinical	   trial,	  Howell	  et	  al.	  evaluated	   the	   impact	   of	   GIK	   therapy	   in	   patients	  with	   left	   ventricular	   hypertrophy	   on	  AKT	  and	  AMPK	  phosphorylation	  due	  to	  their	  well-­‐described	  effects	  of	  insulin	  signalling	  (Howell,	  Ashrafian	  et	   al.	   2011).	  They	   showed	  an	   increase	   in	  phosphorylated	  AKT	  and	  AMPK,	   postulating	   that	   this	   up-­‐regulation	   was	   associated	   with	   clinically	   correlative	  cardioprotective	  effects	  of	  GIK.	  	  	  
This	   study	   aims	   to	   establish	   whether	   the	   activation	   state	   of	   AMPK	   and	   AKT	   in	   the	  myocardium	   before	   cardiac	   surgery	   can	   be	   correlated	   with	   incidence	   of	   low	   cardiac	  output	  episode	  following	  surgery.	  The	  phosphorylation	  of	  ACC	  was	  used	  as	  a	  surrogate	  marker	   for	   AMPK	   activity,	   while	   the	   phosphorylation	   state	   of	   GSK3β	   was	   used	   to	  determine	  PI3K/AKT	  pathway	  activity.	  	  
7.2 Methods	  	  
7.2.1 Patient	  sample	  	  
Patients	  recruited	   into	  the	  HYPER	  trial	  were	  the	  subjects	  of	   this	  study.	  These	  patients	  underwent	   aortic	   valve	   replacement	   ±	   CABG	   for	   aortic	   stenosis	   ±	   coronary	   artery	  disease.	  Left	  ventricular	  hypertrophy	  was	  a	  co-­‐existing	  pathophysiological	  response	  in	  these	  patients	  to	  long-­‐standing	  aortic	  stenosis.	  	  
In	   the	   initial	   six	   hours	   post	   reperfusion	   (removal	   of	   the	   aortic	   cross	   clamp),	  haemodynamic	  parameters	  of	  these	  patients	  were	  optimised	  and	  a	  potential	  low	  cardiac	  output	  episode	  treated	  as	  outlined	  in	  section	  2.11.4	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A	  blinded	  end-­‐points	  committee	  adjudicated	  on	  patients	  that	  met	  the	  criteria	  for	  a	  low	  cardiac	   output	   episode	   (LCOE).	   A	   low	   cardiac	   output	   episode	   was	   defined	   as	  hypotension	   (MAP	   <60)	   with	   a	   cardiac	   index	   <	   2.2	   L/min/m2,	   in	   the	   presence	   of	  adequate	  filling	  pressures	  (CVP	  8-­‐12	  mmHg,	  PCWP	  12–16	  mmHg)	  and	  heart	  rate	  of	  70-­‐110bpm;	   refractory	   to	   appropriate	   intra-­‐vascular	   volume	   expansion	   and	   following	  correction	  or	  attempted	  correction	  of	  any	  dysrhythmias.	  
Five	  patients	  who	  sustained	  a	  LCOE	  and	  five	  that	  did	  not	  within	  the	  placebo	  arm	  of	  the	  HYPER	  trial	  were	  identified	  at	  random,	  for	  the	  following	  analyses.	  	  
7.2.2 Tissue	  extraction	  and	  preparation	  
Left	   ventricle	   (LV)	   free	   wall	   full	   thickness	   biopsies	   were	   obtained	   from	   non-­‐fibrotic	  areas	  between	  the	  left	  anterior	  descending	  artery	  and	  the	  first	  diagonal	  artery.	  This	  was	  performed	   using	   a	   Trucut	   biopsy	   needle	   (Allegiance	   Healthcare,	   McGaw	   Park,	   IL),	  immediately	  after	  institution	  of	  cardiopulmonary	  bypass	  before	  the	  onset	  of	  ischaemia	  (placement	  of	  the	  aortic	  cross	  clamp).	  The	  tissue	  obtained	  was	  immediately	  snap	  frozen	  in	  liquid	  nitrogen	  and	  then	  stored	  in	  an	  -­‐80°C	  freezer	  until	  analysis.	  	  
7.2.3 Laboratory	  methods	  	  
Tissue	   samples	  obtained	  as	  outlined	  above	  were	   lysed	   in	  RIPA	  buffer	  using	  a	  Cryolys	  system.	   Protein	   content	   of	   the	   samples	   was	   assessed	   using	   a	   BCA	   Protein	   Assay	   Kit	  (Novagen,	  USA)	  according	  to	  the	  manufacturer’s	  protocol.	  Samples	  were	  then	  diluted	  to	  a	   standard	   protein	   concentration	   in	   Laemmli	   Buffer	   before	   boiling	   for	   10	   minutes	  followed	   by	   a	   brief	   (5	   second)	   centrifugation.	   	   Samples	   were	   then	   analysed	   using	  western	  blotting.	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7.2.4 Western	  blot	  analysis	  
For	   western	   blotting,	   20μl	   of	   sample	   and	   10μl	   of	   protein	   weight	   marker	   (Thermo	  Scientific)	   were	   resolved	   using	   sodium	   dodecylsulphate	   (SDS)	   polyacrylamide	   gel	  electrophoresis	  with	  8%	  or	  10%	  gels	  where	  appropriate.	  	  
Gels	   were	   subjected	   to	   100V	   constant	   current	   in	   SDS	   Tris-­‐glycine	   running	   buffer	   to	  resolve	   proteins,	   which	   were	   then	   transferred	   onto	   nitrocellulose	   membrane	  (Amersham	  Hybond-­‐ECL,	  GE	  Healthcare)	  using	  the	  wet	  transfer	  system	  (BioRad)	  using	  100V	   constant	   current	   for	   1	   hour.	   Membranes	  were	   then	   blocked	  with	   PBST	   (PBS	   +	  0.1%	  Tween-­‐20)	  with	  non-­‐fat	  dried	  skimmed	  milk	  powder.	  Membranes	  were	  incubated	  with	   anti-­‐phospho-­‐GSK3β	  or	   anti-­‐phospho-­‐ACC	  primary	   antibody	   (1:1000	   in	  5%	  BSA,	  Cell	  Signalling)	  with	  gentle	  shaking	  on	  a	  rocker	  overnight	  at	  4°C.	  
Membranes	  were	   then	   rinsed	  using	  PBST,	  before	   extended	  washes	   (3x10	  minutes)	   in	  the	   same	   buffer	   with	   gentle	   rocking.	   Goat	   anti-­‐rabbit	   IgG,	   horse-­‐radish	   peroxidase-­‐linked	   antibody,	   was	   then	   incubated	   with	   the	   membrane	   for	   1	   hour	   at	   room	  temperature	   before	  washing	  with	   PBST	   as	   above	   and	   final	   incubation	  with	   enhanced	  chemiluminescence	  reagent	  (GE	  Healthcare).	  	  
Antibody	   binding	   to	   the	   nitrocellulose	   membrane	   was	   visualized	   by	   placing	   light-­‐sensitive	   film	   (Amersham	   HyperfilmTM	   Blue)	   onto	   the	   membrane	   for	   various	   times	  before	  developing	  the	  film	  in	  a	  dark	  room.	  The	  exposure	  time	  was	  optimised	  based	  on	  the	  quality	  of	  the	  initial	  film	  exposure.	  	  
In	  order	  to	  assess	  the	  consistency	  of	  sample	  loading	  onto	  the	  gel,	  membranes	  were	  re-­‐incubated	   for	   1	   hour	   at	   room	   temperature	   with	   total-­‐ACC	   or	   total-­‐GSK3β	   antibody	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before	   following	   the	   protocol	   described	   above	   (washing,	   incubation	   with	   secondary	  antibody,	  etc.).	  
The	   resulting	   films	   were	   scanned	   to	   create	   a	   digital	   image,	   which	   was	   then	  densitometrically	   quantified	   using	   ImageJ	   software.	   The	   ratio	   between	   the	   density	   of	  the	  ‘phospho’	  and	  ‘total’	  bands	  was	  then	  calculated	  for	  both	  GSK3β	  and	  ACC	  and	  plotted	  using	  GraphPad	  software	  (Prism).	  	  
7.2.5 Statistical	  analysis	  	  
Analysis	   was	   performed	   using	   SPSS	   software	   (version	   20.0,	   SPSS	   Inc.,	   Chicago,	   IL).	  Continuous	   data	   was	   assessed	   for	   normal	   distribution	   and	   presented	   as	   mean	   ±	  standard	  deviation	  of	  the	  mean	  or	  median	  and	  inter-­‐quartile	  range.	  Student’s	  t-­‐test	  was	  used	  to	  analyse	  normally	  distributed	  data.	  Skewed	  data	  was	  analysed	  by	  Mann-­‐Whitney	  U-­‐test.	  Categorical	  data	  was	  analysed	  by	  Fisher’s	  exact	  test.	  Statistical	  significance	  was	  defined	  as	  a	  p	  <	  0.05.	  
7.3 Results	  	  
7.3.1 Sample	  group	  and	  demographics	  	  
The	  baseline	  demographics	  are	  outlined	   in	  Table	  7-­‐1.	  All	  samples	  were	  obtained	  from	  the	  control	  arm	  of	   the	  study.	  Of	   the	  10	  patients,	  5	  underwent	   isolated	  AVR	   for	  severe	  aortic	  stenosis	  alone,	  and	  the	  remaining	  patients	  had	  concomitant	  IHD	  and	  underwent	  AVR	   +	   CABG	   surgery.	   There	  was	   no	   significant	   difference	   in	   any	   of	   the	   pre-­‐operative	  variables.	  	  




No	  LCOE	  (n=5)	   LCOE	  (n=5)	   P	  Value	  
Age	   74.5	  (68.6	  –	  82.9)	   74.4	  (57.8	  –	  81.6)	   0.69	  
BSA	  	   1.76	  (1.48	  –	  1.96)	   1.85	  (1.70	  –	  2.23)	   0.31	  
Male:	  Female	  	   3:2	  (60:40)	   4:1	  (80:20)	   1.0	  
Status	   	   	   	  -­‐	  Elective	   5	  (100)	   5	  (100)	   	  
EuroSCORE	   7	  (5	  –	  7.5)	   6	  (3.5	  –	  8.5)	   1.0	  
Logistic	  EuroSCORE	   7.41	  (3.45	  –	  8.50)	   6.37	  (2.58	  –	  11.25)	   0.84	  
CCS	  	   	   	   0.44	  -­‐	  1	   5	  (100)	   3	  (60)	   	  -­‐	  2	   0	  	   2	  (40)	   	  
NYHA	   	   	   0.26	  -­‐	  1	   1	  (20)	   1	  (20)	   	  -­‐	  2	   4	  (80)	   2	  (40)	   	  -­‐	  3	   0	   1	  (20)	   	  
Previous	  MI	   0	   0	   	  
Risk	  factors	   	   	   	  -­‐	  Hypercholesterolemia	  	   1	  (20)	   0	   1.0	  -­‐	  Hypertension	   1	  (20)	   0	   0.05	  
Medication	   	   	   	  -­‐	  ACE	   1	  (20)	   1	  (20)	   1.0	  -­‐	  A2	   0	   2	  (40)	   0.44	  -­‐	  Statin	   2	  (40)	   3	  (60)	   1.0	  -­‐	  β	  blocker	   1	  (20)	   1	  (20)	   1.0	  
IABP	  pre	  surgery	   0	   0	   	  
IHD	   3	  (60)	   2	  (40)	   	  
Table	  7-­‐1	  Pre-­‐operative	  variables	  
The	  echocardiographic	  and	  operative	  variables	  are	  outlined	  in	  Table	  7-­‐2	  and	  Table	  7-­‐3	  respectively.	  There	  is	  no	  significant	  difference	  in	  any	  of	  the	  echocardiographic	  variables	  or	  the	  operative	  variables	  between	  the	  groups.	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Variable	  (IQR/%)	   No	  LCOE	   LCOE	   P	  value	  
Ejection	  fraction	   62	  (59	  –	  62)	   51	  (45	  –	  51)	   0.33	  
LVID	   3.2	  (3.2)	   5	  (4.4	  –	  5)	   0.50	  
IVSd	   1.2	  (1.2)	   1.6	  (1.1	  –	  1.6)	   0.70	  
PWd	   1	  (0.9	  –	  1)	   1.1	  (0.9	  –	  1.1)	   1.0	  
Valve	  Area	   0.6	  (0.36	  –	  0.6)	   0.85	  (0.73	  –	  1.0)	   0.14	  
Peak	  gradient	   105	  (94	  –	  105)	   65.5	  (49.8	  –	  76.75)	   0.06	  
Mean	  gradient	  	   63.0	  (46.8	  –	  71.0)	   38.5	  (30.25	  –	  62.5)	   0.11	  
Table	  7-­‐2	  Echocardiographic	  variables	  
	  
Variable	  (IQR/%)	   No	  LCOE	   LCOE	   P	  Value	  
Procedure	   	   	   1.0	  -­‐	  AVR	   2	  (40)	   3	  (60	   	  -­‐	  AVR	  +	  CABG	   3	  (60)	   2	  (40)	   	  
Valve	  type	   	   	   1.0	  -­‐	  Biological	   5	  (100)	   4	  (80)	   	  -­‐	  Mechanical	   0	   1	  (20)	   	  
Valve	  size	   23	  (21	  –	  24.5)	   23	  (20.5	  –	  23.5)	   0.62	  
Cumulative	  CPB	  time	   119	  (106	  –	  136)	   158	  (115	  –	  236)	   0.11	  
Cum	  cross	  clamp	  time	   90	  (73	  –	  99)	   81	  (66	  –	  160)	   0.45	  
Hot	  shot	  administered	   4	  (80)	   4	  (80)	   	  
IABP	   0	   1	  (20)	   	  
Table	  7-­‐3	  Operative	  variables	  
7.3.2 Analysis	  of	  ACC	  phosphorylation	  	  
The	   western	   blot	   images	   acquired	   for	   ACC	   phosphorylation	   are	   shown	   below	  where	  total-­‐ACC	  and	  phospho-­‐ACC	  are	  depicted	  in	  Figure	  7-­‐4	  and	  Figure	  7-­‐5	  respectively.	  The	  western	  blots	  depict	   samples	  1	   through	   to	  10	   (left	   to	   right),	  where	  samples	  1	  –	  5	  are	  non-­‐LCOE	  and	  6	  –	  10	  are	  LCOE.	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Figure	  7-­‐4	  Western	  blot	  showing	  total-­‐ACC	  
	  
Figure	  7-­‐5	  Western	  blot	  showing	  phospho-­‐ACC	  
The	  ratio	  of	  phospho-­‐ACC	  to	  total	  ACC	  (ACC	  phosphorylation)	  was	  greater	   in	  the	  non-­‐LCOE	   group	   compared	   to	   the	   LCOE	   group	   (Figure	   7-­‐6)	   although	   this	   did	   not	   reach	  significance	  (p=0.41).	  	  	  
	  	  
	  
Figure	  7-­‐6	  Comparison	  of	  ACC	  between	  LCOE	  and	  non-­‐LCOE	  groups	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7.3.3 Analysis	  of	  GSK3β	  	  
The	  western	  blot	  images	  acquired	  for	  GSK3β	  phosphorylation	  are	  shown	  below	  where	  total-­‐GSK3β	  and	  phospho-­‐GSK3β	  are	  depicted	  in	  Figure	  7-­‐7	  and	  Figure	  7-­‐8	  respectively.	  The	  western	  blots	  depict	  samples	  1	  through	  to	  10	  (left	   to	  right),	  where	  samples	  1	  –	  5	  are	  non-­‐LCOE	  and	  6	  –	  10	  are	  LCOE.	  
	  
Figure	  7-­‐7	  Western	  blot	  showing	  total-­‐GSK3β	  
	  
Figure	  7-­‐8	  Western	  blot	  showing	  phospho-­‐GSK3β	  




Figure	  7-­‐9	  Comparison	  of	  GSK3-­‐beta	  between	  LCOE	  and	  non	  LCOE	  groups	  	  
7.4 Discussion	  	  
This	   study	   evaluated	   the	   activity	   of	   ACC	   and	   GSK3β	   on	   human	   cardiac	   tissue	   and	  showed	  an	  increased	  phosphorylation	  of	  ACC	  and	  GSK3β	  in	  patients	  that	  do	  not	  have	  a	  low	  cardiac	  output	  episode	  (LCOE)	  post	  cardiac	  surgery	  compared	  to	  those	  that	  sustain	  a	  LCOE.	  Post	  cardiac	  surgery,	  LCOE	  is	  reflective	  of	  a	  failing	  heart	  and	  one	  that	  requires	  additional	  inotropic	  support	  to	  maintain	  an	  adequate	  cardiac	  function	  and	  is	  associated	  with	  increased	  mortality	  and	  morbidity	  (Maganti,	  Rao	  et	  al.	  2005).	  	  
The	   demographic	   characteristics	   of	   the	   groups	   were	   comparable	   with	   similar	   risk	  stratification	  and	  clinical	  status.	  The	  samples	  analysed	  were	  obtained	  from	  the	  placebo	  cohort	  and	  therefore	  this	  study	  projects	  the	  true	  activity	  of	  these	  metabolic	  regulators	  in	   patients	   that	   have	   a	   LCOE.	   Increased	   ACC	   and	   GSK3β	   phosphorylation	   can	   be	  extrapolated	  to	  reflect	  the	  increased	  activity	  of	  AMPK	  and	  AKT	  respectively.	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AMPK	  acts	  as	   the	   fuel	  gauge	   in	   the	  heart	  (Dyck	  and	  Lopaschuk	  2002)	  as	   its	  activity	   is	  controlled	   by	   the	   energy	   levels;	   ATP	   degradation	   to	   ADP	   and	   eventually	   to	   AMP.	  Therefore	  AMPK	  is	  activated	  in	  times	  of	  need	  and	  this	  includes	  the	  period	  of	  myocardial	  ischaemia.	   AMPK	   activity	   inhibits	   the	   formation	   of	   malonyl-­‐CoA	   (phosphorylation	   of	  ACC	  results	  in	  the	  inactive	  form)	  and	  therefore	  there	  is	  a	  drive	  towards	  FFA	  oxidation.	  This	  metabolic	  process	  seems	  to	  be	  in	  paradox	  to	  the	  number	  of	  the	  studies	  that	  show	  inhibition	  of	  FFA	  oxidation	  is	  beneficial	   in	  the	  ischaemic	  period	  (Wang	  and	  Lopaschuk	  2007),	   due	   to	   the	   attenuation	   of	   the	   uncoupling	   effect	   of	   oxidation	   from	  phosphorylation,	  present	  with	  increased	  FFA	  metabolism.	  The	  trend	  towards	  increased	  AMPK	  activity	   in	   patients	  with	   no	   LCOE	  demonstrated	   in	   this	   study	  was	  prior	   to	   any	  ischaemic	   insult	  and	  alludes	   to	   the	  cardioprotective	  mechanisms	  of	  AMPK	  through	   its	  dual	   faceted	   role	   of	   glucose	   and	   fatty	   acid	   metabolism;	   activation	   of	   AMPK	   during	  ischaemia	   increases	   glucose	   uptake	   and	   glycolysis	   and	   also	   increases	   free	   fatty	   acid	  oxidation	  during	   reperfusion	   (Sambandam	  and	  Lopaschuk	  2003).	   Furthermore	  AMPK	  activation	   may	   increase	   energy	   production	   and	   inhibit	   apoptosis	   during	   the	   early	  ischaemic	  phase	  (Dyck	  and	  Lopaschuk	  2006).	  	  
Reperfusion	   Injuries	   Salvage	   Kinases	   (RISK)	   pathway	   (Hausenloy	   and	   Yellon	   2004)	  refers	  to	  a	  series	  of	  pro-­‐survival	  protein	  kinases.	  The	  RISK	  pathway	  mediates	  a	  form	  of	  programmed	   cell	   survival	   and	   there	   is	   growing	   evidence	   that	   stimulation	   of	   the	  RISK	  pathway	  is	  associated	  with	  cardioprotective	  benefits	  (Hausenloy	  and	  Yellon	  2007).	  It	  is	  believed	   that	   activation	   of	   the	   RISK	   pathway	   ultimately	   leads	   to	   inhibition	   of	   the	  mitochondrial	   Permeability	   Transition	   Pore	   (PTP)	   opening,	   which	   offers	  cardioprotection	  (Davidson,	  Hausenloy	  et	  al.	  2006;	  Juhaszova,	  Zorov	  et	  al.	  2009).	  Other	  mechanisms	  include	  an	  improved	  calcium	  uptake	  in	  the	  sarcoplasmic	  reticulum	  and	  the	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recruitment	   of	   antiapoptotic	   pathways	   (Yellon	   and	   Hausenloy	   2007).	   Originally	   AKT	  constituted	  one	  of	  the	  pro-­‐survival	  kinases	  and	  subsequently	  several	  other	  kinases	  have	  been	  identified	  including	  GSK3β	  (Hausenloy	  and	  Yellon	  2007),	  one	  of	  the	  downstream	  targets	  of	  AKT.	  There	  is	  now	  surmounting	  evidence	  that	  AKT	  activation	  and	  subsequent	  GSK3β	   inhibition	   through	   its	  phosphorylation	   is	  cardioprotective	  (Juhaszova,	  Zorov	  et	  al.	   2009).	   Furthermore	   GSK3β	   activity	   has	   been	   implicated	   as	   a	   critical	   element	   in	  ischaemic	   preconditioning	   (Tong,	   Imahashi	   et	   al.	   2002),	   thought	   to	   also	   have	   a	  cardioprotective	  benefit.	  	  	  	  
Our	  group	  has	  recently	  conducted	  a	  study	  on	  the	  role	  of	  GIK	  therapy	  and	  its	  impact	  on	  AKT	   and	   AMPK	   signalling	   in	   patients	   with	   LVH	   undergoing	   cardiac	   surgery	   (Howell,	  Ashrafian	  et	   al.	   2011).	  Howell	  et	  al	   demonstrated	  a	  2.5	   fold	   increase	   in	  phospho-­‐AKT	  compared	  to	  total-­‐AKT	  (p=0.03)	  and	  a	  1.7	  fold	  increase	  in	  phospho-­‐AMPK	  to	  pan-­‐AMPK	  (p=0.0004)	   in	   patients	   treated	   with	   GIK	   therapy,	   postulating	   the	   cardioprotective	  benefit	   of	   GIK	   therapy,	   by	   upregulation	   of	   AKT	   and	   AMPK	   activity.	   This	   study	  corroborates	   these	   findings	   to	  an	  extent.	   	  However	   this	  study	  hypothesises	   further,	   in	  that	  these	  cardioprotective	  properties	  are	  innately	  present	  in	  individuals	  that	  do	  not	  go	  on	   to	  have	  a	  LCOE	  without	  metabolic	  modulation	  (to	  up-­‐regulate	   the	  cardioprotective	  signalling	  pathways).	  	  
This	   is	   the	   first	   study	   to	   evaluate	   the	   activity	   of	   these	   metabolic	   regulators	   on	   pre-­‐ischaemic	   human	   myocardium	   and	   correlate	   this	   to	   LCOE	   post	   cardiac	   surgery.	   It	  appears	   that	   in	   patients	   that	   do	   not	   sustain	   a	   LCOE,	   there	   is	   an	   inherent	  cardioprotective	  benefit	  of	   increased	  AMPK	  and	  AKT	  activity	  prior	   to	   the	   induction	  of	  ischaemia.	   This	   correlation	   is	   at	   present	   purely	   hypothesis	   generating	   and	   is	  demonstrated	   on	   the	   hypertrophic	   myocardium,	   known	   to	   have	   an	   altered	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pathophysiology	   and	   deranged	   energy	   metabolism	   (Sambandam,	   Lopaschuk	   et	   al.	  2002).	  	  	  
Although	  this	  study	  demonstrated	  an	   increased	  phosphorylation	  of	  ACC	  and	  GSK3β	   in	  patients	   that	   had	   no	   LCOE,	   this	   did	   not	   reach	   significance,	   albeit	   almost	   reaching	  significance	  in	  the	  GSK3β	  analysis.	  This	  may	  be	  as	  a	  result	  of	  low	  numbers	  in	  each	  group	  and	   hence	   is	   a	   limitation	   of	   this	   study.	   The	   effect	   of	   perhexiline	   therapy	   on	   ACC	   and	  GSK3β	   activity	   was	   not	   studied	   and	   given	   the	   clinical	   outcomes,	   perhexiline	   therapy	  may	   not	   have	   had	   a	   clinically	   significant	   impact;	   however	   this	   remains	   speculative.	  Although	   there	   was	   no	   significant	   difference	   in	   the	   pre-­‐operative	   echocardiographic	  findings,	  the	  LCOE	  group	  may	  have	  had	  marginally	  more	  hypertrophy;	  this	  assumption	  is	  limited	  by	  the	  incomplete	  echocardiographic	  data	  available	  in	  this	  sample	  group.	  	  
This	  study	  is	  preliminary	  work	  looking	  at	  key	  master	  regulators	  involved	  in	  myocardial	  metabolism	  in	  relation	  to	  cardiac	  surgery	  and	  its	  associated	  ischaemic	  and	  reperfusion	  insults.	  Future	  work	  aims	  to	  evaluate	  the	  activity	  of	  these	  regulators	  during	  ischaemia	  and	   in	   the	   early	   reperfusion	   phase.	   Furthermore	   comparison	   between	   LVH	   and	   non-­‐LVH	   patients	   undergoing	   cardiac	   surgery	   and	   their	   associated	   clinical	   outcomes	   will	  help	   identify	   if	   these	   regulators	   play	   a	   key	   role	   within	   the	   more	   susceptible	   LVH	  population.	  Further	  biochemical	   studies	  on	  human	  myocardium	  performed	   in	  parallel	  to	  their	  clinical	  outcomes	  would	  help	  elucidate	  the	  fundamental	  roles	  of	  AMPK	  and	  AKT	  activation	  and	  their	  downstream	  regulators,	  thereby	  delineating	  their	  cardioprotective	  mechanisms.	  	  
In	   conclusion	   this	   preliminary	   study	   showed	   an	   inherent	   increase	   in	   AMPK	   and	   AKT	  activity	  prior	   to	  an	   ischaemic	   insult	   in	  patients	  who	  did	  not	   sustain	  a	  LCOE	   following	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cardiac	   surgery.	   The	   increased	   activity	   of	   these	   master	   regulators	   may	   provide	   a	  cardioprotective	  benefit.	   	  Hence	  metabolic	  modulation	  to	  activate	  these	  pathways	  may	  prove	   beneficial	   in	   patients	   undergoing	   cardiac	   surgery	   and	   this	   warrants	   further	  examination.	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8 DISCUSSION,	  CONCLUSIONS	  AND	  FUTURE	  WORK	  
8.1 Clinical	  trial	  -­‐	  HYPER	  
8.1.1 Perhexiline	  and	  myocardial	  protection	  during	  cardiac	  surgery	  	  
The	   clinical	   trial	   was	   designed	   to	   evaluate	   the	   hypothesis	   that	  metabolic	  modulation	  with	   perhexiline,	   administered	   orally	   prior	   to	   cardiac	   surgery	   would	   improve	  myocardial	  protection;	  in	  patients	  with	  left	  ventricular	  hypertrophy	  secondary	  to	  aortic	  stenosis.	  These	  patients	  required	  an	  aortic	  valve	  replacement	  for	  symptomatic	  and/or	  prognostic	   benefit	  with	   or	  without	   concomitant	   coronary	   artery	   bypass	   graft	   surgery	  for	   ischemic	   heart	   disease.	   Furthermore	   the	   HYPER	   trial	   was	   designed	   to	   assess	   the	  hypothesis	   that	   perhexiline	   therapy,	   through	   its	  mechanism	   of	   action	  would	   improve	  the	  myocardial	  energetic	  state	  in	  patients	  with	  LVH	  secondary	  to	  AS	  and	  hence	  improve	  the	  overall	  haemodynamic	  state	  and	  cardiac	  performance	  post	  AVR	  ±	  CABG.	  Both	  these	  hypothesis	  have	  been	  refuted	  by	  the	  HYPER	  trial.	  	  
The	  HYPER	   trial	   showed	  no	  overall	   benefit	   from	  perhexiline	   therapy	  as	   an	  adjunct	   to	  standard	  myocardial	  protection	  in	  patients	  undergoing	  AVR	  ±	  CABG.	  	  The	  primary	  end	  point,	   which	   was	   the	   incidence	   of	   inotrope	   use	   to	   treat	   a	   low	   cardiac	   output	   state	  appropriately,	  was	  not	  different	  between	  the	  groups.	  Furthermore	  there	  was	  no	  benefit	  of	  perhexiline	  therapy	  in	  reducing	  post-­‐operative	  myocardial	  injury.	  	  
The	   basis	   for	  myocardial	   protection	  with	   perhexiline	  was	   to	   enhance	   the	  myocardial	  metabolic	   state,	   prior	   to	   cardiac	   surgery	   and	   hence	   through	   metabolic	   modulation,	  achieve	  better	  myocardial	  protection.	  Previous	   studies	  addressing	  an	   improvement	   in	  myocardial	   protection	   conducted	   in	   Birmingham	   followed	   the	   same	   principles	   of	  metabolic	   modulation	   (Quinn,	   Pagano	   et	   al.	   2006;	   Ranasinghe,	   Quinn	   et	   al.	   2006;	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Howell,	  Ashrafian	  et	  al.	  2011;	  Drury	  NE,	  Howell	  NJ	  et	  al.	  2014).	  The	  majority	  of	   these	  studies	   evaluated	   the	   role	   of	   GIK	   associated	   metabolic	   modulation	   and	   showed	   an	  improvement	  in	  myocardial	  protection.	  	  
Low	  cardiac	  output	  episode	  post	  cardiac	  surgery	  has	  been	  used	  as	  a	  surrogate	  marker	  of	  myocardial	  protection	  in	  most	  of	  these	  earlier	  trials.	  It	  is	  well	  established	  that	  during	  cardiac	   surgery	   the	   heart	   undergoes	   a	   period	   of	   ischaemia	   and	   following	   this	   initial	  insult,	   there	   is	   the	   added	   insult	   of	   reperfusion	   classified	   as	   ischaemia-­‐reperfusion	  injury.	   Therefore	   following	   this,	   if	   the	   myocardium	   is	   not	   adequately	   protected,	   the	  heart	   is	   liable	   to	   go	   through	   a	   period	   of	   low	   cardiac	   output	   with	   sub-­‐optimal	  haemodynamic	   function.	   This	   can	   be	   detrimental	   to	   patient	   recovery	   (Hoffman,	  Wernovsky	  et	  al.	  2003;	  Maganti,	  Rao	  et	  al.	  2005).	  Therefore	  once	  a	  low	  cardiac	  output	  episode	  is	  identified,	  inotropic	  support	  can	  be	  provided	  to	  improve	  the	  cardiac	  function	  thereby	   improving	   overall	   haemodynamic	   performance.	   Hence	   the	   incidence	   of	  inotrope	  too	  can	  be	  used	  as	  a	  surrogate	  marker	  of	  myocardial	  protection,	  as	  used	  in	  the	  HYPER	  trial.	  	  Perhexiline	  therapy	  was	  thought	  to	  improve	  the	  pre-­‐ischaemic	  myocardial	  metabolism	  by	  inhibiting	  detrimental	   fatty	  acid	  metabolism	  and	  hence	  driving	  glucose	  metabolism;	  this	  metabolic	  state	  was	  presumed	  to	  be	  beneficial	  during	  the	   ischaemia-­‐reperfusion	   insult.	   However,	   the	   HYPER	   trial	   has	   disproved	   the	   hypothesis	   that	  promoting	   carbohydrate	   metabolism	   prior	   to	   cardiac	   surgery,	   would	   prime	   the	  cardiomyocyte	   to	   deal	   with	   the	   stressors	   of	   ischaemia	   and	   reperfusion.	   Moreover,	  HYPER	   has	   demonstrated	   that	   oral	   perhexiline	   therapy	   does	   not	   augment	   standard	  myocardial	  protection	  in	  patients	  with	  LVH	  undergoing	  cardiac	  surgery.	  	  
Although	   there	   was	   no	   difference	   in	   the	   incidence	   of	   appropriate	   use	   of	   inotropic	  support,	   the	   overall	   incidence	   of	   inotrope	   use	   was	   higher	   in	   the	   perhexiline	   group	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during	   the	   first	  12-­‐hours	   following	   reperfusion	  and	  was	   statistically	   significant	   in	   the	  six	   to	   12	   hour	   period	   post-­‐reperfusion.	   This	   finding	  was	   in	   the	   context	   of	   unchanged	  parameters	  in	  other	  haemodynamic	  measurements	  i.e.	  filling	  pressures,	  heart	  rate	  and	  mean	  arterial	  pressures	  during	  the	  same	  time	  points.	  Increased	  inotrope	  requirements	  during	  the	  six	  to	  12	  hour	  period	  of	  reperfusion,	   is	  consist	  with	  a	  significantly	  reduced	  cardiac	  performance	  measured	  by	  CI	  at	  12	  hours	  after	  reperfusion.	  These	  findings	  are	  concurrent	   to	   a	   significant	   reduction	   in	   cardiac	   index	   at	   6	   hours	   albeit	   insignificant	  when	   corrected	   for	   baseline	   cardiac	   index	   (reduced	   in	   the	   perhexiline	   group)	   in	   a	  preceding	   trial;	   myocardial	   protection	   with	   perhexiline	   in	   coronary	   artery	   surgery	  (CASPER)	  (Drury	  NE,	  Howell	  NJ	  et	  al.	  2014).	  The	  reason	  for	  reduced	  cardiac	  function	  at	  baseline	  associated	  with	  perhexiline	  is	  unclear	  and	  remains	  unanswered	  (Drury	  2012)	  and	  given	  the	  nominal	  nature	  of	  the	  statistical	  test	  for	  this	  analysis,	  the	  play	  of	  chance	  remains	   a	   plausible	   explanation	   of	   the	   result	   not	   withstanding	   the	   apparently	   low	   p	  value.	  	  
Perhexiline	  as	  a	  metabolic	  agent	  has	  been	  extensively	  studied	  and	  it’s	  role	  as	  a	  potent	  metabolic	  modulator	  has	  been	  previously	  advocated.	  Abozguia	  et	  al	  showed	  perhexiline	  improved	  high-­‐energy	  phosphate	  ratios,	  oxygen	  consumption	  and	  NYHA	  symptoms	   in	  patients	  with	  hypertrophic	  cardiomyopathy	  (Abozguia,	  Elliott	  et	  al.	  2010).	  In	  an	  earlier	  study,	  Lee	  and	  colleagues	   showed	  an	   improvement	   in	  oxygen	  consumption,	  quality	  of	  life	   and	   left	   ventricular	   ejection	   fraction	   in	   patients	   with	   chronic	   heart	   failure	   (Lee,	  Campbell	  et	  al.	  2005).	  In	  a	  review	  of	  perhexiline,	  clinical	  applications	  in	  ischaemic	  heart	  disease,	  aortic	  stenosis	  and	  heart	  failure	  have	  been	  explored	  and	  supported	  (Ashrafian,	  Horowitz	  et	  al.	  2007).	  However	  the	  clinical	  application	  of	  perhexiline	  is	  limited.	  In	  one	  such	   study,	   perhexiline	   was	   used	   in	   the	   medical	   management	   of	   symptomatic	   aortic	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stenosis;	   13	  of	   15	   elderly	  patients	   showed	   symptomatic	   improvement	  when	   followed	  up	  for	  30	  months	  (Unger,	  Robinson	  et	  al.	  1997).	  The	  small	  number	  of	  participants	  and	  its	  non-­‐randomised	  nature	  inherently	  limits	  this	  trial.	  In	  addition,	  none	  of	  the	  patients	  were	   suitable	   for	   surgical	   intervention	   and	   did	   not	   undergo	   cardiac	   surgery.	   The	  application	  of	  perhexiline	  in	  surgical	  practice	  is	  scarce	  and	  this	  scarcity	  in	  the	  data	  led	  to	   the	   development	   of	   the	   CASPER	   trial,	   which	   preceded	   the	   HYPER	   trial.	   These	   two	  trials	  aimed	  to	  examine	  perhexiline	  therapy	  in	  two	  distinct	  patient	  populations;	  in	  those	  with	  ischaemic	  heart	  disease	  and	  those	  with	  pressure	  overload	  hypertrophic	  ventricles.	  	  
A	   common	   theme	   throughout	   all	   the	   studies	   that	   support	   perhexiline,	   as	   a	  metabolic	  agent	  is	  that	  therapy	  is	  prolonged,	  monitored	  and	  optimised	  over	  months.	  This	  was	  not	  logistically	   possible	   in	   the	   real-­‐world	   practice	   of	   cardiac	   surgery,	   reflected	   by	   both	  HYPER	   and	   CASPER	   trial.	   HYPER	   was	   the	   first	   to	   evaluate	   the	   role	   of	   perhexiline	   in	  patients	  with	  LVH	  secondary	   to	  AS	  undergoing	   cardiac	   surgery.	   	   Further	   examination	  would	  be	  restricted	  based	  on	  the	  impotent	  nature	  of	  perhexiline	  therapy	  in	  this	  surgical	  population.	  	  
8.1.2 Unexpected	  findings	  from	  HYPER	  	  
In	   this	   study	   the	  percentage	  of	   patients	  needing	  on-­‐going	  vasopressor	   infusion	   in	   the	  first	   six	   hours	   of	   reperfusion	  was	   high	   in	   both	   groups	   (91.4%	   vs.	   88.9%,	   placebo	   vs.	  perhexiline,	  p=0.76),	  and	  within	  the	  perhexiline	  group,	  was	  higher	  during	  the	  six	  to	  12	  hour	  reperfusion	  period	  (63.7%	  vs.	  79.6%,	  placebo	  vs.	  perhexiline,	  p=0.09).	  In	  previous	  trials	   utilizing	   GIK	   therapy,	   GIK	   in	   itself	   may	   have	   proved	   to	   cause	   a	   vasodilatory	  response,	  however	  perhexiline	  per	  se	   is	  not	  known	  to	  have	  such	  properties.	  This	   trial	  used	  phenylephrine	  as	  a	  vasoconstrictor;	  although	  a	  pure	  vasoconstrictor	  with	  only	  α-­‐
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agonist	   properties	   phenylephrine	   is	   considered	   to	   be	   weaker	   than	   other	  vasoconstrictors	  such	  as	  noradrenaline,	  which	  was	  used	  in	  the	  previous	  GIK	  trials.	  This	  may	   have	   created	   an	   immeasurable	   bias	   resulting	   in	   a	   lower	   threshold	   to	   commence	  vasoconstrictor	  support.	  It	  appears	  that	  the	  increase	  in	  vasoconstrictor	  support	  during	  the	   six	   to	   12	   hours	   of	   reperfusion	   coincides	   with	   an	   increase	   in	   overall	   inotropic	  support	   use	   during	   the	   same	   time.	   Phenylephrine	   use	   would	   supplement	   overall	  haemodynamics	   during	   a	   period	   of	   low	   cardiac	   output,	   by	   improving	   perfusion	  pressure.	   It	   would	   be	   speculative	   to	   imply	   that	   perhexiline	   has	   a	   negative	   inotropic	  effect.	   This	   correlation	   has	   not	   been	   extensively	   studied	   in	   patients	   undergoing	  anaesthesia	  or	  surgery;	  however	  similar	  findings	  were	  evident	  in	  the	  CASPER	  trial	  and	  explanation	  for	  this	  remains	  elusive	  (Drury	  2012).	  	  	  	  
HYPER	   has	   shown	   that	   perhexiline	   therapy	   has	   been	   associated	  with	   increased	   renal	  impairment	   (creatinine	   >	   200)	   in	   six	   (11.1%)	   patients,	   two	   (3.4%)	   requiring	  haemofiltration	   and	   one	   needing	   permanent	   dialysis.	   Baseline	   renal	   function	   was	  similar	  between	  the	  groups,	  with	  a	  marginally	  higher	  median	  serum	  creatinine	  level	  in	  the	   perhexiline	   group	   (not	   significant).	   Perhexiline	   is	  metabolised	   in	   the	   liver	   and	   its	  metabolites	   are	   excreted	   in	   the	   urine	   (Ashrafian,	   Horowitz	   et	   al.	   2007).	   Renal	  impairment	   with	   creatinine	   >	   200	   was	   an	   exclusion	   criteria;	   the	   variability	   of	  perhexiline	  metabolism	   amongst	   individuals	   and	   the	   associated	   risk	   of	   hepatotoxicity	  and	   neurological	   complications	   strongly	   contraindicate	   the	   use	   of	   perhexiline	   in	  patients	   with	   renal	   impairment.	   To	   our	   knowledge	   there	   are	   no	   other	   reports	  implicating	  renal	  impairment	  with	  perhexiline	  therapy.	  	  
It	   appears	   that	   perhexiline,	   initially	   hypothesised	   as	   beneficial	   towards	   myocardial	  protection,	  could	  now	  in	  fact	  be	  harmful.	  However,	  the	  unexpected	  secondary	  outcomes	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remain	   secondary	   outcomes	   and	   should	   be	   interpreted	   cautiously.	   Given	   the	   neutral	  primary	   outcome,	   the	   secondary	   outcomes	   have	   to	   be	   interpreted	   as	   exploratory	  (Freemantle	   2001).	   Further	   studies	   to	   evaluate	   these	   secondary	   outcomes	   in	   greater	  detail	  will	   be	   restrained	   due	   to	   the	   neutral	   clinical	   implications	   of	   perhexiline	   in	   this	  setting.	  	  	  
8.1.3 Limited	  potency	  of	  perhexiline	  for	  myocardial	  protection	  
Perhexiline	   is	   known	   for	   its	   inhibitory	   properties	   on	   CPT	   action,	   in	   particular	   CPT-­‐1.	  Fatty	  acid	  metabolism	  is	  dependent	  on	  both	  CPT-­‐1	  and	  CPT-­‐2	  action	  and	  as	  yet	  there	  is	  no	   certainty	   that	   perhexiline	   inhibits	   CPT-­‐2	   adequately.	   Furthermore,	   perhexiline	  remains	   a	   competitive	   inhibitor	   of	   CPT	   (Ashrafian,	   Horowitz	   et	   al.	   2007),	   competing	  with	   the	  highly	  potent,	   endogenous	   enzyme	  malonyl-­‐CoA.	   In	   addition	   to	   the	  potential	  inhibitory	  properties	  of	  perhexiline	  on	  CPT-­‐1,	  this	  action	  is	  tested	  further	  by	  the	  likely	  overwhelming	  flood	  of	  free	  fatty	  acids	  in	  circulation,	  in	  a	  patient	  that	  has	  been	  starved	  overnight	  in	  preparation	  for	  theatre.	  Therefore	  perhexiline	  inhibition	  of	  CPT-­‐1	  may	  not	  be	  effective	  particularly	  in	  the	  ischaemic	  and	  reperfusion	  phases	  during	  cardiac	  surgery.	  	  
To	  the	  contrary,	  one	  of	  the	  benefits	  of	  GIK	  therapy	  as	  shown	  in	  the	  previous	  trials	  was	  that	   GIK	   therapy	   continues	   throughout	   ischaemia	   and	   into	   reperfusion	   and	   hence	   its	  effects	  were	  readily	  employed	  at	  the	  end	  of	  ischaemia	  and	  during	  reperfusion.	   	  This	  is	  independent	  of	  other	   cardioprotective	  properties	  of	  GIK	  such	  as	   substrate	  availability	  with	   glucose	   and	   the	  multifactorial	   cardioprotective	   benefits	   of	   insulin	   including	   up-­‐regulation	  of	  pro-­‐survival	  pathways	  (Howell,	  Ashrafian	  et	  al.	  2011).	  	  
Drury	  et	  al	  have	  recently	  provided	   further	   insight	   into	   the	  correlation	  between	   tissue	  and	  plasma	  concentrations	  of	  perhexiline	  and	  its	  impact	  (Drury,	  Licari	  et	  al.	  2014).	  This	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study	   has	   shown	   good	   correlation	   between	   atrial	   and	   ventricular	   concentrations	   of	  perhexiline	  to	  plasma,	  with	  an	  atrial	  to	  plasma	  ratio	  of	  21.5,	  ventricular	  to	  plasma	  ratio	  of	   34.9	   and	   ventricular	   to	   atrial	   ratio	   of	   1.67	   and	   concluded	   that	   perhexiline	  concentration	   in	   plasma	  was	  predictive	   of	  myocardial	   drug	   concentrations.	   	  However	  despite	   a	   high	   concentration	   of	   perhexiline	   being	   found	   in	   the	   human	   atria	   and	  ventricular	  myocardium,	  it	  may	  not	  be	  adequate	  at	  steady-­‐state	  to	  exert	  the	  maximum	  effects	  of	  CPT	  inhibition	  required	  to	  promote	  carbohydrate	  metabolism	  (Drury,	  Licari	  et	  al.	   2014).	   The	   lack	   of	  metabolic	   change	   is	   further	   confirmed	   by	   a	   novel	  metabolomic	  study	   assessing	   the	   metabolites	   of	   myocardial	   ventricular	   tissue,	   which	   showed	   that	  there	  was	  no	  change	  in	  metabolism	  towards	  a	  carbohydrate	  system	  and	  no	  effect	  on	  the	  myocardial	  metabolome,	  with	  exposure	  to	  perhexiline	  (Drury	  2012).	  
Perhexiline	  has	  a	  single	  known	  utility	  of	  CPT	   inhibition	  and	  therefore	  this	  may	  not	  be	  potent	  enough	  to	  provide	  effective	  clinical	  outcomes	  in	  the	  context	  of	  cardiac	  surgery.	  Despite	  the	  clinical	  outcomes	  demonstrated	  in	  HYPER,	  experimental	  models	  to	  evaluate	  the	   mechanism	   of	   perhexiline	   continue.	   A	   recent	   novel	   study	   employing	   a	   combined	  approach	   of	   proteomics,	   metabolomics	   and	   computational	   modelling	   approach,	   in	   a	  small	   rat	   heart	   model	   has	   shown	   activation	   of	   the	   pyruvate	   dehydrogenase	   complex	  with	  perhexiline	  therapy	  and	  suggests	  that	  perhexiline	  may	  have	  yet	  unknown	  complex	  systemic	  effects	  (Yin,	  Dwyer	  et	  al.	  2013).	  Such	  complex	  experimental	  studies	  may	  help	  elucidate	  some	  specific	  actions	  of	  metabolic	  therapies,	  yet	  clinical	  application	  may	  not	  replicate	  laboratory	  findings.	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8.1.4 Timing	  of	  the	  HYPER	  trial	  	  
The	  HYPER	  trial	  was	  conceived	  on	  the	  back	  of	  a	  series	  of	  myocardial	  protection	  studies	  in	   Birmingham,	   and	   a	   trend	   to	   move	   away	   from	   the	   labour	   intensive	   GIK	   therapies.	  Other	   metabolic	   therapies	   apart	   from	   GIK	   were	   gaining	   increasing	   popularity	   as	   a	  potential	  adjunct	  to	  standard	  myocardial	  protection	  strategies,	  due	  to	  their	  properties	  of	  metabolic	  modulation;	  perhexiline	  was	  one	  such	  metabolic	  therapy	  and	  seemed	  to	  be	  a	  feasible	  IMP.	  Our	  group	  in	  Birmingham	  were	  the	  first	  to	  study	  the	  role	  of	  perhexiline	  in	   the	  context	  of	  cardiac	  surgery	  and	  myocardial	  protection.	  The	   first	  of	   these	  studies	  evaluating	  perhexiline	  in	  cardiac	  surgery	  was	  on	  patients	  with	  ischaemic	  heart	  disease	  undergoing	  CABG	   (CASPER)	   and	   recruitment	   into	   this	   trial	   had	  not	   completed	  by	   the	  time	  recruitment	  into	  HYPER	  had	  begun.	  	  
Earlier	   in	   this	   thesis	   I	   outlined	   that	   LVH	   in	   itself	   is	   a	   marker	   of	   poor	   outcome	   post	  cardiac	   surgery.	   Furthermore,	   LVH	   is	   considered	   to	   be	   metabolically	   deranged,	   and	  hence	  has	  a	  greater	  risk	  of	   injury	  from	  ischaemia	  and	  reperfusion.	   	  This	  principle	  that	  LVH	   is	   different	   to	   the	   myocardium	   affected	   by	   IHD	   posed	   a	   different	   research	  conundrum;	   effect	   of	   perhexiline	   therapy	   on	   LVH	   should	   be	   different	   to	   that	   on	   IHD.	  This	   therefore	   led	   to	   the	   overlap	   and	   simultaneous	   running	   of	   CASPER	   and	   HYPER	  trials.	  In	  hindsight,	  it	  would	  have	  been	  prudent	  to	  await	  the	  results	  of	  the	  CASPER	  trial	  before	  embarking	  on	  another	  large	  randomised	  control	  trial	  using	  the	  same	  IMP.	  	  
The	   HYPER	   trial	   was	   halted	   early	   due	   to	   futility.	   A	   complete	   futility	   analysis	   was	  conducted	   in	   light	   of	   the	   results	   from	   the	   CASPER	   trial.	   The	   CASPER	   trial	   failed	   to	  improve	  any	  of	  the	  clinical	  markers	  of	  myocardial	  protection	  (Drury	  NE,	  Howell	  NJ	  et	  al.	  2014).	  The	  futility	  analysis,	  which	  consisted	  of	  a	  O’Brien	  Fleming	  Alpha	  spending	  plan	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analysis	   for	   the	   primary	   outcome	   demonstrated	   that	   it	   was	   futile	   to	   try	   and	   achieve	  complete	   recruitment	   to	   the	   trial,	   as	   it	   was	   likely	   to	   reach	   a	   neutral	   outcome	   on	   the	  analysis	   of	   the	   primary	   outcome.	   Therefore	   the	   DSMB	   recommended	   to	   the	   trial	  steering	  committee	  that	  the	  trial	  should	  be	  halted	  based	  on	  futility,	  affirming	  the	  limited	  clinical	  benefit	  of	  perhexiline	  in	  cardiac	  surgery.	  Consequently	  this	  had	  knock-­‐on	  effects	  on	  a	  sub-­‐study	  recruiting	  patients	  to	  the	  IMP,	  as	  discussed	  later	  in	  this	  chapter.	  	  
With	   CASPER	   being	   a	   neutral	   trial,	   one	   would	   have	   been	   more	   hesitant	   to	   instigate	  another	  trial	  using	  perhexiline	  as	  an	  IMP	  in	  cardiac	  surgery.	  Yet	  having	  embarked	  down	  this	   journey,	   HYPER	   has	   provided	   ample	   evidence	   to	   add	   to	   the	   literature	   that	  perhexiline	  has	  it’s	  limited	  uses	  and	  in	  cardiac	  surgery	  perhexiline	  therapy	  has	  no	  role	  as	  an	  adjunct	  to	  standard	  myocardial	  protection.	  	  
8.1.5 Limitation	  of	  HYPER	  	  
One	   of	   the	   strongest	   limitations	   of	   HYPER	  was	   that	   39%	   of	   patients	  were	   below	   the	  therapeutic	   range	   of	   serum	   perhexiline	   concentration.	   A	   reason	   for	   this	   was	   the	   low	  minimum	  threshold	  of	  four	  days	  therapy	  prior	  to	  surgery.	  This	  threshold	  was	  adapted	  to	  optimise	   recruitment,	   as	   it	  would	   capture	   some	  patients	  who	  were	   listed	  and	   then	  operated	   on	   earlier	   due	   to	  waiting	   list	   scheduling	   or	  more	   pertinently	   due	   to	   clinical	  urgency.	   However	   it	   is	   uncertain	   what	   impact	   this	   would	   have	   had	   on	   the	   clinical	  outcome	   if	   any,	   as	   a	  propensity	  matched	  analysis	  of	  patients	   in	   the	   therapeutic	   range	  from	  CASPER,	  showed	  no	  difference	  in	  the	  myocardial	  benefits	  with	  perhexiline	  (Drury	  2012).	  	  	  
The	  power	  for	  this	  trial	  was	  calculated	  on	  end-­‐points	  derived	  from	  previous	  GIK	  trials	  in	  the	   department.	   With	   HYPER	   being	   the	   first	   trial	   using	   perhexiline	   during	   cardiac	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surgery	  in	  patients	  with	  LVH	  and	  with	  CASPER	  recruitment	  incomplete,	  there	  were	  no	  comparable	  end-­‐points	  to	  utilise,	  in	  order	  to	  power	  a	  phase	  III	  trial	  using	  the	  same	  IMP.	  Similarly	  the	  end-­‐points	  examined	  in	  this	  trial	  were	  based	  on	  historical	  end-­‐points	  used	  in	  previous	  trials.	  A	  validated	  power	  calculation	  or	  change	  to	  any	  of	  the	  end-­‐points	  may	  not	  have	  changed	  the	  overall	  outcome	  of	  this	  trial,	  but	  these	  concepts	  were	  not	  explored	  when	  the	  trial	  was	  designed.	  	  
In	   this	   trial,	  very	   few	  urgent	  patients	  were	   included;	  due	   to	   the	  minimum	  duration	  of	  trial	   therapy	   required	   before	   surgery.	   This	   latter	   limitation	   disallowed	   assessment	   of	  perhexiline	  therapy	  on	  urgent	  cases,	  however	  given	  there	   is	  no	  overall	  clinical	  benefit	  this	  evaluation	  is	  less	  pertinent.	  	  
8.1.6 Running	  a	  clinical	  trial	  	  
When	   the	  HYPER	   trial	  was	   conceived,	   the	  department	  was	  performing	   approximately	  170	   AVRs	   per	   year,	   which	   included	   40	   concomitant	   CABG	   surgery	   cases	   eligible	   for	  recruitment.	  At	  a	   recruitment	  rate	  of	  80%,	   to	  recruit	   the	   targeted	  220	  patients	  would	  take	  approximately	  30	  months.	  A	  few	  months	  into	  recruitment,	  it	  was	  evident	  that	  this	  target	   was	   not	   feasible,	   and	   the	   recruitment	   rate	   was	   below	   80%.	   One	   of	   the	   main	  reasons	   was	   due	   to	   the	   resistance	   of	   taking	   an	   IMP	   leading	   up	   to	   cardiac	   surgery	  (additional	  oral	  tablets)	  by	  20%	  of	  the	  eligible	  cohort,	  as	  apposed	  to	  an	  infusion	  of	  GIK	  administered	   intravenously	   after	   anaesthetic	   induction.	   Recruitment	   remained	   a	  concern	  throughout	  the	  period	  of	  the	  HYPER	  trial.	  	  
To	  improve	  recruitment	  collaborations	  with	  other	  centres	  were	  established.	   	  One	  such	  centre	   was	   Brighton	  who	   had	   recruited	   into	   the	   CASPER	   trial	   and	  was	   familiar	   with	  some	  of	   the	   trial	   protocols.	  New	  collaborations	  were	  made	  with	  Coventry	   to	   increase	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recruitment	   further	   and	   at	   this	   point	  HYPER	   grew	   into	   a	  multicentre	   trial.	   Expansion	  into	  other	  centres	  once	  trial	  recruitment	  had	  begun	  in	  the	  parent	  centre	  proved	  difficult	  and	   challenging.	   	   Ethical	   approval	   with	   amendments	   took	   their	   natural	   time	   course,	  which	   added	   further	   delays.	   Meanwhile,	   trust	   approval	   had	   to	   be	   sought,	   local	  consultants	  had	  to	  be	  convinced	  of	   the	  merits	  of	   the	  trial	  and	  trial	  protocols	  and	   local	  departmental	  education	  had	  to	  take	  place.	  This	  was	  a	  personally	  demanding	  time,	  and	  to	   achieve	   these	   objectives,	   required	   travelling	   to	   these	   institutions	   on	   multiple	  occasions	  in	  addition	  to	  visiting	  each	  centre	  for	  every	  case	  conducted	  within	  the	  trial.	  	  
In	  addition	  to	  this,	   the	  throughput	  within	  the	  department	   in	  Birmingham	  fell	  annually	  and	  was	  lower	  than	  the	  predicted	  170	  cases	  per	  year	  for	  each	  consecutive	  year	  of	  trial	  recruitment.	  Furthermore,	  during	  trial	  design	  it	  was	  initially	  thought	  that	  35%	  of	  these	  patients	  would	  be	   excluded,	   however	   in	  HYPER	  up	   to	  48%	  met	   the	   exclusion	   criteria	  with	  22%	  of	  patients	  undergoing	  AVR	  ±	  CABG	  being	  diabetic.	  These	   constraints	  were	  not	  immediately	  discernable	  until	  over	  a	  year	  into	  recruitment.	  	  
The	  same	  limitations	  and	  concerns	  pertaining	  to	  recruitment	  in	  HYPER	  were	  mirrored	  in	  the	  HYPER	  sub-­‐study,	  which	  evaluated	  the	  role	  of	  perhexiline	  on	  cardiac	  energetics	  by	  magnetic	  resonance	  spectroscopy.	  	  	  
During	   the	   HYPER	   trial	   there	   was	   a	   MHRA	   inspection	   at	   University	   Hospitals	  Birmingham	  and	  the	  HYPER	  trial	  was	  one	  of	  the	  trials	  that	  used	  an	  IMP	  and	  hence	  was	  at	  random,	  selected	  to	  be	  investigated.	  This	  was	  a	  thorough	  investigation	  of	  the	  entire	  trial	  and	  the	  sub-­‐study	  and	  included	  a	  review	  of	  the	  all	  the	  trial	  processes,	  recruitment,	  randomisation,	   standard	   operating	   procedures,	   management	   of	   trial	   patients,	   data	  collection	  and	  data	  analysis.	  As	  part	  of	  this	  investigation	  the	  HYPER	  trial	  was	  criticised	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for	   the	   manner	   in	   which	   the	   IMP	   was	   handled	   within	   the	   pharmacy	   and	   the	   MHRA	  recommended	  that	  the	  pharmacy	  improve	  their	  data	  recording	  and	  standard	  operating	  procedures	   on	   the	   handling	   of	   the	   IMP.	   Subsequent	   to	   this,	   in	   collaboration	   with	  pharmacy	  I	  wrote	  new	  standard	  operating	  procedures	  for	  the	  handling	  of	  the	  IMP	  and	  this	  was	  internally	  audited	  and	  approved.	  	  
8.2 MRS	  and	  the	  role	  of	  perhexiline	  on	  myocardial	  energetics	  	  
Magnetic	   Resonance	   Spectroscopy	   (MRS)	   is	   an	   established	   research	   tool	   to	   evaluate	  cellular	  energetics	  and	  in	  cardiac	  research	  it	  has	  become	  increasingly	  more	  reliable	   in	  the	   measurement	   of	   cardiac	   energetics	   (Hudsmith	   and	   Neubauer	   2009;	   Beadle	   and	  Frenneaux	  2010;	  Holloway,	  Suttie	  et	  al.	  2011).	  Despite	  some	  experience	  with	  using	  MRS	  for	  the	  measurement	  of	  cardiac	  energetics	  (Abozguia,	  Elliott	  et	  al.	  2010;	  Shivu,	  Abozguia	  et	   al.	   2010;	   Shivu,	   Phan	   et	   al.	   2010),	   our	   group	  had	  not	  undertaken	   a	   comprehensive	  validation	  study	  to	  assess	  the	  reliability	  or	  reproducibility	  of	  the	  acquisition	  protocols	  and	  analysis	  in	  cardiac	  MRS	  at	  3-­‐Tesla	  using	  Image-­‐selected	  in	  vivo	  spectroscopy	  (ISIS).	  Such	   a	   validation	   study	  was	   prudent	   prior	   to	   embarking	   on	   the	   sub-­‐study	   of	  HYPER;	  evaluating	  the	  role	  of	  perhexiline	  on	  myocardial	  energetics	  measured	  by	  MRS.	  Hence	  a	  validation	  study	  was	  undertaken	  recruiting	  healthy	  volunteers.	  Once	  the	  reliability	  and	  reproducibility	   of	   our	   MRS	   protocols	   were	   established,	   the	   HYPER	   sub-­‐study	   began	  recruitment.	  	  
The	   HYPER	   sub-­‐study	   enrolled	   patients	   under	   the	   same	   inclusion	   and	   exclusion	  criterion	   as	   the	  main	  HYPER	   trial.	   In	   addition	   it	   excluded	   those	   patients	  with	   IHD,	   in	  order	   to	   recruit	  a	  homogenous	  patient	  cohort,	  which	  allowed	   the	  study	  of	  myocardial	  energetics	   purely	   on	   pressure	   overload	   hypertrophy	   and	   evaluated	   the	   impact	   of	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metabolic	  modulation	  of	  perhexiline	  in	  these	  patients.	  As	  highlighted	  earlier,	  the	  same	  recruitment	  concerns	  as	  with	  the	  HYPER	  trial	  persisted	  in	  this	  study.	  	  
When	  the	  DSMB	  recommended	  the	  HYPER	  trial	  to	  be	  halted	  on	  the	  basis	  of	  futility,	  this	  also	   referred	   to	   the	   futility	   in	  pursuing	   the	  use	  of	  perhexiline	   in	  any	   form,	   in	  patients	  undergoing	  cardiac	  surgery.	  Therefore	   the	  sub-­‐study	   looking	  at	  myocardial	  energetics	  also	   had	   to	   cease,	   reflected	   by	   the	   small	   number	   of	   patients	   recruited.	   The	   small	  numbers	   recruited	   into	   this	   sub-­‐study	   ultimately	   limits	   the	   interpretation	   of	   the	   data	  and	  influences	  the	  conclusions	  that	  can	  be	  extrapolated	  from	  this	  study.	  	  
In	   hindsight	   studies	   that	   have	   the	   same	   IMP	   being	   evaluated	   should	   not	   be	   so	  intrinsically	  inter-­‐linked	  and	  this	  would	  avoid	  one	  impacting	  on	  the	  other.	  Evaluation	  of	  myocardial	  energetics	  and	  impact	  of	  perhexiline	  in	  left	  ventricular	  hypertrophy	  should	  have	  been	  a	  stand-­‐alone	  study.	  Recruiting	  patients	  that	  were	  awaiting	  cardiac	  surgery	  disrupted	   recruitment	   and	   trial	   progression,	   due	   to	   the	   clinical	   urgency	   for	   an	  operation.	  	  	  
The	  Magnetic	   Resonance	   Spectroscopy	   analysis	   of	   cardiac	   energetics	   has	   refuted	   the	  hypothesis	   that	   perhexiline	   therapy	   via	   metabolic	   modulation	   improves	   the	   cardiac	  energetic	   status	   in	   patients	   with	   left	   ventricular	   hypertrophy	   secondary	   to	   pressure	  overload,	   due	   to	   aortic	   stenosis.	   Furthermore,	   speckle-­‐tracking	   echocardiography	  showed	   no	   difference	   between	   the	   groups.	   This	   is	   unsurprising	   given	   the	   neutral	  findings	  of	  the	  clinical	  trial	  and	  preliminary	  hypothesis	  being	  disproved.	  It	  was	  evident	  at	   this	   stage	   that	   any	   further	   laboratory	   studies	   evaluating	   the	   role	   and	   impact	   of	  perhexiline	  on	  cardiac	  metabolism	  would	  be	  fruitless.	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8.3 Metabolomic	  assessment	  of	  the	  hypertrophic	  myocardium	  
The	   metabolomic	   study	   of	   cardiac	   tissue	   is	   novel	   in	   that,	   to	   our	   knowledge	   the	  metabolomic	   assessment	   of	   myocardial	   halves	   has	   not	   been	   studied	   before.	  Furthermore,	   despite	   the	   expected	  difference	  between	   the	   epicardial	   and	   endocardial	  halves	  due	  to	  known	  pathophysiological	  changes,	   their	  metabolome	  was	  not	  different.	  This	   study	   has	   been	   discussed	   in	   detail	   in	   Section	   6.4.	   This	   metabolomic	   study	   has	  disproved	   the	   hypothesis	   that,	   the	   pathophysiological	   changes	   that	   take	   place	   during	  pressure	   overload	   hypertrophy	   changes	   the	  metabolome	   between	   the	   epicardial	   and	  endocardial	   halves.	   However,	   better	   statistically	   powered	   metabolomic	   studies	   are	  warranted	  to	  examine	  this	  further.	  	  
Cardiac	  tissue	   is	  difficult	   to	  obtain	  and	  most	  metabolomic	  studies	   in	   the	   literature	  are	  performed	  on	  plasma	  and	  serum	  (Mayr	  2011).	  The	  process	  of	  mass	  spectroscopy	  based	  metabolomics	  destroys	  the	  tissue	  being	  examined,	  which	  limits	  the	  number	  of	  analyses	  that	   can	   be	   performed	   on	   a	   specific	   tissue	   sample.	   These	   constraints	   impact	   on	   the	  feasibility	   of	   metabolomic	   assessment	   in	   cardiac	   research	   using	   cardiac	   tissue.	   Our	  group	   have	   performed	   a	   number	   of	   preliminary	   studies	   to	   optimise	   the	  methodology	  and	   analysis	   described	   in	   this	   thesis,	   initially	   by	   using	   animal	   tissue	   and	   then	  subsequently	  running	  a	  series	  of	  studies	  related	  to	  identifying	  the	  metabolomic	  changes	  to	  metabolic	   therapy	   in	  cardiac	   tissue;	   first	  with	  GIK	   therapy	  (Howell	  2010)	  and	   then	  with	  perhexiline	   therapy	  (Drury	  NE,	  Howell	  NJ	  et	  al.	  2014).	  Due	   to	   the	   lack	  of	  clinical	  benefit	  with	  perhexiline	  in	  LVH	  and	  previous	  metabolomic	  studies	  showing	  no	  change	  in	  the	  metabolome	  with	  perhexiline,	  that	  line	  of	  enquiry	  in	  LVH	  was	  groundless.	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8.4 Identifying	  key	  regulators	  involved	  in	  low	  cardiac	  output	  	  
Through	   the	   results	   of	   the	   clinical	   trials	   and	   assessment	   of	   cardiac	   energetics,	   it	  was	  evident	  perhexiline	  had	  little	  if	  at	  all	  no	  impact	  on	  myocardial	  protection,	  let	  alone	  any	  clinical	   outcomes	   associated	  with	   an	   improved	  myocardial	   protection.	   Therefore	   this	  final	  study	  was	  developed	  to	  identify	  key	  master	  regulators	  that	  may	  have	  an	  inherent	  mechanistic	  role	  in	  the	  development	  of	  low	  cardiac	  output	  episode	  (LCOE)	  post	  cardiac	  surgery.	  Our	  group	  had	  previously	  identified	  that	  GIK	  therapy	  may	  improve	  myocardial	  protection	  by	  some	  of	  the	  insulin	  properties,	  that	  increase	  the	  phosphorylation	  of	  AMPK	  and	   AKT	   (Howell,	   Ashrafian	   et	   al.	   2011).	   However	   it	   was	   unclear	   if	   some	   of	   these	  regulators	  were	   individually	   responsible	   towards	   predisposing	   a	   patient	   to	   sustain	   a	  low	  cardiac	  output	  episode.	  	  
This	   study	   supports	   the	   hypothesis	   that	   the	   key	   master	   regulators	   AMPK	   and	   the	  RI3K/AKT	  pathway	  are	  involved	  in	  cardioprotection	  and	  there	  is	  upregulation	  of	  their	  activity	  in	  those	  patients	  that	  do	  not	  develop	  a	  LCOE	  in	  LVH.	  This	  study	  was	  preliminary	  work	  looking	  into	  these	  regulators	  and	  therefore	  is	  more	  hypothesis	  generating,	  as	  the	  study	  had	  no	  statistical	  significance	  (almost	  reaching	  significance	  for	  AKT	  activity).	  	  This	  study	   works	   from	   a	   bottom-­‐up	   approach	   in	   trying	   to	   understand	   the	   difference	   in	  metabolic	   pathways	  between	   those	   that	   have	  LCOE	   compared	   to	   those	   that	   do	  not	   in	  LVH	  prior	  to	  any	  metabolic	  manipulation.	  	  
8.5 Conclusions	  
Perhexiline	  had	  promise.	  	  Through	  initial	  work	  conducted	  by	  our	  group	  in	  patients	  with	  cardiomyopathy	   there	   was	   evidence	   to	   suggest	   that	   perhexiline	   modulated	   the	  myocardial	   metabolism	   reflected	   by	   an	   overall	   improvement	   in	   cardiac	   energetics,	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which	   translated	   to	   improved	   clinical	   outcomes.	  The	  potential	   to	   improve	  myocardial	  metabolism	  and	  make	  it	  more	  efficient	  by	  driving	  the	  glucose	  metabolic	  pathway	  using	  an	  oral	  agent	  such	  as	  perhexiline,	  seemed	  preferable	  to	  the	  labour	  intensive	  GIK	  therapy	  that	   had	   proved	   to	   improve	   myocardial	   protection	   in	   patients	   undergoing	   cardiac	  surgery.	   Current	   myocardial	   protection	   strategies	   although	   adequate	   in	   most	   cases,	  remain	   imperfect	  with	   some	   individuals	   succumbing	   to	   a	   low	   cardiac	   output	   episode	  post	   cardiac	   surgery.	   	   Metabolic	   modulation	   as	   an	   adjunct	   to	   standard	   myocardial	  protection	   therefore	   is	   still	   favourable	   particularly	  with	   patients	  who	   have	  metabolic	  derangement,	  such	  as	  in	  pressure	  overload	  hypertrophy.	  	  
Work	  presented	  in	  this	  thesis,	  shows	  that	  oral	  perhexiline	  has	  no	  additional	  benefit	   in	  augmenting	  standard	  myocardial	  protection	  strategies	   in	  patients	  with	   left	  ventricular	  hypertrophy	   secondary	   to	   aortic	   stenosis.	   There	   were	   no	   apparent	   improvements	   in	  any	   of	   the	   clinical	   outcomes.	   These	   clinical	   findings	   are	   supported	   by	   the	   cardiac	  energetic	  studies	  in	  patients	  with	  left	  ventricular	  hypertrophy.	  	  
The	  validation	  study	  on	  magnetic	  resonance	  spectroscopy	  shows	  that	   the	  protocol	   for	  MRS	  used	  in	  the	  work	  presented	  in	  this	  thesis,	  is	  both	  reliable	  and	  reproducible.	  Cardiac	  energetic	   studies	   evaluating	   the	   role	   of	   perhexiline	   on	   left	   ventricular	   hypertrophy	  showed	   no	   improvement	   in	   cardiac	   energetics	   with	   a	   longer	   duration	   of	   therapy.	   In	  addition,	  perhexiline	  therapy	  failed	  to	  demonstrate	  an	  improvement	  in	  overall	  systolic	  and	  diastolic	  ventricular	  function	  in	  the	  hypertrophic	  heart.	  	  
The	  studies	  using	  perhexiline	  as	  a	  metabolic	  modulator	  in	  the	  context	  of	  cardiac	  surgery	  and	  in	  patients	  with	  left	  ventricular	  hypertrophy,	  shows	  no	  overall	  metabolic	  or	  clinical	  benefit.	  This	  seals	  the	  fate	  of	  perhexiline	  and	  limits	  its	  use	  as	  a	  metabolic	  modulator	  to	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patients	  who	  are	  not	  cardiac	  surgical	  candidates	  and	  are	  refractory	  to	  maximal	  medical	  therapy.	   This	   adds	   to	   the	   body	   of	   evidence	   on	   perhexiline	   and	   further	   hypothesis	  generation	   should	   be	   carefully	   considered	   against	   this	   overwhelming	   weight	   of	  evidence	  showing	  no	  myocardial	  metabolic	  benefit	  in	  cardiac	  surgical	  candidates.	  	  
Evaluation	   of	   the	  metabolome	   of	   the	   hypertrophic	  myocardium	   although	   expected	   to	  show	  a	  difference	  due	   to	   the	  pathophysiological	   stressors	  of	  hypertrophy,	   showed	  no	  difference	   in	   the	   metabolome	   between	   the	   epicardial	   and	   endocardial	   halves.	   This	  suggests	  that	  any	  metabolomic	  differences	  that	  exist	  are	  subtle	  and	  further	  evaluation	  is	  warranted	  to	  corroborate	  these	  initial	  findings.	  	  
This	   thesis	   finally	   presents	   preliminary	   work	   in	   identifying	   key	   regulators	   that	   may	  innately	   be	   responsible	   or	   influence	   a	   low	   cardiac	   output	   episode.	   It	   is	   evident	   that	  although	  no	  statistical	  significance	  was	  reached,	  there	  is	  an	  increase	  in	  AMPK	  and	  AKT	  activity	   in	   patients	   with	   LVH	   that	   do	   not	   sustain	   a	   low	   cardiac	   output	   episode,	  highlighting	   the	   intrinsic	   cardioprotective	   properties.	   This	   study	   was	   the	   first	   step	  towards	   identifying	   key	   regulators	   that	   influence	   low	   cardiac	   output	   episodes.	  	  Subsequent	  studies	  can	  then	  target	  metabolic	  therapies	  that	  up-­‐regulate	  these	  specific	  processes	  and	  this	  may	  improve	  myocardial	  protection	  further.	  	  
8.6 Future	  work	  
8.6.1 Metabolic	  manipulation	  to	  improve	  myocardial	  protection	  	  
The	   neutral	   findings	   from	   the	   HYPER	   trial	   should	   not	   detract	   from	   the	   potential	  therapeutic	   role	   of	   augmenting	   myocardial	   protection	   by	   metabolic	   modulation.	  Through	  the	  trials	  of	  GIK	  in	  cardiac	  surgery,	  it	  is	  evident	  that	  some	  metabolic	  therapies	  are	   associated	   with	   improved	   myocardial	   protection.	   Future	   research	   should	   aim	   to	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identify	  and	  evaluate	  a	  metabolic	  modulating	  agent	  that	   is	  potent,	  easily	  administered	  and	  monitored	   and	   one	   that	   is	   applicable	   in	   real-­‐world	   cardiac	   surgery.	   Despite	   very	  promising	   laboratory	   outcomes	   for	   some	   metabolic	   therapies	   such	   as	   perhexiline,	  translating	   these	   into	   clinical	   practice	   may	   not	   bring	   to	   fruition	   the	   same	   expected	  outcomes.	   Therefore	  when	   using	   an	   IMP	   that	   has	   not	   been	   used	   in	   the	   same	   field	   of	  study,	   it	   is	  prudent	  to	  perform	  a	  phase	  II	  trial	   in	  the	  first	   instance	  and	  this	  would	  also	  help	   towards	   calculating	   an	   adequately	   powered	   study	   if	   the	   IMP	   is	   thought	   to	   have	  adequate	  efficacy	  in	  the	  cohort	  studied.	  	  	  
The	   need	   to	   find	   an	   appropriate	   metabolic	   agent	   that	   will	   augment	   myocardial	  protection	  continues,	  particularly	  in	  the	  most	  vulnerable	  groups	  of	  patients,	  such	  as	  in	  hypertrophic	   or	   dilated	  heart	   disease.	  Metabolic	   therapies	   should	   aim	  both	   to	   reduce	  the	   uncoupling	   effect	   between	   glycolysis	   and	   glucose	   oxidation	   and	   to	   reduce	   the	  burden	  of	   fatty	  acid	  oxidation	  during	   the	   ischaemic	  and	  reperfusion	  phases	  of	  cardiac	  surgery.	  	  
As	  opposed	  to	  modulating	  the	  substrate	  utilised	  and	  driving	  a	  more	  efficient	  metabolic	  pathway,	  an	  alternate	  mode	  of	  metabolic	  modulation	  would	  be	  to	  target	  the	  Krebs	  Cycle	  intermediates.	   Fumarate	   is	   an	   intermediate	  within	   the	  Krebs	   Cycle	   and	   is	   reduced	   to	  succinate	   during	   hypoxia	   (Laplante,	   Vincent	   et	   al.	   1997).	   Our	   group	   have	   conducted	  some	   preliminary	   work	   evaluating	   the	   cardioprotective	   properties	   of	   fumarate.	   In	   a	  mouse	  model,	  inactivation	  of	  the	  gene	  that	  breaks	  down	  fumarate	  (fumarate	  hydratase,	  Fh1)	   showed	   that	   the	   Fh1-­‐knock	   out	   mice	   were	   more	   tolerate	   of	   ischaemia	   with	  reduced	  myocyte	  necrosis,	   improved	  recovery	  of	  coronary	  flow	  reserve	  and	  reduction	  in	  troponin	  release	  (Ashrafian,	  Czibik	  et	  al.	  2012).	  These	  findings	  were	  consistent	  with	  oral	  supplementation	  of	   fumarate.	  This	   increased	  tolerance	  to	   ischaemia	  was	  found	  to	  
	  8-­‐246	  
be	  associated	  with	  an	  increased	  expression	  of	  redox	  sensitive	  transcription	  factor	  Nrf2,	  a	   key	   element	   in	   the	   antioxidant	   pathway.	   These	   findings	   support	   the	   proposal	   to	  perform	  a	  double	  blind	  placebo	  controlled	  randomised	  control	  trial	  evaluating	  the	  role	  of	   oral	   fumarate	   as	   a	   cardioprotective	   agent	   in	   patients	   undergoing	   cardiac	   surgery,	  using	  similar	  markers	  of	  myocardial	  protection.	  Tissue	  obtained	  from	  these	  participants	  will	  help	  understand	  the	  mechanism	  and	  cardioprotective	  properties	  of	  Nrf2	  activation.	  	  	  
8.6.2 Metabolomics	  and	  cardiac	  surgery	  	  
The	   collaboration	   with	   the	   School	   of	   Biosciences	   at	   the	   University	   of	   Birmingham,	  where	  the	  metabolomic	  studies	  were	  conducted	   is	  now	  well	  established.	  Metabolomic	  studies	   on	   cardiac	   tissue,	   can	   be	   taken	   further	   to	   evaluate	   the	  metabolome	   of	   tissue	  from	  different	  chambers	  of	  the	  heart;	  the	  assessment	  between	  right	  and	  left	  ventricular	  myocardium	  may	  help	  understand	  the	  metabolomics	  of	  right	  ventricular	  dysfunction	  in	  some	  individuals	  post	  cardiac	  surgery.	  Furthermore	  a	  study	  of	  the	  metabolome	  between	  pressure	   overload	   and	   volume	   overload	   hypertrophy	   can	   help	   map	   a	   metabolomic	  skeleton	   for	   the	   spectrum	   of	   hypertrophic	   disease.	   Further	   metabolomic	   profiling	   of	  patients	   known	   to	   have	   a	   deranged	  metabolism	   such	   as	   dilated	   cardiomyopathy	  may	  help	  identify	  particular	  metabolic	  pathways	  that	  can	  be	  up-­‐regulated.	  	  
8.6.3 Identification	  of	  key	  metabolic	  regulators	  	  
The	   final	   study	   in	   this	   thesis	   examined	   and	   identified	   an	   increased	   activity	   of	   key	  regulators	   AMPK	   and	   AKT	   within	   the	   group	   that	   did	   not	   have	   a	   low	   cardiac	   output	  episode.	   These	   regulators	   are	   known	   to	   have	   cardioprotective	   properties.	   Further	  studies	   are	   warranted	   to	   evaluate	   the	   activity	   of	   their	   down	   stream	   targets	   and	  potential	  mechanism	  of	  action.	  	  This	  bottom-­‐up	  approach	  in	  identifying	  regulators	  that	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are	  inherently	  more	  active	  in	  patients	  that	  do	  not	  sustain	  a	  low	  cardiac	  output	  episode	  helps	  identify	  the	  specific	  targets	  for	  manipulation.	  The	  activation	  of	  AKT	  is	  intrinsic	  to	  the	   RISK	   pathway;	   therefore	   pharmacological	   agents	   that	   target	   this	   pathway	   can	  enhance	  their	  cardioprotective	  properties	  and	  improve	  myocardial	  protection.	  	  
8.6.4 Other	  potential	  cardioprotective	  pharmacological	  agents	  
Our	   group	   has	   conducted	   a	   retrospective	   analysis	   of	   prospectively	   collected	   data	   on	  diabetic	  patients	  who	  have	  undergone	  cardiac	  surgery	  over	  a	  6	  year	  period,	  and	  found	  that	   there	   is	  an	   increased	  benefit	  with	  reduction	   in	  overall	  mortality	  and	   incidence	  of	  low	  cardiac	  output	  episodes	  in	  patients	  that	  have	  been	  on	  metformin	  compared	  to	  those	  not	   on	  metformin	   (unpublished).	   These	   clinical	   results	   are	   insightful.	   There	   has	   been	  speculation	   for	   some	   time	   that	   metformin	   may	   have	   some	   cardioprotective	   benefits	  (Sasali	   and	   Leahy	   2003),	   however	   this	   needs	   further	   thorough	   evaluation.	   This	   is	  currently	  underway	  by	  way	  of	  laboratory	  based	  testing	  on	  cardiomyocytes	  subjected	  to	  hypoxemic	   testing,	   to	   understand	   the	   mechanistic	   cardioprotective	   properties	   if	   any,	  with	  metformin.	  Retrospective	   identification	  of	  new	  cardioprotective	  pharmacological	  agents	  should	  be	  conducted	  in	  parallel	  with	  laboratory	  studies	  that	  help	  elucidate	  and	  identify	   the	   likely	   mechanism	   of	   cardioprotective	   action.	   Further	   studies	   to	   analyse	  human	  tissue	  from	  patients	  on	  metformin	  undergoing	  cardiac	  surgery,	  are	  planned.	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9 APPENDIX	  
9.1 ACC/AHA	  2008	  Valvular	  heart	  disease	  indications	  for	  AVR	  
Class	  I	  
1. AVR	  is	  indicated	  for	  symptomatic	  patients	  with	  severe	  AS.	  (Level	  of	  Evidence	  B)	  2. AVR	  is	  indicated	  for	  patients	  with	  severe	  AS	  undergoing	  coronary	  artery	  bypass	  graft	  surgery	  (CABG).	  (Level	  of	  Evidence	  C)	  3. AVR	  is	  indicated	  for	  patients	  with	  severe	  AS	  undergoing	  surgery	  on	  the	  aorta	  or	  other	  heart	  valves.	  (Level	  of	  Evidence	  C)	  4. AVR	   is	   recommended	   for	   patients	   with	   severe	   AS	   and	   LV	   systolic	   dysfunction	  (ejection	  fraction	  less	  than	  0.5).	  (Level	  of	  Evidence	  C)	  
Class	  IIa	  
1. AVR	  is	  reasonable	  for	  patients	  with	  moderate	  AS	  undergoing	  CABG	  or	  surgery	  on	  the	  aorta	  or	  other	  heart	  valves	  	  (Level	  of	  Evidence:	  B)	  
Class	  IIb	  
1. AVR	  may	  be	  considered	  for	  asymptomatic	  patients	  with	  severe	  AS	  and	  abnormal	  response	   to	   exercise	   (e.g.,	   development	   of	   symptoms	   or	   asymptomatic	  hypotension).	  (Level	  of	  Evidence:	  C)	  2. 	  AVR	  may	  be	  considered	  for	  adults	  with	  severe	  asymptomatic	  AS	  if	  there	  is	  a	  high	  likelihood	  of	  rapid	  progression	  (age,	  calcification,	  and	  CAD)	  or	   if	  surgery	  might	  be	  delayed	  at	  the	  time	  of	  symptom	  onset.	  (Level	  of	  Evidence:	  C)	  
3.	  	   AVR	  may	  be	   considered	   in	  patients	  undergoing	  CABG	  who	  have	  mild	  AS	  when	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there	  is	  evidence,	  such	  as	  moderate	  to	  severe	  valve	  calcification,	  that	  progression	  may	  be	  rapid.	  (Level	  of	  Evidence:	  C)	  
4.	   	  AVR	  may	   be	   considered	   for	   asymptomatic	   patients	   with	   extremely	   severe	   AS	  (aortic	  valve	  area	  less	  than	  0.6	  cm2,	  mean	  gradient	  greater	  than	  60	  mm	  Hg,	  and	  jet	  velocity	  greater	  than	  5.0	  m	  per	  second)	  when	  the	  patient’s	  expected	  operative	  mortality	  is	  1.0%	  or	  less.	  (Level	  of	  Evidence:	  C)	  
Class	  III	  
1. AVR	   is	  not	  useful	   for	   the	  prevention	  of	  sudden	  death	   in	  asymptomatic	  patients	  with	   AS	   who	   have	   none	   of	   the	   findings	   listed	   under	   the	   CLASS	   IIa/IIb	  recommendations.	  (Level	  of	  Evidence:	  B)	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9.2 Principles	  of	  an	  Aortic	  Valve	  Replacement	  	  
Conventional	   aortic	   valve	   replacements	   are	  performed	   through	  a	  median	   sternotomy,	  although	   minimal	   access	   approaches	   are	   now	   practiced.	   Cardiopulmonary	   bypass	   is	  established	  with	  arterial	  return	  into	  the	  ascending	  aorta	  and	  venous	  drainage	  from	  the	  right	  atrium.	  Myocardial	  protection	  is	  delivered	  through	  a	  cardioplegia	  cannula	  placed	  in	   the	   ascending	   aorta.	  Once	   full	   flow	   cardio-­‐pulmonary	  bypass	   is	   achieved,	   an	   aortic	  cross	  clamp	  is	  placed	  on	  the	  ascending	  aorta	  proximal	  to	  the	  arterial	  return	  cannulation	  and	   distal	   to	   the	   cardioplegia	   cannulation	   site.	   The	   heart	   is	   then	   arrested	   using	   the	  potassium	  rich	  cardioplegia	  solution.	  	  
Once	   the	   heart	   is	   adequately	   arrested	   a	   transverse	   incision	   is	   made	   in	   the	   proximal	  aorta	   to	   expose	   the	   aortic	   valve.	   The	   valve	   is	   excised	   and	   the	   annulus	   of	   the	   aorta	   is	  debrided.	   The	   valve	   is	   sized	   using	   the	   appropriate	   sizing	   instruments.	   The	   tissue	   or	  mechanical	   valve	   is	   implanted	  using	   either	   a	   semi-­‐continuous	   suture	   technique	   or	   an	  interrupted	   suture	   technique.	   The	   valve	   is	   then	   tied	   into	   position	   and	   the	   aortotomy	  closed.	  	  




9.3 HYPER	  statistical	  analysis	  plan	  	  
EFFICACY	  	  Primary	  Outcome	  	  The	  primary	  end	  point	  was	  the	  incidence	  of	  inotrope	  use	  ±	  comparison	  of	  cardiac	  index	  to	  show	  an	  increase	  >	  0.3L/min/m2	  within	  the	  first	  6	  hours	  from	  reperfusion	  	  Secondary	  Outcomes	  	  Cardiac	  index	  Low	  cardiac	  output	  episode	  	  Inotrope	  usage	  Peak	  cardiac	  troponin	  ECG	  evidence	  of	  new	  myocardial	  injury	  Composite	  endpoint	  of	  either	  peak	  cardiac	  troponin	  or	  ECG	  evidence	  of	  new	  myocardial	  injury	  	  Length	  of	  stay	  (Intensive	  Care,	  Hospital)	  	  Safety	  Outcome	  Measures	  	  Postoperative	  death	  Stroke	  with	  residual	  deficit	  Requirement	  for	  renal	  replacement	  therapy	  Reoperation	  Chest	  drainage	  at	  12	  hours	  Treated	  infection	  episodes	  Respiratory	  index	  (PaO2/FiO2)	  on	  arrival	  in	  Intensive	  Care	  and	  12	  hours	  postoperatively	  	  
STATISTICAL	  METHODS	  AND	  DATA	  CONSIDERATIONS	  	  Analysis	  will	  be	  carried	  out	  using	  SAS©	  version	  9.2	  All	  statistical	  tests	  will	  be	  two-­‐sided,	  and	  deemed	  to	  be	  statistically	  significant	  if	  p<0.05.	  No	  adjustments	  for	  multiplicity	  will	  be	   made.	   All	   analyses	   will	   be	   undertaken	   stratified	   for	   LV	   function	   at	   baseline	   and	  elective/urgent	  surgery.	  Consultant	  surgeon	  will	  be	  accounted	  for	  as	  a	  random	  effect.	  	  The	   only	   data,	  which	  will	   be	   formally	   analysed,	   are	   those	  which	   could	   potentially	   be	  affected	   by	   which	   treatment	   group	   they	   are	   assigned	   to.	   Demographic	   and	   other	  baseline	  data	  will	  not	  be	  formally	  analysed,	  other	  than	  descriptively.	  	  The	   two	   treatment	   groups	   of	   patients	   in	   this	   study	   will	   be	   identified	   in	   tables	   and	  listings	  as:	  	  Perhexiline	  Control	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Handling	  of	  missing	  and	  incomplete	  data	  
	  Primary	  efficacy	  variable:	  In	  the	  event	  of	  death	  before	  assessment	  of	  primary	  endpoint,	  LCOE	  will	  be	  assigned.	  	  Secondary	  efficacy	  variables:	  Missing	  secondary	  endpoints	  will	  be	  excluded	  from	  the	  analysis.	  	  	  	  
ANALYSIS	  
	  
Primary	  efficacy	  variable	  The	   primary	   objective	   is	   to	   evaluate	   the	   effects	   of	   perhexiline	   on	   the	   incidence	   of	  inotrope	  use	  ±	  comparison	  of	  cardiac	  index	  to	  show	  an	  increase	  >	  0.3L/min/m2	  within	  the	  first	  6	  hours	  from	  reperfusion	  as	  defined	  by	  the	  Endpoints	  Committee.	  The	  primary	  analysis	   will	   be	   a	   non-­‐linear	   mixed	   model	   accounting	   for	   baseline	   LV	   function	   and	  elective/urgent	  surgery	  with	  surgeon	  as	  a	  random	  effect.	  Odds	  ratio	  95%	  CI	  and	  p	  value	  will	  be	  presented.	  	  
Efficacy	  evaluable	  population	  The	  efficacy	  evaluable	  population	  will	  consist	  of	  the	  all-­‐patients-­‐randomised	  population	  who	  received	  therapy	  (perhexiline	  or	  placebo)	  and	  underwent	  surgery	  on	  cardiopulmonary	  bypass	  and	  had	  a	  Swan	  Ganz	  catheter	  over	  the	  6hrs	  post	  cross	  clamp	  removal	  (reperfusion	  period),	  which	  is	  required	  to	  collect	  the	  primary	  end	  point	  data.	  	  	  Secondary	  outcome	  measures	  	  
Cardiac	  index:	  to	  detected	  an	  increase	  of	  0.3	  L/min/m2	  in	  cardiac	  index	  in	  the	  first	  6	  hours	  from	  release	  of	  aortic	  cross	  clamp	  in	  the	  treatment	  group.	  	  1.	   	   Cardiac	   index	   at	   6	   hours	  will	   be	   analysed	  using	   generalised	   linear	  modelling	  with	  baseline	   cardiac	   index,	   elective/urgent	   surgery,	   baseline	   LV	   function	   and	   treatment	  (Perhexiline/control)	  as	  covariates	  and	  surgeon	  as	  a	  random	  effect.	  	  2.	  Cardiac	  index	  up	  to	  12	  hours	  will	  be	  analysed	  using	  generalised	  linear	  modelling	  with	  cardiac	  index	  (baseline,	  pre,	  post,	  2,	  4,	  6,	  9	  &	  12	  hours)	  as	  repeated	  measures,	  adjusted	  to	  baseline,	  and	  accounting	  for	  elective/urgent	  surgery,	  LV	  function	  and	  perhexiline	  as	  covariates	  and	  surgeon	  as	  a	  random	  effect.	  	  	  	  
Inotrope	  usage:	  assessed	  by	  incidence	  of	  use	  based	  on	  predetermined	  protocols	  and	  total	  dosage/kg	  in	  the	  first	  6	  and	  12	  hours	  postoperatively.	  	  Incidence	  and	  dose	  will	  be	  assessed:	  	  1.	  In	  the	  first	  6	  hours	  after	  removal	  of	  aortic	  X-­‐clamp	  (also	  includes	  on	  cardiopulmonary	  bypass).	  	  2.	  In	  the	  first	  12	  hours	  after	  removal	  of	  aortic	  X-­‐clamp.	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  The	  incidence	  of	  inotrope	  use	  at	  each	  time	  period	  will	  be	  assessed	  using	  a	  non-­‐linear	  mixed	  model	  accounting	  for	  elective/urgent	  surgery	  and	  baseline	  LV	  function	  with	  surgeon	  as	  a	  random	  effect.	  	  	  
Peak	  cTnT:	  in	  the	  first	  24	  hours	  following	  release	  of	  the	  aortic	  cross	  clamp	  	  	  1.	  Linear	  model	  with	  baseline	  cTnT	  as	  covariate	  accounting	  for	  baseline	  LV	  function,	  elective/urgent	  surgery	  and	  with	  surgeon	  as	  a	  random	  effect	  (use	  peak	  cTnT	  at	  any	  timepoint	  in	  model).	  	  2.	  Repeated	  measures	  analysis	  –	  baseline,	  6	  hours,	  12	  hours,	  24	  hours.	  	  	  
ECG	  evidence	  of	  new	  myocardial	  injury:	  assessed	  by	  a	  blinded	  Cardiologist	  according	  to	  standard	  criteria	  using	  the	  presence	  of	  new	  Q	  waves,	  new	  bundle	  branch	  block	  or	  loss	  of	  R	  wave	  progression.	  	  The	  presence	  of	  ECG	  evidence	  of	  new	  myocardial	  injury	  will	  be	  assessed	  using	  a	  non-­‐linear	  mixed	  model	  (logistic)	  accounting	  for	  baseline	  LV	  function	  and	  elective/urgent	  surgery	  with	  surgeon	  as	  a	  random	  effect.	  	  
Length	  of	  stay	  (LOS):	  this	  will	  include	  both	  intensive	  care	  and	  hospital	  stay	  within	  the	  department	  of	  Cardiothoracic	  Surgery.	  	  The	  effect	  of	  perhexiline	  on	  mean	  length	  of	  stay	  (days)	  will	  be	  assessed	  using	  a	  non-­‐linear	  mixed	  model	  (poisson	  distribution)	  accounting	  for	  baseline	  LV	  function	  and	  elective/urgent	  surgery	  with	  surgeon	  as	  a	  random	  effect.	  	  	  	  Safety	  outcome	  measures	  	  Postoperative	  death	  Stroke	  with	  residual	  deficit	  Requirement	  for	  renal	  replacement	  therapy	  Reoperation	  Chest	  drainage	  at	  12	  hours	  Treated	  infection	  episodes	  Respiratory	  index	  (PaO2)/FiO2	  on	  arrival	  in	  Intensive	  Care	  and	  12	  hours	  postoperatively	  Should	   any	   patient	   report	   the	   same	   event	   more	   than	   once	   then	   this	   event	   will	   be	  counted	   only	   once	   in	   the	   summary	   tables	   and	   summarised	   at	   the	   highest	   observed	  severity	  and	  relationship	  to	  study	  drug.	  Specific	  adverse	  events	  that	  occur	  in	  at	  least	  5%	  of	  patients	  will	  be	  formally	  tested	  using	  Fisher’s	  exact	  test.	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9.4 HYPER	  Patient	  invitation	  letter	  	  







Dear …………………….,    
 
 
The HYPER trial: Support of the heart with Perhexiline in left ventricular 
hypertrophy 
 
I have been informed by Prof Pagano that you are due to be admitted to the Queen 
Elizabeth Hospital, Birmingham in the next few months for your heart operation. 
 
I would therefore like to invite you to participate in a study that we are conducting to 
help improve protection of the heart during the operation. I enclose a few pages of 
information regarding the study and would be grateful if you could read through them 
and consider whether you would like to participate. 
 
Prior to admission for their heart operation, most patients are asked to attend the 
Queen Elizabeth Hospital for a Pre-Assessment Clinic. I routinely see patients in this 
clinic and we could discuss the study further then. Otherwise, I will telephone you in 
the next few weeks. 
 
In the interim, if you have any questions, please feel free to contact myself via the 
Queen Elizabeth Hospital, Birmingham switchboard on: 0121 472 1311 or my 







Mr. Eshan Senanayake 
 
Clinical Research Fellow, 
Department of Cardiothoracic Surgery 
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9.5 HYPER	  Patient	  Information	  Sheet	  	  








Support of the Heart with Perhexiline in Left Ventricular Hypertrophy 




AN INVITATION TO PARTICIPATE IN RESEARCH 
 
The heart surgery team at the Queen Elizabeth Medical Centre is inviting patients to participate in 
research aimed at making aortic valve surgery safer. We would like to recruit patients undergoing this 
kind of surgery into a clinical trial where potentially advantageous methods of altering the way we 
treat patients are used to see what differences they actually make to patients’ progress. We include a 
simple and non-technical summary of the reasons for the study and what it will involve for you over 
and above your routine treatment if you take part. 
 
If you are being approached in the outpatient clinic, we would like you to take this patient information 
sheet home with you to read and consider participating in this study. At the Pre-admission clinic, the 
doctor will ask you whether you wish to participate and to sign a consent form. You can only be 
included in this clinical trial if you give your express permission in the form of signed consent. On 
admission for your operation, a heart surgical research doctor will be available to discuss the study 
further and answer any questions.  
 
If you are already an inpatient on the ward, a member of the heart surgical team will be happy to 





Questions? Please contact Mr. Eshan Senanayake, Clinical Research Fellow in Cardiac Surgery at 
University Hospital Birmingham on his mobile: 07810 251454. 
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WHAT IS THE STUDY ABOUT? 
This study is about trying to improve the treatment of patients undergoing aortic valve surgery. To 
perform this heart operation requires the help of a heart-lung machine, which supports your body’s 
circulation whilst the surgeon removes the diseased valve and inserts a new valve, either biological or 
mechanical. During your surgery, the heart has to be protected so that it is not injured by the strain of 
the operation. Despite using standard techniques to protect the heart, some temporary injury still 
occurs from which the heart gradually recovers during the first few hours and days following the 
operation. We are seeking ways to improve on these established ‘protective techniques’ by preparing 
the heart before surgery with a drug that switches the fuel of the heart from less efficient fatty acids to 
more efficient sugars. 
 
In summary, taking the drug Perhexiline before your operation has the potential to benefit the way 
your heart works during periods of strain during and immediately after your surgery. 
 
HOW HAS THIS CLINICAL TRIAL BEEN DESIGNED? 
This study is a two-centre double-blind randomised placebo-controlled trial. This means that if you 
agree to take part, you would be allocated by chance to receive either the drug Perhexiline or a 
placebo – a tablet that looks the same but has no medicinal properties. The tablets are coded so that 
neither you nor the surgical team will know which one you are receiving and therefore the study is 
called ‘double-blind’. The code is revealed once all the patients in the trial have been completed. By 
giving the tablets in this way, we can determine the benefits of using them in patients undergoing 
aortic valve surgery. 
 
HOW WILL WE MEASURE THE EFFECTS OF THIS TABLET? 
To detect changes in heart function, we need to take measurements of performance before, during 
and after surgery to show whether the treatment has made a difference. To do this we will make use 
of small monitoring catheters (plastic tubes) inserted into blood vessels in the neck. These tubes are 
routinely used in two out of three patients who are not in the trial. These catheters are placed in 
position in blood vessels whilst you are under anaesthetic (asleep) and are usually removed on the 
first or second day following surgery. We will record measurements from these catheters during this 
period at specific time points. We will insert an additional sampling catheter into your heart during 
your operation to monitor blood in the veins of your heart. This catheter is normally used as an 
additional way to deliver protection to the heart in patients at high-risk for surgery; in your case, it will 
be used only to withdraw a sample of blood from your heart veins. It will be removed at the end of the 
use of the heart-lung machine. 
 
MEASURING THE POSSIBLE BENEFICIAL EFFECTS OF THE TABLET ON THE HEART’S METABOLISM  
The sampling of additional blood tests: The blood tests performed on these samples can tell us 
how well the heart is tolerating the surgery. These blood samples are removed through the same 
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monitoring lines already mentioned. The total amount of additional blood taken for this study is about 
a cupful (approximately 60 mls / 2 floz). 
 
Health questionnaire: You may be asked to complete a simple health questionnaire twice during the 
study: once before starting the trial tablets and once in the routine follow-up clinic at approximately 6 
weeks after your operation. 
 
Imaging the heart using a transoesophageal echocardiogram: This is a test that uses ultrasound 
(sound waves) to produce pictures of the heart. The ultrasound probe is placed in the gullet whilst you 
are asleep and removed before you are woken up. It allows us to measure the function of the heart 
during the operation as the previous test cannot be used at this stage. This is performed routinely in 
all patients undergoing heart valve surgery but extra pictures will be taken to analyse the heart 
function. 
 
The removal of tiny samples of the heart muscle known as biopsies: This will help tell us how the 
Perhexiline tablet improves the way the heart works. We would aim to obtain 3 heart muscle biopsies, 
all whilst you are asleep under the anaesthetic, one each at the beginning, middle and end of being 
on the heart-lung machine. They will be performed by the operating surgeon and are very small, 
about so long and thin (▬▬). A suture is placed in the tiny defect left behind and their removal incurs 
no increased risk during or after the surgery nor has any effect on the strength of the heartbeat. 
Although there is a hypothetical risk of bleeding in taking this biopsy, we have performed more than 
2000 biopsies in patients at the time of writing this information leaflet with no complications. 
The removal of samples of superficial muscle and fat: The Perhexiline tablet has an effect on 
many other parts of the body as well as the heart. We would take small biopsies, weighing 
approximately one gram, of muscle from the lower end of the normal surgical incision and of fat from 
around the heart. This will allow us to look at how Perhexiline works in more detail. This will be 
performed by the operating surgeon and occur while you are asleep under the anaesthetic. It would 
not affect the strength, appearance or discomfort of the scar after your surgery. 
 
WHAT WILL I HAVE TO DO? 
If you decide to participate, there are a number of stages to the study. You will be guided through 
these stages by us (the research doctors looking after you). You have been given this written 
information sheet and asked to read it at your leisure at home or on the ward, if you are already an 
inpatient. Before your surgery, in either the pre-operative assessment clinic or on the ward, a member 
of the research team will visit so you can ask any questions. If you give signed consent, we will then 
randomise you to receive either the tablet or the placebo and we will give you the medication with a 
date to start taking it, usually 1-2 weeks before your admission. 
 
In the anaesthetic room of the operating theatre, the Anaesthetist will give you a general anaesthetic. 
Once you are asleep, the Anaesthetist will insert the pressure-measuring catheters normally inserted 
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at this stage. The operation will be conducted in a normal way under the care of the Consultant 
Cardiac Surgeon who is in charge of your case. The blood samples and biopsies will be performed 
while you are asleep and you will be unaware of them. The sampling of blood from the veins of the 
heart will also be performed whilst you are asleep during the use of the heart-lung machine only. 
When you awake, you will be on the intensive care unit as routine. Only some further blood samples 
and monitoring tests will remain. The last blood test will be performed at 24 hours after the operation. 
 
In summary, we will be taking measurements from pressure-measuring catheters that are routinely 
used in heart surgery. The entire sampling of blood for the research will total 60 ml and will not affect 
your recovery and, because we can use intravenous pressure-measuring lines, there will be no 
additional need for needles. The biopsies that we take are removed painlessly during the operation 
and have no effect on the heartbeat. 
 
WHAT ARE THE BENEFITS? 
We do not know whether giving patients the tablet Perhexiline will benefit them as an individual – this 
study is investigating that question. It is hoped that this study will provide information that will benefit 
future patients undergoing heart valve surgery. In particular it will help us design more suitable 
treatments for patients who have a very weak heartbeat before surgery and are at high risk of 
complications after surgery. In the future and after more research, the use of this tablet could 
significantly improve their recovery from heart surgery. 
 
WHAT ARE THE RISKS? 
Previous studies with Perhexiline have shown that it is safe. Some patients (less than 10%) may feel 
a bit sick after the first few tablets but this usually passes very soon. If these tablets continue to make 
you feel sick, you can simply stop taking them without harm and your surgery will proceed as planned. 
If you stop taking these tablets, we would be grateful if you could contact the Research team on 
07810 251454. 
 
In some patients who had taken the tablet for long periods of time (many months or years), a very 
small number developed some numbness or muscle weakness and/or mild liver changes including 
going yellow (jaundice) and loss of appetite. It has since been shown that this can be avoided by 
monitoring the level of the drug in the blood. These side effects have never been seen when people 
take the tablet for just a few weeks and so are very unlikely to affect you. However, if you have any 
concerns, we would ask you to contact one of the Heart Surgery Research Team at University 
Hospital Birmingham. You can also contact your GP, who will be given more information about the 
tablet and the trial if you agree to participate. 
 
All heart operations carry some risk and these will have already been discussed with you. For this 
study we insert routinely-used monitoring lines to measure heart function. The risks of this are 
minimal and the possibility of a severe complication is in the region of 1 in 15,000. The only additional 
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invasive procedure performed on you is the biopsy of the heart muscle. Theoretically, there is a very 
small risk of bleeding following this procedure. However, we have performed approximately 2000 
biopsies and this complication has never happened.  
 
WHAT ARE THE ALTERNATIVES? 
If you do not wish to take part in the study, your surgery will be undertaken in the standard manner 
without any additional measurements, treatments or tests. Your surgeon and anaesthetist may still 
use the monitoring lines that we have described if they feel that their use is in your best interest. 
 
WHAT HAPPENS TO THE INFORMATION? 
All the study data will be collected by Mr Pagano’s Research team. It will be stored as paper files and 
on a hospital computer which are kept in a locked office. The information from the study will be 
analysed. The information will be presented at scientific meetings and published in scientific journals 
to inform other doctors and health professionals of the research findings. All data is coded and 
confidential, ensuring that your identity will not be revealed at any time. All necessary measures will 
be taken to keep your data safe and confidential and to comply with the Data Protection Act. Only the 
Heart Surgery Research team and the Research & Development office will have access to this data. 
Following completion of this trial, the data will be kept for 15 years and then destroyed. 
 
WHAT HAPPENS TO THE SAMPLES? 
All of the biopsies will be stored in a coded form in a locked freezer and only the Heart Surgery 
Research team will have access to these samples. The samples will be analysed to look at how much 
Perhexiline is taken up by the heart. We will also look at what effect this has on the heart in terms of 
how it works and how much energy it can store. The biopsies are very small and the simple act of 
analysing them will destroy the sample. At the end of the study, any remaining samples will be 
destroyed within 6 months. 
 
WHO ELSE IS TAKING PART? 
We will recruit 220 patients to this study.  
 
WHAT IF SOMETHING GOES WRONG? 
The standard care of patients undergoing heart surgery involves intensive monitoring. This monitoring 
allows us to detect any problems early in their development. We do not expect the study itself to 
cause any problems, however as for all heart surgery, we are in an ideal position to deal with any 
untoward events during your operation and these will be treated in the normal manner, regardless of 
the research study. At the time of the measurements, you will be in either the theatre or the ITU where 
trained staff are at hand at all times. Your safety during and after surgery is paramount, and takes 
precedence over any research. 
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In the event that something does go wrong and you are harmed during the research study, there are 
no special compensation arrangements. If you are harmed due to someone’s negligence, you may 
have grounds for a legal action for compensation against University Hospital Birmingham but you may 
have to pay your legal costs. The normal National Health Service complaints mechanisms will be 
available to you. Further information can be obtained from the Patient Advice & Liaison Service 
(PALS) which is available Monday to Friday 9am to 5pm on 0121 627 8820. 
 
WHAT HAPPENS AT THE END OF THE STUDY? 
At the end of the study, your treatment will continue as would that of a patient who had not been 
involved with the study. You will only need to take the study tablets before your operation. 
 
WHAT IF I HAVE MORE QUESTIONS OR DO NOT UNDERSTAND SOMETHING? 
Please ask one of the investigators about any questions or worries that you may have so that any 
points can be clarified. You should feel free to ask questions at any time by contacting Mr. Eshan 
Senanayake (Research Fellow) on: 07810 251454. If you are on the ward, ask one of the nurses to 
contact Mr. Senanayake via switchboard. If he is unavailable, ask for either Mr. Drury (Clinical 
Lecturer) or Mr. Pagano (Consultant Surgeon). 
 
WHAT HAPPENS NOW IF I DECIDE TO TAKE PART? 
We will take some details and ask you to sign a consent form that documents your willingness to 
participate. We will give you the tablets, which will be either Perhexiline or the placebo, and 
instructions on when to take them. You will need to take one or more tablets twice per day prior to 
your operation – in the morning and in the evening. We will also write to your GP to let them know that 
you have agreed to join this study and giving them more details. You will be listed for surgery as 
normal. You are free to withdraw from the study after initially consenting without giving reason and 
without prejudice to your continuing care or the standard care of any future treatment. 
 
WHO IS ORGANISING AND FUNDING THIS RESEARCH? 
This research has been organised and developed by the Heart Surgery Research teams at University 
Hospital Birmingham and the Royal Sussex County Hospital, Brighton. It is being funded by the 
British Heart Foundation. 
 
WHO HAS REVIEWED THIS STUDY? 
This study was given a favourable ethical opinion for conduct in the NHS by the Cambridgeshire 1 
Research Ethics Committee, United Kingdom. 
 
THANK YOU 
Finally the Heart Surgery research team would like to thank you for taking the time to consider this 
research proposal. 
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PROPOSED STUDY INVOLVEMENT 
This summary flow chart demonstrates what will happen if you consent to join this study: 
 
When you were seen by your Surgeon for the first time to discuss your operation, you will have been 
invited to join this trial and given this information leaflet. 
↓ 
In your free time, we would like you to read this leaflet and consider joining the study. 
↓ 
In a few weeks, in the pre-operative assessment clinic (or on the ward if you are already an inpatient), 
you will be seen by a member of Mr Pagano’s Research team.   
↓ 
If you are happy to join this trial, we will ask you to give written consent to join the trial. 
You will then be randomised to receive either the Perhexiline tablets or the placebo (the dummy 
tablets). Neither you nor the research team will know which one you are given. 
You will then be given a date for your operation and a date to start taking the tablets. 
An information leaflet and instructions will be included with your tablets. 
↓ 
On your admission to the hospital for your surgery, you will be seen by a member of the Research 
team and asked a few questions regarding your wellbeing. 
↓ 
You will then be taken to theatre for your operation as normal. 
When you are sleep (under a general anaesthetic), we will do some blood tests, measure how well 
your heart is working and take the heart biopsies. 
↓ 
After your operation you will be taken to the Intensive Care unit as normal. 
We will then make further tests of how well your heart is working. 
↓ 
After the operation, you will be have a several extra blood tests, not using a needle but from the 
routine monitoring lines that will be in place. After you recover sufficiently, you will be transferred from 










9.6 HYPER	  Consent	  form	  	  






Support of the Heart with Perhexiline in Left Ventricular Hypertrophy 
Principal Investigator: Mr D Pagano, Consultant Cardiothoracic Surgeon 
 
 
Please initial boxes 
 
I confirm that I have read and understand the information sheet (Version 4a, 
dated 28/02/10) for the above study. I have had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily. 
 
 
I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected. 
 
 
I understand that relevant sections of any of my medical notes and data collected during 
the study, may be looked at by responsible individuals from the NHS Trust, where it is 
relevant to my taking part in this research. I give permission for these individuals to have 
access to my records. 
 
I understand that blood and tissue samples will be kept for the purpose of research and I 
give permission for these samples to be taken and stored. I understand that the process of 
analysing the samples will destroy them and that any remaining samples will be destroyed 
within 6 months of the end of the study. 
 
I confirm that I have read and understand the supplemental information sheet and agree to 




I agree to my GP being informed of my participation in the study. 
 
 




      





      
Name of Person taking consent  Signature  Date 
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9.7 HYPER	  Patient	  information	  on	  dosing	  schedule	  	  
PATIENT INFORMATION ON TAKING STUDY TABLETS 
 
 
Support of the Heart with Perhexiline in Left Ventricular Hypertrophy 
Principal Investigator: Mr D Pagano, Consultant Cardiothoracic Surgeon 
 
 
Thank you for participating in our study. This information sheet provides details of how and 
when to take the study tablets, so that you don’t take too little or too much of the medication. 
 
Your surgery is scheduled for: 
 
Start taking the study tablets on: 
 
For the first 3 days of treatment, take TWO tablets in the morning (breakfast-time) and TWO 
tablets in the evening (tea-time). You may take the tablets before or after a meal. 
 
From the 4th day of taking the study tablets ( ) onwards, take ONE tablet in 
the morning and ONE tablet in the evening. 
 
Continue taking one tablet, twice a day until you are admitted to hospital for your surgery. If 
you are admitted to hospital for any other reason, let the doctors looking after you know that 
you are participating in this trial and ask them to contact Mr Senanayake, Clinical Research 
Fellow in Cardiac Surgery via the Queen Elizabeth Hospital switchboard (including at 
weekends). 
 
If your surgery is postponed for any reason, we will contact you. 
 
 
Questions? Please contact either the secretary to Mr D Pagano, Consultant Cardiothoracic 
Surgeon or  Mr Eshan Senanayake, Clinical Research Fellow in Cardiac Surgery via the 
Queen Elizabeth Hospital, Birmingham switchboard on 0121 472 1311 or mobile: 
07810251454. 	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9.8 HYPER	  Trial	  protocols	  	  
9.8.1 Anaesthesia	  and	  pre-­‐sternotomy	  
All	   patients	   received	   standardised	   pre-­‐medication	   approximately	   90	  minutes	   prior	   to	  anaesthetic	   induction.	   This	   included	   temazapam	   (maximum	  30mg),	   ranitidine	   150mg	  and	  metoclopramide	  10mg.	  	  
Anaesthetic	   induction	  was	   achieved	  with	   fentanyl	  10-­‐15mcg/kg,	   propofol	   0.5-­‐2mg/kg	  and	   pancuronium	   0.1mg/kg	   or	   rocuronium	   0.5-­‐1mg/kg.	   Anaesthesia	  was	  maintained	  with	  propofol	   (1-­‐2%	  neat	   strength	  at	   the	  discretion	  of	   the	  anaesthetist),	   infused	  at	  4-­‐8mg/kg/hr	  and	  alfentanil	  25mg	  in	  50mls	  (neat)	  infused	  at	  50mcg/kg/hr.	  Other	  volatile	  anaesthetic	  agents	  were	  not	  permitted.	  	  
All	   patients	   required	   invasive	   monitoring,	   which	   included	   an	   arterial	   line,	   central	  venous	   pressure	   (CVP)	  monitoring	   line	   and	   Swann-­‐Ganz,	   Pulmonary	   Artery	   Flotation	  Catheter	  (PAFC),	  which	  was	  floated	  prior	  to	  the	  sternotomy.	  	  In	  addition	  to	  arterial	  and	  intravenous	   monitoring,	   all	   patients	   had	   a	   trans-­‐oesophageal	   echocardiogram	   probe	  placed.	  	  
Prior	  to	  cardiopulmonary	  bypass	  (CPB),	  mean	  arterial	  pressure	  (MAP)	  was	  maintained	  between	  60-­‐70mmHg	  using	  aliquots	  of	  phenylephrine	  (5mg	  in	  20ml	  of	  5%	  dextrose)	  or	  an	  infusion	  of	  phenylephrine	  (10mg	  in	  50ml	  of	  5%	  Dextrose).	  Phenylephrine	  was	  used	  as	  the	  first	  line	  vasopressor	  due	  to	  its	  pure	  α-­‐agonist	  properties.	  	  
In	   line	  with	   unit	   practice	  mannitol	   (20%)	  was	   administered	  0.5mls/kg	   as	   an	   osmotic	  diuretic	   and	   antibiotic	   prophylaxis	   was	   administered	   intravenously	   prior	   to	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sternotomy.	  An	  anti-­‐fibrinolytic	  such	  as	  aprotinin	  or	  tranaexamic	  acid	  was	  used	  at	  the	  discretion	  of	  the	  surgeon.	  	  
Heparin	  was	   administered	   prior	   to	   institution	   of	   CPB	   to	   achieve	   full	   anti-­‐coagulation	  (400units/kg)	  and	  this	  was	  reversed	  with	  protamine	  (1mg	  protamine	  per	  100	  units	  of	  heparin)	  after	  termination	  of	  CPB.	  	  
9.8.2 Operative	  procedure	  	  
After	  induction	  with	  anaesthesia,	  the	  patients	  were	  transferred	  into	  the	  operating	  room	  and	  appropriately	  prepped	  and	  draped	  according	  to	  standard	  departmental	  procedures.	  If	   CABG	   was	   being	   performed,	   conduit	   was	   sourced.	   This	   usually	   included	   the	   left	  internal	   mammary	   artery	   and	   long	   saphenous	   vein,	   which	   were	   harvested	  simultaneously.	  	  Approach	  to	  the	  heart	  was	  via	  a	  median	  sternotomy.	  	  
After	  adequate	  conduit	  was	  harvested,	  the	  patient	  was	  instituted	  on	  CPB	  and	  cooled	  to	  32°C,	   with	   venous	   drainage	   via	   a	   two-­‐stage	   cannula	   place	   in	   the	   right	   atrium	   and	  arterial	   return	   established	   by	   placement	   of	   a	   single	   arterial	   cannula	   in	   the	   ascending	  aorta.	  Before	  administration	  of	  cardioplegia	  an	  aortic	  cross	  clamp	  was	  placed	  across	  the	  ascending	  aorta,	  proximal	  to	  the	  aortic	  cannula	  and	  distal	  to	  the	  coronary	  arteries.	  	  
In	   patients	   that	   received	   concomitant	   re-­‐vascularisation	   with	   CABG,	   the	   distal	  anastomoses	  of	  all	  free	  grafts	  were	  performed	  first.	  Then	  the	  aorta	  was	  opened	  through	  a	   transverse	   or	   hockey	   shaped	   incision	   and	   the	   aortic	   valve	   explanted	   and	   annulus	  debrided.	  The	  aortic	  annulus	  was	  sized	  and	  the	  new	  valve	  (biological/mechanical)	  was	  implanted	   as	   per	   the	   individual	   surgical	   technique.	   Throughout	   the	   process	   of	   valve	  explantation	   and	   implantation,	   cardioplegia	   was	   administered	   intermittently	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(approximately	   every	   20	   mins)	   directly	   into	   the	   coronary	   ostia,	   at	   the	   surgeons’	  discretion.	  The	  heart	  was	  vented	  either	  through	  a	  direct	  left	  ventricular	  vent	  placed	  at	  the	  apex	  or	   right	   superior	  pulmonary	  vein	  vent.	  The	  heart	  was	   then	  de-­‐aired	  and	   the	  aortotomy	   closed.	   If	   a	   pedicled	   coronary	   artery	   graft	   was	   to	   be	   placed,	   the	   distal	  anastomoses	  of	  this	  was	  performed	  next.	  These	  steps	  were	  undertaken	  during	  a	  single	  cross	   clamp	   period.	   Having	   completed	   the	   above	   steps,	   the	   aortic	   cross	   clamp	   was	  removed	   and	   all	   proximal	   coronary	   artery	   bypass	   graft	   anastomosis	  were	   performed	  using	   a	  partial	   occlusion	   technique	  using	   a	   side-­‐biting	   clamp.	  However	   if	   the	  use	  of	   a	  side	   biting	   clamp	   was	   difficult	   due	   to	   severe	   aortic	   calcification,	   these	   proximal	  anastomosis	  were	  performed	  during	  a	  single	  complete	  aortic	  cross	  clamp	  period.	  	  
The	   patient	   was	   re-­‐warmed	   on	   CPB	   using	   a	   heat	   exchanger	   to	   a	   nasopharyngeal	  temperature	  of	  36-­‐37°C.	   	  Two	  right	  atrial	  and	  ventricular	  pacing	  wires	  were	  placed	  to	  allow	   sequential	   pacing.	   Patients	  were	   gradually	  weaned	   and	   discontinued	   from	   CPB	  with	   a	   heart	   rate	   of	   70	   –	   110bpm	   (native	   or	   paced),	   without	   inotropic	   support	   if	  possible.	  Drains	  were	  placed	  to	  the	  mediastinal	  and	  open	  pleura.	  The	  patient	  was	  closed	  with	   sternal	   wires	   and	   a	   layered	   closure	   to	   soft	   tissues,	   following	   appropriate	  haemostasis	  and	  a	  period	  of	  haemodynamic	  stability.	  The	  patient	  was	  then	  transferred	  to	  the	  cardiac	  intensive	  care	  unit.	  	  
Inta-­‐operative	  arrhythmias	  were	  treated	  with	  internal	  defibrillation	  at	  the	  discretion	  of	  the	  surgeon.	  Furthermore,	  intravenous	  glycopyrollate	  or	  atropine	  was	  used	  to	  improve	  and/or	  achieve	  the	  above	  target	  native	  cardiac	  rhythm.	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9.8.3 Cardiopulmonary	  bypass	  and	  cardioplegia	  	  
Cardiopulmonary	   bypass	   was	   utilised	   in	   all	   patients	   to	   perform	   AVR±CABG	   and	   was	  established	  in	  all	  cases	  using	  a	  roller	  pump.	  The	  lines	  were	  primed	  with	  2L	  Hartman’s	  solution	   and	   10,000	   units	   of	   heparin.	   For	   oxygenation	   during	   CPB,	   a	   Capiox	   SX	  oxygenator	  was	  used.	  CPB	  was	  maintained	  with	  a	  flow	  rate	  of	  2.4	  L/min/m2	  and	  mean	  radial	   artery	   blood	   pressure	   was	   maintained	   between	   50-­‐60	   mmHg.	   During	   CPB,	  phenylephrine	   aliquots	   or	   infusion	   (described	   above)	   was	   used	   to	   maintain	   these	  pressures.	  	  
All	   patients	   were	   actively	   cooled	   to	   32°C.	   Blood/water	   temperature	   gradient	   was	  maintained	  ≤7oC	  on	  the	  heat	  exchanger	  during	  cooling	  and	  re-­‐warming	  phases.	  Once	  the	  patient	  reached	  a	  nasopharyngeal	  temperature	  of	  35°C,	  the	  heat	  exchanger	  temperature	  was	  set	  to	  37°C.	  	  
Cardioplegia	   was	   used	   as	   the	   main,	   predominate	   myocardia	   protection	   strategy.	   To	  achieve	   and	   maintain	   diastolic	   cardiac	   arrest,	   antegrade	   intermittent	   cold	   blood	  cardioplegia	   was	   used.	   This	   was	   initially	   administered	   via	   the	   aortic	   root	   following	  aortic	   cross	   clamp	   placement.	   Once	   the	   aorta	   was	   opened,	   cardioplegia	   was	  administered	   directly	   down	   the	   coronary	   arteries.	   For	   induction,	   St	   Thomas	   A	   stock	  solution	  (800ml	  blood	  +	  200ml	  stock	  A)	  was	  used	  at	  12ml/kg,	  and	  for	  maintenance	  St	  Thomas	   B	   stock	   solution	   (400ml	   blood	   +	   100ml	   stock	   B)	   was	   used	   at	   6ml/kg.	   The	  composition	  of	  St	  Thomas	  solution	  (Martindale	  Pharma,	  Brentwood,	  UK)	  is	  outlined	  in	  Table	  9-­‐1.	  	  
The	   cardioplegia	  was	  maintained	  between	  4-­‐7	   °C	   and	  delivered	  at	   a	  pressure	  of	  120-­‐150	  mmHg.	  Maintenance	  doses	  were	  administered	  at	  intervals	  of	  20mins	  or	  earlier,	  or	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at	  the	  discretion	  of	  the	  surgeon.	  Supplemental	  retrograde	  cardioplegia	  was	  not	  allowed.	  Supplemental	  cardioplegia	  ‘hot	  shots’,	  were	  allowed	  at	  the	  discretion	  of	  the	  surgeon.	  	  
St	  Thomas	  A	   St	  Thomas	  B	  898ml	  Ringers	  compound	  sodium	  chloride	   966	  Ringers	  compound	  sodium	  chloride	  	  102ml	  cardioplegia	  solution	   34ml	  cardioplegia	  solution	  -­‐	  16.6g	  magnesium	  chloride	  	   -­‐	  5.2g	  magnesium	  chloride	  	  -­‐	  6.1g	  potassium	  chloride	  	   -­‐	  1.9g	  potassium	  chloride	  	  -­‐	  1.4g	  procaine	  hydrochloride	  	   -­‐	  0.4g	  procaine	  hydrochloride	  	  
Table	  9-­‐1	  Composition	  of	  cardioplegia	  solution	  
9.8.4 Post	  operative	  care	  	  
All	  patients	  were	  managed	  according	   to	  predetermined	  protocols	  with	  regard	   to	   their	  peri-­‐operative	   and	   post-­‐operative	   intensive	   care	   management.	   These	   are	   outline	  below:-­‐	  
9.8.4.1 Haemodynamic	  parameters	  	  
All	   patients	   were	   maintained	   within	   the	   optimal	   haemodynamic	   targets.	   Filling	  pressures	   (pre-­‐load),	   as	   advised	   by	   the	   clinical	   team	   based	   on	   the	   patient’s	   existing	  condition	  and	  haemodynamic	  behaviour	  prior	  to,	  during	  and	  post	  CPB	  were	  maintained.	  	  If	   no	   specific	   targets	   were	   set	   by	   the	   surgical	   team	   the	   following	   targets	   were	  maintained:	  -­‐	  
-­‐ Heart	  rate	  70-­‐110bpm	  (native	  or	  paced	  rhythm)	  -­‐ CVP	  8-­‐12	  mmHg	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-­‐ MAP	  65-­‐85	  mmHg	  -­‐ CI	  ≥	  2.2	  L/min/m2	  	  -­‐ Haemoglobin	  >	  7	  	  
To	   meet	   these	   parameters	   and	   achieve	   an	   ideal	   preload	   state	   intravenous	   colloid	  (gelofusin,	   volulyte	  or	  human	  albumin	   solution)	  was	  used.	   If	   blood	  or	  blood	  products	  were	  necessary	  based	  on	  drain	  losses,	  these	  were	  administered	  at	  the	  discretion	  of	  the	  clinical	  team.	  	  
9.8.4.2 Assessment	  and	  management	  of	  post-­‐operative	  hypotension	  	  Hypotension	  was	  defined	  as	  a	  MAP	  <	  60	  mmHg.	  Prior	   to	  any	   intervention	   the	  arterial	  line	   calibration,	   cardiac	   rhythm,	   CVP/PAWP	   and	   drain	   losses	   were	   assessed	   and	  optimised.	  If	  the	  preload	  was	  not	  adequate	  measured	  by	  CVP	  of	  <	  8	  mmHg	  the	  patient	  was	   resuscitated	   with	   volume,	   guided	   by	   the	   trend	   in	   filling	   pressures	   and	  haemodynamic	   measurements.	   Depending	   on	   serial	   haemodynamic	   measurements	  trends	  and	  the	  above-­‐mentioned	  parameters,	  the	  following	  actions	  were	  taken:	  -­‐	  
1. If	  CI	  <	  2.2	  L/min/m2	  with	  a	  normal	  SVR	  (800-­‐1200	  dyne/cm/sec)	  –	  the	  patient	  was	  managed	  as	  per	  LCOE.	  2. If	   CI	   >	   3	   L/min/m2	   with	   a	   low	   SVR	   (<800	   dyne/cm/sec)	   –	   vasoconstrictor	  support	  was	   instituted	  with	   an	   infusion	   of	   phenylephrine	   (10mg	   in	   50	  ml	   5%	  Dextrose)	  and	  titrated	  to	  maintain	  MAP	  >	  60mmHg.	  	  3. If	  further	  vasoconstrictor	  support	  was	  required	  after	  reaching	  the	  ceiling	  levels	  of	  phenylephrine,	  vasopressin	  (20U	  in	  40ml	  of	  5%	  dextrose)	  was	  instituted.	  	  
Phenylephrine	  (10mg	  in	  50ml	  5%	  Dextrose)	  was	  the	  1st	  line	  vasoconstrictor	  used	  in	  this	  trial.	   Vasopressin	   (20U	   in	   40	   ml	   5%	   dextrose)	   was	   the	   2nd	   line	   vasoconstrictor.	   	   If	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further	  vasoconstriction	  was	  required,	  Noradrenaline	  (2mg	  in	  50ml	  5%	  dextrose)	  was	  then	  used.	  	  
9.8.4.3 Other	  parameters	  	  
Urine	  output	  was	  maintained	  at	  ≥	  0.5	  ml/kg/hr.	  Potassium	  was	  maintained	  at	  4.5-­‐5.0	  mml/L	   and	   boluses	   of	   10	   and	   20mmol	   of	   potassium	   chloride	   diluted	   in	   30ml	   5%	  dextrose	  were	  administered	  to	  maintain	  this.	  Blood	  glucose	  was	  maintained	  4-­‐10mml/L	  and	  intravenous	   insulin	  therapy	  as	  per	  the	  unit’s	  policy	  was	  administered	  to	  maintain	  these	  blood	  sugar	  levels.	  	  Arterial	  blood	  gas	  measurements	  were	  performed	  regularly	  in	  addition	  to	  the	  trial	  requirements	  and	  aided	  the	  management	  of	  the	  above	  targets.	  	  
Extubation	   was	   achieved	   through	   an	   existing	   nurse-­‐led	   unit’s	   protocol	   and	   the	   same	  was	  followed	  for	  the	  trial	  patients.	  	  
All	   patients	   received	   a	   continuous	   infusion	   of	   maintenance	   fluid	   of	   5%	   dextrose	   at	  1ml/kg/hr.	   Maintenance	   of	   sedation	   was	   achieved	   with	   propofol	   10mg/ml	   and	  alfentanil	  (25mg/50ml	  5%	  dextrose).	  	  
Initial	  post-­‐operative	  hypertension	  (BP	  >	  160/90)	  was	   treated	  with	  glyceryl	   trinitrate	  solution	   (GTN)	   (50mg/50ml)	   and/or	   sodium	   nitroprusside	   (SNP)	   (50mg/50ml	   5%	  dextrose)	  and/or	  doxazosin	  1-­‐2mg	  orally.	  	  
For	  patients	  on	  the	  ITU	  and	  ward,	  the	  unit’s	  policy	  for	  the	  treatment	  and	  management	  of	  the	  following	  standard	  post-­‐operative	  conditions	  were	  followed:	  -­‐	  
-­‐ Anti-­‐emetic	  therapy	  	  -­‐ Antibiotic	  prophylaxis	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-­‐ Thrombo-­‐embolic	  prophylaxis	  -­‐ Analgesia	  -­‐ Anti-­‐platelet	  therapy	  	  -­‐ Diuresis	  	  -­‐ Gastric	  protection	  -­‐ Sustained	  hypertension	  	  -­‐ Re-­‐starting	  cardiovascular	  drugs	  and	  other	  pre-­‐existing	  medication	  
The	  decision	  to	  re-­‐open	  a	  patient	  due	  to	  excessive	  blood	  loss,	  cardiac	  arrest	  or	  cardiac	  tamponade	  is	  purely	  a	  clinical	  decision	  and	  was	  at	  the	  discretion	  of	  the	  clinical	  team.	  In	  this	  instance,	  the	  findings	  were	  recorded	  and	  discussed	  at	  the	  end-­‐points	  meeting.	  	  
ITU	   and	   ward	   discharge	   was	   at	   the	   discretion	   of	   the	   clinical	   team.	   The	   patients’	  involvement	   in	   the	   trial	  ceased	  when	  they	  were	  discharged	   from	  the	  hospital	  or	  upon	  in-­‐hospital	  death.	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9.9 HYPER	  Trial	  measurements	  	  
9.9.1 Baseline	  blood	  samples	  	  
Before	   induction	   of	   anaesthesia,	   fasting	   arterial	   blood	   samples	  were	   taken	   from	   each	  patient.	  These	  were	  collected	  separately	  into	  Z	  Serum	  Sep	  Clot	  Activator,	  K3E	  K3EDTA	  and	   Z	   Serum	   clot	   Activator	   (plain)	   vacuette	   bottles	   and	   immediately	   centrifuged	   at	  3000g	  for	  5	  mins.	  The	  supernatant	  was	  pipetted	  out	  into	  NUNC	  cryotubes	  and	  frozen	  at	  -­‐80	   °C.	   A	   further	   sample	   of	   blood	   was	   collected	   into	   a	   Z	   Serum	   Sep	   Clot	   Activator	  vacuette	   bottle	   and	   sent	   to	   the	   clinical	   chemistry	   department	   at	   the	   Queen	   Elizabeth	  Hospital,	  to	  assess	  the	  baseline	  cardiac	  Troponin.	  
9.9.2 Haemodynamic	  studies	  	  
The	  PAFC	  or	  Sawn-­‐Ganz	  has	  a	  balloon	  at	   the	  end	  of	   the	  catheter.	  This	  was	   introduced	  into	   the	  Swan-­‐Ganz	   sheath;	   at	   approximately	  20cm	   it	   sits	   in	   the	   internal	   jugular	  vein.	  The	  balloon	  was	  then	  inflated	  and	  floated	  through	  the	  right	  atrium,	  right	  ventricle	  and	  into	  the	  pulmonary	  artery,	  where	  it	  usually	  wedges	  itself	  in	  one	  of	  the	  pulmonary	  artery	  branches.	  The	  balloon	  is	  then	  deflated	  and	  the	  tip	  of	  this	  catheter	  continues	  to	  sit	  in	  this	  position.	  This	  allows	  PAFCs	  to	  be	  used	  to	  perform	  haemodynamic	  flow	  studies	  based	  on	  the	   Fick	   principle	   of	   thermodilution.	   Haemodynamic	   measurements	   were	   thus	  conducted	  at	  specific	  time	  points	  as	  follows:	  -­‐	  
1. Baseline	  after	  induction	  of	  anaesthesia	  and	  ideally	  before	  sternotomy.	  2. Immediately	  before	  administration	  of	  protamine	  after	  complete	  discontinuation	  from	   CPB,	   having	   optimised	   the	   rhythm,	   pre-­‐load,	   optimum	   haemodynamic	  parameters	  and	  afterload.	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3. Approximately	   10	   mins	   after	   administration	   of	   protamine	   and	   whilst	  maintaining	  optimum	  haemodynamic	  parameters.	  	  4. 2,	  4,	  6,	  9	  and	  12	  hrs	  post	  AXC	  removal	  (these	  measurements	  were	  usually	  done	  on	  the	  ICU).	  
The	   Fick	   principle	   of	   haemodynamic	  measurements	   allows	   the	   assessment	   of	   cardiac	  output	  and	  this	  in	  turn	  is	  used	  to	  calculate	  the	  cardiac	  index	  based	  on	  body	  surface	  area	  (BSA).	  	  
The	  measurement	  at	  each	  time	  point	  was	  an	  average	  of	  3	  successive	  injections	  of	  10ml	  of	   cold	   (6-­‐10°C)	   5%	  dextrose	   solution	   through	   the	   proximal	   port	   of	   the	   PAFC	   at	   end	  expiration.	  The	  PAFC	  allows	  the	  measurement	  of	   the	   temperature	  of	   the	   injectate	  and	  the	   temperature	  at	   the	  distal	  port	   (sitting	   in	   the	  pulmonary	  artery).	  The	  difference	   in	  temperature	  between	  these	  points,	  against	  time	  allows	  the	  calculation	  of	  cardiac	  output.	  	  
Data	   on	   the	   heart	   rate,	   systemic	   and	   pulmonary	   artery	   pressures,	   pulmonary	   artery	  wedge	  pressures	   and	   central	   venous	  pressures	  were	   also	   recorded	   at	   the	   above	   time	  points.	  	  
9.9.3 Serial	  blood	  samples	  
Arterial	  blood	  gas	  analysis	  was	  done	  intra-­‐operatively	  and	  in	  the	  peri-­‐operative	  period	  on	   the	   ITU	   at	   the	   above	   mentioned	   time	   points	   coinciding	   with	   the	   haemodynamic	  studies.	  Further	  arterial	  blood	  samples	  were	  collected	  at	  6,	  12	  and	  24	  hrs	  post	  aortic	  XC	  removal	  into	  Z	  Serum	  Sep	  Clot	  Activator,	  K3E	  K3EDTA	  vacuette	  bottles	  and	  centrifuged	  at	  3000g	  for	  5	  mins.	  The	  supernatant	  was	  pipetted	  out	  into	  NUNC	  cryotubes	  and	  frozen	  at	  -­‐80	  °C.	  Another	  set	  of	  arterial	  blood	  samples	  were	  collected	  at	  6,	  12	  and	  24	  hrs	  post	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AXC	  removal	   into	  a	  Z	  Serum	  Sep	  Clot	  Activator	  vacuette	  bottle	  and	  sent	  to	  the	  clinical	  chemistry	   laboratories	   at	   the	  Queen	  Elizabeth	  hospital,	   for	   cardiac	  Troponin	   analysis.	  Samples	  taken	  overnight	  were	  stored	  in	  a	  4°C	  blood	  fridge	  overnight	  and	  processed	  as	  above	  the	  following	  morning.	  	  
9.9.4 Trans-­‐oesophageal	  echocardiography	  	  
Transoesophageal	   echocardiography	   (TOE)	   was	   performed	   in	   all	   patients	   after	   the	  induction	  of	   anaesthesia	  and	  prior	   to	   the	   institution	  of	  CPB.	  This	  was	   to	  quantify	  and	  assess	  the	  degree	  of	  hypertrophy	  intraoperatively.	  Furthermore	  TOE	  was	  used	  to	  assess	  biventricular	  diastolic	  and	  systolic	   function	  and	   the	  aortic	  valve	  gradient.	  Aortic	  valve	  area	  was	   calculated	   using	   the	   continuity	   equation;	   calculating	   the	   left	   ventricular	   out	  flow	   tract	   diameter,	   and	   the	   continuous	   and	   pulse	  waveform	  Doppler	   assessments	   of	  velocities	  at	   the	  aortic	  valve	  (Shanewise,	  Cheung	  et	  al.	  1999;	  Lang,	  Bierig	  et	  al.	  2005).	  After	  discontinuation	  from	  CPB,	  the	  above	  TOE	  measurements	  were	  repeated	  to	  assess	  ventricular	  function,	  valve	  area	  and	  flow	  velocities.	  	  
9.9.5 Electrocardiographic	  measurements	  	  
A	   baseline	   12-­‐lead	   electrocardiogram	   (ECG)	   was	   performed	   in	   all	   patients	   pre-­‐operatively.	   This	   was	   compared	   against	   a	   12-­‐lead	   ECG	   that	   was	   performed	   prior	   to	  hospital	   discharge	   (usually	   on	   day	   4	   post-­‐operatively),	   to	   assess	   for	   new	  myocardial	  injury.	  	  
New	  myocardial	  injury	  identified	  on	  an	  ECG	  was	  defined	  as:	  -­‐	  
-­‐ The	  presence	  of	  new	  Q	  wave	  of	  ≥	  2mm	  in	  ≥	  2	  contiguous	  leads	  -­‐ The	  presence	  of	  new	  buddle	  branch	  block	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OR	  -­‐ Loss	  of	  R	  wave	  progression	  	  
9.9.6 Myocardial	  tissue	  biopsies	  	  
Myocardial	  tissue	  biopsies	  were	  obtained	  from	  all	  possible	  patients.	  An	  intra-­‐operative	  surgical	   assessment	   of	   tissue	   quality	   was	   undertaken	   before	   obtaining	   the	   biopsies.	  Right	  atrial	  biopsies	  were	  obtained	   just	  before	   the	   institution	  of	  CPB.	  This	  biopsy	  site	  was	  incorporated	  into	  the	  surgical	  technique	  of	  placing	  the	  right	  atrial	  venous	  drainage	  cannula.	   Left	   ventricle	   (LV)	   free	  wall	   full	   thickness	  biopsies	  were	  obtained	   from	  non-­‐fibrotic	  areas	  between	  the	  left	  anterior	  descending	  artery	  and	  the	  first	  diagonal	  artery.	  This	  was	  performed	  using	  a	  Trucut	  biopsy	  needle	  (Allegiance	  Healthcare,	  McGaw	  Park,	  IL).	  The	  LV	  biopsy	  sites	  were	  oversewn	  and	  repaired.	  LV	  biopsies	  were	  obtained	  at	  the	  following	  time	  points:	  -­‐	  
1. After	  the	  institution	  of	  CPB	  but	  before	  the	  application	  of	  the	  aortic	  XC	  (onset	  of	  ischaemia).	  2. Just	  prior	  to	  removal	  of	  the	  aortic	  XC	  (end	  of	  ischaemia).	  	  3. Approximately	  10	  mins	  after	  the	  removal	  of	  the	  aortic	  XC	  (reperfusion).	  	  
When	  possible,	  further	  biopsies	  were	  obtained	  of	  skeletal	  muscle	  (rectus	  or	  intercostal),	  epicardial	  fat	  and	  leg	  fat	  (during	  saphenous	  vein	  harvestation)	  before	  the	  institution	  of	  CPB.	  	  




9.10 EQ-­‐5D	  Quality	  of	  life	  questionnaire	  	  
	  	  	  	  	     2 
 
By placing a tick in one box in each group below, please indicate which statements 
best describe your own health state today. 
 
Mobility 
I have no problems in walking about ! 
I have some problems in walking about ! 
I am confined to bed ! 
 
Self-Care 
I have no problems with self-care ! 
I have some problems washing or dressing myself ! 
I am unable to wash or dress myself ! 
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities ! 
I have some problems with performing my usual activities ! 
I am unable to perform my usual activities ! 
 
Pain/Discomfort 
I have no pain or discomfort ! 
I have moderate pain or discomfort ! 
I have extreme pain or discomfort ! 
 
Anxiety/Depression 
I am not anxious or depressed ! 
I am moderately anxious or depressed ! 
I am extremely anxious or depressed ! 
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     3 
 
 
To help people say how good or bad a health state is, we 
have drawn a scale (rather like a thermometer) on which 
the best state you can imagine is marked 100 and the 
worst state you can imagine is marked 0. 
 
We would like you to indicate on this scale how good 
or bad your own health is today, in your opinion. 
Please do this by drawing a line from the box below to 
whichever point on the scale indicates how good or 
















































9.11 HYPER	  Trial	  safety	  and	  standard	  operating	  procedures	  	  
Report	  of	  Serious	  Adverse	  event	  for	  HYPER	  trial	  	  	  Patient	  ID	  Number	  –	  Patient	  Study	  number	  –	  	  The	  research	  nurse/clinical	  fellow	  should	  report	  any	  SAE	  related	  to	  the	  research	  procedures	  and	  those	  that	  are	  unexpected,	  by	  email	  to	  eshan.senanayake@uhb.nhs.uk	  as	  soon	  as	  the	  SAE	  is	  known.	  	  	  The	  clinical	  research	  fellow	  (Mr.	  Eshan	  Senanayake)	  will	  then	  inform	  the	  sponsor	  through	  the	  sponsor’s	  online	  reporting	  system	  and	  also	  inform	  the	  necessary	  authorities	  i.e.	  MHRA.	  REC	  etc	  
	  
Details	  of	  the	  person	  reporting	  	  Name:	  Designation:	  Telephone:	  Email:	  	  
Type	  of	  Event	  	  Death	  	  	   	   Life	  threatening	  	   	  	   Unexpected	  drug	  reaction	   	   	  Persistent	  or	  significant	  disability	  or	  incapacity	  	   	   	  Congenital	  anomaly	  or	  birth	  defect	  	   	   	   Other	  	  
	  
Description	  of	  the	  event	  Date	  of	  the	  event:	  Time	  of	  the	  event:	  Location:	  Description	  of	  the	  circumstances	  of	  the	  event:	  	  	  
Assessment	  of	  Causality	  	  Did	  the	  trial	  drug	  cause	  this	  serious	  adverse	  event?	  No-­‐unrelated	  	  	   Possibly	   	   Probably	   	   Definitely	  	  
Assessment	  of	  Expectedness	  	  Was	  the	  serious	  event	  expected	  or	  unexpected?	   	   Expected	   Unexpected	  	  
Declaration	  Signature	  of	  person	  reporting:	  Print	  Name:	  Date	  of	  report:	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Code	  breaking	  procedure	  
	  
	  
Responsibilities	  Clinical	  research	  nurse	  and	  clinical	  research	  fellow	  
	  
SOP	  
• If	  an	  event	  such	  as	  a	  SUSAR	  (refer	  to	  safety	  reporting	  procedure)	  occurs	  that	  requires	  the	  code	  to	  be	  broken,	  the	  following	  procedure	  must	  be	  followed:	  
o Contact	  pharmacy,	  who	  will	  confirm	  the	  bottle	  number	  allocated	  to	  the	  subject	  participant	  
o Clinical	  research	  fellow,	  Mr.	  Eshan	  Senanayake	  is	  informed	  regarding	  the	  need	  to	  break	  the	  code	  for	  a	  particular	  participant	  (contact	  number	  07810251454)	  
o Mr	  Eshan	  Senanayake	  will	  inform	  the	  following:	  
§ Local	  principal	  investigator,	  Mr.	  Mike	  Lewis	  
§ Main	  PI	  Mr.	  Pagano	  
§ Sponsor	  	  and	  contact	  Mr.	  Neil	  Howell	  (unblinded	  member	  of	  the	  research	  team),	  who	  has	  access	  to	  the	  code	  and	  group	  allocation	  	  
o In	  the	  event	  that	  Mr.	  Eshan	  Senanayake	  is	  not	  contactable,	  Mr.	  Neil	  Howell	  can	  be	  contacted	  directly	  on	  07977454540	  
o The	  local	  collaborator/PI;	  Mr.	  Mike	  Lewis	  (consultant	  cardiothoracic	  surgeon),	  must	  be	  informed	  regarding	  the	  above	  events	  
o In	  the	  event	  that	  Mr.	  Neil	  Howell	  is	  not	  contactable,	  Mr.	  Domenico	  Pagano	  (PI	  for	  the	  HYPER	  trial)	  must	  be	  contacted	  
o Once	  the	  code	  is	  broken	  and	  treatment	  arm	  is	  identified	  standard	  operating	  procedures	  for	  reporting	  adverse	  incidents	  will	  be	  followed	  as	  per	  R&D	  guidelines	  
o All	  reporting	  will	  be	  done	  by	  Mr.	  Eshan	  Senanayake	  and	  overseen	  by	  Mr	  Domenico	  Pagano	  
Requirements	  	  The	  following	  persons	  are	  required	  to	  read	  the	  above	  SOP	  and	  follow	  the	  above	  instructions:-­‐	  Clinical	  Research	  nurse	  Clinical	  research	  fellow	  Local	  PI	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Responsibilities	  Clinical	  research	  nurse	  and	  clinical	  research	  fellow	  
	  
SOP	  
• Cardiac	  surgery	  alone,	  by	  itself	  is	  a	  significant	  intervention	  
• There	  are	  well	  known,	  expected,	  well	  recognised	  complications	  that	  would	  require	  either	  an	  extended	  ITU	  stay,	  ward	  stay	  or	  overall	  extended	  stay	  in	  hospital	  
• There	  is	  also	  an	  expected	  risk	  of	  death	  and	  morbidity,	  which	  is	  incorporated	  to	  the	  consent	  process	  for	  cardiac	  surgery	  
• Therefore	  the	  following	  expected	  complications	  in	  addition	  to	  the	  side	  effects	  outlined	  in	  the	  investigational	  brochure	  should	  not	  be	  reported	  as	  an	  adverse	  event.	  However,	  these	  events	  are	  recorded	  as	  per	  the	  data	  collection	  forms.	  	  
o Re-­‐operation	  	  
§ Low	  cardiac	  output	  syndrome	  
§ Tamponade	  
§ Bleeding	  
§ Cardiac	  arrest	  
o Respiratory	  complication	  	  
§ Pneumonia	  
§ CPAP	  support	  
§ Re-­‐intubation	  
§ Tracheostomy	  
o Renal	  complications	  
§ Renal	  impairment	  (Cr>200)	  
§ CVVH	  
o Neurological	  complications	  
§ Patient	  not	  waking	  
§ Focal	  CVA/TIA	  
§ Type	  II	  neurological	  complication	  	  
o Abdominal	  complications	  
§ Ischaemic	  gut	  	  
§ GI	  bleed	  
§ Pancreatitis	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o Sternal	  wound	  dehiscence	  and	  infection	  
o Led	  wound	  dehiscence	  and	  infection	  	  
o Atrial	  Fibrillation	  
o Requirement	  for	  Permanent	  pacemaker	  
o Extended	  stay	  due	  to	  mobility	  and	  social	  issues	  	  
• However	  all	  deaths	  occurring	  before	  or	  after	  surgery	  once	  the	  patient	  is	  recruited	  into	  the	  study	  should	  be	  reported	  	  	  
Requirements	  	  The	  following	  persons	  are	  required	  to	  read	  the	  above	  SOP	  and	  follow	  the	  above	  instructions:-­‐	  Clinical	  Research	  nurse	  Clinical	  research	  fellow	  Local	  PI	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9.12 HYPER	  DSMB	  recommendation	  	  
	  
	  
DSMB Hyper – Minutes 22nd June 2012 
Paul Jordan, 
 Nick Freemantle 
 
Thank you for the excellent preparations in support of our meeting. 
Recommendation 
We note that recruitment has proven difficult and have no suggestions on approaches which may 
improve the rate in this somewhat complex trial. 
We are concerned that one patient took a week of trial medication and then withdrew, and thus 
may have been exposed to the investigational product.  We are not convinced that all appropriate 
steps have been taken by the study team to ensure that the patient’s clinical follow up is complete 
as per protocol.   
We believe that, if the trial continues at the current rate, the recruitment objective is unlikely to be 
achieved in less than 20 months.   
We note that we have been asked to assess the trial for futility, in addition to safety and efficacy, 
and are content to do this, using an O’Brien Flemming alpha Spending approach for futility in 
addition to our existing schedule. 
We assess that the trial is unlikely to achieve its scientific objectives and are content for the trial to 
be halted at this point, ensuring patients already in follow up receive appropriate care and 
assessment under the protocol, and for their clinical need. 
Further, we are concerned that there are some signs of reduced cardiac output associated with 
exposure to perhexiline in this trial and in the completed CASPER trial although are unsure of its 
clinical importance.  Given the apparent futility on the scientific objective of the trial we believe that 
the appropriate course of action is for the Trials Steering Committee to halt recruitment to the trial 
at this point.  We are happy to discuss this recommendation further. 
  
Closed Meeting Minutes 
We assessed analyses of the primary and secondary outcomes, and noted differences in cardiac 
output and cardiac index (see report).  In addition we noted the apparent futility of the trial 
according to the predefined criteria.   
We had concerns about the difference in serum creatinine post procedure. 
We saw no evidence of clinical benefit associated with the investigational treatment, and note that a 
similar trial was also neutral on this outcome. 
We recognised the likely logistic challenges particularly in staffing associated with completion of the 
study as originally planned, but regard this as a study management issue rather than one relating to 





9.13 The	  Borg	  Scale	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The 6MWT should be performed indoors, along a long, flat,
straight, enclosed corridor with a hard surface that is seldom
traveled. If the weather is comfortable, the test may be per-
formed outdoors. The walking course must be 30 m in length.
A 100-ft hallway is, therefore, required. The length of the cor-
ridor should be marked every 3 m. The turnaround points should
be marked with a cone (such as an orange traffic cone). A start-
ing line, which marks the beginning and end of each 60-m lap,




A shorter corridor requires patients to take more
time to reverse directions more often, reducing the 6MWD.
Most studies have used a 30-m corridor (51), but some have
used 20- or 50-m corridors (52, 53). A recent multicenter study
found no significant effect of the length of straight courses
ranging from 50 to 164 ft, but patients walked farther on con-
tinuous (oval) tracks (mean 92 ft farther) (54).
The use of a treadmill to determine the 6MWD might save
space and allow constant monitoring during the exercise, but
the use of a treadmill for 6-minute walk testing is not recom-
mended. Patients are unable to pace themselves on a tread-
mill. In one study of patients with severe lung disease, the
mean distance walked on the treadmill during 6 minutes (with
the speed adjusted by the patients) was shorter by a mean of
14% when compared with the standard 6MWD using a 100-ft
hallway (55). The range of differences was wide, with patients
walking between 400–1,300 ft on the treadmill who walked
1,200 ft in the hallway. Treadmill test results, therefore, are




1. Countdown timer (or stopwatch)
2. Mechanical lap counter
3. Two small cones to mark the turnaround points
4. A chair that can be easily moved along the walking course
5. Worksheets on a clipboard
6. A source of oxygen
7. Sphygmomanometer
8. Telephone




1. Comfortable clothing should be worn.
2. Appropriate shoes for walking should be worn.
3. Patients should use their usual walking aids during the test
(cane, walker, etc.).
4. The patient’s usual medical regimen should be continued.
5. A light meal is acceptable before early morning or early af-
ternoon tests.
6. Patients should not have exercised vigorously within 2 hours




1. Repeat testing should be performed about the same time
of day to minimize intraday variability.
2. A “warm-up” period before the test should not be performed.
3. The patient should sit at rest in a chair, located near the
starting position, for at least 10 minutes before the test
starts. During this time, check for contraindications, mea-
sure pulse and blood pressure, and make sure that cloth-
ing and shoes are appropriate. Compete the first portion










4. Pulse oximetry is optional. If it is performed, measure and





and follow manufacturer’s instructions to maximize the sig-
nal and to minimize motion artifact (56). Make sure the
readings are stable before recording. Note pulse regularity
and whether the oximeter signal quality is acceptable.
 
The rationale for measuring oxygen saturation is that al-
though the distance is the primary outcome measure, im-
provement during serial evaluations may be manifest either
by an increased distance or by reduced symptoms with the




 should not be used for
constant monitoring during the exercise. The technician





during the walk, the pulse oximeter must be lightweight (less
than 2 pounds), battery powered, and held in place (perhaps
by a “fanny pack”) so that the patient does not have to hold
or stabilize it and so that stride is not affected. Many pulse
oximeters have considerable motion artifact that prevents
accurate readings during the walk (57).
 
5. Have the patient stand and rate their baseline dyspnea




 Table 2 for
the Borg scale and instructions [58]).
6. Set the lap counter to zero and the timer to 6 minutes. As-
semble all necessary equipment (lap counter, timer, clip-
board, Borg Scale, worksheet) and move to the starting
point.
7. Instruct the patient as follows:
 
“The object of this test is to walk as far as possible for 6
minutes. You will walk back and forth in this hallway. Six
minutes is a long time to walk, so you will be exerting your-
self. You will probably get out of breath or become ex-
hausted. You are permitted to slow down, to stop, and to
rest as necessary. You may lean against the wall while rest-
ing, but resume walking as soon as you are able.
You will be walking back and forth around the cones.
You should pivot briskly around the cones and continue
back the other way without hesitation. Now I’m going to
show you. Please watch the way I turn without hesitation.”
Demonstrate by walking one lap yourself. Walk and
pivot around a cone briskly.
“Are you ready to do that? I am going to use this
counter to keep track of the number of laps you complete. I
will click it each time you turn around at this starting line.
Remember that the object is to walk AS FAR AS POSSI-
BLE for 6 minutes, but don’t run or jog.
Start now, or whenever you are ready.”
 
TABLE 2. THE BORG SCALE
 
0 Nothing at all










10 Very, very severe (maximal)
This Borg scale should be printed on heavy paper (11 inches high and perhaps lami-
nated) in 20-point type size. At the beginning of the 6-minute exercise, show the scale
to the patient and ask the patient this: “Please grade your level of shortness of breath
using this scale.” Then ask this: “Please grade your level of fatigue using this scale.”
At the end of the exercise, remind the patient of the breathing number that they
chose before the exercise and ask the patient to grade their breathing level again. Then
ask the patient to grade their level of fatigue, after reminding them of their grade be-
fore the exercise.
	  9-­‐284	  
9.14 Dosing	  regime	  for	  extended	  trial	  therapy	  	  
Dose	  planning	  based	  on	  Perhexiline	  assays	  result	  on	  day	  7	  
Perhexiline 











Dose	  planning	  based	  on	  Perhexiline	  assays	  result	  at	  ≥	  4	  weeks	  on	  therapy	  
Perhexiline 
concentration(mg/L) Recommended new daily dose (mgs) 
<0.15 Double the daily dose 
0.15-0.60 No change 
0.60-0.90 Reduced dose by 25% 
0.90-1.20 Halve the daily dose 
>1.20 
Cease for 1 week then reduce the daily dose to 25% of the 
previous dose 	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9.15 Protocol	  for	  tissue	  preparation	  and	  MS	  analysis	  	  
Tissue	  preparation	  and	  extraction	  for	  metabolomic	  analysis	  	  
This	   process	   used	   a	   methanol:chloroform	   tissue	   extraction	   process	   for	   very	   small	  samples	  (≤	  10mg)	  	  Equipment	  required:	  	   	  Precellys	  24	  homogeniser	  	   1.8ml	  glass	  vials	  with	  aluminium	  lined	  caps	  (Fisher	  TUL	  520	  006	  J)	  	   2ml	  Eppendorfs	  	  	   Glass	  Pasteur	  Pippettes	  	   Hamilton	  Syringes	  (Fisher	  500µl)	  Solvents	  requires:	   	  100%	  MeOH	  (FPLC	  Grade)	  	   100%	  CHCl3	  (Pesticide	  Grade)	  	   100%	  HPLC	  grade	  H20	  	  
Protocol:	  
• Frozen	  myocardial	  biopsy	  tissue	  is	  stored	  in	  Precellys	  tubes	  with	  beads	  in	  -­‐80°C	  freezer	  
• All	  solvents	  at	  4°C	  and	  kept	  on	  ice	  
• Add	  32µl/mg	  of	  tissue	  of	  MeOH	  and	  1.2µl/mg	  of	  H20	  keeping	  precellys	  tubes	  on	  ice	  
• Place	  tubes	  in	  Precellys	  24	  homogeniser	  for	  2×10s	  burst	  at	  6400rpm	  
• Remove	  homogenised	  mixture	  into	  a	  clean	  1.8ml	  glass	  vial	  using	  Pasteur	  pipette	  
• Place	  glass	  vials	  back	  on	   ice	  and	   then	  add	  32µl/mg	  CHCl2	  and	  16µl/mg	  H2O	   to	  each	  vial	  
• Vortex	  vials	  on	  full	  power	  for	  30s	  each	  
• Leave	  on	  ice	  for	  10	  mins	  
• Centrifuge	  glass	  vials	  at	  4000rpm	  at	  4°C	  for	  10	  mins	  
• Set	  samples	  on	  bench	  at	  room	  temperature	  for	  5	  mins	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At	  this	  stage	  the	  samples	  should	  be	  biphasic,	  with	  protein	  debris	  separating	  the	  upper	  (polar)	  and	  lower	  (non-­‐polar)	  layers.	  
For	  the	  following	  2	  steps	  care	  must	  be	  taken	  not	  to	  remove	  any	  of	  the	  interface	  regions	  (1-­‐2mm	  on	  either	  side	  of	  the	  protein	  layer)	  
• Using	   a	   Hamilton	   syringe,	   remove	   the	   polar	   phase	   into	   2	   clean	   eppendorfs	   (1	  postive,	  1	  negative)	  
• Using	  a	  Hamilton	  synringe	  remove	  the	  non-­‐polar	  phase	  into	  2	  clean	  1.8ml	  glass	  viasl	  (1	  positive,	  1	  negative)	  
• These	  are	   then	  dried	  using	  a	  Speed	  Vac	  Concentrator	   (approximately	  1h	   in	  NO	  heat)	  
• The	   samples	   can	   then	   be	   stored	   in	   the	   -­‐80°C	   freezer	   until	   needed	   for	   further	  analysis	  
Preparation	  for	  analysis	  of	  dried	  polar	  extracts	  
The	  dried	  polar	  extracts	  are	  re-­‐suspended	  in	  80:20	  methanol:water,	  containing	  0.25%	  formic	   acid	   or	   20mM	   ammonium	   acetate	   for	   positive	   and	   negative	   ion	   analysis	  respectively.	   Following	   this	   Fourier	   transform	   ion	   cyclotron	   resonance	   mass	  spectrometry	  (FT-­‐ICR	  MS)	  based	  metabolomic	  analysis	  was	  conducted	  using	  a	  hybrid	  7-­‐T	   LTQ	   FT	   (Thermo	   scientific,	   Berlin,	   Germany)	   equipped	   with	   a	   chip-­‐based	   direct	  infusion	  nanoelectrospray	  ion	  source	  (Triversa,	  Avion	  Biosciences,	  Ithaca,	  NY).	  	  
The	   nanoelectrospray	   conditions	   compromised	   of	   a	   200ml/min	   flow	   rate,	   0.3psi	  backing	  pressure	  and	  +1.7	  or	  -­‐1.7	  kV	  electrospray	  voltage	  for	  positive	  and	  negative	  ion	  analysis	   retrospectively,	   controlled	   by	   ChipSoft	   software	   (version	   8.1.0	   Advion	  Biosciences,	  UK).	  
Each	   sample	   was	   analysed	   in	   triplicate	   with	   FT-­‐ICR	   MS,	   collecting	   multiple	   adjacent	  selected	   ion	  monitoring	   (SIM)	  windows,	  which	   are	   stitched	   together	   from	  m/z	   70	   to	  500.	  Each	  window	  overlaps	  by	  m/z	  10	  (3)	  with	  an	  automatic	  gain	  control	  (AGC)	  target	  of	  1	  ×	  105	  charges	  and	  a	  mass	  resolution	  of	  100,000.	  Data	  was	  recorded	  for	  5.5	  minutes	  per	  replicate	  analysis	  using	  Xcalibur	  software	  version	  2.0	  (Thermo	  Scientific,	  USA).	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Transient	   data	   from	   the	   FT-­‐ICR	   detector	   were	   processed	   using	   the	   averaging	   of	  transients,	  Hanning	  apodisation	  and	  application	  of	  a	  fast	  Fourier	  transformation;	  using	  custom	  written	  codes	  in	  MATLAB	  version	  7.0	  (The	  MathWorks,	  MA,	  USA).	  	  
Following	  this	  the	  SIM-­‐stitching	  algorithm	  was	  applied	  (Custom	  written	  code,	  MATLAB	  Version	   7.0	   The	   MathWorks)	   (Southam,	   Payne	   et	   al.	   2007),	   which	   stitched	   together	  multiple	  SIM	  windows,	   rejected	  all	  peaks	  with	  a	  signal-­‐to-­‐noise	  ratio	   (SNR)	  <3.5.	  This	  algorithm	  then	  internally	  calibrated	  each	  mass	  spectrum	  using	  a	  pre-­‐defined	  calibrant	  list	  of	  metabolites.	  	  
Probabilistic	   Quotient	   Normalisation	   (PQN)	   was	   used	   to	   normalise	   the	   data.	   This	  minimised	  the	  effects	  of	  particularly	  high	  and	  low	  intensity	  peaks	  (Dieterle,	  Ross	  et	  al.	  2006).	  To	  avoid	  the	  highest	   intensity	  peaks	  from	  dominating	  the	  multivariate	  analysis	  and	  to	  stabilise	  the	  variance	  across	  the	  numerous	  peaks	  detected,	  they	  were	  subject	  to	  a	  generalised	  log	  transformation	  (Parsons,	  Ludwig	  et	  al.	  2007).	  	  
Principle	   component	   analysis	   (PCA)	   was	   used	   to	   assess	   the	   metabolic	   differences	  between	   the	   sample	   groups	   in	   an	   unbiased	   manner,	   using	   the	   PLS_Toolbox	   (version	  3.53,	  	  Eigenvector,	  Manson,	  WA,	  USA)	  within	  MATLAB	  (Version	  7.0	  The	  MathWorks,	  Ma,	  USA)	  and	  confirmed	  using	  students	  t-­‐tests	  (MS	  Excel,	  Seatle,	  USA).	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